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With the awareness that healthcare is a limited resource, decision-makers are challenged to 
allocate it rationally and efficiently. Health economic methods of evidence synthesis for 
decision-making are useful to quantify healthcare resource utilisation, critically evaluate 
different interventions and ensure the implementation of the most effective or cost-effective 
strategy. The nine studies included in the present cumulative doctoral thesis aim to 
demonstrate the capability of statistical and decision-analytic modelling techniques to inform 
and support rational healthcare decision-making in Germany. Five studies apply statistical 
modelling in analyses of public health and health economic data. They show that the 
developed models are valuable instruments for examining patterns in the data and 
generating knowledge from observable data which can further be used in devising disease 
management and care programs as well as economic evaluations.     
Further, two health economic evaluations, which adopt the decision-analytic-modelling 
approach, show that decision-analytic modelling is a powerful tool to represent the 
epidemiology of infectious and non-infectious diseases on a population level, quantify the 
burden of the diseases, generalise the outcomes of clinical trials, and predict how the 
interventions can change the impact of the diseases on the health of the population. 
Additionally, two literature reviews examine the application of decision-analytic modelling in 
health economic evaluations. The first study reviews and empirically analyses health 
technology assessments by the German Institute for Medical Documentation and Information 
and demonstrates that the application of decision-analytic models improves the evidence 
produced for policy-making in the healthcare sector in Germany. The second systematic 
review focuses on methodological choices made in constructing decision-analytic models 
and explains how critically the structural and parametrical assumptions can influence the final 
message of the economic evaluations and shows that building a validated, reliable model as 
well as the transparent reporting is of high priority in facilitating the communication and 
implementation of the most cost-effective course of action.  
Overall, the present thesis shows the relevance and advantage of the application of models 
in synthesising evidence for decision-making. The included studies contribute to the current 
and future development of the methods used to address the problems of health economic 
efficiency. Further advances in the computational modelling techniques and data collection, 
from one side, will ease the decision-making process, but, from another side, will require 
increasing competence and understanding within the decision-making bodies. 
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1. Introduction  
Healthcare is a highly complex, dynamic and diverse economic sector which functions within 
conditions of numerous uncertainties, individual preferences and technological progress. 
This environment creates a constant challenge for decision-makers to reconcile the 
increasing costs and the growing demand with limited resources and funds. The rational 
allocation of scarce healthcare resources requires evidence-based decision-making (1). 
Evidence can be primarily obtained through observation and data collection (2), however, the 
production of knowledge needs the process of synthesis. Modelling techniques facilitate the 
synthesis of evidence, which cannot be directly observed, and serve as decision-supporting 
tools in economic efficiency problems (3). They become increasingly important in the health 
economic methodology and are frequently emphasised in questions of healthcare resource 
allocation. 
Two modelling approaches are the focus of the present work: statistical and decision-analytic 
modelling. 
Synthesising evidence using statistical modelling is achieved via the application of statistical 
models directly to the observed public health and economic data. It comprises of the 
examination of patterns in the data as well as the investigation, explanation, and prediction of 
relationships between the observed variables (4). A wide variety of statistical models has 
been developed for the analysis of public health and health economic data, making it 
challenging to choose the right modelling approach for the problem at hand (5). This choice 
should be guided by the structure of the data and hypotheses about the relationships 
between the variables (4). The latter is driven by the existing knowledge, and the former 
requires the analysis of the statistical distributions of the included variables.  
Synthesising evidence using a decision-analytic model includes the integration of the 
observed data from different sources into one system within a health economic evaluation 
(6). Health economic evaluations are performed to assess the costs and consequences of 
preventive and therapeutic interventions, estimate maximal or threshold values of important 
characteristics (e.g. a break-even price), and optimise strategic parameters (e.g. age-range 
and time of administration). A health economic evaluation comprises of a set of comparative 
methodologies that weigh the costs of a strategy against its benefits or consequences. The 
most frequently used forms of health economic evaluations are cost-utility analysis, cost-
effectiveness analysis and cost-benefit analysis (7).   
The assessment of randomised controlled trials (RCT) and decision-analytic modelling are 
the two main vehicles for a health economic evaluation providing evidence for the 




estimates of health outcomes, effects, and resource utilisation, they do have limitations. 
RCTs tend to report evidence specific to their particular setting for a group of patients and 
can contain a possible bias due to participant selection (8). Also, RCTs are not suitable to 
provide estimates on the population level and might be of duration too short to capture all 
relevant long-term outcomes (7). Moreover, even well designed and conducted RCTs can 
provide evidence only on a few options of one intervention but cannot facilitate the inclusion 
of multiple varying alternatives. In addition, RCTs often report relevant clinical data but do not 
provide the evidence necessary for an economic evaluation such as impairment of quality of 
life and/or resource utilisation.  
A decision-analytic model (DAM) uses input data from different sources, projects outcomes 
of alternative decisions and produces information on costs and benefits of a healthcare 
intervention. Decision-analytic modelling proves to be useful if there is a need to generalise 
the outcomes of RCTs to other settings and population groups, combine evidence from a 
range of sources, and extrapolate their impacts beyond the time horizon of the respective 
RCTs (7). In addition, decision-analytic modelling facilitates detailed comparisons of 
alternatives where trials do not exist. 
Frequently, the term “decision-analytic model” represents an economic analysis based on a 
decision-tree (6). Therefore, for the purpose of this work the term “mechanistic model” will be 
used to denote more complex mathematical formulations, which are used to simulate a 
natural process, such as a dynamic-transmission model or a microsimulation model while the 
term “decision-analytic model” will be reserved for describing a complete computation of 
evidence needed for a decision-analysis which includes a mechanistic model and an 
economic evaluation conducted on its basis. The design of a mechanistic model (9) is based 
on what is known about the process that it is intended to reproduce and includes the states 
of the natural course of events (e.g. disease, infection, exposure, etc.), transition principles, 
and time. Depending on the model type, the output values of a mechanistic model illustrate 
trajectories of either an individual or a population entered into the modelled system. 
Aggregations of the returned output values are consequently used in health economic 
comparative analyses.  
The increasing complexity of the decision-analytic methodology has raised the need to 
establish guidelines for a good practice of model development which have been published in 
increasing numbers (10–15). In this work, the following generalised framework is suggested 
to broadly describe the general approach of the application of decision-analytic models in 





Figure 1: Framework for the application of decision-analytic modelling to synthesise evidence for 
decision-making. 
Source: own representation based on (7, 10–15). 
This framework can be understood as follows: 
1) Obtaining the observed data on the topic of study. The list of sources of data used for 
health economic evaluations includes, but is not limited to, epidemiological 
observational studies, clinical trials, observational cohort studies, socio-economic 
population statistics, costs, and quality of life data. The information provided in the wide 
range of data from different sources is combined in a systematic approach using a 
decision-analytic model. This can be seen as being composed of two parts: a 
mechanistic model and an economic appraisal which is informed with the output values 
of the mechanistic model and the economic data.  
2) Researching the knowledge base. The development of a mechanistic model begins with 
a reconstruction of a sequence of events and pathways which represent the natural 
course of the studied health condition. If there is sufficient information about its 
biological and epidemiological features, the course of events and governing transition 
principles can be known and sketched. Although the knowledge base of many health 




to the smallest detail. Thus one natural process can be reconstructed using different 
models with one being the closest to reality.  
3) Writing and programming a mathematical formulation. The sketched model structure is 
converted into a mathematical formulation using, for example, the theory of differential 
equations, mathematical equations with stochastic assumptions, survival analysis, 
and/or other approaches.  
4) Parameterising the model. The models are parameterised with input values that are 
obtained using the available evidence; however, often, not all governing parameters can 
be observed. For example, mathematical models based on differential equations have 
been proven to be a powerful tool in understanding dynamic behaviour such as the 
epidemiology of infectious diseases and predicting their impact on the population (16). 
However, in infectious diseases, often only a part of the reality is observed. As 
examples might serve a) the proportion of the ill people who seek healthcare or become 
hospitalised as compared to all the people infected or b) the time of symptoms onset 
but not of the transmission of the pathogen. Therefore, the problem of model 
parameterisation is twofold: from one side, it depends on the model chosen to 
reproduce the reality and, from another side, the connection of this reproduction to the 
observed data. The connection of the model to the data is conducted through a process 
of fitting, i.e. a process of parameterisation of the model to induce it to return output 
values which are close to those observed in reality (17). Commonly used techniques 
comprise of simulation-based inference which combines mechanistic and statistical 
approaches. They are based on calculations of probabilities that, given a particular 
vector of inputs, the observed data are the model output. The estimated parameters are 
further used to inform the model to predict the outputs over a time horizon which cannot 
be observed. 
5) Conducting health economic evaluation. The constructed mechanistic model can be 
used either to investigate the natural course of a disease or, of more importance, to 
simulate the effects of a preventive or therapeutic intervention. The model output values 
for each strategy inform the succeeding economic analysis, which also has to be 
adequately conceptualised to correctly address the decision problem. It requires a 
detailed consideration of intervention settings, perspectives, time horizons, discounting 
rates, representative costs, and health outcomes. 
6) Analysing uncertainty. The exploration of uncertainty and a critical overview of the 
results is the next key component of decision-analytic modelling (10, 15). Uncertainty 
comes from multiple sources such as demographic and epidemiologic uncertainties, the 
observational process, the data collection, parameter estimation procedures, and 




7) Informing decision-making. The evidence synthesised using a decision-analytic 
modelling study is used to convey a message about the most effective and cost-
effective alternatives to allow for rational decision-making. 
It is important to note that in the field of decision-analytic modelling, it is impossible to come 
up with a “one size fits all” methodology. It is, therefore, up to the researcher to address the 
nature of the disease, the intervention, and the available data to determine which method to 
use. Due to the likely complexity of the models, it is important to thoroughly review the 
assumptions made and the evidence used in the development of the model before deciding 
whether the results of this model are credible and valid for the decision at hand. Decision-
makers need to “trust” the model and be able to screen out those of low predictive quality to 
foresee the true potential health and economic impacts of different strategies as well as 
select programs that maximise the effects of the invested healthcare resources. A 
fundamental problem for a judgment about the validity of a decision-analytic model is to see 
whether the model adequately represents the epidemiological and economical setup behind 
the envisioned intervention and provides the best possible evidence given the available data. 
In other words, is the model fit for the stated purpose or rather misleading? This concerns 
both the mechanistic model, which represents the epidemiology of the studied disease as 
well as the economic appraisal. Although there are multiple instruments and checklists, 
which can be used to assess the quality of economic evaluations (18), only a few of them 
include critical considerations of the assumptions and the methods used in the modelling 
studies. Therefore, a systematic examination and transparent reporting of the parametric and 
structural uncertainty is a requirement for a decision-model-based health economic study of 
good quality and value for decision-makers. 
The present cumulative doctoral thesis focuses on the evidence synthesis for decision-
making in public health and the healthcare sector via collecting data, conducting extensive 
statistical analyses, and building complex decision-analytic models. The overall framework is 
shown in Figure 2. Primary evidence is obtained via observations, experiments and data 
collections from first-hand sources (19). Statistical models are applied to synthesise 
knowledge from the primary data for policy-making (Articles 1 to 5). Decision-analytic models 
are applied to integrate the primary data from various sources in order to produce new data 
needed for comparing and evaluating different public health strategies (Articles 6 to 9). The 
thesis includes two economic evaluations where both statistical and decision-analytic 
modelling approaches are applied in one analysis. This includes using the outcomes of 
statistical models as input values for a decision-analytic model and probabilistic analyses of 
uncertainty, incorporating the estimated statistical distributions and regression models in a 
mechanistic model as structural elements, as well as applying the methods of simulation-




fitting. Additionally, these multiple possible interconnections are demonstrated throughout the 
present text to point out that the application of both statistical and decision-analytic 
approaches in one decision-analytic modelling study increases the ability of the model to 
approximate reality and provide evidence with less uncertainty.  
 
Figure 2: Integrated framework of evidence synthesis using statistical and decision-analytic modelling 
and contribution of the included studies.  
JIA - juvenile idiopathic arthritis; DAM - decision-analytic modelling, A - Article; WTP - 
willingness to pay; WTU - willingness to use. 
Source: own representation. 
This text describes the nine included studies and is structured along with the following central 
research questions: 
1. What is the contribution of statistical models in the synthesis of evidence for health 
economic evaluations and decision-making in public health and the healthcare 
sector? 
2. What are the capabilities of decision-analytic modelling to synthesise evidence about 
complex public health interventions? 
3. Does decision-analytic modelling as an instrument of health economic evaluations 
advance evidence synthesis for rational decision-making in public health and the 
healthcare sector? 
The text begins with the description of data collection and the application of statistical models 
in order to investigate and analyse the patterns in the observed public health and health 
economic data in Germany as well as to synthesise evidence for policy-making. The section 




of, firstly, health-related behaviour and, secondly, estimations and investigations of costs and 
health-related quality of life (Section A: articles 1 to 5).  
The text continues with a discussion of the usage of decision-analytic models built on 
complex mechanistic models. It demonstrates how these modelling techniques can facilitate 
decision-making on complex healthcare interventions (Section B: articles 6 and 7). The 
section presents two health economic evaluations which are conducted to address decision 
problems for two large-scale public health interventions: screening and prevention. Due to 
their nature, these two interventions require different approaches in the development of the 
corresponding mechanistic model to facilitate an economic evaluation of their payoffs. A 
decision problem on preventive measures includes a population without the disease of 
interest and intervention, which aims at reducing the risk of acquiring this disease (6). 
Screening, in turn, affects individuals at a high and average risk of developing the disease or 
those who have developed the disease but present no symptoms. Screening, therefore, aims 
at the detection of the underlying disease at an earlier and more treatable stage (6). The 
particularities of the decision-problem at hand, the development of decision-models as well 
as the application of statistical models to inform the mechanistic models and the economic 
analyses are described and discussed.  
Further, two reviews address the application of decision-analytic modelling as an instrument 
of health economic evaluations (Section C: articles 8 and 9). The first review and empirical 
analysis of health technology assessments of the German Institute for Medical 
Documentation and Information demonstrates the advantages of using decision-analytic 
models in producing evidence for policy-making in the healthcare sector in Germany. The 
second publication is a comprehensive systematic review of economic evaluations 
addressing the issues of transparent reporting, choices of assumptions and methods in 
conducting decision-analytic modelling thereby showing their impact on the validity of the 
models and the evidence synthesis for decision-making. 
Finally, the third chapter summarises the contribution of the nine articles, describes the 










2. Contribution of the present cumulative doctoral thesis 
A. Synthesising evidence using health economic and public health data: 
contribution of statistical modelling  
(1) Analyses of data on health-related behaviour (articles 1 and 2) 
The examination of health-related behaviour is of high importance in public health because 
major behavioural risk factors, such as smoking, obesity, and alcohol consumption, are 
proved to adversely affect health outcomes and induce consumption of healthcare resources 
(20, 21). Two papers of this thesis address smoking behaviour from different perspectives.  
In the first study, “Estimation of age -, gender - and birth cohort-specific parameters of 
smoking behaviour for the German population” (Article 1), we use statistical modelling to 
establish time-dependent patterns of smoking behaviour of multiple German birth cohorts. 
We perform comprehensive analyses of smoking history trends in Germany for birth cohorts 
from 1920 to 1980 and obtain summaries of their lifetime smoking which contribute to our 
understanding of the adverse impacts smoking might have on the health of the population. 
We also project these estimates forward to the year 2025, aiming to instigate further 
research in this field. The statistical models are determined after examining the dataset 
obtained from three cross-sectional surveys conducted by the Robert Koch-Institute (RKI) 
between 1997 and 2012. They provide a large pooled sample size of 77,882 respondents 
and contain all variables of interest for our analyses: smoking status at the interview date, 
age at starting and quitting smoking, the form of smoking, and the number of cigarettes 
smoked per day. To find and explore the patterns in these data we use logistic age-cohort 
models to estimate conditional probabilities and apply thin plate regression splines, a 
technique for data interpolation and smoothing (22), within the logistic models due to 
nonlinearity of the relationships between the variables. Similar models are used in the 
analysis of surveys conducted in the USA (23). However, the consumption of cigarettes 
varies throughout the world, and our representation of the experience in Germany provides a 
valuable addition to our understanding of the smoking trends.  
The results of this study include estimates of smoking initiation probability, smoking 
cessation probability, current and former smokers’ prevalence and smoking intensity. For 
instance, the highest probability of starting smoking is estimated to be between the age of 16 
and 18. Also, women in their 20ies and the elderly 60 to 65 years old have a higher 
probability of quitting smoking. Additionally, both men and women achieve the highest 
smoking intensity between 40 and 45 years of age. The graphical representations of the 
estimates provide an opportunity to explore the prevalence of active smoking and quit 




It is important to note, that the use of cross-sectional surveys in order to obtain longitudinal 
estimates such as the prevalence can be challenging. In our study, the estimation of the 
smoking trends in the early cohorts, which were only included in the survey at a higher age 
brings a critical bias. For example, in the case of the 1920 birth cohort, the participants were 
77 years old when the earliest survey was conducted in 1997. The bias is in favour of the 
participants that never smoked due to their likelier survival until 1997. The smokers of the 
1920 birth cohort had likely died because of the adverse health effects of cigarette smoking 
or other causes before the survey took place. Despite this limitation of our study, the 
projections for the recent birth cohorts comprise valuable inputs to studies of smoking trends. 
For instance, from the data created in this study researchers can estimate accumulated 
exposure to cigarette smoking and the risk of smoking-related diseases of people in 
Germany. As it is further described, the obtained gender-, birth cohort- and age-specific 
estimates of the probabilities of smoking initiation and cessation are applied as input values 
into a microsimulation model in order to predict future smoking behaviour of the modelled 
population and adjust the computation of individual probabilities of onset of lung cancer in a 
study which is dedicated to the economic evaluation of lung cancer prevention using lung 
screening with a computed tomography (CT) scan (Article 6). 
In the second study, “Analysis of driving factors of willingness to use and willingness to pay 
for existing pharmacological smoking cessation aids among young and middle-aged adults in 
Germany” (Article 2), we address smoking cessation as a target of a possible public health 
campaign. The main aim of the study is to collect data on willingness to use (WTU) and 
willingness to pay (WTP) for pharmacological aids to quit smoking. WTU and WTP are 
recorded as yes/no answers. Additionally, WTP is quantified using a contingent valuation 
method with payment cards (24) and categorised into 10-Euro intervals. The collected data 
are further statistically analysed to provide inference on the main drivers of the maximum 
price a current smoker would accept to pay. The odds ratios of WTP and WTU are estimated 
using logistic regressions which are the most popular models for dichotomous dependent 
variables such as yes/no records of WTU and WTP. The predictors are chosen based on the 
hypothesised relationships between the outcome variables and a set of characteristics that 
describe the socio-economic status of the respondents, their smoking habits, and their 
environment. We use another technique to analyse the dependent variable WTP, which is 
given as an interval variable. WTP bids are regressed against the same set of predictors 
using an accelerated failure-time model (25). Although being an unconventional technique to 
be applied for WTP, it allows the calculation of odds ratios in terms of WTP of a higher or a 
lower value using the intervals as the dependent variable (26). The model is informed with a 
Weibull distribution which gives the best approximation of the upper and lower values of the 




addiction level; however, the average measure of WTP is still below the market price for all 
therapeutic options. The findings of this study suggest that when aiming to reduce smoking 
exposure by means of pharmacological smoking cessation aids, policy developers should 
consider targeting the smokers with a higher addiction level and include measures which 
would decrease out-of-pocket payments, i.e. by lowering the effective price. The sample, 
however, is limited to young and middle-aged people and is not representative of the total 
German population. Further investigations in this direction would benefit from a larger and 
more heterogeneous sample of smoking individuals and a more thorough questionnaire 
which allows the exploration of non-monetary incentives for quitting smoking. Although it has 
not been done yet, the results of the study might be applied in a decision-analytic model as a 
preventive comparator to an intervention such as a lung screening program, that is, as 
another public health intervention that would target the reduction of exposure to the 
carcinogenic agents rather than the detection of lung cancer in an early stage.  
(2)  Analyses of data on healthcare costs and health-related quality of 
life (articles 3 to 5) 
 (2.1) Measuring healthcare utilisation, costs and health-related quality of life 
Cost data are commonly obtained by multiplying appropriate costs per unit by the quantities 
of healthcare resources utilised. The costing data used in economic evaluations frequently 
come from administrative databases collected by hospitals, statistics offices, and insurance 
companies (27). Alternatively, self-reported questionnaires present an opportunity to capture 
data on the patient costs and resource utilisation such as out-of-pocket expenditures, 
caregiver time, travel time and costs, as well as waiting time (28). These inputs are valuable 
when representing the cost side of disease and considering what intervention could save, 
from the societal perspective.  
Both methods of data collection have their advantages and disadvantages. The 
administrative data allow for a sufficient sample size needed to obtain representative 
estimates, but do not include complete direct and indirect patient costs and spent resources. 
The data collected using self-reported questionnaires might be of small sample size, 
unobtainable in a timely manner, and at risk of biases and distortions due to, for example, 
inaccurate recalls, sample selections, and survey processes (28). This might as well bring 
bias into an economic evaluation and impact the validity of the obtained conclusions. A 
survey using questionnaires for the evaluation of resource utilisation is often accompanied by 
other questionnaires for measuring health-related quality of life which is quantified either with 
a generic preference-based instrument such as EQ-5D (EuroQol five dimensions) or with as 
a disease-specific instrument. The former instruments are commonly used in health 




In this thesis, three studies illustrate analyses of data collected with the goal to capture costs 
and quality of life of patients using self-reported questionnaires:  
The study “Social/economic costs and health-related quality of life in patients with juvenile 
idiopathic arthritis in Europe” (Article 3) reports the data collected from patients with juvenile 
idiopathic arthritis (JIA) from several countries of Europe. The survey captures data on 
resource utilisation by and outcomes for the patients and caregivers, providing an insight into 
additional societal losses due to JIA. The study demonstrates a considerable increase in 
annual healthcare costs for JIA patients compared to other published studies. The reasons 
for these estimates are the inclusion of costs of non-professional caregivers, usage of 
biologics, and longer hospital stays. The study also measures the impairment of quality of life 
of the patients as well as the caregivers, showing that the costs and outcomes of non-
professional caregivers should be included in economic evaluations of interventions against 
JIA. Due to a low response rate, the collected dataset is of small size (total of 161 patients) 
and shows heteroscedasticity of the age variable. Therefore, no regression is applied. 
Economic evaluations, however, require a range of valid cost estimates across population 
groups and in order to produce more informative analyses a larger and a more 
representative sample would be necessary.  
(2.2) Statistical analyses of healthcare costs and health-related quality of life 
The following two studies examine a dataset obtained during a 96-week longitudinal survey 
of people living with HIV in Germany: “Cost and Resource Utilization Study in Antiretroviral 
Therapy (CORSAR)”. Data were collected in eight healthcare providers and present a 
sample of 1154 HIV-infected individuals in Germany which is considered to be a 
representative sample (around 2% of people living with HIV and AIDS in Germany). 
Demographic, clinical, and medication data were obtained using a standardised patient 
questionnaire.  
In the paper “Analysis of contemporary HIV/AIDS health care costs in Germany: driving 
factors and distribution across antiretroviral therapy lines” (Article 4) we analyse observed 
costs and resource usage attributable to an HIV infection. For this analysis, resource 
utilisation and healthcare expenditures are summarised into annual total costs calculated 
with a bottom-up approach. The total costs include both direct (medical and non-medical) 
and indirect costs for the selected patients with HIV. All costs are calculated based on price 
information obtained from publicly-available databases. Annual total costs in the resulting 
dataset are modelled as the dependent variable. The aim of this study is to investigate 
relationships between the mean annual total costs and the characteristics of the patients with 
a positive HIV diagnosis. An initial investigation of the distribution of the costs data shows 




examining costs and resource usage in healthcare (29). Other characteristic difficulties of 
cost data are multimodality, missing observations, outliers, and excess zeros.  
The following classes of estimators are employed in the publication: a linear regression using 
log-transformation of the cost data and generalised linear models (GLM) with logarithmic link 
functions. These include models common to the medical and econometric literature. GLMs 
are convenient for statistical analyses of cost data in healthcare due to the possibility of 
linking non-normal dependent variables to linear combinations of independent characteristics 
(29). In a generalised linear model, predictors are combined additively as in the linear 
models, and the properties of the response variable are characterised by the particular 
distribution (mostly from the exponential family of distributions). Additionally, the variance is a 
function of the mean, and the link function determines the appropriate scale (30). In the 
study, two generalised linear models are compared, each with a logarithmic link function and 
with conditional distributions that are inverse Gaussian and gamma. The inverse Gaussian is 
applied to report the results because it provides a better fit and approximation of the 
CORSAR cost data.  
The added benefit of the application of GLMs with logarithmic link functions is that the 
estimates of the coefficients are interpretable as the logarithm of a relative change in the 
mean cost associated with a one-unit change in the predictor variable. Therefore, using the 
estimates of the regression coefficients and the covariance matrix we can describe the 
relationship between the costs and the patient characteristics in terms of relative cost ratios, 
i.e. how the annual costs would change relative to the mean costs of the reference patient 
when one or more patient characteristic is varied. The obtained cost ratios can also be 
transferred to other populations with reasonably similar socio-demographic settings. 
The study, however, could provide more information if the survey included questions about 
the path of the HIV-transmission and the patients who have not received combined 
antiretroviral therapy (cART). Despite some limitations, the study shows possible ways to 
optimise the costs of HIV-care and clinical practice. For example, the prescription of non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens can result in lower total 
costs compared to the standard protease inhibitor regimens. Also, management aiming to 
improve adherence and further development of cART regimens with enhanced forgiveness 
(meaning the ability of antiretroviral therapy to sustain viral suppression, despite insufficient 
adherence) have a potential to prevent part of the high-cost cases of HIV treatment. These 
measures should be seen as necessary elements of strategies in the management of HIV 
infections.  
In the subsequent study “Estimation of utility values and factors driving health-related quality 




cohort study” (Article 5), we analyse data collected on the quality of life of the participants in 
the CORSAR survey. Health utilities are measured using the generic preference-based 
instrument, EQ-5D-3L, and therefore can be applied in calculations of the health outcomes in 
health economic evaluations of interventions targeting HIV management and prevention. 
Health utilities are valuated using time trade-off (TTO) method and quality of life with the 
visual analogue scale (EQ-VAS). We provide a comprehensive descriptive analysis so that 
the reported health utilities estimated across varying HIV-related health states (CD4-T cell 
count, CDC (The Centers for Disease Control and Prevention) classification, comorbidity, 
etc.) as well as demographic and therapeutic (treatment regimen) characteristics can be 
applied in further research. 
Additionally, we perform a regression analysis seeking to identify factors that are associated 
with the quality of life of people living with HIV and AIDS in Germany. The utility values, by 
definition, are bound between 0 and 1. Therefore, the chosen regression model has to 
perform well in terms of bias and precision, given the bounded nature of the dependent 
variable. A generalised linear model is chosen to regress the utility outcomes against patient 
characteristics with the application of a three-parameter beta-inflated distribution for the TTO 
values and a four-parameter beta-inflated distribution for the EQ-VAS values (31). The beta 
distribution is a common choice to approximate the values in a range of 0 to 1 and is often 
applied in the analysis of health utilities in health economics (7). The independent predictors 
are chosen based on the previously published review of major factors influencing the quality 
of life of people living with HIV and AIDS (32). As results, we obtain an explanatory model of 
the health-related quality of life and measure the relationships between the utility values and 
a wide set of patient characteristics. The overall results present a quantification of the quality 
of life impairment and can be applied as such in further studies in the field. The main 
limitation of this study is the application of the single EQ-3D-5L instrument without 
complementing it with an HIV-specific instrument. It is, however, somewhat inconvenient for 
the participants of a survey with self-reported questionnaires to fill out multiple forms. The 
main contribution of this study is the representative estimates of utility values over multiple 
health states for people living with HIV and AIDS in Germany.  
With the development of strategies to manage an HIV-infection as a chronic condition and 
with the ongoing search for therapeutic agents and vaccines, the results of both studies 
provide valuable input parameters for costs and health outcomes in health economic 
evaluations. Additionally, the estimated distributions will facilitate probabilistic sensitivity 
analyses. For example, this work is being continued with an ongoing study which conducts a 
health economic evaluation based on a dynamic-transmission model of HIV pre-exposure 





B. Synthesising evidence about complex public health interventions: 
contribution of decision-analytic models  
(1)  Application of decision-analytic modelling in the evaluation of a 
screening intervention (article 6) 
The study entitled “Trade-off between benefits, harms and economic efficiency of low-dose 
CT lung cancer screening: a microsimulation analysis of nodule management strategies in a 
population-based setting” (Article 6) examines probable outcomes of the introduction of a 
screening program for non-small cell lung cancer in Germany. Questions such as “What are 
possible screening strategies?”, “What are the payoffs of the alternative screening 
strategies?”, and “What is the most effective and cost-effective strategy?” are addressed and 
answered. A decision-analytic approach is employed in this study to assess the payoffs of 
different possible screening strategies and to suggest an optimal program. For that, an 
individual-based simulation (microsimulation) model of modular design is developed, which 
serves as the basis for the subsequent economic appraisal. The following considerations 
need to be addressed before designing the microsimulation model.  
Lung cancer is a non-communicable, i.e. non-transmittable disease, which may be caused by 
multiple factors. Also, it is non-curable in its late stage. Often the symptoms of lung cancer 
resemble other obstructive lung diseases which may lead to delays in the diagnosis and a 
lower survival rate (33). Screening aims to detect cancer in its early more treatable stage in 
individuals who are at risk but yet show no clinical symptoms, thereby reducing lung cancer 
mortality. The main health risk, which is linked to the onset of malignancy in the lungs, is an 
intensive exposure to tobacco, which is clinically quantified as pack-years. Therefore, 
smoking behaviour was included as the major hazard predictor and a selection factor for the 
screening.  
At the time of the study, two ongoing clinical trials of lung cancer screening with CT present 
their findings: the Netherlands-Leuvens Screening Trial (NELSON) in Europe (34) and the 
National Lung Screening Trial (NLST) in the USA (35). In the trials, the screening strategies 
comprised of eligible age, exposure to tobacco smoking, screening intervals, and a 
description of steps on how to proceed with a CT finding, defined in a so-called nodule 
management protocol (NMP). The clinical trials use different selection criteria and nodule 
management protocols with different approaches to the quantification of nodules size and 
growth (which define probable malignancy), numbers of follow-up CT scans, and work-up 
procedures. The inferences about possible malignancy in NLST are based on the diameter of 




is assessed and two measures of growth are used: a 25% increase in volume and a growth 
rate as volume doubling time. The insights on the clinical outcomes of the two different 
approaches show the importance of the eligibility criteria and the nodule management 
protocol: comparing to NELSON, NLST reports a greater number of false-positive outcomes. 
False-positive outcomes and overdiagnosis both lead to redundant diagnostic and 
therapeutic procedures, which in turn increase costs and reduce the quality of life, constitute 
harms of screening. Whereas cured cases, decreased mortality and, although not considered 
in this study, detected other lung diseases are the benefits it provides.  
An evaluation of the results of the trials provides sufficient evidence to address the decision 
problem of whether to implement lung screening or not. However, the consideration of the 
differences in the outcomes of the two trials makes it difficult to choose an optimal strategy 
for implementation, to provide a generalisation of the payoffs, as well as to evaluate other 
possible strategies. These points can be addressed using decision-analytic modelling.   
Fine-tuning of a possible screening strategy requires the simulation of variations of the key 
characteristics as well as the comparison of their positive and negative health outcomes and 
costs. This depends on the eligible age range, exposure to smoking (pack-years and the 
maximal number of years since quitting for former smokers), and nodule management 
protocol (NELSON or NLST approach). For example, the upper limit of the age range of 
eligibility for screening may reduce the cases of overdiagnosis and the nodule management 
aids in the interpretation of the results seen during a CT test to determine malignancy.  
The choice of a microsimulation model is guided by the gradually progressive course of 
cancer and its non-transmittable nature, i.e. there is no need to simulate interactions 
between individuals to represent its epidemiology. In addition, microsimulation models 
constitute a practical tool for combining information from a wide range of sources, including 
clinical trials, demographic data, and simulated data. In this study, the model consists of the 
following six structural modules interacting with each other to represent the epidemiology of 
lung cancer: natural history, population, clinical detection, survival, screening, and life history.  
The natural history module is a reconstruction of the natural course of cancer development 
mathematically formulated as a set of equations with stochastic assumptions which return 
individual trajectories from a disease-free state to death. The foundation of the natural history 
model is the biological two-mutation model of carcinogenesis published by Moolgavkar and 
Luebeck in 1990 (36). This model comprises of probability generating functions where age, 
gender and personal exposure to cigarette smoke are translated into the piecewise constant 
parameters of the hazard functions.  
The respective input values are generated by the population module which reconstructs the 




age and produces as output age and exposure to tobacco at each point of time in the 
simulation. As it is described before, the data of the three RKI surveys are used to elicit the 
trends of smoking behaviour in the German population and to project them further. The 
natural history module returns the time (age) of onset of malignancy, the histology of cancer, 
its growth, lymph nodes involvement, and metastasis – these output values are observed 
with a time of the event in the model simulation but cannot be observed in reality. These 
processes are latent and underlying the clinical diagnoses through symptoms in the standard 
care, which are the observed data. 
The module of clinical diagnosis is also formulated as a stochastic process. It is informed by 
the natural history module and returns the number of diagnosed cases, histology, size, and 
tumour-node-metastasis stage of cancer. Thereby it adds another step in an individual’s 
trajectory.  
The natural history and clinical diagnosis modules include a set of unknown parameters of 
the distributions used in the model which are not directly observed and therefore need to be 
fitted. Examples for this are the distribution of the tumour volumes at the time of clinical 
diagnosis, the distributions of the threshold volumes of lymph nodes involvement, distant 
metastases as well as age- and cancer type-dependent malignant conversion rates. The 
data on age and cancer type-specific annual incidental lung cancer are obtained from a 
population-based survey of 132,612 lung cancer patients conducted in Germany between 
2010 and 2012.  
The screening module is designed to allow for the fine-tuning of a screening strategy, so it 
detects as many as possible of the simulated cancers in their earlier stage but minimises the 
numbers of false positives and overdiagnoses. It comprises of several structural 
components: eligibility assessment, screening-detection, nodule management (including 
follow-up), diagnostic work-up, and lung cancer survival. The module is structured to 
replicate the nodule management protocols of NLST and NELSON, which can be varied in 
their underlying parameters according to a formulated strategy. The simulation of individual 
trajectories continues with the screening history, which returns the results of the screening: 
screen-diagnosed malignancy, its size, stage, and survival outcome. The survival module is 
a relatively straightforward application of known and observed probabilities of survival based 
on the cancer stage. 
The output values of the microsimulation model for all variations of the screening strategy 
and the no screening scenario inform the economic model which consists of computation of 
costs of screening, follow-ups, diagnostic work-ups, and treatment as well as health benefits 




discounting is applied in the calculation of the cost-effectiveness ratios (as costs per life-year 
gained (LYG) in comparison with no program).  
The uncertainty is explored by means of one-way sensitivity analyses with varying 
assumptions about CT sensitivity parameters, parameters of long-term survival after the 
screening, attendance rate, cost per CT exam, and lifetime treatment costs. The stochastic 
nature of the developed model and the large population included in the simulation also cover 
the variation of outcomes due to the uncertainty in the biology of cancer. We, therefore, 
concentrate on altering the deterministic parameters and documenting variations of 
effectiveness and cost-effectiveness of the screening strategies. The economic evaluation 
resulted in two efficiency frontiers which represent weighting two major benefits of screening 
(LYG and averted lung cancer deaths) against the resulting costs.  
We find that the strategy setup of NLST is less efficient than other strategies proposed in our 
study. We also show that efficient scenarios include the volumetric assessment of the nodule 
size, i.e. the NELSON approach to the nodule assessment and conclude that changing the 
threshold values of the volume to 300 mm3 and the volume doubling time to 400 days would 
result in a more sensitive NMP. The nodule management protocol is shown to be a critical 
component in the search for an optimal strategy, which would minimise not only the cost-
effectiveness ratio but also balance beneficial and harmful health outcomes. Incremental 
cost-effectiveness ratios of the efficient scenarios were 16,754–23,847 Euro per life-year 
gained and 155,287–285,630 Euro per averted lung cancer death, which in general could be 
considered cost-effective in Germany.  
To sum up, the application of the microsimulation model allows optimising the screening 
strategy, which would otherwise not be feasible within the two major clinical trials. We 
conclude that the screening would be necessary, effective, and cost-effective; however, 
careful consideration of the eligibility criteria and the nodule management protocol is required 
before the implementation of screening in the clinical practice. This model can be further 
used to evaluate other screening strategies, to consider alternative comparators as well as it 
can be tailored to examine other hazardous effects such as the exposure to carcinogenetic 
elements of environmental or occupational origin.    
(2)  Application of decision-analytic modelling in the evaluation of a 
vaccination program (article 7) 
Vaccination is one of the most effective preventive measures of public health systems. 
Vaccines can save lives, decrease utilisation of healthcare resources, and improve quality of 
life. However, not all vaccination programs are economically reasonable. Vaccination policies 
usually target a large group of a population aiming to reduce the transmission of an infection 




this group, the introduction of a vaccination against it will require resources without providing 
sufficient benefits. From another side, even if the prevalence is high enough but the vaccine 
efficacy is low, it will come to the same inefficient result. 
Clinical evidence of efficacy of vaccines is generated in clinical trials, however, comparing to 
the real settings of the general population where the vaccine is to be introduced, clinical trials 
cover only a limited sample of the population and may run too short to capture all the effects 
of a vaccination program. Mathematical models of infectious diseases, which incorporate the 
evidence generated in clinical trials in their structure, can provide needed generalisations, 
projections over a longer time horizon, and simulate multiple vaccination alternatives. They 
provide therefore powerful and useful tools for assessing the epidemiological and the 
economic impacts. The outputs of adequately built and validated decision-analytic models 
are valuable for policymakers of national vaccination programs. They provide estimates of 
morbidity and mortality averted, prevented healthcare resource utilisation and saved quality-
adjusted life-years, budget impact, effectiveness and cost-effectiveness output, all necessary 
inputs in planning, as well as decisions on further additions to the national vaccination 
policies. In Germany, the Standing Vaccination Committee at the German Robert-Koch 
Institute (STIKO) is the main decision-making body on the national immunisation programs 
since August 2006. In the appraisal of and decision on vaccination programs, the Committee 
uses estimates of disease burden as well as expected epidemiologic and health economic 
impacts of vaccination alternatives for the German healthcare system. STIKO has issued a 
methodological paper with guidelines for modelling projections of epidemiologic and health 
economic effects of vaccinations for decision-making (37). It shows the increasing 
importance of decision-analytic models in public health policy-making in Germany. 
One study included in this thesis is conducted to support the decision-analysis of the STIKO. 
In the study “Pneumococcal Disease in Adults: a health economics evaluation of various 
vaccination scenarios in Germany” (Article 7), we address the decision problem about 
vaccinating German elderly with 13-valent pneumococcal conjugate vaccine (PCV13) which 
is widely used in children programs but only recently approved for the older population. The 
STIKO recommends the routine vaccination of children with PCV13 against pneumococcal 
infections; however, at the time of the study, no recommendation about the elderly 
vaccination with PCV13 was issued.  
The methodology of the analysis adopts a cost-utility approach to evaluate the elderly 
vaccination with PCV13 and whether it is beneficial for the society to replace the currently 
recommended 23-valent pneumococcal polysaccharide vaccine (PPSV23). An underlying 




with Streptococcus pneumoniae (S. pneumoniae) in the German population and the 
epidemiological impact of the vaccination alternatives.  
Pneumococcal infections present modellers with multiple challenges of formulating a 
mathematical representation of the epidemiological system. These include: (i) the existence 
of over 90 serotypes of the bacteria with different pathogenic potential and prevalence, (ii) 
the ability of the bacteria to colonise the nasopharynx of individuals without making them 
sick, (iii) the transmission via airborne droplets, (iv) the fact that infected and colonised 
children are the source of transmissions to adults, and (v) the possibility of invasive and non-
invasive diseases. Moreover, the dynamic epidemiological system of pneumococcus in 
Germany has undergone a disturbance induced by the immunisation programs in children, 
firstly, with PCV7 and then with PCV13. As in other countries, in Germany, childhood 
vaccinations have led to an indirect decline in invasive and non-invasive infections (caused 
by the serotypes contained in the applied vaccines) in the unvaccinated adults. This indirect 
effect is mainly caused by the vaccine-induced reduction in the carriage and the transmission 
of vaccine serotypes from children to adults. This reduction of the PCV7-serotypes created 
an ecological niche which serotypes not covered by the vaccine were able to occupy, leading 
to a considerable increase in infections attributable to non-vaccine serotypes. These two 
opposing effects are known as herd immunity effect and replacement effect induced by a 
large-scale vaccination. The indirect effects of the childhood immunisation program are 
observed in the data on the elderly where the incidence of vaccine-preventable infections 
has decreased and, as a consequence, so has the potential beneficial effects of the 
introduction of the same vaccine in the elderly. The indirect effects observed in the 
epidemiology strongly influence the outcomes of the cost-effectiveness assessment. 
Therefore, a dynamic transmission model is adopted to represent the epidemiology of S. 
pneumoniae in the German population. Transmission models incorporate interactions 
between individuals and allow the modelling of dynamics of serotype competition for the 
colonisation, herd immunity and replacement effects as well as the natural course of 
infection. The structure comprises of the following compartments or states where the 
modelled population spends its modelled time governed by rules of transitions between 
them: (i) susceptible, (ii) colonised carriers of one or two serotype groups, (iii) cleared of 
carriage, (iv) infectious, (iv) invasive or non-invasive diseased, (iv) recovered and, (v) dead. 
The vaccination is modelled as a reduction of the probability to be ill from invasive or non-
invasive diseases caused by the vaccine-covered serotypes. According to the current 
knowledge, the vaccine protection is modelled to wane over time which corresponds to the 
inverse of the expected duration of immunity.   
The population is of a simplified structure and modelled as 400 age classes, each containing 




the epidemiological model, the simplified population structure, as well as the grouping of the 
serotypes, are required to create a steady-state with a reasonable computational effort. The 
transmission probability is governed by a so-called force of infection function, which 
represents “effective” contact rates between the compartments leading to colonisation or 
infection. The demographic contact rates are estimated using the statistical approach of 
generalised additive models with thin plate regression splines as the smoothing term using 
the contact data collected within a large survey conducted in Europe (38). The parameters 
which model the effective contact, i.e. transmission of infection per contact cannot be 
observed and have to be elicited through the fitting of the model to the observed incidence 
data using Markov chain Monte Carlo method. The mathematical formulation comprises of a 
large system of ordinary differential equations which can be solved using numerical methods. 
The developed epidemiological model simulates the carriage states, the direct and indirect 
effects of the childhood vaccination with PCV7 in the years 2004 to 2009 and consequently 
with PCV13 in 2010 till 2015 as well as the direct effects of alternative vaccination scenarios 
on the epidemiology in the elderly. The results are age- and serotype-specific pneumococcus 
carrier prevalence and incidences of pneumococcal infections as functions of time. 
The epidemiological output values for different vaccination strategies serve as inputs into the 
consequent health economic analysis. The age-specific numbers of infections are used to 
calculate and predict over the lifetime horizon the number of invasive and non-invasive 
cases, hospitalisations, disease-caused deaths, (discounted) quality-adjusted life-years 
gained, healthcare utilisation, total costs for each program, as well as cost-effectiveness 
ratios using the current program with PPSV23 as a central comparator. To further assist the 
STIKO in the decision process, additional measurements of vaccination performance are 
computed. These include number needed to vaccinate to prevent one case of infection or 
disease-related death, the impacts of the age at vaccine administration, and the impact of the 
frequency of revaccination on the outcomes. 
The results suggest that, in terms of effectiveness, the vaccination scenario of PPSV23 being 
followed by vaccination with PCV13 (sequential vaccination) would have the largest 
preventive effect on the infections and deaths. Meanwhile, the vaccination with PPSV23 
would be more efficient based on the number needed to vaccinate in order to prevent one 
pneumococcal infection or one death. The economic analysis shows that using PPSV23 for 
the vaccination would require considerably fewer resources and costs than the sequential 
scenario. Moreover, for PCV13 due to the weaker effects through herd immunity and its 
higher price, using PCV13 in the vaccination of the elderly (77,000-92,000 Euro/QALY 
gained) is considered not cost-effective compared to the vaccination with PPSV23 (36,000-




that the implementation of a revaccination scheme would be more efficient. In conclusion, the 
economic evaluation suggests that vaccination with PPSV23 at age 60 being followed by 
periodic revaccination with PPSV23 every six years after the initial vaccination should be the 
preferred strategy. Based on the evidence, the STIKO currently recommends this vaccination 
program for the elderly in order to prevent pneumococcal infections (39). 
Future directions for research should include studies which evaluate the vaccines that are 
currently being developed as well as represent the pneumococcal epidemiology more 
detailed. The recent epidemiological data suggest that a few serotypes (e.g. 3 and 19A) (40, 
41) which are covered in PCV13 persist and are less affected by the vaccination in children. 
Accurate representations would require the modelling of the epidemiology of these serotypes 
separately from the others and would need data on the serotype-specific carriage and 
infection incidences. Additionally, this study points out the necessity of observational studies 
to examine in greater detail the vaccine effectiveness against non-invasive pneumococcal 
diseases. The availability of data will facilitate more accurate decision-modelling and the 
implementation of more effective vaccination strategies.  
 
C. Application of decision-analytic modelling in health economic 
evaluations 
(1)  Application of decision-analytic models as a basis for health 
economic evaluations (article 8) 
Although the application of decision-analytic modelling has become widespread in health 
technology assessments (HTA), in Germany, the use of DAM is not yet required for decision-
making in the healthcare sector. In the study “The Role of decision-analytic modelling in 
German health technology assessments” (Article 8), we examine the application of decision-
analytic models, and its impact on the evidence provided in HTA reports published by the 
German Institute of Medical Documentation and Information (DIMDI) – one of two leading 
HTA organisations in Germany. The second organisation is the Institute for Quality and 
Efficiency in Healthcare (IQWiG) which at the time of our study did not carry out economic 
evaluations. Therefore, we did not consider its database. In this review, 107 HTA reports 
published between 1998 and 2012 are examined for the purpose of assessing the quality of 
the conclusions they provide. In this selection, 17 HTAs applied DAM for the economic 
evaluation and, compared to others, report evidence of higher relevancy for decision-making. 
Additionally, 24 studies of a lower quality point out that the application of DAM would likely 
improve the relevancy of the evidence provided in the respective economic evaluation. 




may in turn influence decisions about the program implementation, resource allocation or 
provide the basis for future research. We also examine the developed decision-analytic 
models in the selected 17 HTAs and conclude that the applied methods differ in the 
dimensions of economic analyses (such as perspective, measures of effectiveness, 
discounting, and sensitivity analyses) probably due to the absence of methodological 
requirements on the part of DIMDI. 
(2)  Validity of evidence for decision-making produced using decision-
analytic-modelling in economic evaluations (article 9) 
This section continues the discussion about the application of decision-analytic models for 
the assessment of vaccination programs. Although decision-analytic models have been 
widely applied in health economic evaluations of vaccines, comparatively little attention has 
been paid to the issues around potential biases and misleading interpretations they may 
evoke.  
In the study “Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of 
Higher‑Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature 
Review with Focus on Methods and Assumptions” (Article 9), we review and summarise the 
results of modelling studies which evaluate the cost-effectiveness of the elderly vaccination 
against pneumococcal infections. Additionally, we assess the validity of these studies based 
on the assumptions and methods the researchers apply in the construction of their decision-
analytic models. This study is motivated by ongoing debates around the cost-effectiveness of 
the elderly vaccination with PCV13 which continues even after the clinical trial “Community-
Acquired Pneumonia Immunization Trial in Adults” (CAPiTA), which presents its results about 
the efficacy of PCV13 in the elderly. In contrast to earlier studies, several recently published 
economic evaluations demonstrate that PCV13 may not be cost-effective when children are 
routinely vaccinated with higher-valent pneumococcal conjugate vaccines such as PCV10 
and PCV13. We look at the economic evaluations which have been published after the 
results of CAPiTA and aim to gain an insight into the driving factors for differences in the 
respective conclusions. We separately examine the assumptions and inputs of the 
mechanistic models which simulate the epidemiological setup as well as of the economic 
models which weight the costs against the benefits of alternative strategies. Both directly 
drive the outcomes of cost-effectiveness analyses; however, the former can be easily 
overlooked when interpreting the results of the analyses. 
In order to assess the validity of the authors’ respective methodological choices for the 
epidemiology, we conceptualise key components of a model for the epidemiological setup of 




children on the vaccine-preventable infections in the adult population, i.e. indirect effects, and 
the duration of vaccine protection in vaccinated adults (Figure 3).  
 
Figure 3: Constituents of the vaccination effects over time: a graphical representation.  
The outcomes of the elderly pneumococcal vaccination depend on the initial vaccine 
effectiveness against vaccine-type pneumococcal diseases (PD) and its protection over time 
(illustrated in B) and the PD incidence caused by vaccine-type serotypes over time, which is 
also influenced by the indirect effects of childhood vaccination with PCV (illustrated in A). 
Asterisk: vaccination rate assumed to be 100% and vaccine effectiveness, according to B. 
Source: Article 9, Figure 1. 
The combination of these two integrals majorly drives the epidemiological system and the 
outcomes of the vaccination. The indirect effects of the childhood program include the herd 
immunity, which impacts not only infections in the children but also in the adults with whom 
the vaccinated children have contact. The herd immunity reduces the probability of 
transmitting the bacteria to the adults and leads to an indirect decrease in the incidence (see 
Figure 3, panel A). Although it does not make the adults immune to the infection, the herd 
immunity provides indirect protection and makes the direct vaccination less effective: the 
number needed to vaccinate in order to prevent one case becomes higher, which translates 
to higher costs needed to provide additional benefit. Therefore, a thorough investigation of 
the underlying epidemiological outlook in the population is highly important before devising a 
model which is supposed to accurately represent it. In this review, we find several 
methodological approaches to reproduce the herd immunity effects of childhood vaccination. 
Although the incidence rates of infections with S.pneumonia are comparatively well-reported 
and analysed, the reconstruction of the epidemiology in a model is complicated. This is due 
to numerous uncertainties in the interconnecting elements of the infection transmission and 
its spreading, which are not directly observed and measured. 
To begin with, there exist over 90 different strains (serotypes) of S.pneumonia, with several 
of them having a higher potential to cause the disease and a higher prevalence in the 
susceptible groups. Thirteen of them constitute antigens in PCV13 and 23 in the PPSV23 
vaccine. The epidemiological surveillance rarely provides numbers on prevalence and 
incidence of each serotype, therefore, modelling the serotype-specific epidemiology is very 




modelling purposes. Another factor which complicates the modelling is the data we observe, 
i.e. the surveillance data commonly records the disease cases but not the infections and the 
carriage. In contrast, a dynamic-transmission model represents the epidemiological 
circulation and the transmission process (including herd immunity) which leads to the cases 
of the disease. The types of models, which do not simulate interaction, do not include the 
indirect effects of the childhood vaccination in their structure which results in assumptions 
having to be made. Under these circumstances, the separation of the serotypes, i.e. a 
serotype-specific approach, plays a crucial role, because when assuming an indirect 
reduction in the vaccine-preventable incidence in the adults due to the childhood program it 
is reasonable to suggest that this reduction only occurs in the cases caused by the types 
which are included in the childhood vaccine. The time-varying decrease of the vaccine-
preventable serotypes in the overall serotype distribution is not accounted for in serotype 
non-specific approach, which, therefore, would lead to a considerable underestimation of the 
herd immunity.  
On the other hand, vaccine efficacy and its protective impact (Figure 3, panel B) directly 
define the number of preventable cases which in turn translates into vaccination-preventable 
costs of care and quality of life impairment. CAPiTA provides clinical evidence for PCV13 
vaccine efficacy and its stable protection over five years in adults over 60 years of age. 
However, the follow-up period is too short to capture the full length of the protective effects of 
the vaccine. Therefore, the modelling of the protective effects, i.e. the duration of the 
protection, is subject to assumptions. Additionally, CAPiTA provides little evidence about the 
age-dependency of the vaccine efficacy. Thus, assumptions for the age-dependency of the 
vaccine efficacy and for the duration of the protection of PCV13 are examined in our review. 
In order to be able to compare these assumptions, we define a measure that reproduces the 
total protective effect of the vaccine – the expected vaccine protection over time (EVPOT). It 
is calculated by integrating the years of protection adjusted for the vaccine efficacy at a given 
point in time which is represented by a waning curve. EVPOT is measured in efficacy-
adjusted protection years (EAPY) and quantifies the assumption about the initial vaccine 
efficacy and the waning of its protection in one number, which makes comparative analyses 
and visualisations easier. Figure 4 represents a variety of approaches to the modelling of 
vaccine protection that the authors used. Some studies simulate EVPOT of 3.75 EAPY and 





Figure 4: Representation of constructed waning patterns reported in the selected studies by the first 
author, vaccine, and age group (when reported).  
Source: Article 9, Figure 3. 
The methodological choices in modelling the herd immunity and the vaccine protection over 
time along with every key dimension of the economic evaluation are summarised and 
assessed in terms of transparent and complete reporting as well as relevancy and validity for 
decision-making. The detailed assessment is conducted using the “Evidence and Value: 
Impact on DEcisionMaking”(EVIDEM) (42) instrument which is adapted to the goals of the 
review where the section devoted to the parameters and methods is extended to assess the 
validity of the methodological choices made for the modelling of the epidemiological setup 
and vaccination effects over time. EVIDEM allows for transparent work of the reviewers and 
provides a framework for the assessment of the quality of the economic evaluation across its 
key dimensions. We use its scoring system to categorise the evaluations into the higher and 
lower quality and report the cost-effectiveness estimates provided by the studies of higher 
validity. Four out of 13 studies are considered of lower quality, i.e. the derived conclusions 
are judged to be questionable and misleading due to the applied methodological choices and 
assumptions. Three of these studies assess the cost-effectiveness of PCV13 in the elderly 
and conclude that PCV13 was highly cost-effective under the ongoing herd effects of the 
childhood program with PCV13. These studies are seen to underestimate the indirect 
reduction of the incidence due to the PCV13 program in children and possibly, in 




the elderly vaccination. Although these evaluations are funded by the industry, we could not 
elicit a funding bias because other studies, which are also industry-supported, are of a higher 
quality. We consider the other nine studies to be fit for the purpose of vaccine evaluation and 
summarise their results. These results, however, do not provide a straight forward conclusion 
and an overall agreement that the usage of PCV13 in the elderly is cost-effective, but they 
suggest that the outcomes cannot be easily translated from one epidemiological setting to 
another and are driven by the predictions of the pneumococcal disease incidence and the 
estimates of the pneumococcal vaccine effectiveness over time.  
Although within the scope of the review, we cannot elicit a relative contribution of each factor, 
we emphasise the importance of understanding of the methods and assumptions applied in 
the modelling behind the economic calculations. Numerous uncertainties and methods to 
address them have to be well communicated to decision-makers.This would require the 
authors to provide a transparent report of their work and to properly validate their models. 
Without properly conducted adequate justification of the applied methods, inputs, and 
assumptions, there is little basis for decision-makers to have confidence that the results of 




















3. Results and outlook on further research needs 
Currently, the healthcare sector collects and possesses an increasing amount of observable 
data on healthcare production, insurance services, epidemiological surveillance, clinical 
research, and social processes. Decision-makers constantly face a challenging task of 
navigating through the emerging evidence while it is the task of researchers and practitioners 
of health economics to provide them support in evidence-based rational decision-making. 
Health economics possesses a wide spectrum of methods and techniques which can be 
used in a variety of decision-making problems. On the one hand, the application of statistical 
methods to healthcare data allows synthesising evidence and putting it together in a 
comprehensible way in order to devise clinical practices and public health policies. Methods 
of health economic evaluation in conjunction with decision-analytic modelling, on the other 
hand, integrate new evidence and observable data from a wide range of sources into one 
framework which enables a comparative analysis of alternative healthcare interventions in 
terms of both their costs and health benefits. Health economic evaluations result in 
estimations of the effectiveness of different courses of action and offer strategies with the 
best value for the money.   
The present thesis demonstrates the importance and capability of statistical and decision-
analytic modelling methods in generating evidence for rational decision-making in healthcare 
policy. Each study in this collection contributes to the current and future debates around the 
studied interventions as well as into the discussions about methods and study designs. Each 
paper includes a transparent reporting and rationale for the applied methods. The two papers 
which include decision-analytic modelling using complex methods describe the model 
structure, parameterisation, calibration of unknown parameters, and uncertainty analyses in 
great detail. 
The methodological approaches and results of the included studies contribute to answering 
the formulated research questions.     
What is the contribution of statistical models in the synthesis of evidence for health 
economic evaluations and decision-making in public health and the healthcare sector? 
This thesis contains examples of quantitative analyses starting with a simple descriptive 
analysis and ending with complex computational statistics. As it is shown, a mere description 
of a collected dataset has limits in its production of knowledge. Although observations are 
made and described, connecting these observations into an interpretation depends upon the 
application of inference statistics. Inference statistics offers a large variety of methods to 
analyse data of different types, whereas choosing the right approach determines the 
accuracy of the resulting explanatory or predicting statements. The datasets analysed in the 




self-reported questionnaires (Article 3), a multicentre prospective observational survey 
(Articles 4 and 5), and online interviews (Article 2). The analysed dependent and predictor 
variables vary in their nature; however, they can be seen as merely numerical or categorical 
vectors characterised by a certain statistical distribution, including concentrated values and 
influential outliers.  
For example, the two studies, which address smoking behaviour, examine datasets where 
the outcomes of interest are a measurement of the likelihood of an action, i.e. staring and 
quitting smoking at a certain age (Article 1) and of being willing to use and to pay for aid to 
cease (Article 2). Logistic regression models are applied in these studies to analyse the 
patterns in the data. The combination of the findings of these two studies may contribute to 
designing a policy which aims at a reduction or prevention of cigarette smoking. 
Policymakers can consider the fact that Germans at the age between 16 and 18 are likely to 
start smoking. Development of a preventive program could include, for example, an 
introduction of educative measures about the hazardous effects of tobacco consumption in 
this age group before the behaviour becomes addictive and more difficult to manage. 
Additionally, aiming at reducing the size of the peer group, as shown in the other study 
(Article 2), might increase the probability of a young smoker to use a smoking cessation aid.   
Two other studies (Articles 4 and 5) demonstrate the application of generalised linear models 
in the analyses of cost and quality of life data in HIV care. Both costs of care and quality of 
life outcomes are not normally distributed. The former due to a small part of the patients 
having high costs of treatment and the latter due to the measurement scale from 0 to 1. Not 
appropriately controlling for the nature of the data in the application of regression models 
leads to inaccurate information. In these studies, generalised linear models are used, which 
give a framework for the analyses of not normally distributed data of the costs and utility 
values without a transformation. The findings allow for an understanding of the influential 
factors and can contribute to the development of better HIV management programs. For 
example, (i) improving the adherence to medication and prescription of a medically justified 
NNRTI-based treatment could save costs, (ii) the development of treatment guidelines, which 
recommend the initiation of cART even in asymptomatic patients with normal CD4-T cell 
counts may reduce both the costs and quality of life impairment. They also contribute to the 
understanding of common methodologies used to address health economic data such as the 
utilisation of healthcare resources, costs and quality of life as well as provide detailed 
estimates of the cost of the disease and utility values which can be an important basis for the 
implementation of future health economic evaluations in the field of HIV care and prevention. 
These papers, therefore, show that the findings obtained using appropriate comprehensive 




value for clinical practice and policy-making. However, it is to be noticed, that when the data 
are incomplete or collected with shortcomings, the application of statistical analyses is limited 
in the answers it may provide. For example, the CORSAR survey does not include patients 
who are naïve to cART, making it impossible to investigate health-related quality of life and 
the costs in this group (Articles 4 and 5). Further, in the study which investigates smoking 
cessation aids the survey does not incorporate participants from higher age groups due to 
resource limitations resulting in a sample which is not representative for the German 
population (Article 2). From another side, the study which is based on three large population 
surveys conducted by the RKI also contains a bias despite its large sample size (Article 1). 
This bias originates from the inclusion of older people who are likely to be healthier because 
they survived until the beginning of the survey. The inclusion of these people in the statistical 
modelling can result in an underestimation of the prevalence of smokers in the early cohorts. 
Therefore, consideration of the statistical methods which are to be applied to analyse the 
data should be included in the planning of an observational study in the early stage along 
with the formulation of the policy-relevant research questions.  
What are the capabilities of decision-analytic modelling to synthesise evidence about 
complex public health interventions? 
Two studies which provide economic evaluations of two preventive public health measures – 
screening (Article 6) and vaccination (Article 7) – show the capacity of decision-analytic 
models to integrate data stemming from different sources into a system which simulates and 
extrapolates the epidemiological and economic effects of the interventions. The flexibility of 
the models facilitates comprehensive comparative analyses of alternative courses of action, 
using different health outcomes and comparators as well as examining the uncertainty of the 
results by varying input values. Using current clinical, epidemiological, biological, and 
demographic knowledge, we construct (i) an individual-based simulation model for the 
economic evaluation of a screening program to prevent lung cancer morbidity and mortality 
among smokers (Article 6), and (ii) a dynamic-transmission model for the evaluation of a 
vaccination program against pneumococcal infections in the elderly in Germany (Article 7). 
The availability of health economic inputs allows the estimation of the economic effects of the 
interventions across various comparative scenarios and uncertainty analyses. The 
elaborated models also facilitate fine-tuning the interventions and generalisation of their 
outcomes over the population groups and time horizons beyond the settings of the clinical 
trials. The findings of the economic evaluation of the screening have a great capability to 
guide policy-making in lung cancer prevention, whereas the economic evaluation of the 
elderly vaccination has been used in decision-making by the STIKO in her recommendation 
on pneumococcal vaccination. Although the developed decision-analytic models are highly 




epidemiologic and economic data, the models are to be updated to provide new predictions 
and include new scenarios. Additionally, structural uncertainty analyses have not been 
provided in these evaluations. In the modelling of infectious diseases (Article 7), individual-
based models can be applied to reproduce the stochasticity of individual contacts and 
disease transmission. However, the development of such a model would require more data 
on contacts (e.g. within households, weather dependent, etc.), demography and 
epidemiology. The current model for lung cancer screening does not include a treatment 
module and contains only life-years gained as the measure of health outcomes. The 
inclusion of the costs and quality of life data in the patients treated for lung cancer will 
produce a better representation of the reality and new estimates of cost-effectiveness.  
Does decision-analytic modelling as an instrument of health economic evaluations 
advance evidence synthesis for rational decision-making in public health and the 
healthcare sector? 
The review and analysis of DIMDI's HTA reports demonstrate that the relevancy and validity 
of technology assessments can be increased by including a decision-analytic model into the 
economic analysis (Article 8). It is, however, important to note that the development of a 
(complex) decision-analytic model involves structural and parametrical assumptions which 
can be decisively influential on the final outcomes and the message being given to the 
policymakers. As it is demonstrated in the review of decision-modelling based economic 
evaluations of the elderly pneumococcal vaccination programs (Article 9), the assumptions 
about vaccine effectiveness, duration of protection, choices of modelling the herd immunity, 
and the replacement effect determine the output values of the epidemiological models. 
Additionally, to the epidemiological outcomes, input values used in the economic analysis 
directly drive the estimates of cost-effectiveness. Therefore, careful consideration and 
justification of the chosen methods and assumptions, as well as a detailed investigation of 
structural uncertainty are necessary before reporting an evaluation which is intended to 
inform decision-making. When inaccurate and invalid assumptions are made in the structure, 
and for the input values, decision-analytic models become misleading instruments rather 
than powerful supporting tools and the message being communicated to decision-makers 
becomes of low value. In summary, it can be stated that decision-analytic modelling provides 
methods of great capacity in facilitating decision-analyses and supporting policy-making in 
Germany. 
Overall, statistical and decision-analytic models have become indispensable in health 
economic studies. Further production of knowledge relies on the availability and quality of the 
data. Although current data collected in Germany give an opportunity for comprehensive 




the surveillance systems, data collection, storage, and availability for research are required. 
The currently starting “age of big data” in the healthcare sector also requires a 
comprehensive mastering of the methodologies for research. 
Further development of mathematical methods and techniques of computational statistics, as 
well as biological and epidemiological knowledge, demand interdisciplinary approaches 
which go beyond the specialisation of individual disciplines. For example, developments in 
the field of mathematical biology can bring techniques for modelling cancers of various 
biology or approaches of molecular epidemiology can allow integrating the variation between 
different epidemics caused by shifts in viral genetics. Given the growing complexity of 
methods and the integration of a large range of data sources in healthcare, it is imperative for 
researchers to provide a transparent communication of the methods and assumptions on 
which their inferences are based. In turn, decision-makers should have a good 
understanding of the principles and the decision-analytic-modelling methods currently used 
in economic evaluations. Furthermore, the increasing methodological complexity will require 
advancing the knowledge and the competence of the decision-making bodies. This will 
improve critical appraisal of the developed models, allow rational decision-making, and 
optimised channelling of limited resources. Additionally, provided the existence of continuous 
technological progress in the healthcare and the growing demand for healthcare services, 
the methods of health economics will be required to provide possibilities for conducting 
studies which are not only directed to the achievement of technical and productive efficiency 
but also allocative efficiency, i.e. to generate a framework for decision-analyses across 
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Introduction and Aims: The prevalence of smokers in a population is an essential indicator of 
public health. Current literature lacks studies which capture smoking history summaries for 
different birth cohorts in Germany. This study estimates the age- and birth cohort-specific cig-
arette smoking patterns for Germany.  
Design and Methods: Data are obtained from cross-sectional surveys conducted in 1997–2012 
in Germany. Parameters of smoking behaviour were statistically estimated for the German 
1920–1980 birth cohorts and projected up to the year 2025. Estimated parameters include 
age- and cohort-specific smoking initiation probability, smoking cessation probability, current 
and former smokers’ prevalence, and smoking intensity. Thin plate regression splines and cu-
mulative logistic models were applied.  
Results: Smoking prevalence declines over time. People ages 14-18 are at the highest risk to 
start smoking regardless of the birth cohort. People are more likely to quit at ages 20-30 and 
at the age of transition into retirement (60-65). Increased smoking cessation among young- 
and middle aged people is the major driver of decreasing smoker prevalence. The average 
smoking dose is lower for the recent birth cohorts. Women show more complex patterns of 
smoking behaviour than men.  
Discussion and Conclusions: The obtained estimates of smoking behaviour can be used to 
optimize the current approach to smoking prevention and support further development of anti-
smoking interventions that can be applied in clinical practice. Smoking prevention programs 
should target individuals of ages 14-18. Smoking cessation interventions should be optimised 
to reach smokers at ages 20-30 and those who are soon to retire. 





Although antismoking campaigns have reduced smoking prevalence in Germany from 36.9% 
to 29.2% over the 15-year period starting in 2000 [1], it is still considered to be high. Among 
smokers 16.3% of men and 8.8% of women consume more than 20 cigarettes per day, placing 
themselves in the category of heavy smokers [2]. Cigarette smoking leads to roughly 121,000 
premature deaths per year [3] in Germany and is a major cause of many cardiovascular, se-
vere respiratory, and oncological diseases [4] such as chronic obstructive pulmonary disease 
(COPD) and lung cancer.  
Individual smoking exposure can be featured as age at smoking initiation, age at smoking 
cessation and smoking intensity, which is depicted by the average number of cigarettes 
smoked per day. Population level of smoking behaviour can be described through smoker 
prevalence, probabilities to initiate- and to quit smoking. Analysis of these parameters for spe-
cific ages and birth cohorts can support the development of optimal healthcare interventions 
directed to prevent or decrease the harmful consequences for the population. Studies which 
focus on these interventions benefit from the available data on the smoking history of individ-
uals, difference in their age, gender and birth year [5, 6]. Such estimates have been generated 
for the USA [7], however, the smoking behaviour of Americans are not similar to the European 
people. Since 2000, for example, smoking prevalence in the US has been showing a steeper 
decline than in the Europe [1]. Due to the differences in the smoking behaviour, the estimates 
and their projections obtained for the US cannot be applied in studies, which focuses on the 
European populations without having biased inferences. 
In this study, we produce the data which describe cohort-specific smoking patterns differenti-
ated across genders and ages and represented by the prevalence of ever-, current-, and for-
mer smokers, smoking initiation and cessation probabilities, and smoking intensity indicated 
by the number of cigarettes smoked per day (CPD). The obtained data reflects the effects of 
the age groups and birth cohorts on smoking behaviour. Additionally, social forces and histor-
ical events can be gleaned from the obtained data.  
Methods. 
Data: 
Data on smoking behaviour in Germany was obtained from three cross-sectional surveys con-
ducted by the Robert Koch Institute (RKI) between 1997 and 2012: the German National 
Health Interview and Survey (GNHIES98) (1997-1999 with 7,124 participants), the German 
 
 
Health Interview and Examination Survey for Adults (DEGS) (2008-2011 with 8,152 partici-
pants), and the German Health Update (GEDA) which engaged 21,262 (2009), 22,050 (2010) 
and 19,294 (2012) participants. 
Statistical analysis: 
Smoking initiation and cessation probabilities were estimated for each birth year (1920-1980) 
by a single year of age by fitting logistic regression models to the data from the surveys. We 
applied thin plate regression splines within the logistic models due to nonlinearity of smoking 
patterns. Smoking intensity was estimated as probabilities that fall into one of five ranges of 
CPD. The resultant estimates were used to determine the mean of smoking doses [7]. The 
prevalence of ever-, current- and former smokers were computed for each birth cohort (1920 
-1980) using the estimates of the smoking initiation and cessation probabilities obtained from 
the regression analyses. All smoking parameters were projected up to the year 2025.  
Detailed description of the datasets, the applied regression models and calculation of the prev-
alences is available in the online supplement. 
Results. 
Smoking initiation probability 
The age- and birth cohort specific smoking initiation probabilities are illustrated on Figure 1 
(left) by decennial birth cohort, age, and gender. Across all cohorts, a rapid increase in initiation 
probability is seen for ages 12–18, followed by a decrease after 19 up to 25 years of age. After 
the age of 35 the probability to start smoking is very low independent of the birth cohort.  The 
probability to start smoking for men ranges from 11% to 15% being the highest between the 
ages of 16 and 18 years old regardless the birth year. For women the highest is in ages 17–
18.  
Smoking cessation probability  
The curves of the statistically estimated probabilities of quitting smoking show cumulative con-
ditional probability to stop smoking at a particular age, given that an individual was a smoker 
until that age (Figure 1, right). Although, the absolute number of people who quit smoking 
decreases starting at the age  of 41, the cumulative probability to quit is continually increasing 
until it reaches maximum around age 62. After this age it continuously decreases with increas-
ing age. A rapid increase of cessation probability is seen for ages between 20 and 30, partic-
ularly among women, and around the retiring age. Although, no decrease in initiation probabil-








Figure 2 illustrates age- and birth cohort-specific percentage of people who ever smoked (both 
former- and current smokers). Majority of people start smoking between the ages of 15 and 
20, however, a significant number begin to smoke earlier. The percentage of people who start 
smoking after the age of 35 is negligible. The prevalence of ever smoking females remains at 
a low level in the birth cohorts 1920-1940 and sharply increases in cohorts born after the end 
of the Second World War. Following a decrease in ever smoking female prevalence for the 
mid60s-mid70s birth cohorts, the percentage of women who ever smoked increases again in 
the recent birth cohorts. The prevalence of ever smoking males shows similar patterns across 
the birth cohorts, however, it is considerably higher for earlier cohorts and increases less rap-
idly later.  The increase in prevalence in the most recent birth cohorts is less noticeable. There-
fore, one can see that the ever smoking female prevalence approaches the male prevalence. 
The former smoker prevalence tends to increase with age for all birth cohorts and is at its 
highest level in the most recent birth cohorts (Figure 2). The age-specific proportion of former 
smokers in ever smoker prevalence in women is relatively constant until the late 50s birth 
cohorts (Figure 3). From the early 60s birth cohorts the ratio increases for all ages due to high 
smoking cessation probability among young- and middle aged people from the recent cohorts. 
The age-specific ratios for men display a similar but less emphasized trend.  
Current smoking prevalence peaks occur for the ages around 20-25 years across all cohorts 
and regardless of gender (Figure 4). It reaches the highest point for the 1960 birth cohort and 
then decreases over time when moving towards the recent birth cohorts. An increase in smok-
ing initiation for the late 70s cohorts is not visible in the current smoking prevalence due to an 













Figure 5. Age- and birth cohort-specific smoking intensity given in average number of ciga-
rettes smoked per day for men and women.   
Smoking intensity 
Figure 5 illustrates the distribution of the average number of cigarettes smoked per day by age 
for decennial one-year birth cohorts of men and women. Overall, the numbers for women are 
lower than those for men. For both genders, the mean of CPD reaches its maximum at ages 
40–45 and steadily declines during the later ages. The curves for men show a sharper decline. 
The mean number of cigarettes smoked per day remains below 25 for men and below 20 for 
women across birth cohorts. With time, smoking intensity tends to fall, with its peak in birth 




Figure 5. Age- and birth cohort-specific smoking intensity given in average number of ciga-
rettes smoked per day (CPD) for men and women.   
Discussion. 
The present study statistically estimates the major age- and birth cohort-specific parameters 
of smoking histories for the German population. Using the obtained estimates one can analyze 
temporal patterns of the smoking behaviour for young- and old-, male- and female smokers of 
different birth cohorts. The results can help to understand the trends observed in the cross-
sectional data.  
For the considered birth cohorts, the age-specific estimates of the current smoking prevalence 
shows that the percentage of the population who currently smoke decreases with an increasing 
age starting with age of around 25 years. The respective birth cohort-specific estimates repre-
sent temporal patterns and show a decrease in the prevalence over time when moving towards 
the recent years. These differences are governed by the age- and the birth cohort-specific 
 
 
smoking initiation and cessation probabilities. Examination of the curves for the smoking initi-
ation probability and the ever smoker prevalence allows for the conclusion that there are no 
temporal trends in the age of the highest smoking initiation probability, so that, people between 
ages 14 and 18 years are at the highest risk to begin smoking regardless of the birth year. At 
this age an individual reaches the peak of puberty and tends to seek autonomy. People at this 
age are considered to be the most susceptible to be influenced by friends and social environ-
ment [8]. Unfavorable social environment can play a central role in inducing smoking among 
individuals at middle of adolescence.  
Smokers of the recent birth cohorts have a considerably higher probability to quit after the age 
of around 20 years than those of the older cohorts. It is illustrated by a steeper slope of the 
curves for the younger cohorts (starting with 1980) for ages between 20 and 30 years. As long 
as the smoking initiation probability does not show a constant decrease over time, the in-
creased smoking cessation probability majorly contributes to the decline of current smoking 
prevalence.  The effects of tobacco control measures implemented in Germany can be gleaned 
from these patterns. The tobacco control included an approximately 42.5% tobacco tax raise 
[9], restrictions on tobacco commercials, a ban on the smoking in public places and the mini-
mum age of legal cigarette consumption [10–12] . According to the Deutsches 
Krebsforschungszentrum (German Cancer Research Center), these measures led to an ap-
proximately 34% decrease in cigarette consumption during 2002–2005 [9]. The increase in the 
smoking cessation probability may be caused by the reduction of peer group effect resultant 
from implementation of the tobacco control. This hypothesis can be supported by a study from 
the USA which concludes that introducing clean indoor air laws led to a spread of voluntary 
smoke-free-home policies [13]. Additional reasons for the comparatively easy smoking cessa-
tion in the recent cohorts can be the reduction of the addiction level resultant from a decrease 
in the smoking intensity in these cohorts [14]. A rapid increase in the smoking cessation prob-
ability is seen for ages characterized as approaching parenthood and retirement. A study by 
Lang et al suggests that individuals who go through the transition into retirement are more 
likely to quit smoking than those who do not [15]. 
In our resultant data, women show more complex smoking patterns compared to men. In the 
related literature, gender patterns of smoking behaviour in a historical context have been ex-
tensively examined [16–18]. From the 19th century to the beginning of the 20th century, tobacco 
consumption was mainly a male habit [16, 19]. During the Second World War, the well-estab-
lished tobacco consumption among men continued to increase [19]. These tendencies are 
reflected in our estimates of the initiation probability and current smoker prevalence for female 
cohorts born in the first half of the 20th century, which are significantly lower than their male 
counterparts. During the later period of the 20th century, the imagery surrounding cigarette 
 
 
smoking changed through advertising campaigns targeting women. The consequent rise in 
tobacco consumption among women is represented in our estimates by the increase in female 
smoking prevalence in the period after the war. After the reunification of Germany in 1990, the 
smoking prevalence in women from East Germany has been reported to increase significantly, 
while in the Western part of Germany the smoking prevalence among women decreased [20]. 
In turn, for the male population the reunification is reported to not bring considerable changes 
in the smoking prevalence [20].  
Currently, the female smoking prevalence represented by younger cohorts in our estimates 
tends to reach the male smoking prevalence. These results correspond to the results obtained 
from the Micro Census data [21] . The curves for the probability of quitting smoking for women 
reflect quitting tendencies at the age of becoming a mother for the first time. According to the 
German birth tables, the mean age of giving birth to a first child was 26.6 in 1960 and 30.9 in 
2014 [22] . The patterns for men show flatter curves for these ages.  
The resultant estimates are subject to certain limitations of the applied data. The surveys are 
cross-sectional but not longitudinal studies, meaning that the interviewed individuals have not 
been observed over time and the smoking parameters are estimated based on individual 
smoking histories recorded at the time of the survey. The estimations for the cohorts born 
before 1935 might be biased because of a limited number of observations for them in the 
datasets. Additionally, it was assumed that cessation age does not depend on the initiation 
age and smoking intensity. Due to the cross-sectional nature of the data, the average number 
of cigarettes smoked per day was recorded on the date of the interview and taken to be con-
stant for the period of smoking. Despite these limitations, our study provides estimates of 
smoking histories by single years of age (8–84) and birth cohorts (1920–1980) and current and 
former smoker prevalence over time. The obtained estimates capture population dynamics of 
exposure to cigarette smoking over time, as opposed to simply representing the point preva-
lence obtained from the surveys [7]. The fields of application include topics in medical and 
public health research of smoking-related issues such as the modelling of smoking-induced 
diseases (e.g., lung cancer, COPD), health economic evaluations (e.g., lung cancer screen-
ing), and evaluations of the effects of different political measures on smoking behaviour. The 
results suggest that interventions should be developed to specifically target prevention of 
smoking initiation among people at the age of 14-18 and promote smoking cessation among 
those who are soon to retire and individuals of ages  20-25 years old, particularly young 
women. Interventions such as the tobacco-counselling steps [23] could be optimized for the 
target group and incorporated into clinical practice in order to prevent high risk individuals to 
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Data description : 
Data on smoking behaviour in Germany were obtained from three cross-sectional surveys 
conducted by the Robert Koch Institute (RKI) between 1997 and 2012: the German National 
Health Interview and Survey (GNHIES98) (1997-1999 with 7,124 participants), the German 
Health Interview and Examination Survey for Adults (DEGS) (2008-2011 with 8,152 
participants), and the German Health Update (GEDA) which engaged 21,262 (2009), 22,050 
(2010) and 19,294 (2012) participants. We chose these surveys because they provided a large 
pooled sample size of 77,882 respondents and contained all the variables of interest to our 
analysis: smoking status at the interview date, age at starting and quitting smoking, form of 
smoking, and the number of cigarettes smoked per day. In our analysis we focused on the 
smoking of boxed and hand-rolled cigarettes which constitute the major means of daily tobacco 
consumption in Europe[12]. Alternative large surveys (Micro Census [13], the German Socio-
Economic Panel (SOEP) [14], German Epidemiological Survey of Substance Abuse (ESA)) 
[15] provided insufficient information for our analyses. 
For the estimation of the smoking parameters, datasets from GEDA and DEGS were combined 
into a single data set (DEGS/GEDA). GNHIES98 and DEGS/GEDA applied different weights 
to the observations; therefore, we did not combine all three of them into one single data set. 
Instead, we examined GNHIES98 and DEGS/GEDA separately. We performed a statistical 
analysis using data from each dataset with the application of the respective weights and then 
the resultant estimates were aggregated based on the proportions of weighted observations 
for a single birth year. 
The German National Health Interview and Survey (GNHIES98), was administered from 1997 
to 1999 11. A total of 7, 124 individuals between 18 and 79 years of age participated in this 
survey. All participants were asked to fill out a questionnaire; additionally, some subgroups 
were invited to give more details on different topics related to smoking.  
The second survey, the German Health Interview and Examination Survey for Adults (DEGS), 
took place from 2008 to 2011 and involved 8,152 people between the ages of 18 and 79 12. 
This study collected a wide range of data on health and lifestyle employing standardized 
computer-assisted personal interviews, self-administered questionnaires, standardized 
measurements, and tests. 
The third survey, the German Health Update (GEDA), was conducted in 2009, 2010, and 2012 
and included 21,262 (2009), 22,050 (2010) and 19,294 (2012) participants of 18–86 years of 
age respectively 13. Computer-aided telephone interviews were used.  
Statistical analysis: 
The surveys contained a restricted range of survey years which limited the ability to estimate 
period effects, therefore, the period was excluded from the analysis, and the age and cohort 
were the only temporal components affecting smoking history. 
Estimating smoking initiation probability: 
We estimated the smoking initiation probability for each dataset and gender using a single year 
of age and one-year birth cohort. We constructed a binary variable with two possible values: 1 
if the i-th individual (cohort,𝑐) started to smoke at age 𝑎 and 0 otherwise. The probability of the 
outcome was determined as a function of age and cohort:  logit{𝑝(𝑎, 𝑐)} = 𝛽0 + 𝛽𝑎(𝑎) + 𝛽𝑐(𝑐), 
 
 
where 𝑝(𝑎, 𝑐) is the probability of smoking initiation, 𝛽0 is an intercept, and 𝛽.(∙) is given by a 
thin plate regression spline. For each cohort represented in each dataset, we defined 
individuals who started smoking at age𝑎 and who had never smoked up to that age 9. The data 
comprise datasets which were used for fitting the logistic model. The cohort effect,𝛽𝑐, was 
assumed to remain constant for the cohorts born after 1982. Using the resultant coefficients, 
the estimates of smoking initiation probability were projected to the year 2025 for ages 15–76.   
 
Estimating smoking cessation probability: 
Smoking cessation was characterized as having quit smoking and having not smoked for at 
least two years before the interview. 
For the estimation of smoking cessation probabilities, we followed the respondents of each 
year of age starting with the age at smoking initiation through the age at smoking cessation. 
Using this data, we determined the smokers who quit and smokers who continued to smoke 
at the given age and the year of birth. The data was then used to fit an additive logistic model 
in order to obtain the conditional probabilities of quitting:  logit{𝑞(𝑎, 𝑐)} = 𝛽0 + 𝛽𝑎(𝑎) + 𝛽𝑐(𝑐), 
where 𝑞(𝑎, 𝑐) is the probability of quitting smoking, 𝛽0 is an intercept, and 𝛽.(∙) is given by a 
thin plate regression spline. Using this regression, we obtained the estimates of the conditional 
probability of quitting at a particular age, given the subject was a smoker. Based on the results 
of the regression, the estimates were projected to the year 2025 for ages 15–84. Fitting was 
performed in R using  the GAM function.  
Estimating prevalence of ever-, current-, former smokers:  
To estimate the prevalence of current and former smokers for each dataset and gender, we 
used the estimated probabilities for smoking initiation and cessation. Therefore, following 
Holford et. al., we calculated the proportion of subjects who had ever been smokers, 𝑃𝐸 and 
the cumulative proportion of smokers who had not quit smoking, 𝑄 [10]:  𝑃𝐸(𝑎, 𝑐) = 1 − ∏ [1 − 𝑝(𝑖, 𝑐)]𝑎𝑖=1   𝑄(𝑎, 𝑐) = ∏ [1 − 𝑞(𝑖, 𝑐)]𝑎𝑖=15  with 𝑞(𝑎, 𝑐) = 0𝑖𝑓𝑎 < 15  
The respective prevalence was then defined by the following equations [10]: 𝑃𝐶(𝑎, 𝑐) = 𝑃𝐸(𝑎, 𝑐)𝑄(𝑎, 𝑐) 𝑃𝐹(𝑎, 𝑐) = 𝑃𝐸(𝑎, 𝑐) − 𝑃𝐶(𝑎, 𝑐) ,  
where 𝑃𝐶 is  the prevalence of current smokers and 𝑃𝐹 is prevalence of former smokers. 
Estimating smoking intensity: 
Both datasets contained records on the average number of cigarettes smoked per day (CPD), 
which were used to analyze smoking intensity. In order to include smoking intensity, we 
constructed an ordered categorical outcome variable and defined the following intervals of 
CPD with the centre of the intervals given in brackets: CPD≤5 (3); 5< CPD≤15 (10); 
15<CPD≤25 (20); 25<CPD≤35 (30); 35<CPD≤45 (40); and 45<CPD (60) 9.  
The outcome variable was regressed against age and cohort using a cumulative logistic model 
and thin plane regression splines. The model was fitted to the data from the two datasets for 
 
 
each gender separately. The fitted estimates represented the probabilities of each cohort aged 
15–76 falling into each category of smoking intensity. The resultant estimates were used to 
determine the mean smoking dose 9, and were also projected to 2025.  
Validation.  
In order to validate our findings with the studies, which determine smoking prevalence in 
Germany, we accumulated the estimates over the birth-cohorts and ages. Our findings on 
prevalence and cigarette smoking intensity conform to the statistics given in the WHO report 
(WHO)[4] for Germany and those obtained by Kraus et al. (Kraus, L., Pabst, A., Gomes de 
Matos, E., Piontek, D. 2014)[17]. The WHO reports its estimates and projections of current 
smokers’ prevalence (over 15 years old) in Germany for 2000–2025. Our results not only align 
with the estimates of WHO, the generated estimates add essential age and birth cohort–
specific details.  
 Table 1 summarizes the estimates given by WHO and those obtained in this study for that 
period.   
Table 1: Comparison of the study results with the results reported by WHO: prevalence of 
current smokers over 14 years of age. 



















2000 36.9 36.2 26.5 25.7 
2005 34.0 34.7 25.5 25.6 
2010 31.6 33.0 24.4 25.0 









FIGURE 2: FORMER SMOKER PREVALENCE  
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Abstract
Background Smoking cessation is a challenging task with
a high risk of relapse. Depending on the choice of medi-
cation and duration of therapy, the costs of using a smoking
cessation aid can be high. Additionally, these costs are not
covered by health insurance in Germany. Information on
willingness to use (WTU) and willingness to pay (WTP)
for smoking cessation aids is valuable for developing dif-
ferent smoking cessation strategies.
Objectives The study analyses WTU and WTP for three
pharmacological smoking cessation aids (nicotine
replacement therapy (NRT), bupropion and varenicline)
among young and middle-aged adults in Germany and
attempts to determine their major driving factors.
Methods Two cross-sectional internet-based surveys of
smokers over 18 years of age were conducted in 2014 and
2015 in Germany. Respondents were asked about smoking-
related issues and WTU and WTP for each therapy. The
contingent valuation method with payment cards was used
to measure WTP. Descriptive statistics, logistical regres-
sion and accelerated failure-time regression models were
performed.
Results The total sample size is 505. Half of the
respondents are willing to use NRT and one-third are
willing to use bupropion and/or varenicline. WTU induces
positive WTP; however, the magnitude of WTP is beneath
the market price. WTU significantly increases with a higher
addiction level and if smokers have previously heard about
the therapy.
Conclusion This study indicates different points to be
considered for policy development. Promotion information
and improving awareness about medication aids might
increase WTU, and development of monetary incentives
for young smokers could create a better chance for suc-
cessful smoking cessation.
Key Points for Decision Makers
Pharmacological smoking cessation methods should
be directed to smokers with strong addiction.
People who are familiar with NRT therapy are likely
to be willing to use and pay for it. Promotion
information and improving awareness about
medication aids and their efficacy might increase
willingness to use them.
Willingness to pay for pharmaceutical smoking
cessation aids is below the market price for all
therapy options; therefore, different strategies, e.g.
reducing the price of medications or development of
co-payment options or bonus payments by health
insurance companies under the condition of
successful quitting, should be discussed.
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1 Introduction
Smoking is one of the main contributing factors to leading
causes of death such as chronic obstructive pulmonary dis-
ease, lung cancer and cardiovascular diseases. According to
the World Health Organization (WHO), smoking-related
conditions are responsible for sixmillion deaths annually [1].
In Germany, smokers account for 26 % of the population, a
percentage similar to the smoking prevalence in Europe
(28 %). Most of the current smokers are young and middle-
aged adults. The smoking rate for these groups is higher than
the population-level prevalence: approximately 29 % for
young adults (aged 15–24 years) and 37 % for people aged
35–39 years [2]. The WHO also reports that more than half
of the smokers in Europe are interested in quitting smoking
[3]. According to statistics, over the last year, 21 % of
European smokers have tried to quit smoking and the overall
percentage of people in Europe who have attempted to stop
smoking has reached 63 %.
Owing to the physically and mentally addictive nature of
smoking, quitting is a considerable challenge, with a high
risk of relapse. To support quitting smoking, various
measures are available: psychological counselling (face-to-
face or via telephone), self-help measures (books, appli-
cations and websites), individual or group therapy, and
alternative methods such as acupuncture. Additionally,
nicotine replacement therapy (NRT), bupropion and
varenicline have been found to be effective in supporting
smoking cessation [4]. However, in Germany, the cost of
these medications is borne by the user, whereas other
interventions targeting smoking behaviour are either free of
charge or covered by health insurance programs.
Evidence-based clinical practice guidelines for tobacco
cessation recommend a combination of pharmacotherapy,
physician counselling and social support as a key strategy
for smoking cessation [5]. Although usage of medications
is included in the recommendations, smokers generally do
not use pharmacotherapy. A recent smoking cessation trial
in Germany reported that only 1 % of smokers have used
prescription drugs like varenicline and bupropion [2].
Information about the number of persons who have used
NRT is not available.
Several studies have analysed the cost-effectiveness of
pharmacological therapies for smoking cessation; however,
the authors point out the need to define a threshold at which
a therapy is considered to be cost-effective [6]. Among the
several factors that predetermine the choice of a cost-ef-
fectiveness threshold is the amount of money that people
are willing to spend to gain the benefits of the intervention.
Five studies have analysed willingness to pay (WTP) for
different pharmacological smoking cessation therapies in
different countries [7–11]. Most of these studies focus on
WTP in hypothetical scenarios such as the development of
a new effective medication [7] or a smoking cessation
therapy that gives a guarantee for stopping smoking [8].
In Germany, WTP for smoking cessation medication has
not yet been investigated. Most of the smokers in Germany
are young adults and the German health insurance com-
panies do not reimburse pharmacological smoking cessa-
tion therapies, so people must bear the costs of these
medications themselves. In these settings, estimation of
WTP and investigation of its driving factors might be
useful for developing public health programs that target
smoking cessation.
In this study, we investigate willingness to use (WTU)
and WTP for smoking cessation therapy in young and
middle-aged adults in Germany. We focus on three medi-
cations which have been approved in Germany as smoking
cessation aids: NRT, bupropion and varenicline. NRT is an
over-the-counter (OTC) medicine; it exists in different
forms such as patches, gum, lozenges, inhalers and nasal
sprays [12]. In contrast to NRT, bupropion and varenicline
are available only on prescription and are sold in the form
of pills. Although all the substances serve to reduce nico-
tine cravings, they differ in efficacy, drug delivery form,
side effects and price. We examine the effects of demo-
graphical, socioeconomic and smoking-related character-
istics on WTU and WTP for each therapy. In our analysis,
we aim to inform development of smoking cessation
policies among young people.
2 Methods
2.1 Study Type and Dataset
Two cross-sectional Internet-based studies were conducted
in Germany over two periods: between May and August
2014 and between May and June 2015. The major criteria
for enrolment in the survey were being a current smoker
and age between 18 and 65 years. People who were
undergoing a smoking cessation program were excluded
from the survey. Participants were recruited actively via
mail and passively via social networks, several smoking
forums and self-help groups. No incentive was offered for
participation in the survey. The study was approved by the
Committee for Clinical Ethics of the Hanover Medical
School.
2.2 Questionnaire
In order to examine WTU and WTP for the three therapies,
we developed a questionnaire which included sections on
demographic and socioeconomic characteristics and
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smoking habit issues (see Supplemental Material, Appen-
dix A). It also included questions regarding experience
with smoking cessation therapies as well as WTU and
WTP for each of the three drugs.
In the first part, respondents were asked questions
related to their smoking history and nicotine dependency.
Smoking addiction was measured using the Fagerström test
[13]. Additionally, participants were asked about the age at
which they began smoking, the number of smokers in their
social environment (peer group) and whether they wish to
quit smoking.
The second part of the questionnaire focused on the
pharmacological treatment options and questions about
WTU and WTP. To inform respondents about the therapy
options, a description of each therapy was provided:
Characteristics of the nicotine patches, administration of
bupropion or varenicline, and information about intake,
dosages, odds of success and potential side effects. Treat-
ment effectiveness rates were based on the mean values
obtained from different studies [12, 14]. In the following
sequence of therapy-related questions, respondents were
asked (1) whether they had heard about the therapy and had
experience using the indicated medication; (2) based on the
provided information about the therapy, whether they
would be willing to use it if it is free of charge; (3) and
regardless of the response to the WTU question, whether
they would be willing to pay for the medication aid. By
including the yes-no question on WTP for all respondents,
we sought to prevent misunderstanding. Those who stated
‘no’ when asked about WTU and ‘yes’ when asked about
WTP were excluded from further analysis.
To measure WTP, the contingent valuation method with
payment cards was used. Contingent valuation usually
involves asking individuals directly in a survey about the
maximum amount of money they are willing to pay to gain
the commodity in question [15–18]. In our survey,
respondents were first asked whether they are willing to
pay for the therapy, and those who chose ‘yes’ were asked
to choose a range of values within which they are ready to
spend for the related therapy. The range of values has been
defined according to results from prior interviews with
smokers. We asked this group which value ranges they
would find understandable and preferable. The common
answer was 10-Euro intervals, and the usual reason was
that €10 was the amount of money they usually paid for
nearly two cigarette packages. Ten-Euro intervals were
constructed ascending and descending from a middle
interval which included the current market price of the
product under consideration. We also constructed the
lowest interval as less than a certain amount without giving
a certain low boundary in order not to lose information,
particularly answers from people who would have omitted
choosing an interval if they had not found a proper
category.
Figure 1 illustrates this process, showing questions that
lead to possible response options for WTP. The example is
given for NRT and is similar for other therapies, but the
WTP intervals were adjusted for each medication. At the
end of the questionnaire, respondents were asked to pro-
vide information on characteristics such as age, sex, edu-
cation, current employment status, income and insurance
status.
2.3 Statistical Analyses
Descriptive statistics were calculated separately for each
therapy for the outcome and predictor variables. Deter-
minants of WTU and WTP were assessed for each med-
ication separately using regression methods based on
distributional characteristics of the outcomes (see equa-
tions in Supplemental Material, Appendix B). According
to the design of the questionnaire, the outcomes consisted
of three variables of interest for each therapy: (1) WTU,
which had two possible values termed ‘yes’ and ‘no’; (2)
WTP, which also had two possible values termed ‘yes’
and ‘no’; (3) and ordered WTP, shown as 10-Euro
intervals. Only respondents who stated ‘yes’ when asked
if they are willing to pay were asked to choose one of the
intervals in accordance with their preferred amount.
Therefore, a point value of WTP is uncertain; however, it
falls within a particular interval. When interval-censoring
occurs, survival analysis can be applied by exchanging a
failure time for WTP [19–21]. Although accelerated
failure-time models are not conventional for WTP studies,
they allow an analysis of WTP interval bids as dependent
variables and have been considered appropriate for deal-
ing with WTP intervals in previous studies [21–25]. In
our study, distribution of upper and lower values of the
resultant intervals was better approximated by a Weibull
distribution. Therefore, for the regression analysis of the
ordered WTP, we used accelerated failure-time models
with a Weibull distribution.
For the dichotomous outcomes of WTP and WTU, we
applied logit regressions, which are conventional for this
type of outcome.
Predictors were chosen in accordance with the related
literature, research hypotheses and a backward variable
selection procedure. They included age, gender, income,
employment, presence of health restrictions due to smok-
ing, willingness to quit smoking, attempts to quit smoking,
addiction degree, peer group, having heard about the
therapy and experience with usage of related therapy.
All regression analyses were performed using the sta-
tistical software R.
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3 Results
3.1 Descriptive Statistics
Overall, 1735 participants clicked on the URL to the
questionnaire during both periods of the survey; of these,
709 started filling it out and 505 respondents completed it.
The total sample consisted of 505 individuals with a mean
age of 32.63 years. It also had a well-balanced gender ratio
(57.43 % male). The largest part of the sample (68.51 %)
had completed their education up to high school. In terms
of profession, one-third of the sample (31.88 %) is cur-
rently studying, and 55.05 % chose the option ‘currently
employed’, which also includes self-employment.
Smoking addiction level, as assessed using the Fager-
ström test, was ‘low’ or ‘low-moderate’ for most of the
sample (61.79 %) and ‘moderate’ or ‘high’ for the
remainder (38.02 %). Most of the respondents (61.79 %)
estimated the proportion of smokers in their social envi-
ronment (peer group) to be between 11 and 50 %. Around
37 % of the respondents wanted to quit smoking, while the
other respondents had not decided yet or did not want to
quit (62.7 %).
Further details of respondents’ characteristics are given
in Table 1. Responses to the part of the questionnaire about
smoking cessation aids show that NRT is better known
than bupropion or varenicline. Most of the respondents
(87.13 %) reported having heard about NRT, whereas only
12.48 and 13.07 % had heard about bupropion and
varenicline, respectively. Responses to the question on
experience with usage of the medications showed the same
tendency: the greatest proportion of the respondents among
those who have attempted to stop smoking (374 out of 505)
have used NRT (19.25 %), 1 % have used bupropion and
3 % have used varenicline. The other 76.75 % did not use
any pharmacological smoking cessation therapies in their
last attempts to stop smoking.
Analysis of WTU for medication when it is free of
charge shows that NRT is preferred over the other therapy
options: more than half of the respondents expressed their
willingness to use NRT and only one-third did so for
bupropion and varenicline. Most of these respondents are
not willing to quit smoking (77.90 % for NRT, 77.78 % for
bupropion and 79.46 % for varenicline).
In contrast to WTU, half as many respondents are
willing to pay for pharmacotherapy. Out of the total sam-
ple, 20.79 % are willing to pay for NRT and 12.87 % are
willing to pay for bupropion and varenicline. The intervals
chosen by those who responded ‘yes’ to WTP show that
they do not want to pay the amount of the market price.
Fig. 1 Questions for assessing
willingness to use and
willingness to pay for nicotine
replacement therapy
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Table 1 Main characteristics of the analysis sample
n = 505 Percentage or mean
Sex (%) Female 42.57
Male 57.43
Age (years), mean (SD) 32.62 (11.62)
Health restrictions due to smoking (%) No 63.96
Yes 33.66
NA 2.38
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Most of the respondents (74.28 %) are willing to pay less
than €87 for NRT, which is below the market price in
Germany. Out of the 105 people who are willing to pay for
NRT, 60 also state WTP for varenicline and 46 for
bupropion. Although fewer smokers are willing to pay for
varenicline (n = 80) and bupropion (n = 65), most of the
respondents chose lower price intervals: lower than €96
and €74, respectively.
We examined the variation inWTUandWTP for the three
alternative medications across different respondent charac-
teristics. The resultant estimates are given in Tables 2, 3, 4
for each therapy. We calculated 95 % confidence intervals
(CIs) to estimate the precision of the odds ratios (ORs).
3.2 Results for ‘Willingness to Use’ (WTU) if it is
Free of Charge
Out of 11 variables, six show statistical significance at
p\ 0.05 for WTU if the medication is free of charge for
NRT, five for varenicline and four for bupropion. Of these,
an addiction level has the same effect on the occurrence of
the answer ‘yes’ for all three medications: with its increase,
the odds of the positive WTU (‘yes’) outcome rise. Results
also show a few common trends across the therapies: an
increasing effect of male gender and a decreasing effect of
‘yes’ and ‘not decided’ with regard to willingness to quit.
Other determinants of WTU vary across the medications
(Table 2). The employment variable shows statistical sig-
nificance for NRT and varenicline. Compared with
employed smokers, smokers who are currently studying or
not working are less likely to be willing to use the smoking
cessation aid.
Being familiar with medication in terms of having heard
about or having used it shows an increasing effect on WTU
for NRT. Opposite results are obtained for varenicline.
Smokers who have used varenicline before are less likely
to use it again.
3.3 Results for Positive ‘Willingness to Pay’ (WTP)
We conducted a logit regression to examine the effects of
the respondents’ characteristics on WTP in the form of
binomial data. Resultant ORs are presented in Table 3.
According to the resultant ORs, addiction level has a
similar effect on WTP as it does on WTU: people who state
stronger addiction are more likely to be willing to pay for a
smoking cessation therapy. Willingness to quit shows an
opposite decreasing effect on WTP.
Table 1 continued
n = 505 Percentage or mean
Willingness to use yes (%) NRT 52.87
Bupropion 32.08
Varenicline 36.63
Willingness to pay yes (%) NRT 20.79
Bupropion 12.87
Varenicline 12.87


















NRT nicotine replacement therapy, NA not available



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Willingness to Use and Pay for Pharmacological Smoking Cessation Aids 449
These results hold for the three therapies. Effects of job,
income and experience of usage differ among the medi-
cations. For NRT, shifting from employed to not working
status has a decreasing effect, and both having heard about
NRT and having used it show an increasing effect. Addi-
tionally, peer group shows that smokers who have less than
10 % smokers in their social environment are likelier to be
willing to pay for NRT as compared to those whose peer
group has around 25 % smokers.
Results for bupropion also show a decreasing effect of
decreasing income and an increasing effect of presence of
health restrictions due to smoking. These variables have
similar effects on WTP for varenicline. Additionally,
smokers who are studying are likelier to be willing to pay
for varenicline compared with smokers who are employed.
3.4 Results for WTP Value
Respondents who reported positive WTP also provided
responses to the payment card. Values were combined to
create interval data on WTP. The resultant samples differ
in their sizes among the therapies. These samples are used
in the regression analysis of interval WTP, with application
of accelerated failure-time models. The Weibull distribu-
tion is the best-fitting distribution of the outcome variable
for the three samples. Table 4 shows the obtained results
and respective sample sizes. In addition to the previous
regression results, several determinants of WTP are found
for each therapy. For NRT, two variables show statistical
significance: gender and addiction level. Men are likelier to
be willing to pay more than women. A decrease in addic-
tion level decreases the probability of being willing to pay
more. Addiction shows the same effect for varenicline. A
shift in peer group from ‘[50 %’ to ‘26–50 %’ increases
the probability of a higher WTP value.
For bupropion, presence of health restrictions and a shift
from employed to not working status decrease this proba-
bility. Additionally, age shows an increasing effect. TheORs
show that peoplewho have used bupropion are less likely and
people who have used varenicline are more likely to be
willing to pay a higher amount for these medications.
4 Discussion
In this study, we consider three smoking cessation aids
which are approved by the European Medicines Agency
and the US Food and Drug Administration (NRT, bupro-
pion, andvarenicline), and investigate driving factors of
WTU and WTP for each of them among young and middle-
aged smokers in Germany.
Mainly we aimed to produce an analysis supporting the
development of a policy which would target smoking
cessation among young adults. Therefore, we focus our
investigation on the existing medications which allowed us
to compared WTP and current market price [26, 27].
According to our results, the amount which the majority of
young and middle-aged smokers are willing to pay is lower
than the market price for all therapies. The relatively high
price might be related to the low prescription rates of these
medications [2].
In our survey, we included both smokers who stated a
willingness to quit smoking and smokers who were not
willing to quit smoking. We believe that exclusion of the
latter might bring a selection bias into an analysis of
smokers’ WTP, for instance, when comparing market price
with WTP [8]. Furthermore, when a smoking cessation
policy is being developed, consideration of those who are
not willing to quit is desirable in order to elaborate mea-
sures directed towards enhancing motivation to quit
smoking, supporting it with provision of information about
available medication aids for smoking cessation.
Inclusion of the willingness-to-quit variable in our
analysis shows that smokers who indicate willingness to
quit are less likely to be willing to use and to pay for
smoking cessation aids, contrary to our expectations. This
finding is supported by a study previously conducted by
Morphett et al. [28, 29]. The authors report that unassisted
quitting is frequently described as the best way to quit
smoking, and smokers see motivation to quit as the foun-
dation of successful quitting, so that when a smoker is truly
motivated, no medication aid is necessary.
Another explanation for this result may relate to our
sample, which mostly includes people who indicate a low
to moderate addiction level. Low addiction level, according
to our results, decreases WTP for smoking cessation aids.
The same effect is described by Nguyen at al. [30], who
found in a quantitative analysis that light smokers (1–10
cigarettes per day) are less likely to believe that medica-
tions would give them a better chance of quitting, and
prefer group counselling.
Overall, in our study, addiction level is found to be
one of the major drivers of WTU and WTP. WTU and
WTP increase with increasing addiction level. This
effect has been already reported by Olsen et al. [15];
however, the authors applied the Cigarette Dependence
Scale (CDS-12) to measure addiction. We used the
Fagerström test and support their findings. With regard
to this result, policy measures related to pharmacological
smoking cessation aids (e.g. distribution and promotion
information about them) should target smokers with a
high addiction level, as their amount of WTP is not high
enough to buy the medications. Furthermore, this group
is particularly at risk of contracting a smoking-related
disease. Therefore, it is necessary to support these
groups of smokers first.
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Generally, driving factors of WTP and WTU seem to
coincide; however, they differ between therapies. Smokers
who have used NRT before are more likely to use it again
than are smokers who have not had this experience. For
varenicline, this is not the case. This might be because of
the discouraging side effects of varenicline. Etter and
Schneider indicate that one-third of varenicline users report
the side effects as being too strong, while only 13.5 % state
the same for NRT [31].
Additionally, we investigated how the magnitude of
WTP varies with individual characteristics of smokers.
According to our results, most people are willing to pay for
smoking cessation medication at a value less than the
market cost in Germany. The average price of NRT is
around €87 [32] per month, which, according to our results,
is perceived as high: more than 70 % of the respondents
state that they are not willing to pay that amount. Other
therapy alternatives are similarly perceived as expensive by
the majority of smokers. Of the respondents who are
willing to pay for bupropion, only 26.15 % have a maxi-
mum WTP higher than the market price (€74 per month
[32]). For varenicline, only 11.25 % are willing to pay the
market price (€106 per month [32]) or more. The low
magnitude of WTP for pharmacological smoking cessation
therapies might be a reason for the very low prescription
rate (1 %) for bupropion and varenicline [2]. According to
these results, it seems that most young and middle-aged
smokers in Germany are not willing to pay the market price
for smoking cessation aids. Some changes in this direction
might be addressed when developing a public health
smoking cessation strategy, e.g. reducing the price of
medications or development of co-payment options or
bonus payments by health insurance companies on condi-
tion of successful quitting.
The results of the analysis show that people who are
familiar with NRT therapy are likely to be willing to use it
and pay for it. Promoting activities to inform smokers
about available support with NRT and provision of accu-
rate safety information can increase WTU [33, 34]. How-
ever, knowledge about NRT does not necessarily lead to a
higher magnitude of WTP for NRT.
A few limitations of our study should be mentioned.
First, we targeted smoking young and middle-aged adults,
so the sample is not representative of the German popu-
lation. Second, the results of the regression for magnitude
of WTP should be interpreted with caution because of the
small number of respondents who gave intervals for WTP
for the therapies. Furthermore, we analyse WTP for
existing medications but not hypothetical constructs;
therefore, respondents’ choices might be biased by
awareness of the market price, though we attempted to
control for this during the enrolment process. An advantage
of analysing existing products is that results can be used to
compare WTP with real market prices and to explain
statistics like low prescription rate for the medications.
Additionally, one methodological limitation is the online
form of the survey, as certain population groups are less
likely to fill out online questionnaires or do not have
Internet access.
Further research with a representative and more hetero-
geneous sample is needed. Among other research questions,
it remains interesting to identify the determinants of low
magnitude of WTP among smokers and what policy options
would increaseWTP to the level of themarket price. It is also
necessary to explore differences in WTU and WTP between
smokers who indicate willingness to quit and those who do
not. A qualitative research design might be necessary to
identify factors which cause these differences in behaviour.
Additionally, investigation of non-monetary incentives for
quitting might be needed for a better understanding of the
motives and preferences of smokers.
5 Conclusion
To sum up, this study indicates four main points to be
considered for development of a smoking cessation policy
which pertains to pharmacological aids. First, it has to
target smokers who are both willing to quit and those who
are not; however, it is necessary to take into account
smokers’ perception of their own ability to quit and pro-
mote additional support. Second, in order to achieve a
better impact, measures should be directed towards
smokers with a strong addiction. Third, promotion infor-
mation and improving awareness about medication aids
and their efficacy might increase willingness to use them.
Last, WTP for pharmaceutical smoking cessation aids is
below the market price for all therapy options; therefore,
development of monetary incentives for young smokers
can create a better chance for successful smoking cessation.
These findings can inform development of health poli-
cies and strategies which target smoking cessation among
young and middle-aged smokers.
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Supplemental Digital Content 





1/0 Dear Participants, 
The following questionnaire is addressed to you as a smoker. To quit smoking is often a difficult task 
and can be supported by different types of medicine. We would like to present you with the following 
different medicines that can help you stop smoking. The questionnaire will only take a few minutes to 
complete, please make sure to read the questions carefully. Your answers will be evaluated 
anonymously. 
 
Participants must be 18 or older to participate in the study. Non-smokers or smokers undergoing a 
smoking cessation therapy cannot participate in the study. But we thank you for your interest. 
 
Thank You in advance for your participation! 
2/1 Before we start, we need some information about your smoking status. 
 
How old were you when you started smoking? If the exact age is unknown please write in an 
approximation 
 
_______ Years old 
 
2/2 Have you ever tried to quit smoking and if so how many times. 
 No  
 Yes       ___________ times  
  
 
2/3 Have you tried to quit smoking through the  following forms: 
 
 No yes No response  
 Behavior Therapeutic Measures (ex: Group Therapy or 
Individual Therapy) 
   
 Medicament: Nicotine    
 Medicament: Bupropion     
 Medicament: Varenicline    
 Other types of medicine    
 Other types of Therapy (ex: Acupuncture, Hypnoses, etc)     
 
 
2/4 Do you have any health problems due to smoking? (Illnesses, shortness of breath, etc.)  
 Yes  
 No  
 No Response    
  
2/5 How much percentage of your social circle (Friends, Family, co-workers) are smokers? 
 0-10%  
 11-25%  
 26-50%    
 >50%  
 No Response   
 
2/6 Do have any interest in quitting smoking? 
 
 Yes maybe yes            undecided       maybe No No 




3/7 Now we will show you three different types of medicine used to quit smoking. Please read through the 
following therapy information carefully and then answer the following questions. 
3/7 Therapy 1  
Therapy Information: 
Medicine: Nicotine 
Administration type/ duration/ doses: Patch; 3 months; 1 patch per day  
Effectiveness: 15.4 % of the patients have quit smoking after a year  
(For Comparison: about 5% have successful quit smoking without the help of medications.) 
Possible Side Effects: Basically no other Nicotine side effects than smoking, but skin lesions can 
appear at the site of the patch. 
3/7 Have you ever heard of Nicotine Therapy with Nicotine Patches? 
 Yes  
 No  
 No Response    
 
3/8 Would you pay for a Nicotine therapy with Nicotine patches?  
 
 Yes  
and if so how much?  
o <67€  
o 68-77€  
o 78-87€  
o 88-97€  
o 98-107€  
o >107  
  
 No  
 No Response    
 
3/9 Would you use the Nicotine Therapy with Nicotine patches if it was free? 
 Yes  
 No  
 No Response    
 
4/10 Therapy 2 
Therapy Information: 
Medicine: Bupropion, sold in Germany under the brand name Zyban 
Administration type/ duration/ doses: Tablet; 8 weeks; In the first week 1 tablet per day, then 2 tablets 
per day.  
Effectiveness: 15.9 % of the patients have quit smoking after a year  
(For Comparison: about 5% have successful quit smoking without the help of medications.) 
Possible Side Effects: occurring in more than 1 in 10 people: Insomnia, Headache, dry mouth, nausea, 
vomiting.  
4/10 Have you ever heard of the Medical Therapy with Bupropion? 
 Yes  
 No  
 No Response    
 
4/11 Would you pay for the Medical Therapy with Bupropion?  
 
 Yes  
and if so how much?  
o <54€  
o 55-64€  
o 65-74€  
o 75-84€  
o 85-94€  
o >94  
  
 No  






4/12 Would you use the Medical Therapy with Bupropion if it was free? 
 Yes  
 No  
 No Response    
 
5/13 Therapy 3       
Therapy Information: 
Medicine: Varenicline, sold in Germany under the brand name Champix 
Administration type/ duration/ doses: Tablet; 12 weeks; In the first week 1 tablet per day, then 2 tablets 
per day.  
Effectiveness: 22.9 % of the patients have quit smoking after a year  
(For Comparison: about 5% have successful quit smoking without the help of medications.) 
Possible Side Effects: occurring in more than 1 in 10 people: Insomnia, Headache, abnormal dreams, 
nausea. 
5/13 Have you ever heard of the Medical Therapy with Varenicline? 
 Yes  
 No  
 No Response    
 
5/14 Would you pay for the Medical Therapy with Vareniclin?  
 
 Yes  
and if so how much?  
o <76€  
o 77-86€  
o 87-96€  
o 97-106€  
o 107-116€  
o >116  
  
 No  
 No Response    
 
5/15 Would you use the Medical Therapy with Varenicline if it was free? 
 Yes  
 No  
 No Response    
 
6/16 After waking up in the morning how long do you wait before lighting your fist cigarette? 
 After 5 minutes   
 After 6-30 minutes   
 After 31-60 minutes   
 After more than 60 minutes   
 
6/17 Do you find it hard to not smoke in smoking-free areas? 
 Yes  
 No  
 
6/18 Which cigarette would you not want to give up? 
 The first in the morning   
 Other   
 
6/19 Generally, how many cigarettes do you smoke per day? 
 0-10   
 11-20   
 21-30  
 31 or more    
 
6/20 Do you generally smoke more in the morning than during the rest of the day? 
 Yes  
 No  
 
6/21 Does it happen that you smoke more when you are sick and need to stay in bed all day? 
 Yes  






7/22 What is your gender? 
 Female   
 Male   
 
7/23 What is your age?  
 I am   ________ Years old  
7/24 Insurance status? 
 insured under a statutory insurance  
 private insurance  
 
7/25 What is your highest academic degree? 
 Main / primary school completion  
 General certification of secondary school  
 Advanced technical college entrance qualification  
 General or technical University entrance qualifications  
 No school qualifications  
 Other ________________  
 No response   
 
7/26 What is your highest professional degree? 
 Completed Professional-company training 
(apprenticeship) 
 
 Completed Professional-school education (Technical 
school, commercial school) 
 
 Training at a specialized school (Technical school)  
 Completed a degree at a polytechnic college  
 University degree  
 Still doing my professional training (Professional trainee, 
Student , intern) 
 
 No professional Training  
 Other ________________  
 No response   
 
7/27 What is your current job status? 
 Employed or Self-employed  
 In company training/education or occupational retraining  
 Federal Voluntary Service/ Voluntary Social Year  
 Pension  
 Stay at home Mom/Dad  
 College Student  
 High School Student  
 Unemployed due to Medical Reasons  
 Unemployed or in search of a job  
 Other ________________  
 No response   
 
7/28 What is your monthly net income? 
 0-500€  
 1001-1500€  
 1501-2000€  
 2001-2500€  
 >2500€  








Appendix B: Regression Equations 
To fulfill the aim of determining the driving factors WTP and WTP different multiple regression models were 
employed. 
For the dichotomous outcomes of WTP and WTU, we applied logit regressions. The model in general form was 
specified as follows: 
Let variable Yi denote WTP (WTU) which takes on two values, 0 and 1, representing whether a responder i is 
willing to pay for (willing to use) the smoking cessation aid. Let X=(X1,X2,X3…Xj) be a set of explanatory 
variables. The binary logistic regression for WTP (WTU) estimates the probability that WTP (WTU) is present 
given the values that the predictors take (𝑥𝑖𝑗). 
𝑌𝑖 = { 0 𝑖𝑓 𝑛𝑜1 𝑖𝑓 𝑦𝑒𝑠 }   and 𝑌𝑖~𝐵𝑖𝑛(𝑛𝑖 , 𝜋𝑖) ,  𝜋𝑖 = Pr (𝑌𝑖 = 1|𝑋𝑖𝑗 = 𝑥𝑖𝑗) 
The logit models of the following general form were estimated for WTP and WTU for each smoking cessation 
aid: 
logit(𝜋𝑖) = log ( 𝜋𝑖1 − 𝜋𝑖) = 𝛽0 + 𝛽𝑗𝑋𝑖𝑗 
The set of the explanatory variables for WTU and WTP was defined as X = (age, gender, income, employment, 
addiction level, health restrictions due to smoking, peer group, willingness to quit, attempts to quit smoking, 
having heard about the therapy, have used this therapy). The regressions were estimated using glm function of 
the statistical software R.  
For the WTP interval bids accelerated failure–time models were applied. The accelerated failure time model in 
general form was specified as a linear model of relationship between the logarithm of the WTP interval bids and 
the predictors:  
log(𝑊𝑇𝑃𝑖) =  𝛽𝑗𝑋𝑖𝑗 + 𝜀𝑖  
Where 𝜀𝑖 is a random error which determines the probabilistic behaviour of WTP and is assumed to follow the 
Weibull distribution.   
The set of the predictors for the interval regression was analogously defined as X = (age, gender, income, 
employment, addiction level, health restrictions due to smoking, peer group, willingness to quit, attempts to quit 
smoking, having heard about the therapy, have used this therapy). 
The accelerated failure time models were estimated for each therapy using survreg function of the “survival” 
package in R.  
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Abstract
Objective The aim of this study was to determine the
economic burden from a societal perspective and the
health-related quality of life (HRQOL) of patients with
juvenile idiopathic arthritis (JIA) in Europe.
Methods We conducted a cross-sectional study of
patients with JIA from Germany, Italy, Spain, France, the
United Kingdom, Bulgaria, and Sweden. Data on demo-
graphic characteristics, healthcare resource utilization,
informal care, labor productivity losses, and HRQOL were
collected from the questionnaires completed by patients or
their caregivers. HRQOL was measured with the EuroQol
5-domain (EQ-5D-5L) questionnaire.
Results A total of 162 patients (67 Germany, 34 Sweden,
33 Italy, 23 United Kingdom, 4 France, and 1 Bulgaria)
completed the questionnaire. Excluding Bulgarian results,
due to small sample size, country-specific annual health
care costs ranged from €18,913 to €36,396 (reference year:
2012). Estimated direct healthcare costs ranged from
€11,068 to €22,138; direct non-healthcare costs ranged
from €7837 to €14,155 and labor productivity losses
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Sanità (ISS), Rome, Italy
10 Centro di Ricerche Cliniche per Malattie Rare Aldo e Cele
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ranged from €0 to €8715. Costs are also shown to differ
between children and adults. The mean EQ-5D index score
for JIA patients was estimated at between 0.44 and 0.88,
and the mean EQ-5D visual analogue scale score was
estimated at between 62 and 79.
Conclusions JIA patients incur considerable societal
costs and experience substantial deterioration in HRQOL
in some countries. Compared with previous studies, our
results show a remarkable increase in annual healthcare
costs for JIA patients. Reasons for the increase are the
inclusion of non-professional caregiver costs, a wider use
of biologics, and longer hospital stays.
Keywords Rare diseases  Juvenile idiopathic arthritis 
Costs  Costs of illness  Quality of life
JEL Classification I1
Introduction
Juvenile idiopathic arthritis (JIA) is a general term for a
group of conditions characterized by chronic arthritis with
no defined cause. The disease commonly occurs in children
before the age of 16 and lasts for a minimum of 6 weeks.
According to the results of the International League of
Associations for Rheumatology (ILAR) Meeting in 2001,
JIA combines the following seven subtypes: systemic
arthritis, oligoarthritis, rheumatoid-factor-negative
polyarthritis, rheumatoid-factor-positive polyarthritis, pso-
riatic arthritis, enthesitis-related arthritis, and undifferen-
tiated arthritis. These subtypes represent heterogeneous and
autonomous diseases, apart from the undifferentiated
arthritis, which defines diseases that cannot be classified or
are related to more than one of the above subtypes [1]. The
prevalence in Europe ranges from 4.2 to 20.5 per 100,000,
depending on the specific subtype [2]. Country-specific
values are not available.
The progression of JIA varies across the subtypes in
terms of the number and type of inflamed joints, type of
complication (fever or rash), time of occurrence, and the
duration. Consequently, children with JIA are under threat
of suffering from long-term complaints like joint destruc-
tion. Treatment of JIA is subject to the subtype. In general,
it combines drug treatment, physiotherapy, occupational
therapy, and, if required, psychological therapy [1]. The
drug therapy covers a broad spectrum of medicines, e.g.,
non-steroidal anti-inflammatory agents, intra-articular cor-
ticosteroid injections, disease-modifying anti-rheumatic
drugs, anti-interleukin therapy, and biologics. The choice
of medication depends on the subtype of JIA [3].
The aim of this study was to estimate JIA-related social/
economic costs in Europe. We provide analysis of the
related costs, including direct healthcare costs, direct non-
healthcare costs (formal and informal care) and loss of
labor productivity. We quantify health-related quality of
life (HRQOL) for patients with JIA and JIA-related non-
professional caregivers. We provide our analysis on sam-
ples obtained during 2012 from eight EU countries.
Methodology
Research design and subjects This was a cross-sectional
study of people diagnosed with JIA who received outpa-
tient care and were living in the community. All patients
and caregivers were informed about the study objectives
and data confidentiality and were asked to state their
understanding of the study conditions and agreement to
participate. Cases were recruited from the specific JIA
associations and registries. The survey was completely
anonymous, as the patients were contacted by their patient
organization and their responses were sent directly to the
researchers without any identification data (name, identi-
fication, address, e-mail).
Information and variables of interest The fieldwork was
carried out between September 2011 and April 2013.
Questionnaires were administered by e-mail and postal
survey through patient organizations. The information
sources used in the study were the self-completed ques-
tionnaire filled out by patients and their caregivers.
Demographic and clinical data were collected from patients
diagnosed previously with JIA and their caregivers.
Most studies of cost-of-illness and HRQOL use infor-
mation gathered at a specific point in time. The question-
naire we used was detailed enough to reduce either
exaggeration or underestimation. To estimate resource
utilization, the questionnaire solicited information covering
the 6-month period prior to the study (12 months for hos-
pitalizations). Data for the preceding 6 months were
extrapolated to the entire year. We considered 6 months to
be an appropriate recall period. Patients and caregivers
were asked about reductions in working time (temporary
and permanent sick leave or early retirement), and these
data were used to estimate losses of labor productivity.
Also, when care was provided by non-professional care-
givers, they were asked about the informal care time.
Information about HRQOL was collected from JIA patients
through the generic EuroQol 5-domain (EQ-5D) ques-
tionnaire [4].
Costing methodology We used the prevalence approach
to estimate costs from a societal perspective. Disease
prevalence takes into account all existing cases during a
given year and all health care resources used for preven-
tion, treatment and rehabilitation, plus other resources used
(formal and informal care) or loss of labor productivity
S80 A. Kuhlmann et al.
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within that year as a consequence of the illness considered.
Prevalence-based cost-of-illness analysis has the advantage
of incorporating measurements of total annual healthcare
expenditure, which is particularly relevant for chronic
conditions such as JIA that require long-term treatment. In
this context, a bottom-up costing approach was used to
estimate total and average annual costs [5].
Data on resource utilization were collected for each
patient. The resources used were multiplied by unit costs to
estimate the annual cost per patient, with 2012 as the ref-
erence year.
Direct healthcare costs Direct costs were derived from
healthcare utilization. The value of resources used by
patients was calculated in terms of the relevant unit costs
and the average cost per patient in the sample. Information
about the number of hospital admissions was obtained from
the questionnaires.
Data for the volume of outpatient care (rehabilitation,
medical tests and examinations, visits to health profes-
sionals, and home medical care) and the number of emer-
gency visits were obtained from the questionnaires. Unit
costs that were obtained from different sources and
healthcare cost databases (see Supplementary Annex 2)
were then multiplied by the units of each resource used.
Information regarding the medications used by patients
with JIA was obtained from the questionnaires. The cost of
drugs used by patients was calculated by determining the
daily cost for each of the products used (based on the cost
of each pack dispensed and the dose used) and then mul-
tiplying by duration of use. When no information con-
cerning the number of units per pack was available, we
assumed the largest pack-size was dispensed. The costs of
prescription drugs used were obtained from the list of
approved drugs in the different countries (see Supple-
mentary Annex 2).
Information concerning the use of orthopedic devices
and healthcare-related transportation was obtained from the
questionnaires. The costs of orthopedic devices were
obtained from different distribution firms.
Direct non-health care costs Informal care is defined as
the performance of tasks by non-professionals that help
maintain or enhance patient independence. Informal ser-
vices are therefore defined as the group of tasks or care
provided by non-professional caregivers, who are often
relatives but may also be friends or neighbors. Information
about informal care was obtained from the questionnaires,
specifically from the items concerning the time spent
helping the patient with his or her basic activities of daily
living and the time spent helping with necessary instru-
mental activities of daily living (recall method). As a
conservative criterion, and for preventing conjoint pro-
duction, we have censored the time of care to a maximum
of 16 h per day (112 h per week) when the time of care
reported exceeded this figure.
The approach used to value the care hours was the proxy
good method, which values time as an output. This method
values the care provided by the informal caregiver con-
sidering that if he/she did not provide these services, their
presence would have to be substituted by another person
who could provide them [6]. Therefore, we took into
consideration the question of how much it would cost to
take on said substitution or replacement by hiring a pro-
fessional caregiver [7].
Information on formal paid care provided by profes-
sional caregivers and other social services was obtained
from the questionnaires and comes under the category of
social services. Data on unit costs were provided by dif-
ferent sources (see Supplementary Annex 2).
Loss of labor productivity Data on loss of labor pro-
ductivity were obtained from physical units converted into
monetary units with a human capital-based approach [8].
According to human capital theory, the average earnings
(gross wages) of a worker can be considered a good proxy
for labor productivity losses. Therefore, our calculations
were based on average gross wage figures in the Wage
Structure Surveys by the National Statistics Institutes of the
participating countries. Annual losses of labor productivity
were estimated for the year 2012.
Patient and caregiver outcomes Patient and caregiver
outcomes were obtained by means of self-administered
questionnaires such as the EQ-5D, the Barthel index, and
Zarit burden interview. The EQ-5D is a simple generic
instrument developed by a multidisciplinary group of
researchers [9]. This questionnaire has been validated in
many countries in Europe, and is commonly used in eco-
nomic evaluation and health technology assessment. There
are five dimensions in the EQ-5D covering the areas of
mobility, self-care, everyday activities, pain/discomfort,
and anxiety/depression. A total of 245 possible health
states can be defined in this way. Evaluations of these
health states have been reported for the general population
[9]. The values or utilities are indicated on a scale on which
death has a value of 0 and perfect health a value of 1, with
negative values being possible.
The Barthel index is a widely used tool for the assess-
ment of disability and measures the ability of a person to
perform ten basic activities of daily living, providing a
quantitative estimate of the subject’s degree of dependence
[10, 11]. It is easy to apply, has a high degree of reliability
and validity, is capable of detecting changes, and is easy to
interpret. The Barthel index is recommended as the
instrument of choice for measuring physical disability, both
in clinical practice and public health research. A score of
91–99 shows mild dependence, 61–90 moderate
Social/economic costs and health-related quality of life in patients with juvenile… S81
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dependence, 21–60 severe dependence, and\20 complete
dependence [11].
Caregivers also completed the Zarit Burden Interview (22-
item version), which measures the subjective burden among
caregivers. Each item is a statement which the caregiver is
asked to respond to using a 5-point scale, with options ranging
from 0 (never) to 4 (nearly always) [12]. The total score
ranges from 0 to 88, with scores under 21 corresponding to
little or no burden and scores over 61 to severe burden.
Results
One hundred and sixty-two questionnaires from six coun-
tries were collected within the study. The largest number of
questionnaires (67) was obtained from Germany. Italy and
Sweden contributed equally to the total sample, providing
33 and 34 filled out questionnaires, respectively. The rest
were obtained from the UK (23), France (four), and Bul-
garia (one). The latter was excluded from further analysis
due to the low response rate.
The resultant total sample consisted of 161 patients with
JIA. The major part of the sample was children and ado-
lescents (78 %) with a mean age of 14 years. Comparison
between countries of mean ages and numbers of adults
showed that the samples from France and Italy consisted
only of children and patients in the UK sample were, on
average, older than those from the other countries.
In contrast to the age of the patients, gender distribution
in the samples did not significantly vary across the coun-
tries, with females accounting for 70.1 to 78.8 % in the
total sample. The sample from France was an exception
and contained only one female participant (25 %).
The overall sample also included the responses of 47
informal caregivers. Response rate varied across the
countries, with the largest number of responses obtained
from Germany (16), followed by Sweden (12), Italy (nine),
the UK (eight), and France (two). The age of the caregivers
ranged from 34.5 (Germany) to 47.0 (France), with a mean
of 38.8 years. The share of female carers varied from
50.0 % in France to 91.7 % in Sweden. In total, 16 care-
givers were parents and 29 were relatives. The amount of
care provided ranged from 16 h a week in France to 52 in
Germany, with the average being 34 h per week. Table 1
summarizes the samples obtained from each country.
We quantified HRQOL for patients with JIA and for
non-professional caregivers using different approaches.
Table 1 summarizes the resultant estimates.
Estimates of the patients’ HRQOL calculated using the
EQ-5D instrument (TTO tariff) differed among Germany,
Sweden, and the UK. Although patients’ HRQOL showed
relatively high values in the German (0.729) and the
Table 1 Characteristics of the study participants
Bulgaria France Germany Italy Sweden UK
Patients
No of responses 1 4 67 33 34 23
Mean age (SD) 5.0 (NA) 6.5 (3.9) 13.1 (7.2) 10.5 (4.6) 14.5 (7.9) 21.4 (16.8)
Mean age at diagnosis, years (SD) 5.0 (NA) 4.3 (4.7) 8.8 (6.3) 4.2 (4.0) 7.7 (5.7) 5.2 (4.4)
Female (%) 0 (0) 1 (25) 47 (70.1) 26 (78.8) 26 (76.5) 18 (78.3)
Informal caregivers
No of responses 1 2 16 9 12 8
Mean age (SD) 33.0 (NA) 47.0 (4.2) 34.5 (13.1) 41.7 (11.3) 37.6 (10.0) 43.1 (9.7)
Female (%) 1 (100) 1 (50.0) 13 (81.3) 6 (66.7) 11 (91.7) 7 (87.5)
Relationship to patient
Parent to the patient 0 0 14 0 1 1
Other relative to the patient 1 2 2 8 11 6
Partner or other 0 0 0 1 0 0
Informal caregivers, hours per a week (SD) 0.0 (NA) 15.8 (22.3) 52.0 (41.1) 29.3 (26.8) 22.9 (32.8) 25.3 (23.8)
Health outcomes
Utilities adult patients (SD) NA NA 0.729 (0.139) NA 0.642 (0.128) 0.262 (0.239)
Utilities caregivers (SD) 0.649 (NA) 0.377 (NA) 0.745 (0.259) 0.799 (0.144) 0.594 (0.105) 0.663 (0.367)
VAS adult patients (SD) NA NA 60.2 (19.2) NA 56.1 (18.6) 49.0 (12.4)
VAS caregivers (SD) 50.0 (NA) 65.0 (NA) 71.6 (20.2) 78.3 (17.1) 69.8 (15.6) 67.1 (26.1)
Barthel index (patients) (SD)a NA 97.5 (3.5) 93.4 (13.1) 97.2 (7.9) 89.3 (14.3) 80.9 (18.1)
Zarit scale (caregivers) (SD) NA 50.0 (8.5) 24.6 (11.9) 16.4 (6.7) 30.9 (15.4) 22.9 (6.6)
a Barthel scores for Sweden and UK were re-escalated from 20-point scale to 100-point scale
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Swedish (0.642) samples, variating inconsiderably from
each other, the UK patients’ HRQOL took a significantly
lower value of 0.262.
Similarly to the patients with JIA, the caregivers were
seen to have quality of life below 1.0 value, however,
comparison between the estimates of the patients’
HRQOL and the caregivers’ HRQOL brought no clear
inference about the existence of correlation between them.
Considering the samples separately, the caregivers’
HRQOL estimate obtained in the UK (0.663) was con-
siderably higher than the patients’ HRQOL (0.262); in
Germany, it minimally differed from the patients’ one,
being 0.016 units higher (0.745); in Sweden, on opposite
it was slightly lower, and took a value of 0.594. Overall,
among all countries in the study, the estimates of the
caregivers’ HRQOL ranged from 0.594 to 0.799, with
exception of the French sample, which showed the lowest
value (0.377).
HRQOL estimates obtained over the total sample using
EQ-5D showed a mean value of 0.56 for the patients and
0.7 for the caregivers.
Estimates of HRQOL calculated with the VAS scale
showed a different pattern. According to this scale, the
patients’ quality of life was seen to considerably lower than
that of the caregivers across all samples.
Additionally, HRQOL was analyzed applying the Bar-
thel index and the Zarit scale. The Barthel index yielded
scores 80.9 (UK) to 97.5 (France) with an average for the
total sample of 91.5. The ranges in the Zarit scale values
varied from country to country, from 16.4 in Italy to 50.0 in
France, with a mean of 25.1 for the total sample.
Annual costs Resultant annual total costs varied from
€18,913 in France to €36,396 in Sweden, with a mean for
the total sample of €30,034 (±SD 33,945) per patient. The
largest cost fraction was direct healthcare costs, taking up
over 50 % of the total cost across all countries except the
UK. Although the direct healthcare costs fraction for the
UK was 46 %, they had the highest percentage of lost
productivity (27.6 %), due to having the largest number of
adults in the sample. The percentage of direct non-health-
care costs varied from country to country, with the lowest
in the UK sample (26 %) and the highest in the French
sample (41.48 %). Table 2 summarizes total annual costs
and costs in each cost fraction for each country.
Although the structure of the direct healthcare differed
across the countries, expenditures for medication consti-
tuted the largest share for all samples. The next largest
fraction differed from country to country, but was either
medical visits or hospitalization. The UK sample had the
largest share of aggregated expenses for healthcare
Table 2 Average annual costs per patient, all patients (2012, €)
Costs € 2012 Bulgaria France Germany Italy Sweden UK
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Drugs 0 NA 6585 7521 6227 9044 15,522 29,368 11,524 12,410 6667 9206
Medical tests 49 NA 397 239 386 343 152 264 986 1503 2493 2662
Medical visits 427 NA 3073 4170 3919 3771 1681 1609 7770 8582 4169 3206
Hospitalizations 2262 NA 974 1948 5331 6278 3454 6000 1310 2387 1047 2962
Health material 0 NA 40 79 227 1022 0 0 47 830 114 162
Healthcare transport 21 NA 0 0 70 394 0 0 76 262 19 91
Direct healthcare costs 2759 NA 11,068 3663 16,161 12,705 20,808 34,092 22,138 17,245 14,508 14,877
Professional carer 0 NA 0 0 20 165 0 0 0 0 597 2546
Non-healthcare transport 91 NA 219 320 249 278 187 319 630 719 75 143
Social services 0 NA 0 0 1210 6599 26 146 3772 8928 50 241
Direct non-healthcare formal costs 91 NA 219 320 1479 6593 212 337 4402 9442 722 2532
Main informal carer 0 NA 4106 8213 8420 20,144 4043 9533 7081 19,228 5661 11,722
Other informal carers 0 NA 3520 7039 1483 6272 3583 9355 2673 7360 1940 9027
Direct non-healthcare informal costs 0 NA 7626 15,252 9903 24,271 7625 18,436 9753 25,999 7601 18,703
Direct non-healthcare costs 91 NA 7845 15,157 11,382 24,989 7837 18,437 14,155 30,405 8323 18,665
Direct costs 2850 NA 18,913 12,277 27,543 28,022 28,645 42,218 36,293 40,737 22,831 24,728
Sick leave 0 NA 0 0 91 465 0 0 103 599 190 513
Early retirement 0 NA 0 0 0 0 0 0 0 0 8525 14,673
Labor productivity losses patients 0 NA 0 0 91 465 0 0 103 599 8715 14,566
Total costs 2850 NA 18,913 12,277 27,634 28,008 28,645 42,218 36,396 40,742 31,546 28,568
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transportation, health material, and medical tests (18 %).
The fractions of direct healthcare costs are illustrated in
Fig. 1.
The main part of direct non-healthcare costs in all
countries was for informal caregivers plus professional
carers, ranging from 68.90 % in Sweden to 98.49 % in the
UK. Another direct non-healthcare cost fraction, social
services, showed no similarities across the countries, ranging
from 0 % in the French sample to 26.65 % in Sweden.
Among all fractions of direct non-healthcare costs,
transportation costs were the smallest, varying from 0.9 %
(UK) to 4.45 % (Sweden). The direct non-healthcare costs
are presented in Fig. 2.
When looking specifically at the costs incurred by
adults (36 patients), the data were included in the analysis
based on the sample sizes of the UK, France, Germany,
Sweden, and Italy. Mean annual costs ranged from
€15,201 per patient in Sweden to €40,940 in the UK
(Table 3). Direct healthcare costs ranged from €10,504
per patient in Sweden to €20,985 in Germany and direct
non-healthcare costs ranged from €1933 per patient in
Germany to €5116 in the UK (Table 3). Loss of labor
productivity costs ranged from €349 per patient in Swe-
den to €20,045 in the UK (Table 3).
For pediatric patients, 125 were included in the analysis.
Mean annual costs ranged from €18,913 per patient in
France to €45,227 in Sweden (Table 4). Direct healthcare
costs ranged from €11,068 per patient in France to €26,985
in Sweden and direct non-healthcare costs ranged from
€7837 per patient in Italy to €18,242 in Sweden (Table 4).
Discussion
In this study, we analyzed JIA-related healthcare costs and
quality of life based on the samples obtained from six
European countries. We estimated direct healthcare and
non-healthcare costs and labor productivity losses and
quantified HRQOL for patients with JIA and their non-
professional caregivers. We compared differences between
the countries and analyzed the collected sample as a whole.
The study populations included show some heteroscedas-
ticity in terms of the sample size and age. Given that the
number of participants in Italy, Sweden, and the UK was
similar, the sample from France provided four questionnaires
and the sample obtained for Germany had the largest size,
estimates of JIA-related costs and HRQOL obtained for the
total sample are driven by the German study population.
Furthermore, the age structure of the UK sample sig-
nificantly differed from other countries. The main differ-
ence lies in the number of adults who participated in the
survey. In the UK sample, the number of adults was almost
twice that of any other country, whereas the French and
Italian samples contained no adult population. In contrast
to the age structure, the gender ratio did not significantly
vary from country to country, except for France, where the
sample only consisted of four patients, with one female.
While there was a moderate difference in the mean age
between Italy, Germany, and Sweden, the gap between the
UK and the other countries ranged from 6.9 to 10.9 years.
This can be explained by the differences in the number of
adult participants, with adults making up 43.48 % of the
UK sample but comparatively less of the samples from
Germany and Sweden, with 23.88 and 29.41 %, respec-
tively. In comparison with these countries, the samples
obtained from Italy and France contain a younger popula-
tion with a mean age of 10.5 and 6.6 years, respectively.
The difference in the estimates of the mean age ranged
from 4 to 8 years, determined by the absence of adult
patients in the French and Italian samples.
Weekly amount of care and relationship between informal
caregivers and the patients also varied from country to
country. The samples from Italy, Sweden, and the UK
reported the average amount of care to be from 22.9 to 29.3 h
per week. These samples also showed that patients receive
mostly non-parental care. The share of the informal care-






































Fig. 2 Direct non-healthcare costs
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100 %.Germany stands apart from these countries, reporting
significantly larger estimates for both the share of parental
care (87.5 %) and the weekly amount of care (52 h), which
results in considerably higher time expenditure.
We found that JIA had a significant impact on the
HRQOL of patients and their caregivers regardless of the
country. In adults, direct healthcare costs, especially drugs,
hospitalizations and medical visits, represented the vast
majority of costs, while in children, drugs, hospitalizations,
medical visits, and direct non-healthcare informal costs,
i.e., caregivers’ time, were predominant.
A study carried out by the London School of Economics
and Political Science within the BURQOL-RD project [13]
identified eight costing studies, from which only three
Table 3 Average annual costs
per adult patient, adult patients
(2012, €)










Drugs 6313 – 11,542 8 –
Medical tests 3226 – 278 1583 –
Medical visits 4102 – 5504 7033 –
Hospitalizations 1887 – 3563 1343 –
Health material 207 – 85 414 –
Healthcare transport 43 – 13 124 –
Direct healthcare costs 15,779 – 20,985 10,504 –
Professional carer 1372 – 0 0 –
Non-healthcare transport 110 – 333 474 –
Social services 0 – 8 2737 –
Main informal carer 3633 – 1592 1137 –
Other informal carers 0 – 0 0 –
Direct non-healthcare costs 5116 – 1933 4348 –
Direct costs 20,895 – 22,917 14,852 –
Productivity loss patients 437 – 383 349 –
Early retirement patients 19,609 – 0 0 –
Indirect costs 20,045 – 383 349 –
Total costs 40,940 – 23,300 15,201 –
Table 4 Average annual costs
per pediatric patient, pediatric
patients (2012, €)










Drugs 6939 6585 4560 16,322 15,522
Medical tests 1929 397 420 737 152
Medical visits 4220 3073 3422 8077 1681
Hospitalizations 401 974 5886 1296 3454
Health material 42 40 271 496 0
Healthcare transport 0 0 88 57 0
Direct healthcare costs 13,531 11,068 14,648 26,985 20,808
Professional carer 0 0 27 0 0
Non-healthcare transport 48 219 223 694 187
Social services 89 0 1587 4204 26
Main informal carer 7220 4106 10,562 9557 4042
Other informal carers 3432 3520 1948 3786 3583
Direct non-healthcare costs 10,789 7845 14,346 18,242 7837
Direct costs 24,320 18,913 28,994 45,227 28,645
Productivity loss patients 0 0 0 0 0
Early retirement patients 0 0 0 0 0
Indirect costs 0 0 0 0 0
Total costs 24,320 18,913 28,994 45,227 28,645
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examined labor productivity losses in addition to direct costs
[14–16]. The mean annual cost per patient was estimated to
be between €3471 [14] and €4663 [15], with estimates that a
very small proportion of the population (12 %) is respon-
sible for 80 % of the overall costs incurred [14].
The estimates of average annual total costs per patient
ranged in our study range from €18,913 to €36,396 and are
significantly higher than the reported estimates. The main
reason for this difference is that, in contrast to those
studies, we included costs for non-professional caregivers
in the cost calculation. In our analysis, costs for non-pro-
fessional care make up a substantial fraction (68.9–98.5 %)
of the direct non-healthcare costs. Subtracting these costs,
the direct healthcare costs calculated in our analysis still
show a considerable difference compared with previous
studies. In Germany, the average total costs per patient
excluding costs for non-professional caregivers are
€17,731, which is still significantly higher than the esti-
mates (€4663) obtained by Minden et al. for 2008 [15]. The
main difference in the results is down to differences in the
medication applied and length of hospital stay. In the study
by Minden et al., the proportion of patients treated with
biologics was 6 %, compared to 53.73 % in the BURQOL-
RD survey. In Germany, the annual costs for biologics
ranged from €5,223.33 to €19,720.39 per patient, so the
increasing number of patients receiving biologics therefore
has a high impact on the mean total costs. The average
length of hospital stay also significantly differs between the
BURQOL-RD (10.79 days) and the study by Minden et al.
(4.34) days [15].
Three patterns were seen when comparing structures of
direct healthcare costs across the countries. First, medica-
tion costs took up the largest share in all samples. Second,
in the German and Italian samples, hospitalizations made
up the second largest cost fraction followed by medical
visits, with the remaining fractions contributing less to the
direct costs. Third, in contrast to Germany and Italy, costs
for medical visits in France, Sweden, and the UK were
higher than those for hospitalizations. Additionally, in the
UK sample, the costs for medical tests took up a consid-
erable share.
In the structure of the direct non-healthcare costs, two
major fractions were observed for all countries: costs for
main informal caregivers; and costs for the other informal
caregivers, with the former being the largest. Costs for
social services are the largest observed for the Swedish
sample and costs for professional carers the largest for the
UK. Transport costs have the smallest share in the direct
non-healthcare costs.
Although in the French, German, Italian, and Swedish
samples the second largest part is direct non-healthcare
costs, in the UK, the cost of loss of labor productivity
makes up a considerable share of the total. The UK sample
contains a relatively large number of adults and in this
sample, productivity losses are mainly caused by early
retirement; however, due to the small study sample, it is
difficult to derive a valid inference about stable causality.
A review of HRQOL instruments used for rare dis-
eases was carried out within the BURQOL-RD project
by the Swedish Institute for Health Economics (IHE)
[17]. Thirty articles studied HRQOL in patients with
JIA, whereof the majority (24 articles) used generic
measurements, such as the Childhood Health Assessment
Questionnaire (CHAQ), SF-36 or EQ-5D; with the latter
two showing impairment compared to the general pop-
ulation [18–20]. Only four articles applied a disease-
specific questionnaire, either the Juvenile Arthritis
Quality of Life Questionnaire (JAQQ) [21–23] or
Arthritis Impact Measurement Scales [19].
In this study, we used a range of instruments to quantify
health-related quality of life for patients with JIA and non-
professional caregivers: the EQ-5D index score and the
VAS scale were used to measure HRQOL in both patients
and caregivers; the Barthel index was applied to patients
only; and the Zarit scale was used for caregivers only.
The EQ-5D index score estimates HRQOL obtained for
the patients were close to the middle of the possible range
and lower than for caregivers. The estimates obtained with
the VAS scale similarly showed lower values of the patients’
HRQOL as those of the caregivers, supporting the results
obtained using the EQ-5D index. Both instruments indicated
a reduction in health status for patients with JIA. Addi-
tionally, the average Barthel index score of 91.5 implied the
presence of mild dependence, however, this could be caused
by inclusion of children in the calculations.
Comparison of the results among the countries indicated
contrastingly low HRQOL estimates for patients in the UK
sample. The population structure of this sample differed
from the German and the Swedish samples, presenting
older adult population of 38.5 years old on average,
whereas the German and Swedish samples had younger
adults with an average age of 22.8 and 24.2 years.
The resultant difference in the estimates of HRQOL
might point to an age bias in average HRQOL; however,
the small sample size made it difficult to provide a clear
statement about a causal relationship between these
variables.
Estimates of HRQOL for JIA-related non-professional
caregivers indicated the existence of a caregiving burden.
According to the mean Zarit score of 25.1, the burden is, on
average, small. On average, the highest burden of 50.0 was
reported in the French study sample, corresponding to the
lowest EQ-5D utility for caregivers. The lowest burden of
16.4 was in the Italian study sample, which also corre-
sponded to the highest EQ-5D index score estimate for
caregivers.
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Conclusions
The results of the BURQOL-RD project confirm the exis-
tence of socio-economic burden caused by juvenile idio-
pathic arthritis in Europe. Although JIA-related healthcare
and non-healthcare costs vary across the countries, the
estimated magnitudes of costs are high. Compared with
previous studies, our results show a remarkable increase in
annual healthcare costs for JIA patients. Reasons for the
increase are the inclusion of non-professional caregiver
costs, a wider use of biologics, and longer hospital stays.
The related quality of life worsens for both patients and
non-professional caregivers. Patients with JIA show a
medium impairment in health status and caregivers have a
life burden. The estimates of HRQOL also varied across
the countries. Variation in the age structures is seen to be a
possible reason for these differences.
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Abstract
To analyze contemporary costs of HIV health care and the cost distribution across lines of combination antiretroviral therapy (cART).
To identify variations in expenditures with patient characteristics and to identify main cost determinants. To compute cost ratios
between patients with varying characteristics.
Empirical data on costs are collected in Germany within a 2-year prospective observational noninterventional multicenter study.
The database contains information for 1154 HIV-infected patients from 8 medical centers.
Means and standard deviations of the total costs are estimated for each cost fraction and across cART lines and regimens. The
costs are regressed against various patient characteristics using a generalized linear model. Relative costs are calculated using the
resultant coefficients.
The average annual total costs (SD) per patient are €22,231.03 (8786.13) with a maximum of €83,970. cART medication is the
major cost fraction (83.8%) with a mean of €18,688.62 (5289.48). The major cost-driving factors are cART regimen, CD4-T cell
count, cART drug resistance, and concomitant diseases. Viral load, pathology tests, and demographics have no significant impact.
Standard non-nucleoside reverse transcriptase inhibitor-based regimens induce 28% lower total costs compared with standard PI/r
regimens. Resistance to 3 or more antiretroviral classes induces a significant increase in costs.
HIV treatment in Germany continues to be expensive. Majority of costs are attributable to cART. Main cost determinants are CD4-T
cells count, comorbidity, genotypic antiviral resistance, and therapy regimen. Combinations of characteristics associated with higher
expenditures enhance the increasing effect on the costs and induce high cost cases.
Abbreviations: ALT = alanine aminotransferase, ARV = antiretroviral, cART = combination antiretroviral therapy, CCR5 = C-C
chemokine receptor type 5, CDC = Centers for Disease Control and Prevention classification system, CORSAR = Cost and
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Resource Utilization Study in Antiretroviral Therapy, GLM = a generalized linear model, HIV = the human immunodeficiency virus,
LDL= low-density lipoprotein cholesterol, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = protease inhibitor,
PLWHIV = people living with HIV, SD = standard deviation.
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1. Introduction
The introduction of combined antiretroviral (ARV) therapy and
its successful scale-up have resulted in major reductions in HIV-
associated morbidity and mortality,[1–3] and transformed HIV
into a chronic and manageable condition.[4] cART regimens have
been proven effective and well tolerated, and have become the
standard in HIV-related health care[4–6]; however, cART is
expensive and together with the growing number of people living
with HIV, who receive cART and their prolonged life expectancy,
it poses an increasing financial burden on public health systems.
Continuous accurate estimations of the related costs have become
important for decision-making in management of HIV infec-
tion.[7] Estimates of annual total expenditures per patient have
been obtained worldwide[8–13]; however, in Germany relatively
few studies have investigated costs of HIV treatment since the
advent of cart.[8,14–16] For the period from 2006 to 2009, mean
average costs for Germany were estimated as € 23,298 per
patient.[14] It has been determined that patient characteristics,
such as CD4-T cell count are good predictors of annual costs;
however, the authors point to a need for further research in this
field.[7,14]
The objective of the present study is to explore links between
costs and a wide set of patient characteristics using data, which
were collected within a 96 weeks noninterventional, multicenter
prospective cohort study: Cost and Resource Utilization Study in
Antiretroviral Therapy (CORSAR).[16] Previously, we conducted
a descriptive analysis of the cost data obtained over the first 48
weeks of this survey.[16]
In this analysis, we examine composition of the annual costs,
determine major cost drivers,[17] and estimate relative cost
ratios[18] between patients with varying characteristics. The
relative cost ratios, in comparison to point estimates, have the
advantage of possible stability across various populations, and
therefore, they may be applicable to populations other than the
German case.[18]
2. Methods
2.1. Setting and study design
Themulticenter CORSAR study recruited patients in 8 regionally
and structurally different health care providers from different
areas in Germany for a prospective noninterventional survey
from 2009 to 2012: 4 specialized private practices (outpatient
centers) and 4 hospitals offering both HIV-related inpatient and
outpatient services. The multicenter design and absence of
preselection minimized a risk of bias.
Major criteria for enrolment of the patients to the survey were
HIV-positive status, age older than 18 years, and ongoing cART.
At the beginning of the survey, the participating sites recorded full
patient data as at the date of individual entry to the study;
thereafter, the observation and recording of the data were
documented every 3 months on an individual schedule. The
resultant database provided information on (i) demographics:
age, gender, education, and income status; (ii) clinical conditions:
diagnosis, time after initial diagnosis ofHIV infection, CD4-T cell
count, Centers for Disease Control and Prevention classification
system (CDC) class, viral load, pathology tests, disability, and
comorbidities; (iii) therapy: therapeutic regimen (dosage, sub-
stances, and treatment periods), line of ARV regimen at start of
the study, genotypic resistance testing, and details of concomitant
medications.
The following classifying parameters were assigned to the
patients at the date of entry and were not changed during the
follow-up period: age, CDC classification, time since the initial
diagnosis of HIV before entering the study, assigned therapy
regimen, and cART therapy line.
For the analysis, ARV regimens were classified according to the
classes of the ARV substances (further references to the defined
here ARV regimens are highlighted in Italic format and used for
the purpose of the present analysis only):
1. “NNRTI” (non-nucleoside reverse transcriptase inhibitor):
NNRTI-based regimen, consisting of 1 NNRTI in addition to
nucleos(t)ide analogues;
2. “PI-standardized”: PI-based regimen, consisting of 1 ritona-
vir-boosted PI (Protease inhibitor, PI/r) in addition to nucleos
(t)ide analogues;
3. “PI-individualized”: individualized PI/r-based cART regimens
consisting of elements of more than 2 different ARV classes
and more than 3 different ARV substances including boosted
PIs (predominantly used as a salvage regimen in multiple pre-
treated patients);
4. “Other”: other cART regimens that do not meet the criteria of
the 3 previous regimen classes, that is, regimens that consist
neither of PI nor NNRTI elements, that is, those based on the
INSTI (integrase strand transfer inhibitor) raltegravir or the
CCR5 (C-C chemokine receptor type 5) inhibitor maraviroc,
nor nuke-sparing regimens, for example, boosted double PI/r
therapy;
5. “Mixed”: if patients spent less than 95% of the year on one of
the aforementioned regimen classes, their therapy classes were
classified as “Mixed.”
2.2. Ethical review
The CORSAR survey was approved by the national regulatory
authorities and local ethics committees of all participating
centers. All patients were given thorough information on the
survey. Before the participation in the interviews, the patients
gave a written consent. No incentive was offered for the
participation in the survey.
2.3. Cost calculations
The collected data contained detailed information on utilization
of various resources, including (i) cARTmedication and non-HIV
medication; (ii) outpatient care (physicians’ services, outpatient
rehabilitation, nutritional, and psychological support); (iii)
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inpatient care (hospital stay, inpatient costs, rehabilitation,
physiotherapy, and overhead expenses); (iv) indirect costs; and
(v) out-of-pocket costs.
The expenditures were calculated by taking the volume of
resource utilization for inpatient days, outpatient specialist visits,
lab tests, usage of in- and outpatient rehabilitation, and services
of nutritionists and psychologists, and multiplying these by the
respective unit cost in accordance with the current German
recommendations for the assessment of health care resource
consumption.[19,20] Following these recommendations,[20] we
calculated drug costs taking pharmacy retail prices and
subtracting manufacturer and pharmacy discounts paid to the
statutory health insurance.
We estimated the unit cost of an inpatient stay based on
German hospital statistics.[21] The calculation of in- and
outpatient rehabilitation unit cost was performed using data
from the statutory health insurance fund, retirement insurance,
and the Federal Association for Rehabilitation.[22–24] Data on
the unit cost for a specialist visit were retrieved from the salary
report provided by the German Association of Statutory
Health Insurance Doctors.[25] Publically available reports on
supportive medical care were used in estimating the unit cost for
massages and physiotherapy services.[26–28] Indirect costs were
calculated as the product of number of days of absence from
work and work compensation per day. To avoid overestimation
of the indirect costs of early retirements or permanent
occupational disability, we put an upper limit to the days of
absence fromwork equal to the vacancy time of jobs in Germany
in 2012 (77 days).[20] This approach is a simplification of the
friction costs approach.[29]
Cumulative annual costs were calculated prospectively by
annualization. Total costs were computed as the sum of the cost
fractions following a bottom-up method.
2.4. Analysis
Total costs were analyzed separately for each year of the
observational period. We excluded from the obtained data all
individuals on treatment break, all patients who had abandoned
the survey during the first year, and those patients who incurred
extremely high expenditures on non-HIV medication (over
€100,000/year). We defined proportions for each of the cost
components and analyzed the variation of the total costs across
the patient variables. We calculated means and standard
deviations of the total costs as well as the costs in each fraction.
In order to estimate mean annual costs as a function of various
patient characteristics, we employed different multiple regression
models. We developed the models based on distributional
characteristics of the cost data and selected the best-fitting
model using McFadden’s pseudo-R2 and measures of prediction
ability.[30] We used the obtained estimates to calculate cost
ratios[18] that allowed the comparison of cost projections for
patients with varying indicative characteristics while holding
others unchanged. Detailed description of the model develop-
ment and estimation of the cost ratios are given in Appendix A
(see Appendix A and to that related Table 9, Table 10, and
Figures 2–5, Supplemental Content, http://links.lww.com/MD/
B55, which describe the applied methods in greater detail).
3. Results
Overall, CORSAR enrolled 1154 adult patients. In total, we
excluded 132 patients: 63 people with treatment interruptions,
65 people who abandoned the survey during the first year and
4 patients who incurred extremely high expenditures on
non–HIV-related medications. Eighty patients did not follow
the survey into the second year. The resulting sample was of 1022
patients who had completed the first year and 942 who had
completed both years of the survey, totally resulting in 1964
patient years.
Table 1 reports details on the patient data and estimates of
the average annualized total costs stratified across clinical and
demographic variables.
The patient data for subjects lost to follow-up during the first
year of the study are given in supplement (see Table 6,
Supplemental Content, http://links.lww.com/MD/B55) and show
no particular differences from the rest sample. Results of the
descriptive analysis of the costs do not show a considerable
difference between the estimates obtained for the first and the
second year as well as there were no significant differences in
the cost of HIV care across the 8 health care provider sites
in the survey. For the first and the second year, the mean annual
total costs (SD) per patient were €22,477.57 (8809.45) with a
maximum of €87,920, and €22,231.03 (8786.13) with a
maximum of €83,970, respectively. cART medication was found
to be the major contributor (83.8%) to the total costs with mean
(SD) of €18,852.53 (5297.44) in the first and €18,688.62
(5289.48) in the second year. The second largest fraction was
medication costs on treatment of comorbidities with mean values
of €1499.36 (3718.50) and €1805.05 (5034.45) and for the first
(6.6%) and second (8.1%) years, respectively. Expenditures on
inpatient care were estimated as €1246.98 (3850.15) and
€984.53 (2894.06) and contributed 5.6% and 4.4% into the
total costs, respectively. Further data on costs stratified by
therapy line and therapy class are given in Table 2 for both years.
Tables presenting the cost data across the 8 health care
providers stratified by cost categories (see Table 7, Supplemental
Content, http://links.lww.com/MD/B55) and annualized costs of
HIV care by cost category for both years of CORSAR(see
Table 8, Supplemental Content, http://links.lww.com/MD/B55)
are given in the supplemental content.
The regression analysis was performed using the full patient
data collected at the beginning of the survey and data on
expenditures obtained over the following 1-year period of the
CORSAR survey (n=1022; Table 1). Patients with CD4-T count
below 200cells/mm3 incur the highest total costs, cART
medication costs, and inpatient costs compared with those for
patients with less advanced cellular immunodeficiency. Table 3
reports mean (SD) total costs for each therapy line and therapy
class stratified by CD4-T cell count showing the same pattern of
variability of the costs for different disease stages across therapy
classes and cART lines.
As assessed by 1-way analyses of variance, overall differences
in mean total costs were statistically significant across the
categories of the following variables: CD4-T cell count, plasma
viral load of HIV, genotypic antiviral resistance, comorbidity,
ARV therapy line, and therapy class.
We regressed the annual total costs against 14 explanatory
variables using a generalized linear model (GLM) with a log link
function and inverse Gaussian distribution of the error term.[31]
The estimates with 95% confidence intervals resulting from
fitting the model are given on a log scale in Table 4.
Exponentiating the value of the intercept gives an estimate of
the mean total costs for a hypothetical patient with the reference
characteristics as €22,959.80. All estimates represent the mean
differences in total costs relative to these control categories.
Treskova et al. Medicine (2016) 95:26 www.md-journal.com
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Table 1








Age group Age group of a patient in years 20–29 2.45 20433.52 (5832.53)
30–44 35.03 21204.40 (7139.14)
45–59 48.43 23293.55 (9619.25)




Gender Gender Female 11.15 21135.21 (7313.19)
Male 88.16 22631.30 (9001.27)
n.a. 0.68
Education The highest educational level achieved Graduated 17.22 22899.59 (9874.76)
‘ Neither nor 69.57 22593.78 (8792.30)
No school certificate 1.86 22257.89 (5689.44)
n.a. 11.35
Income Stable or nonstable income Full-time employment 36.89 22109.67 (9331.49)
Pensioner 26.22 24353.18 (9792.38)
Other 23.48 21553.61 (7067.69)
n.a. 13.41
HIV-related variables
Time since diagnosis of HIV Time after initial diagnosis of HIV infection
before entering the survey (in years)
0–10 45.89 20887.23 (6546.21)
10–20 33.37 22856.04 (9426.28)
>20 10.96 26947.46 (12355.37)
n.a. 9.78
CDC class Class according to the CDC classification
system for HIV infection
Category A: Mildly symptomatic 29.26 20444.96 (6887.97)
Category B: Moderately symptomatic 43.25 23013.70 (8742.01)
Category C: Severely symptomatic 27.50 23759.40 (10400.28)
n.a. 0.00
Viral load HIV viral load (RNA copies/mL) <50 85.23 22114.38 (8523.27)
50–500 6.36 24674.51 (10423.58)
>500 2.05 26808.55 (16209.45)
n.a. 6.36
CD4-T CD4-T cell count (cells/mm3) >500 55.09 22014.91 (8559.18)
200–500 38.36 22203.99 (8151.42)
<200 6.46 27960.86 (12774.61)
n.a. 0.10
Treatment-related variables
Therapy class Assigned antiretroviral drugs classes PI-ind 5.58 38333.72 (13250.53)
PI-standard 40.90 25057.94 (6769.53)
NNRTI 26.52 18221.90 (5457.26)
Mixed 7.63 22575.21 (9796.56)
Other 19.37 18295.04 (7014.85)
n.a. 0.00
Therapy line Combination antiretroviral therapy (cART) line First line 42.27 21182.04 (7193.05)
Second and third line 17.03 21259.52 (7562.71)
Beyond the third line 27.89 25285.13 (10824.55)
n.a. 12.82
Resistance Genotypic resistance against
antiretroviral medication
No resistance 82.58 21737.98 (8164.37)
Three classes (PI, NNRTI, and NRTI) and more 4.31 16546.00 (4625.89)
NNRTI 0.20 27411.45 (11468.56)
NRTI 1.08 27876.00 (10467.59)
NRTI and NNRTI 0.49 23194.37 (9335.68)
PI 7.63 23491.32 (9016.87)
PI and NRTI 3.72 32670.73 (12439.09)
n.a. 0.00
General health-related variables
ALT test Alanine aminotransferase test (U/L) <110 94.81 22454.79 (8787.94)
≥110 2.64 24926.26 (11215.06)
n.a. 2.54
LDL test Low-density lipoprotein cholesterol test (mg/dL) <200 76.91 22645.74 (8996.35)
≥200 1.96 22207.95 (4438.80)
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The results of the regression revealed that low CD4-T cell
count, genotypic resistance against ARV medication, and a
greater number and severity of concomitant diseases were strong
predictors of more intensive health care utilization and increased
treatment costs. Higher costs were induced by the following levels
of the predictors: evidence of cellular immunodeficiency at entry
to CORSAR (“CD4-T cell count between 200 and 500/mm3” or
“less than 200/mm3”) vs. nonimpaired immune status (“more
than 500/mm3”), disability with index “>50” versus index “0,”
comorbidity classified as more than 2 nonsevere concomitant
diseases and more than 2 severe concomitant diseases versus
control category of fewer than 2 nonsevere concomitant diseases,
therapy class defined as “PI-individualized” versus “PI-stan-
dardized,” drug resistance to PI-based regimens or to 3 or more
ARV classes versus no genotypic resistance.
The following categories of the predictors were associated with
lower costs relative to the control categories: female gender,
“10–20 years” versus “0–10 years” after the first positive
diagnosis of HIV infection, a laboratory test of blood creatinine
with level of “>1.5” versus “<0.9,” therapy class of “NNRTI,”
“Mixed,” and “Other” category versus “PI-standardized”
category. Age, CDC-class, laboratory tests low-density lipopro-
tein (LDL) and alanine aminotransferase (ALT), and viral load
did not appear to have a significant effect on the total costs within
the study.
Using the obtained estimates, we calculated cost ratios between
patients with different characteristics.[18] Assuming all other
patient characteristics being held constant, cost ratios were
estimated relative to the following comparison group: “male”
gender, “PI-standardized” therapy class, “<500” CD4-T cell
count, comorbidity of fewer than 2 nonsevere diseases, no drug
resistance. The ratios were calculated across genders, all CD4-T
cell strata, all therapy classes, and 2 categories of drug resistance:
resistance to at least 3 therapy classes and no resistance. Figure 1
illustrates calculated cost ratios. The values of the ratios and
respective confidence intervals are given in Table 5.
The relative costs show either increasing or decreasing effects
of the selected categories of the patients characteristics on the
costs in terms of factors relative to the reference case, and can be
used to explore interactions among groups of the patient
characteristics.
The cost ratios show an enhanced increasing effect of a
combination of the patient characteristics associated with higher
costs. For instance, for those with resistance to 3 or more ARV
classes the costs increase by a factor of 1.266. For those with
combination of this resistance with a complex individualized
cART regimen, the costs increase by a factor of 1.818. Adding to
this combination a low CD4-T cell count and severe comorbidity
increases the costs by more significant factors: of 2.202 and
2.722, respectively.
4. Discussion
The strength of CORSAR is that it provides recent cost-of-disease
data of HIV infection in a prospective, multicenter study design
within a large national cohort in Germany, representing different
structures of the German health care providers. It reflects the
actual state of cART for patients in different stages of HIV disease
and on different ARV treatment lines, including more recently
approved ARVs, complies with current treatment guidelines, and
takes into account actual price changes in the cART medication
during the observation period. Additionally, the present work
gains an advantage with estimating the cost ratios that can be
applicable for other populations.
The estimated average annual total costs per patient
(€22,231.03) are slightly lower comparing with the results of
Mostardt et al (€23,298)[14] who conducted their study in
Germany, using 2008 as the price reference year. As well as, our
estimates fall into ranges of estimates provided in different studies
conducted in the United States[7,32,33] and European countries.[8]
Overall, comparison of the results between the studies should
be done cautiously due to considerable differences in the design
of the observational surveys and the resultant population
samples.
The proportion of cART costs in total costs has risen from
about 67% to about 84% and the fraction of inpatient care costs
has decreased from the level estimated in 2001,[34] suggesting a







Creatinine test Serum creatinine level test (mg/dL) < 0.9 49.12 21853.01 (8385.95)
0.9–1.5 46.67 23165.05 (8911.07)
>1.5 1.66 28518.82 (17065.95)
n.a. 2.54
Comorbidity Number of concomitant diseases and degree
the severity of the severest among the diseases
2non-severe 33.46 21153.69 (8564.13)
2 severe 8.61 24335.64 (9100.47)
>2 nonsevere 25.05 21886.39 (7486.47)
>2 severe 4.01 28704.37 (14693.85)
None 28.86 21004.24 (8180.29)
n.a. 0.00
Disability Disability index according to the
German the Disabled Persons Act†
0—No disability 50.39 21206.26 (7834.82)
<50—Intermediate/moderate disability 11.35 22169.72 (8152.56)
≥50—Severe disability in activities of daily living 28.96 24762.82 (10245.40)
n.a. 9.30
ALT = alanine aminotransferase; CDC = Centers for Disease Control and Prevention classification system; HIV = human immunodeficiency virus; LDL = low-density lipoprotein cholesterol; NNRTI =
non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
∗
Not available observations.
† Grad der Behinderung (GdB), Deutsches Schwerbehindertenrecht.
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Mean cART costs are higher for first-line therapy compared
with second- and third-line therapies. The difference is a
consequence of the applied ARV regimens: PI/r or INSTI-
based regimens were commonly used in first-line therapy and
were more expensive than NNRTI-based cART regimens,
which were widely applied in second- or third-line cART in
Germany before 2013. The predominance of PI/r-based cART
in first-line therapy has been previously described in theGerman
Clin-Surv cohort and explained by the assumption of an
elevated risk of virologic failures and selection for viral
resistance by NNRTIs in cART-naïve patients with a high viral
load.[34]
Table 4
Summary of the regression analysis for annualized total costs (GLM with inverse Gaussian distribution of the error term and log link
function; n=1022).




Age group/45–59 20–29 0.0925 0.0716 0.2567 0.2698
30–44 0.0012 0.0510 0.0533 0.9647








CDC class/B A 0.0398 0.0149 0.0945 0.1540
C 0.0545 0.0053 0.1143 0.0747
Therapy line/the first line Beyond the third 0.0334 0.0954 0.0287 0.2926
The second and the third 0.0555 0.1212 0.0102 0.0984
Lab ALT/< 110 ≥110 0.0712 0.0683 0.2107 0.3178
Lab CREAT/<0.9 > 1.5 0.2205
∗
0.0435 0.3975 0.0150
0.9–1.5 0.0119 0.0370 0.0609 0.6335
Lab LDL/<200 ≥ 200 0.0150 0.1517 0.1818 0.8598







None 0.0381 0.0990 0.0228 0.2204
Viral load/<50 > 500 0.0995 0.2895 0.0905 0.3051
50–500 0.0196 0.0810 0.1203 0.7023
CD4-T cells count/>500 200 0.1917
∗∗∗
0.3017 0.0816 0.0007
200–500 0.0474 0.0969 0.0022 0.0615
Time since diagnosis/0–10 years 10–20 years 0.0573
∗
0.0004 0.1143 0.0491
>20 years 0.0816 0.1706 0.0073 0.0728
Drug resistance/none Three classes (NNRTI, PI, NRTI) 0.2359
∗∗∗
0.3743 0.0975 0.0009
NNRTI 0.0711 0.4326 0.5748 0.7820
NRTI 0.0523 0.3056 0.2009 0.6855
NRTI and NNRTI 0.2837 0.7547 0.1873 0.2383
PI 0.0742 0.1546 0.0062 0.0710
PI and NRTI 0.0048 0.1186 0.1089 0.9335












ALT = alanine aminotransferase; CDC = Centers for Disease Control and Prevention classification system; LDL = low-density lipoprotein cholesterol; NNRTI = non-nucleoside reverse transcriptase inhibitor;
PI = protease inhibitor.






”, 0.05; “.”, 0.1; “ ”, 1.
Table 3
Mean annualized total costs (SD) by CD4-T cells count stratum, the therapy line, and the therapy class.
Mean of total costs (SD) across combination antiretroviral therapy lines stratified by CD4-Tcell count (n=1022; Euro)
CD4–T cells/mm3 The first The second and the third Beyond the third
>500 21551.78 (8152.84) 20739.94 (7130.33) 23911.55 (10345.39)
200–500 20609.06 (5824.29) 21056.82 (7239.24) 26060.39 (10305.20)
<200 22592.92 (7701.60) 27489.64 (10824.19) 32418.55 (14193.73)
Mean of total costs (SD) across antiretroviral drugs classes stratified by CD4-T-cell count (n=1022; Euro)
CD4–T cells/mm3 PI-ind PI-stand NNRTI Mixed Other
>500 37762.54 (13829.54) 25234.02 (7661.74) 17569.25 (4773.33) 20696.30 (6837.91) 17445.12 (4510.64)
200–500 37407.90 (12499.68) 24476.15 (5203.15) 18993.48 (6276.20) 21702.12 (9941.09) 18020.45 (6544.42)
<200 42763.12 (13935.73) 27503.20 (5701.21) 20455.50 (5685.62) 28441.08 (15167.92) 26177.79 (15844.88)
NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
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The second- and third-line therapies, however, are associated
with higher utilization of nonmedicationHIV care: hospital stays,
outpatient care, and rehabilitation. Higher health care services
consumption is mainly caused by occurrence of intercurrent
diseases or immune reconstitution inflammatory diseases among
late-presenting patients with HIV in the first years after initiation
of cart.[35,36] Patients under therapy beyond the third-line report
the highest direct costs for cART medication, these being driven
by more complex ARV treatment regimens: a higher amount of
used substances and increased doses of certain ARVs. Although it
was not documented in CORSAR, it is reasonable to suggest that
switching to a beyond the third-line therapy might be induced
either by treatment failures or strategic aspects of ARV treatment
or by an intention to overcome adverse long-term effects or
individual intolerances against certain ARVs.
The modeling methods applied in this study reveal possible
determinants of the average annual costs per patient. Mean total
costs increase with a decline in CD4-T cell count. This result is
consistent with findings of other studies[7,14]; however, when
considering the clinical stage, CDC classification variable,
particularly class C, which defines the AIDS stage, shows an
absence of statistically significant estimates. It suggests that long-
term surviving the AIDS stage does not impact on annual costs;
thus, only actual CD4-T cell count below 200/mm3 is a strong
predictor of higher costs due to the higher risk of related
infections and diseases. This observation might be relevant to 3
different patient subgroups in the CORSAR cohort: (i) late
presenters with advanced cellular immunodeficiency who
recently started cART, (ii) patients with an immunological or
clinical failing of cART, and (iii) immunological long-term
nonresponders, usually late presenters, who started cART with a
profound cellular immunodeficiency with a CD4-T cell count
below 50/mm3. All 3 subgroups have a higher risk of receiving a
more advanced cART treatment line or to have intercurrent or
concomitant diseases or both. In contrast to these subgroups,
those late presenters who have been receiving cART for more
than 1 or 2 decades and belong to the CDC-C class, but
have actual CD4-T cell counts within the normal range, are more
likely to receive less complex cART or to have no active
concomitant diseases. Female patients incur fewer costs than
male patients. These differences have been previously reported
elsewhere.[14,37–39] One might hypothesize a number of reasons
for gender-specific differences in costs[14]; in our study,
considerable differences lie in expenditures on non–HIV-related
medication and indirect costs.
We also found an association between costs and the presence of
concomitant diseases and disability. The source of these
increasing total costs is expenditures on non-HIV medication
and additional care. According to the estimated cost ratios,
worsening of comorbidity, in terms of number of diseases and
their severity, induces a considerable rise in annual total costs. In
the CORSAR database, the reported concomitant diseases are
grouped into: cardiovascular, respiratory, gastrointestinal,
endocrine, neurological, psychiatric, dermatological, hematolog-
ical, and allergological diseases. Defining cost variation across
types of concomitant diseases requires additional data and
further analysis.
With regard to the therapy-related predictors, the total costs
are linked to the cART regimens, costs of which are directly
related to drug prices and the number of ARVs used; when
holding all other factors constant, variation of the therapy class
from PI/r-based cART to NNRTI-based treatment which is
available as a less expensive alternative in Germany[40] decreases
annual costs in the CORSAR cohort. However, individual risks
of treatment failure, development of drug resistance or occur-
rence of toxicity are not modeled in this study; therefore, the
impact of these events on the resulting costs in long term cannot
be defined. Additionally, the total costs increase when drug
Figure 1. Spider web plot of cost ratios between patients with varying characteristics. Points on the axis give either increasing or decreasing effects of the
presented groups of patient characteristics relative to the reference case for men (left) and women (right). Point types represent the respective therapy classes. The
blue rhombus in the middle of the plot (left) gives the reference case, which corresponds to a cost ratio of 1 and the following characteristics: male, therapy
class= “PI-stand,”CD4= “>500,” comorbidity= “2 nonsevere,” drug resistance= “no resistance.” All other ratios (including those given on the plot for women) are
presented relative to the reference case. Res, drug resistance; CD4, CD4-T cells count group; Com, comorbidity (categories are described in Table 1).
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resistance occurs; average total costs are particularly responsive
to genotypic PI-resistance and resistance to 3 or more ARV
classes, respectively. One of the results of the regression is that
kidney insufficiency (creatinine >1.5 vs. <0.9) decreases total
costs, which is opposite to our expectations; however, the small
number of observations in this category (1.66%) prevents a
possibility to provide this inference for the whole population.
Viral load is not identified as a cost determinant. Although a
link between occurrence of detectable viremia and an increase of
annual costs would be suggestive, the design of the CORSAR
might not be capable of observing such an effect: (i) the 2-year
observation period of the survey might be too short, (ii) the
proportion of viremic patients is rather small, and (iii) most cases
have either a singular viremic “blip,” low viremia, or both, which
are associated with a low risk for subsequent virological failure or
short-term progression of HIV infection. Further studies with a
longer observational period and a rather more restrictive
definition of viremic patients will be necessary to investigate
the long-term effects of HIV viremia in cART-treated patients on
the costs of HIV therapy.
The calculated cost ratios can be interpreted in a similar way as
the odd ratios estimated from proportional hazard models.[18]
Using relative costs, one can explore interactions among the
patients, for example, compare relative costs between patients
with varying characteristics. Particularly, combination of a low
CD4-T cell count, multiple resistance against PI or more than 1
ARV class, severe comorbidity leads to high cost cases. Table 5
and Figure 1 bring additional information and could be useful
particularly to health care payers. Some of these cases might be
prevented with improvement of ARV adherence, that is by a
Table 5
Estimated cost ratios relative to the comparison group (male individuals with therapy class “PI-stand,” CD4=“>500,” comorbidity=
“2 nonsevere,” and drug resistance=“no resistance”), 95% confidence intervals in parentheses.
Patient characteristics Comorbidity PI-stand PI-indiv NNRTI Mixed Other
Male. No resistance. CD4: >500 2 nonsevere 1.000
∗
1.436 (1.249,1.652) 0.723 (0.681,0.767) 0.831 (0.753,0.918) 0.735 (0.691,0.781)
>2 nonsevere 1.082 (1.016,1.151) 1.553 (1.330,1.814) 0.782 (0.471,1.230) 0.899 (0.798,1.012) 0.795 (0.730,0.865)
>2 severe 1.236 (1.093,1.397) 1.775 (1.466,2.148) 0.894 (0.778,1.027) 1.027 (0.874,1.207) 0.908 (0.793,1.034)
Male. No resistance. CD4: 200–500 2 nonsevere 1.049 (0.998,1.102) 1.506 (1.301,1.743) 0.758 (0.703,0.817) 0.871 (0.781,0.972) 0.771 (0.713,0.833)
>2 nonsevere 1.134 (1.045,1.231) 1.629 (1.384,1.916) 0.820 (0.742,0.907) 0.943 (0.829,1.072) 0.834 (0.754,0.921)
>2 severe 1.296 (1.133,1.482) 1.861 (1.528,2.267) 0.937 (0.808,1.087) 1.077 (0.909,1.276) 0.953 (0.824,1.102)
Male. No resistance. CD4: < 200 2 nonsevere 1.211 (1.085,1.350) 1.740 (1.461,2.071) 0.876 (0.772,0.994) 1.007 (0.872,1.162) 0.890 (0.788,1.006)
>2 nonsevere 1.310 (1.151,1.491) 1.882 (1.557,2.273) 0.948 (0.821,1.094) 1.089 (0.928,1.278) 0.963 (0.838,1.106)
>2 severe 1.497 (1.273,1.760) 2.150 (1.734,2.665) 1.083 (0.909,1.290) 1.244 (1.032,1.501) 1.100 (0.930,1.302)
Male. Resistance: Three classes.
CD4: >500
2 nonsevere 1.266 (1.102,1.454) 1.818 (1.130,2.926) 0.916 (0.574,1.461) 1.052 (0.656,1.687) 0.931 (0.583,1.485)
>2 nonsevere 1.369 (1.176,1.594) 1.967 (1.624,2.382) 0.991 (0.838,1.171) 1.138 (0.951,1.363) 1.007 (0.853,1.188)
>2 severe 1.565 (1.304,1.877) 2.247 (1.806,2.796) 1.132 (0.930,1.377) 1.301 (1.056,1.601) 1.150 (0.867,1.276)
Male. Resistance: Three classes.
CD4:200–500
2 nonsevere 1.327 (1.148,1.535) 1.906 (1.588,2.289) 0.960 (0.818,1.126) 1.103 (0.928,1.311) 0.976 (0.831,1.145)
>2 nonsevere 1.436 (1.224,1.685) 2.062 (1.694,2.509) 1.039 (0.873,1.235) 1.193 (0.991,1.437) 1.055 (0.888,1.254)
>2 severe 1.641 (1.358,1.982) 2.356 (1.885,2.945) 1.187 (0.970,1.452) 1.364 (1.102,1.687) 1.206 (0.988,1.472)
Male. Resistance: Three classes.
CD4: <200
2 nonsevere 1.533 (1.284,1.831) 2.202 (1.790,2.709) 1.109 (0.917,1.342) 1.275 (1.046,1.553) 1.127 (0.935,1.359)
>2 nonsevere 1.659 (1.371,2.006) 2.382 (1.912,2.968) 1.200 (0.979,1.470) 1.379 (1.117,1.701) 1.219 (0.999,1.487)
>2 severe 1.895 (1.535,2.340) 2.722 (2.141,3.461) 1.371 (1.096,1.714) 1.575 (1.243,1.997) 1.393 (1.120,1.732)
Female. No resistance. CD4: >500 2 nonsevere 0.915 (0.851,0.983) 1.314 (1.123,1.537) 0.662 (0.601,0.729) 0.760 (0.674,0.858) 0.672 (0.609,0.741)
>2 nonsevere 0.989 (0.901,1.086) 1.421 (1.199,1.684) 0.716 (0.638,0.803) 0.822 (0.718,0.942) 0.727 (0.649,0.814)
>2 severe 1.131 (0.984,1.298) 1.624 (1.328,1.985) 0.818 (0.700,0.955) 0.940 (0.791,1.116) 0.831 (0.714,0.967)
Female. No resistance.
CD4: 200–500
2 nonsevere 0.959 (0.877,1.048) 1.377 (1.169,1.622) 0.694 (0.622,0.773) 0.797 (0.670,0.908) 0.705 (0.631,0.787)
>2 nonsevere 1.037 (0.930,1.157) 1.490 (1.248,1.779) 0.750 (0.661,0.851) 0.862 (0.745,0.998) 0.763 (0.673,0.864)
>2 severe 1.185 (1.020,1.377) 1.703 (1.381,2.096) 0.857 (0.727,1.011) 0.985 (0.822,1.180) 0.871 (0.741,1.024)
Female. No resistance. CD4: <200 2 nonsevere 1.108 (0.973,1.262) 1.591 (1.319,1.919) 0.801 (0.692,0.928) 0.921 (0.786,1.078) 0.814 (0.706,0.939)
>2 nonsevere 1.199 (1.035,1.386) 1.721 (1.409,2.103) 0.867 (0.738,1.018) 0.996 (0.838,1.183) 0.881 (0.754,1.029)
>2 severe 1.370 (1.152,1.628) 1.967 (1.573,2.458) 0.991 (0.821,1.194) 1.138 (0.934,1.387) 1.007 (0.840,1.206)
Female. Resistance: Three classes.
CD4: >500
2 nonsevere 1.158 (0.990,1.354) 1.663 (1.372,2.016) 0.838 (0.705,0.995) 0.963 (0.803,1.154) 0.851 (0.716,1.011)
>2 nonsevere 1.253 (1.059,1.481) 1.799 (1.467,2.205) 0.906 (0.754,1.088) 1.041 (0.858,1.262) 0.921 (0.768,1.104)
>2 severe 1.431 (1.180,1.736) 2.056 (1.637,2.581) 1.035 (0.841,1.275) 1.190 (0.958,1.477) 1.052 (0.857,1.291)
Female. Resistance: Three classes.
CD4: 200–500
2 nonsevere 1.214 (1.031,1.429) 1.744 (1.432,2.123) 0.878 (0.735,1.049) 1.009 (0.837,1.216) 0.893 (0.747,1.066)
>2 nonsevere 1.313 (1.102,1.565) 1.886 (1.531,2.324) 0.950 (0.786,1.148) 1.092 (0.895,1.331) 0.965 (0.799,1.165)
>2 severe 1.501 (1.228,1.834) 2.155 (1.708,2.719) 1.086 (0.876,1.344) 1.247 (0.998,1.557) 1.103 (0.893,1.362)
Female. Resistance: Three classes.
CD4: <200
2 nonsevere 1.403 (1.117,1.761) 2.015 (1.566,2.591) 1.015 (0.798,1.289) 1.166 (0.914,1.486) 1.031 (0.813,1.306)
>2 nonsevere 1.517 (1.196,1.924) 2.179 (1.677, 2.831) 1.098 (0.966, 1.246) 1.261 (0.977,1.627) 1.115 (0.872,1.425)
>2 severe 1.734 (1.346,2.232) 2.490 (1.886,3.286) 1.254 (0.962,1.634) 1.441 (1.101,1.885) 1.274 (0.982,1.653)
NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
∗
The cell with a cost ratio of 1 indicates reference categories: all other ratios are estimated relative to them.
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patient’s ability to follow a prescribed cART plan in accordance
with the time lines.[41,42,43]
Our study has certain limitations. First, as a consequence of the
selection criteria, ARV-naïve patients were excluded from the
study and costs were calculated exclusively for patients under
ARV therapy. Therefore, we cannot provide inferences on the
costs of ARV-naïve patients or those without cART. Second,
information on transmission risks is not available in all
participating centers and, therefore, not analyzed. In conclusion,
the annual total costs per patient of HIV-related health care in
Germany continue to be high and vary greatly depending on
severity of the infection, comorbidity, and treatment attributes of
patients. The cost ratios and respective confidence intervals show
considerable variation within the stratum of CD4-T cell count,
genotypic resistance, and ARV classes. The high-cost cases are
induced by combinations of low CD4-T cell counts, resistance to
at least 3 ARVs and individualized PI-based therapy. Improve-
ment of adherence as well as development of cART regimens with
enhanced forgiveness (the ability of ARV to sustain viral
suppression, despite insufficient adherence) may prevent occur-
rence of a part of high cost cases of HIV treatment and, therefore,
they should be seen as major objectives in management of HIV
infection.
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Methods: Development of a multiple regression model. 
To fulfill the aim of determining the driving factors of HIV treatment costs, multiple regression 
models were employed.  
In order to specify relevant candidate predictors for the model, first, the number of observations and 
the number of missing observations for each category of each potential predictor were calculated 
(Table 1 in the main text). 
We found that levels “NNRTI” and “Mixed” of predictor “resistance” had a small sample size. 
However, there was no possible method based on medical reasoning to combine the categories, and 
the predictor was included in the model without modifications; therefore, the coefficient estimates for 
these categories must be interpreted with caution. 
Variance inflation factor (VIF) was used to assess potential multicollinearity among the predictors. 
Perfect collinearity took place between two variables that describe comorbidity: number of diseases 
and their severity at the level of “none.” To avoid the impact of this collinearity on the model, these 
variables were combined into one variable that describes comorbidity in terms of both severity and 
number of diseases. The severity variable in this case described the severity of the severest among 
the diseases. With this modification, VIF analysis showed acceptable results and all variables were 
considered as candidate predictors.  
Variable selection. 
Thereafter, statistical significance of each covariate was compared using F-tests and applying the 
classical ANOVA analysis of a linear model. For all analyses, statistical significance was determined 
at p < 0.05.  
Further, a backward stepwise variable selection procedure was performed. The selection began with 
a saturated model that included all effects of interest as well as all first, second, and third-factor 
interactions between covariates. All variables and interactions were extracted from the model 
stepwise, while conclusions on the selection of variables or interactions were based on the Akaike 




No interactions between predictors showed statistical significance, therefore, a simple additive model 
was adopted. Those predictors that showed no statistical significance but added statistical power were 
included in the model.  
Additionally, we used regression subset selection and considered possible subsets of the pool of the 
predictors and compared these using AIC.  
When selecting candidate predictors we considered variables that were predetermined to be included 
based on previous research and theoretical interest to explore the links between these variables and 
total costs, as well as using the statistical methods described above. The resulting system was 
specified as an additive model with 14 explanatory variables: age group, gender, time since diagnosis 
of HIV group, CDC classification, therapy class, therapy line, drug resistance, viral load, CD4-T cell 
count, laboratory alanine aminotransferase test(Lab ALT), laboratory low-density lipoprotein 
cholesterol test (Lab LDL), laboratory serum creatinine level test (Lab Creat), comorbidity, and 
disability. 
First, a classic linear model was employed to analyze the relationship between mean total costs and 
patient characteristics. The Breuch Pagan test was applied to check formally for the presence of 
heteroscedasticity in the linear model. A positive result (p=0.00404) rejected the null hypothesis of 
constant variance, therefore, in the further analysis the following models were used: an OLS of log 
transformed costs and generalized linear models with a log link function and an exponential family 
of the error term. 
Distributional characteristics of cost data. 
In order to develop a regression model, distributional characteristics of the data on total costs were 
initially investigated as follows: (i) a histogram of the total costs was plotted, (ii) values of skewness 
and kurtoses were computed, (iii) the Shapiro-Wilk test was used to investigate whether the log 
transformation yielded normalization, (iv) quintile-quintile plots were used to compare the cost 
distributions and theoretical distributions: lognormal, gamma and inverse Gaussian, (v) mean-
variance relationships were plotted, with means and variances of the total costs being computed 
within each level of each variable and a plot of the variance versus the mean being built [18]. R 
statistical software (version 3.1.1) was used. 
For the selected patients (n=1022) a histogram of the annual total costs is given by Figure 2 (Appendix 




It can be seen that the distribution is skewed to the right, which is common for data on expenditures 
in healthcare. The numerical measure of skewness of the present data took a value of 2.27 and that of 
kurtosis was 10.66. Both measures indicated a substantial positive skewness. Log transformation of 
the total costs data did not yield a normal distribution (Shapiro-Wilk W-test: W = 0.7963, p < 2.2e-
16), however, the values of skewness (0.86) and kurtosis (4.34) were altered.  
For the further investigation of the distributional characteristics of the total costs, quintile-quintile 
(Q-Q) plots were built. Figure 3(Appendix A) shows plots of the total costs against three selected 
theoretical distributions, in particular, gamma distribution with shape parameter = 6.489 and scale 
parameter = 3465.14; inverse Gaussian distribution with mean(mu) = 22485.97 and lambda = 
145915.7, where Var = mu3 /lambda; and lognormal distribution with parameters meanlog= 10.021 
and sdlog = 0.337. According to the plots, total costs were best approximated by the inverse Gaussian 
distribution.  
As long as a log transformation of the dependent variable did not normalize its distribution, the 
relationship between its mean and variance was analyzed. The values of these quintiles were 
calculated for each category of each variable. The following Figure 4(Appendix A) illustrates the 
mean-variance relationship on the log scale. The line was fit employing weighted least squares using 
degrees of freedom associated with each variance as weights [19]. The resulting slope takes a value 
of approximately 2.94, supporting the initial preference for the inverse Gaussian family (variance = 
mean3) 
Regression model. 
The resulting model was specified as follows: 
Denotation: Age group: a = 1,2,3,4; Gender: b = 1,2; Time  since diagnosis of HIV(HIVtime): c = 
1,2,3; CDC- classification: d =1,2,3; Therapy class: h=1,2,3,4,5; Therapy line: i = 1,2,3; Drug 
resistance: j= 1,2,3,4,5,6,7; Viral load: k=1,2,3; CD4-T cells count: l= 1,2,3;Lab ALT: m=1,2; Lab 
LDL: n=1,2; Lab Creat: p=1,2,3; Comorbidity: r=1,2,3,4,5; Disability: v= 1,2,3. 
Let denote the mean total costs for individuals of the ath age group and the 
bth gender who have clinical characteristics c, d, h, i, j, k, l, m, n, p, r, v as denoted above, then the 





 log(μabcdhijklmnprv)=  β0 + Age Groupa +  Genderb + Disabilityv + CDCd + TherapyLinei + ALTm+ Creatp + LDLn + Comorbidityr + VirLoadk + CD4l + HIVtimec+ Resistancej + TherapyClassh 
where  is a constant,  is the effect due to the ath age group,  is the effect 
due to the bth gender group,  is the effect due to the vth disability degree,  is the 
effect due to the dth class according to the CDC-classification for HIV infection,  is 
the effect due to the ith therapy line,  is the effect due to the mthgroup of alanine 
aminotransferase test results,  is the effect due to the pthgroup of laboratory serum creatinine 
testresults,  is the effect due to the nth group of laboratory low-density lipoprotein cholesterol 
test results,  is the effect due to the rth number of diseases and severity indexgroup, 
is the effect due to the kth viral load group, is the effect due to the cthtime after 
initial diagnosis of HIV infection before entering the survey (in years) group,  is the effect due 
to the lth CD4-T cellcount group,  is the effect due to the jthgenotypic 
antiretroviralresistance group, and  is the effect due to the hthARV class. 
Before fitting the given GLMs, reference categories for each predictor were specified. If previous 
literature or knowledge allowed us to make a specific hypothesis we used these planned contrasts in 
the model. Otherwise reference categories were defined for each predictor as the factor level with the 
largest number of observations among other levels for the respective predictor (see Table 1).All 
categorical variables were coded using dummy coding so that each level of factor was compared with 
the mean of the reference category.  





The following multiple regression models were applied and compared: (i) a linear regression on log 
transformed data, (ii) GLM with gamma family and log link, and (iii) GLM with inverse Gaussian 
family and log link function.  
Model performance. 
The adequacy of the models was assessed using goodness-of-fit measures, quantitative predictive 
indices, a plot of residuals, and a plot of predicted versus observed costs. The goodness-of-fit was 
appraised using R2 for the linear model and McFadden’s pseudo-R2 for each GLM, the value of which 
was computed as: where  is the log-likelihood for the fitted GLM and  is the 
log-likelihood for the model with just the constant term. The ability to predict was assessed using 
mean absolute error (MAE), root mean squared error (RMSE),and bias measures: 
 
where  denotes the predicted mean of the total costs for patient , and  denotes the observed 
values of costs for this patient. The obtained estimates are given in Table 9 (Appendix A). 
The quantitative predictive indices were computed on an independent data set. For the further 
analysis, the model with inverse Gaussian family and the log link function was preferred. Figure 
5(Appendix A)illustrates a plot of predicted versus observed costs for this model. 
The value of McFadden’s pseudo-R2 suggested that 50% of the total costs could be explained by the 
selected patient characteristics. The resulting coefficients represent the percentage change in the 
annual total cost from its average as a response to a one-unit shift in the explanatory variable 
compared with the reference category. A Wald test was performed to test whether the pairwise 
difference between the coefficient of the reference class and the other class is different from zero. 
The p-values in Table 4 indicate whether each level’s mean is significantly different from the 
reference level’s mean. 
Cost ratios. 
Application of the log link function was supported by the given distribution of total costs and the 
model showeda good fit, which made it possible to compute cost ratios between patients with different 




(2000)[18], ratios of mean total costs were calculated based on the factors: ARV class, gender, CD4-
T cell count, drug resistance, and comorbidity.  
We constructed an analytical form of the cost ratio for a patient who differs from the reference patient 
only in these selected characteristics. Following the notation given in the section on the model 
specification,these variables have the following number of categorical classes: therapy class: 
h=1,2,3,4,5; CD4-T cell count: l= 1,2,3; comorbidity: r=1,2,3 (with levels: ≤2nonsev, >2nonsev, 
>2severe respectively), gender: b=1,2, drug resistance: j=1,2 (with levels: “no resistance”, “at least 
three classes”respectively). 
As long as the estimated coefficients resulted not on the true scale it is reasonable to analyze the 
logarithm of the ratio between the total costs for the reference patient and the patient defined above. 
It is given by:  
 log(ρbhlrj) = log ( μbhlrjμ11111) = log(μbhlrj) − log(μ11111)= (Genderb +  TherapyClassh + CD4l + Comorbidityr + Resistancej)− (Gender1 +  TherapyClass1 + CD41 + Comorbidity1 + Resistance1)  
When coding the model, all the reference categories were set to 0. Therefore, using estimated 
coefficients the costs ratio is simplified to:  
 
ρ̂bhlrj = μ̂bhlrjμ̂11111 = exp(Gen̂derb +  TherapyCl̂assh + CD̂4l + Comor̂bidityr + Resiŝtancej)  
 
Confidence intervals for the corresponding cost ratios were also computed using the variance and 
variance-covariance matrix of the parameter estimates[18]. For example, the following equation 
illustrates the calculation of variance for the ratio of the mean total costs of male individuals with 
therapy class “PI-stand”, CD4 = “>500”, comorbidity = “≤2nonsev” and drug resistance = “no 
resistance” compared with the mean total costs of male individuals with therapy class “PI-stand”,CD4 




𝑉𝑎𝑟(log(ρ11222))= 𝑉𝑎𝑟(CD̂42) + 𝑉𝑎𝑟(Comor̂bidity2) + 𝑉𝑎𝑟(Resiŝtance2)+ 2𝐶𝑜𝑣(CD̂42, Comor̂bidity2) + 2𝐶𝑜𝑣(CD̂42, Resiŝtance2)+ 2𝐶𝑜𝑣(Comor̂bidity2, Resiŝtance2) 
We obtained the result . Therefore, the 95% confidence interval 
for  ranges from 0.20212 to 0.52176 with thecorresponding confidence interval for the 
true ratio being (1.224,1.685). 
The cost ratios and respective confidence intervals are presented in Table 5 in the main text. The cell 
with a cost ratio of 1 indicates that all other ratios are estimated relative to these reference categories.  



















Supplemental Digital Content. Figure 2, Histogram of annual total costs, that relates to the Appendix 
A and displays distributional characteristics of the annual total costs. This histogram shows skewness 




Supplemental Digital Content. Figure 3, Quintile-quintile (Q-Q) plots of the total costs against 
theoretical distributions, that relates to the Appendix A and further presents the distributional 
characteristics of the cost data and shows Q-Q plots of the total costs against three selected 
















Supplemental Digital Content. Figure 4, Mean-Variance relationship of the annual total costs, that 
relates to the Appendix A and illustrates mean-variance relationship of the total costs data on the 




Supplemental Digital Content. Figure 5, plot observed vs predicted values, that relates to the 
Appendix A and gives a plot of observed values against predicted values for the model used in the 






Table 6.  Description of the patients’ data for the patients who abandoned the survey during the first year of 
CORSAR (n=65). 
 
Variable Description Categories Percentage of 
observations,  % 
Age Group   
 




n.a.*  0.00 
Gender  Gender   female 7.58 
male 92.42 
n.a. 0.00 
Education The highest educational level 
achieved 
graduated 9.09 
neither nor 59.09 
no school certificate 1.52 
n.a. 30.30 






HIV related variables 
Time  since diagnosis of 
HIV 
Time after initial diagnosis of 
HIV infection before entering 
the survey (in years) 




CDC class Class according to the CDC 
classification system for HIV 
infection 
 




















Treatment related variables 
Therapy Class Assigned antiretroviral drugs 
classes 
PI-ind 0.00 








Therapy Line Combination antiretroviral 









Resistance Genotypic resistance against 
antiretroviral medication  
 
no resistance 83.33 
three classes(PI, 





NRTI and NNRTI 0.00 
PI 7.58 
PI and NRTI 3.03 
n.a. 0.00 
General Health related variables 





Lab LDL Low-Density Lipoprotein 




Lab CREAT Serum creatinine level test 
(mg/dL) 




Comorbidity Number of concomitant diseases 
and degree the severity of the 
severest among the diseases. 
≤2non-severe 36.36 
≤2 severe 7.58 
>2 non-severe 22.73 
>2 severe 7.58 
none 0.00 
n.a. 25.76 
Disability Disability index according to the 
German the Disabled Persons 
Act** 
0 – No disability  
 
34.85 




≥50 – Severe 
disability in 












Table 7. Mean of costs (SD) across the eight healthcare provider sitesstratified by cost categories 
(Euro). 
Site Cost Categories 



















310.40   
(913.69) 
 
979.56   
(1701.80) 
 


















983.34   
(1679.37) 
 












179.84   
(277.04) 
 
























1349.07   
(2743.64) 
 












151.62   
(213.50) 
 
144.13   
(267.04) 
 
876.81   
(2404.60) 
 

































294.21   
(302.01) 
 


















244.70   
(338.19) 
 






*The estimates of the annualized total costs presented in Table 7 include also negligible cost fractions e.g. massages, 





Table 8.Data on the annualized costs forpatients who completed both years of the CORSAR survey (n = 942).  
 
Costcategory Mean costs (SD) 
(Euro), Data for the 
first year of 
CORSAR 
Mean costs (SD) 
(Euro), Data for the 
second year of 
CORSAR 
Total costs 22477.57(8809.45) 22231.03(8786.13) 




Out-of-pocket 212.23(588.61) 200.87(605.36) 
Indirect 1462.79(3997.91) 1779.37(4175.84) 
Hospital stay 1246.98(3850.15) 984.53(2894.06) 







Massages 14.34(40.50) 14.66(40.46) 










Table 9. Model performance  
Model Predicted Mean (SD) R2or Pseudo-R2 AIC MAE RMSE Bias 
GLM with inverse 
Gaussiandistribution 
and log link 
function 
22379.42 (6051.59) 0.5029296 10499 4500.22 6566.329 19.16293 
GLM with Gamma 
distribution and log 
link function 
22360.16 (5984.769) 0.5020352 10575 4076.246 6788.719 -534.6144 






Table 10. Variance-covariance matrix of the parameter estimates (partial).   

























































































































































































































Estimation of utility values and factors driving health-related quality 
of life in people living with HIV and AIDS and receiving cART in 
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HIV has become a chronic disease since the widespread of combined antiretroviral therapy 
(cART). Understanding the influence of therapeutic and preventive interventions on health-related 
quality of life (HRQoL) of people living with HIV and AIDS (PLWHA) is important. In health 
economic evaluations the patient benefits are often measured in utilities. Utilities represent the 
value which the society gives to a specific health state whereas HRQoL takes the perspective of 
the patients. Commonly required effectiveness measure is quality adjusted life years (QALY) 
which is calculated using utility values. Information about health state utilities and HRQoL in 
PLWHA after the introduction of cART is limited, especially in Germany. There are no estimates 
of HRQoL weights for German PLWHA on cART. 
Methods:  
This study longitudinally estimated utilities and HRQoL over time in PLWHA in Germany using 
the generic EQ-5D-3L questionnaire. Health state utilities were calculated based on the EQ-5D 
descriptive system using the German EQ-5D-3L time trade-off (TTO) value set. HRQoL was 
calculated based on the EQ visual analogue scale (EQ-VAS). Extensive descriptive analyses 
were performed to represent utility values for different groups of the patients. Generalized linear 
models (GLMs) with beta-inflated distributions were used to determine patient characteristics and 
clinical factors that influence on HRQoL. 
Results 
1,056 PLWHA completed the EQ-5D-3L questionnaires at the baseline. The mean TTO utility 
value is 0.912 (SD±0.154) and the mean VAS HRQoL is 84.32 (SD±18.55). Utility and HRQoL 
decrease with the time living with HIV. The patients with symptomatic HIV infection and AIDS 
have lower utility values and HRQoL. A higher age, a longer period of living with HIV, a higher 
CD4-cell count and having symptomatic HIV or AIDS are associated with a lower probability of 
having HRQoL of perfect health. 
Conclusion 
Though HIV-infection is a chronic disease, its impact on patients’ quality of life is manageable. 
Provision of additional specific psychological and social support for PLWHA may improve their 
quality of life.  
 





Combined antiretroviral therapy (cART) sustains HIV-virological suppression and 
consecutively immunological reconstitution in people living with HIV infection(1, 2). If cART is 
initiated timely and taken regularly it can prevent HIV transmission, reduce HIV-related 
morbidity(3) and increase life-expectancy of PLWHA close to that of the general population(4). 
Nonetheless, HIV infections and HIV-caused morbidity and mortality continue to be a public 
health issue. In Germany, the Robert Koch institute estimated 86,000 (80,000 – 92,400) people 
living with HIV with 68,800 receiving cART by the end of 2017 (5).  
Given the current public health burden of chronic HIV infections and ongoing research and 
development of new therapies(3), prevention strategies(6) and screening programs, health 
economic evaluations are required to provide information for decision-making in HIV-
management. Economic evaluations comprise of weighing the costs and benefits of alternative 
strategies and provide comparative analyses of payoffs of different courses of action (7). 
Quality adjusted life years (QALYs) is a widely applied measure of health outcomes in 
economic evaluations and recommended by the Second Panel on Cost-Effectiveness in Health 
and Medicine(8) as well as by several decision-making bodies in public health, including: 
National Institute for Health and Clinical Excellence (NICE)(9), Canadian Agency for Drugs 
and Technologies in Health (CADTH)(10), Pharmaceutical Benefits Advisory Committee 
(Australia)(11), the National Health Care Institute in the Netherlands(12) and the Standing 
Vaccination Committee (STIKO)(13) at the German Robert-Koch Institute. Additionally, due to 
the chronic nature of HIV infection measurement of health-related quality of life plays a crucial 
role in our understanding of the impacts of life-long therapeutic interventions on the patients’ 
health. Furthermore, analyses of the data allow identification of the most influential factors 
which can be addressed when aiming to improve HRQoL. 
In order to calculate QALY for a given health condition health utilities (also known as quality of 
life weights) are necessary. For application in health economic evaluations indirect elicitation 
methods, which are based on pre-scored generic preference-based measures, are preferred 
(14). EuroQol (EQ)-5D(15), the Short Form 6D (SF-6D)(16) and the Health Utilities Index 
(HUI)(17) constitute commonly used generic questionnaires applied in measurement of health 
utility values. 
In this study we evaluate health utilities in a German multicenter cohort of PLWHA who receive 
cART using the EuroQol instrument. The study is based on the data collected in a nationwide 
multi-centre, non-interventional, prospective 96-week survey conducted in PLWHA in 
Germany: “Cost and Resource Utilisation Study in Antiretroviral Therapy (CORSAR)”. The 
survey has been previously described in a paper by Kuhlmann et al. who provide a 
summarization of the collected data for the 48-week period and report the costs and utility 
 
 
values across three therapy lines(18). Another study thoroughly examines and describes the 
cost data of CORSAR(19). The present study reports the HRQoL data collected over the whole 
period of the survey in greater detail and identifies influential clinical and therapy-related 
factors.   
Methods 
Study population  
Inclusion criteria for CORSAR were: (i) HIV positive diagnosis, (ii) age of at least 18 years, and 
(iii) receiving cART at the study entry. The survey was not intended to include primarily 
treatment, i.e. naïve patients. The observation period was 96 weeks between April 2009 (first 
patient started) and April 2012 (last patient finished) with scheduled quarterly visits at the 
involved physicians. The participating physicians from the four hospitals and eight private 
practices specialized in HIV went through a six-month preparation period with baseline 
examinations. The CORSAR study population included 1,154 PLWHA representing a 2.3% 
sample of treated PLWHA in Germany. 
The data were collected using the self-reported questionnaires and from the clinical records of 
the participants, and include: demographical characteristics (age, gender, education, 
employment), HIV- and general health-related records (CD4-T cell count, viral load, disability, 
comorbidities, conditions, results of laboratory tests), details of diagnosis (time after initial 
diagnosis of HIV infection, CDC category) and records of the antiretroviral therapy (line of 
antiretroviral regimen at start of the study, medications, genotypic resistance tests).   
Measurement of quality of life 
In CORSAR, the preference-based EQ-5D-3L self-reported questionnaire was employed for 
measurement of HRQoL. EQ-5D contains the descriptive system and the visual analogue 
scale. The EQ-5D-3L descriptive system comprises of five domains (mobility, self-care, usual 
activities, pain/physical discomfort, anxiety/ depression). Each domain was assessed by the 
patients using in three levels of perceived problems (none, moderate, severe). Different 
combinations of the recorded levels for the five areas were weighted based on the preferences 
identified by the general population for which the tariffs from Germany were used. This 
weighted utility summary score is further referred to as (TTO) utility value. 
The EQ-VAS is a scale reaching from 0-100 (worst imaginable health state – best imaginable 
health state) on which patients mark how good or bad they assess their current health. This 
scale is another measure of HRQoL. In CORSAR, the participants were asked to fill out the 
questionnaires at all visits. For the following analyses only those participants were include who 





The CORSAR survey was approved by the national regulatory authorities and local ethics 
committees of all participating centres. All patients were given thorough information on the 
survey. Before the participation in the interviews, the patients provided written consent. No 
incentive was offered to the patients for their participation in the survey. 
Data analyses 
Descriptive and regression analyses were carried out. The regression analysis was performed 
to identify factors which were associated with HRQoL in PLWHA. A generalized linear model 
was fitted using a three-parameter beta-inflated distribution for the TTO utility values and a 
four-parameter beta-inflated distribution for the VAS HRQoL values. This distribution type is 
able to account for the nature of the quality of life measures being bound between the values 
zero and 1. The selection of the predictor variables was based on expert opinion and a 
systematic review of relevant factors on quality of life of HIV patients(20). All metric variables 
were transformed to z-scores by subtracting their mean and dividing by their standard 
deviation. Levels of the categorical variables were clustered via the fusion-based approach 
(21). A random intercept was included to capture the hierarchical structure of the data. All 
analyses were carried out using R software (version 3.4) and the gamlss package. The function 
pcat() was used for the level reduction of categorical variables with the method GAIC and LP1 
(lasso-type) penalty  and the random() function for the random intercept. 
Results 
Study population 
Out of the recruited 1,154 patients, 1,056 completed the EQ-5D-3L questionnaires at the first 
visit (further baseline). Table 1 presents the socio-demographic and the clinical characteristics 
of the participants who completed the questionnaires at baseline (all visits are given in 
supplemental tables: S1 and S2). The sample encloses mostly male HIV-infected patients 
(88.8%) and those in the 30-60 age group (82.7%). Majority of the participants have school-
level education (70.7%) and have a steady income: employed (39.6%) and retired (22.8%). At 
baseline, 42% of the participants were listed in category CDC-B (symptomatic HIV infection), 
28.6% were in category CDC-A (asymptomatic HIV infection) and 27.1% were in category 
CDC-C (AIDS-indicator). Majority of the participants had CD4 counts over 200cells/µL (93.5%) 
and HIV viral load below quantification limit (less than 50 copies/mL, 89.9%) at baseline. 82.6% 
of the participants had comorbidities. Of them, 58 patients had lipodystrophy, 13 - diabetes 
mellitus, 35 - Hepatitis C, 52 - Hepatitis B, and 8 participants had depression (see S1 in 
supplement). Other comorbidities were categorized into groups which are presented in Table 
1. The table also gives the clinical characteristics of the patients for other visits.
 
 
Table 1: Socio-demographic and clinical characteristics of the patients in CORSAR. (n=participants who completed EQ-5D-3L questionnaires at baseline) 
Socio-demographic Characteristics 




at Visit 0 
(Baseline) 
(n=1056) 
Age (mean. SD) 47.6 11.0 Years since diagnosis of HIV (mean. SD) 10.7 7.0 
Age (n.%)   HIV infection stage (CDC classification) (n. %)   
<20 years old 1 0.1 Asymptomatic (Category A)  302 28.6 
20-29 years old 43 4.1 Symptomatic (Category B) 443 42 
30-39 years old 207 19.6 AIDS-Indicator (Category C) 286 27.1 
40-49 years old 444 42 Not recorded 25 2.4 
50-59 years old 223 21.1 CD4+ cell count (n. %)    
>60 years old 138 13.1 <200 cells/µL 65 6.2 
Gender (n.%)   200-499 cells/µL 402 38.1 
Male 938 88.8 ≥500 cells/µL 585 55.4 
Female 112 10.6 Not recorded 4 0.4 
Transsexual 6 0.6 HIV viral load (different grouping) (n. %)   
Education level (n.%)   Below quantification limit 949 89.9 
No qualifications 88 8.3 <10.000 90 8.5 
Secondary school leaving certificate 
(leaving after 9th grade) 243 23 
10.000-100.000 
7 0.7 
Intermediate school-leaving certificate 
(leaving after 9th grade) 308 29.2 
≥100.000 
6 0.6 
School diploma corresponding to university 
entrance level 195 18.5 
Not recorded 
4 0.4 
Professional training 86 8.1 Comorbidity (n. %)   
University  115 10.9 Presence of comorbidity  872 82.6 
Other 3 0.3 1-4 conditions 655 62 
No response 88 8.3 >5conditions  216 20.5 
Employment status (n. %)   Allergy 188 17.8 
Full-time employed 418 39.6 Dermatological  286 27.1 
Part-time employed 77 7.3 Respirational 183 17.3 
Self-employed 73 6.9 Cardiovascular 248 23.5 
Unemployed 95 9 Endocrine  134 12.7 
Retired 241 22.8 Gastro-intestinal  249 23.6 
House 17 1.6 Haematological 89 8.4 
In study 10 0.9 Neurological 145 13.7 
Other 17 1.6 Psychiatric 209 19.8 





Classes of antiretroviral regimens were categorized into three groups, according to the 
treatment status of the patient and in accordance with the existing German treatment 
guidelines: “standardized” and “individualized”. “Standardized” regimens included either 
NNRTI (non-nucleoside reverse transcriptase inhibitor)-based regimen, consisting of one 
NNRTI in addition to nucleos(t)ide analogues or PI (Protease inhibitor)-based regimen, 
consisting of one ritonavir-boosted PI (PI/r) in addition to nucleos(t)ide (NRTI) analogues, 
which summarizes regimens of cART recommended as preferred in the actual German-
Austrian treatment guidelines at the time of the study conduction(22). “PI-individualized” class 
was assigned to the PI/r-based cART regimens in patients with a history of multiple treatment 
failure and acquiring multi-resistant HIV. Their regimens consist of the elements of more than 
two different antiretroviral classes and more than three different antiretroviral substances 
including boosted PIs, “other cART regimens” are those that did not meet the criteria of the 
standardized and individualized PI/r-based regimens. The cART regimens used in the survey 
are summarized in Table S3 in the supplement. At the start of CORSAR-study the first 
integrase strand transfer inhibitors (INSTI) was newly available in Germany. Hence, at 
baseline, most of the patients received PI-based regimens (516 patients) and NNRTI-based 
regimens (292 patients). 
Estimation of utility values and HRQoL values 
Table 2 summarizes most reported health states at baseline, the recorded levels for the five 
EQ-5D areas and mean and standard deviations for TTO utility scores and HRQoL VAS scores 
(see Table S4 for all visits in the supplement). For the total sample, the mean TTO score is 
0.912 (±0.154) with 59.3% ranging from 0.9 to 1.0 and the mean VAS score is 84.32 (±18.55) 
with 54.5% ranging from 90 to 100. For the five EQ-5D domains, most patients report “no 
problems” in the “mobility” (83.8%) and “self-care” (97.7%). In contrast, in the areas “emotional 
health” and “physical discomfort” a large part of the patients reports “some problems” (24% 










Table 2: Records of measurement of quality of life of the patients in CORSAR at baseline (n=1056) 
Most reported health states at baseline 
 (n.% of total) 
EQ-5D-3L domains and levels (n.%) 
11111 479 45.4 
Mobility 
None  885 83.8 
11112 111 10.5 Some 171 16.2 
11121 96 9.1 Severe 0 0 
11122 96 9.1 
Self-care 
None  1032 97.7 
11212 13 1.2 Some 23 2.2 
11221 16 1.5 Severe 1 0.1 
11222 46 4.4 
Usual activities 
None  857 81.2 
21121 26 2.5 Some 187 17.7 
21122 21 2 Severe 12 1.1 
21221 20 1.9 
Pain/discomfort 
None  632 59.8 
21222 36 3.4 Some 395 37.4 
TTO value 
mean, SD 0.912 0.154 
Severe 29 2.7 
Anxiety/depression 
None  664 62.9 
VAS value 
mean. SD 84.32 18.55 
Some 366 34.7 
Severe 26 2.5 
  
Additionally, Table 3 presents the mean estimates of TTO utility values by CDC category, age 
group, group of years since HIV diagnosis and cART regimen (at baseline). 
Mean estimate of TTO utility values at baseline for the patients who have AIDS (listed in CDC 
class C) lower than for people who have no AIDS. The descriptive analysis of utility values 
across age groups does not allow the conclusion that health state utilities decrease in older 
people. The variation for CDC category A is between 0.927 (40-49 year olds (yo)) and 1.00(<20 
yo) and for CDC B is 0.963 (20-29yo) – 0.889 (50-59yo). For CDC category C the older people 
seem to have worse utility vales with a range of 0.934 (20-29 yo) – 0.855 (>60yo).
 
 
Table 3: TTO utility values (mean, SD) across CDC categories and by age group, years living with HIV and cART regimen at baseline 
(n=1056) 
CDC category 
TTO utility values (mean, SD) 
Age groups 
<20 20-29 30-39 40-49 50-59 >60 
CDC-A 1.000, na 0.980, 0.044 0.951, 0.101 0.927, 0.129 0.941, 0.108 0.946, 0.136 
CDC-B na 0.963, 0.070 0.935, 0.140 0.901, 0.167 0.889, 0,173 0.919, 091 
CDC-C na 0.934, 0.076 0.928, 0.157 0.892, 0.178 0.857, 0.181 0.855, 0.244 
CDC category 
Years living with HIV 
<10 10 -20 >20 
CDC-A 0.960, 0.081 0.928, 0.151 0.846, 0.146 
CDC-B 0.911, 0.167 0.922, 0.112 0.882, 0.145 
CDC-C 0.914, 0.179 0.882, 0.154 0.818, 0.241 
CDC category 
cART regimen 
NNRTI individ. NNRTI standard. PI individ. PI standard. Other Therapy <14 days 
CDC-A 0.943, 0.065 0.946, 0.133 0.931, 0.073 0.922, 0.131 0.962, 0.081 0.962, 0.065 
CDC-B 0.866, 0.101 0.902, 0.162 0.871, 0.210 0.913, 0.150 0.928, 0.121 na 




The consideration of cART regimen suggests higher utility values for PI-based regimen than 
for NNRTI-based regimen in the patients listed in CDC categories B and C. Analysis of mean 
estimates of TTO utility values by the “years since HIV” groups suggests worsening of quality 
of life with time. Figure 1 illustrates TTO utility values plotted against years since HIV-diagnosis 
for the whole sample.  
 
Figure 1. TTO utility values in dependence on time living with HIV (years). 
Descriptive analysis does not allow identification of impact of each factor on the utility values. 
The following section describes the results of the regression analysis conducted to determine 
the effects of separate patient characteristics on the utility values.  
Driving factors  
The results of the explanatory models of health state utilities and HRQoL can be seen in Table 
4. The main focus will be on the utility scores, as these are more relevant to health economic 
evaluations. Clustering the factor levels of the variables “Education”, “Job” and “Treatment” in 
the utility model lead to a reduction in factor levels from 7 to 4, 7 to 3 and 7 to 5, respectively. 
For education, patients with no or other education and secondary school (grade 9) were 
summarized into one category and high school and university were clustered together. Middle 
school (grade 10) and patients with a vocational training remained in a single level, 
respectively. In the VAS model, patients with high school and university degree showed a 
similar effect as patients in the category “none/other/secondary school” and were grouped into 
one level.  
 
 
Table 4: Results of the GLM model of the analysis of TTO values and VAS scores via a 
beta-inflated distribution. 
 TTO VAS 
Mu (logit-link)   
     mu Intercept 1.950 (0.065)*** 1.095 (0.054)*** 
     Age in years (z-score) -0.114 (0.019)*** -0.085 (0.008)*** 
     Gender: male Reference Reference 
     Gender: transsexual 0.213 (0.180) -0.060 (0.114) 
     Gender: female 0.223 (0.052)*** -0.115 (0.028)*** 
     Education: vocational training Reference Reference 
     Education: junior high school 0.355 (0.052)*** 0.136 (0.025)*** 
     Education: none/other/secondary school 0.480 (0.052)*** - 
     Education: high school/university 0.276 (0.054)*** - 
     Education: none/other/secondary school/high 
school/university 
 0.188 (0.023)*** 
     Job: Retired Reference - 
     Job: House/student - Reference 
     Job: Part-time -0.153 (0.054)** 0.524 (0.052)*** 
     Job: Full-time/house/other/self-
employed/student/unemployed 
-0.104 (0.034)** - 
     Job: Unemployed - 0.147 (0.053)** 
     Job: Other/retired - 0.376 (0.049)*** 
     Job: Self employed - 0.257 (0.054)*** 
     Job: Full-time - 0.258 (0.048)*** 
     No. of co-morbidities (z-score) 0.020 (0.016) -0.055 (0.008)*** 
     Lipodystrophy 0.092 (0.059) 0.092 (0.030)** 
     Diabetes 0.530 (0.136)*** 0.147 (0.055)** 
     Hepatitis C -0.920 (0.084)*** -0.595 (0.042)*** 
     Hepatitis B 0.012 (0.070) -0.316 (0.036)*** 
     Depression -0.192 (0.257) -0.439 (0.137)** 
     Years with HIV (z-score) -0.028 (0.003)*** -0.023 (0.001)*** 
     CDC Group A Reference Reference 
     CDC Group B -0.088 (0.041)* -0.139 (0.017)*** 
     CDC Group C -0.249 (0.045)*** -0.031 (0.020) 
     CD4 cell count (z-score) 0.087 (0.016)*** 0.092 (0.008)*** 
     Viral load < quantification limit Reference Reference 
     Viral load <10,000 -0.015 (0.060) -0.024 (0.030) 
     Viral load 10,000 - 100,000 -0.037 (0.172) -0.078 (0.090) 
     Viral load >100,000 -0.829 (0.230)*** -0.225 (0.127) 
     No. of treatment changes (z-score) -0.023 (0.013) -0.065 (0.006)*** 
     Tx: PI norm Reference - 
     Tx: NNRTI norm - Reference 
     Tx: NNRTI ind/NNRTI norm/break 0.012 (0.037) - 
     Tx: therapy < 14 days 0.518 (0.266) - 
     Tx: PI ind 0.185 (0.049)*** - 
     Tx: Sonst 0.235 (0.042)*** 0.307 (0.020)*** 
     Tx: NNRTI ind/PAUSE/PI ind/PI norm/therapy < 14 days - 0.057 (0.017)*** 
Sigma (logit-link)   
     sigma Intercept -0.826 (0.042)*** -1.457 (0.023)*** 
     Age in years (z-score) -0.007 (0.019) -0.067 (0.012)*** 
     Gender: transsexual -0.579 (0.250)* 0.120 (0.183) 
     Gender: female -0.251 (0.055)*** 0.278 (0.040)*** 
     Years with HIV (z-score) -0.006 (0.003)* 0.004 (0.002)* 
 
 
     CD4 cell count (z-score) 0.093 (0.016)*** 0.074 (0.011)*** 
     CDC Group A Reference Reference 
     CDC Group B  0.160 (0.042)*** 0.000 (0.001) 
     CDC Group C  0.205 (0.046)*** 0.018 (0.026) 
Nu (log-link)   
     nu Intercept  -6.674 (0.784)*** 
     Age in years (z-score) (3)  0.042 
     Gender: transsexual (3)  -13.490 (49.375) 
     Gender: female (3)  -15.412 (56.410) 
     Years with HIV (z-score) (3)  0.079 (0.032)* 
     CD4 cell count (z-score) (3)  -0.229 (0.733) 
     CDC Group B (3)  -18.015 (78.485) 
     CDC Group C (3)  -18.266 (72.719) 
Tau (log-link)   
     tau Intercept 0.455 (0.066)*** -3.117 (0.165)*** 
     Age in years (z-score) (4) -0.114 (0.030)*** -0.127 (0.074) 
     Gender: transsexual (4) -0.251 (0.474) -15.670 (58.885) 
     Gender: female (4) 0.154 (0.092) 0.935 (0.178)*** 
     Years with HIV (z-score) (4) -0.047 (0.005)*** -0.026 (0.011)* 
     CD4 cell count (z-score) (4) -0.066 (0.030)* -0.222 (0.078)** 
     CDC Group B (4) -0.234 (0.068)*** -0.181 (0.178) 
     CDC Group C (4) -0.236 (0.075)** 0.418 (0.175)* 
Num. obs. 5179 5179 
Nagelkerke R2 0.446 0.727 
Generalized AIC 433.094 -8410.667 
***p < 0.001, **p < 0.01, *p < 0.05 
 
For the variable “Job”, all levels besides “retired” and “part-time” were grouped into one level 
for the TTO utility score model, but in the VAS HRQoL model only “other” and “retired” as well 
as “house” and “study”, respectively, were grouped into one level. For the different treatments, 
the levels “PI-stand”, “PI-ind”, “therapy < 14 days” and “other” remained as individual levels in 
the utility model while “NNRTI-ind”, “NNRTI-stand” and “break” were grouped together. In the 
HRQoL model, “NNRTI-stand” and “other” remained as individual levels and all other treatment 
options showed similar effects on the HRQoL and were thus summarized into one level. 
Regarding the mu parameter of the beta distribution (corresponding to the mean) the intercept 
of 1.950 corresponds to an utility value of 0.875 given all metric variables being at their mean 
and for male patients with vocational training, being retired, in CDC category A, a viral load 
below the quantification limit and PI-standardized treatment.  
All the coefficients should be interpreted in relation to this reference case. Starting with the 
socio-demographic variables, each increase of the age by one standard deviation decreases 
the estimate of utility value. For example, the patients who are 1 standard deviation (SD) (10.2 
years) older than the mean age of 47.4 years have utility value of 0.862. No significant 
difference in the estimates was found for transgender patients, but women show a significantly 
higher utility value of 0.898. Compared to persons with a vocational training as the highest 
level of education, patients with high school diploma or a university degree have a higher utility 
 
 
value (0.903). Patients with middle school or no or the lowest school degree have even higher 
utility value estimates with 0.909 and 0.919, respectively. In the context of occupational levels, 
part-time employed persons show a decreased utility value of 0.858 compared to retired 
patients. This is also true for persons falling into the last category of full-time workers, students 
and unemployed although to a lesser extent (0.864).  
The quality of life is further altered by the comorbidities of the patients. In the utility model 
however, the number of comorbidities as well as lipodystrophy, hepatitis B and depression 
show no significant association with utility values. Patients with diabetes seem to even have a 
higher utility value of 0.923. On the other hand, patients with hepatitis C have a lower utility 
value of 0.737. 
With respect to HIV-related variables, utility values are also negatively associated with a longer 
time of living with HIV. Increasing this time by 6.8 years above the mean of 10.4 years 
corresponds to a lower utility value of 0.872. The disease stage classified into the CDC 
categories is also associated with the utility values: compared to category A, the patients listed 
in the category B have a significantly utility value of 0.866 and the patients in the category C 
(AIDS) show an even lower utility value of 0.846. In addition, the coefficient of 0.087 for the 
CD4 cell count corresponds to utility score of 0.885 when increasing the mean CD4 cell count 
of 605 by 281 (i.e. 1 SD). The utility model suggests no significant differences between the 
viral load between the levels “below quantification limit”, “<10,000” and “10,000 – 100,000”. A 
viral load above 100,000 is associated with a strong and significant decrease in utility value 
(0.754). 
The last group of variables captures the cART-related factors. The number of changes in the 
treatment regime seems to show no significant association with the quality of life weights, 
although the p-value of 0.07 is slightly above the threshold of 0.05. The coefficient would 
suggest, that utility value is lower with an above average number of treatment changes. 
Compared to the reference level “PI-stand”, the patients with the summarized level “NNRTI-
stand/NNRTI-ind/break” show no significant difference in their HRQoL weights. If the therapy 
started just within 14 days of data collection, the utility value is higher (0.922) but this 
association is not significant at the 0.05 level (p-value 0.051). Being treated with “PI-ind” or 
“other” is associated with a significantly higher utility values of 0.894 and 0.899, respectively. 
Discussion 
This study is an analysis of quality of life data collected in a major longitudinal study undertaken 
between 2009 and 2012 in people living with HIV and AIDS in Germany. This multi-centric, 
nationwide study draws on a large sample by including the main healthcare providers for 
PLWHA and provides a representative population to study HRQoL. 
 
 
The results suggest that the mean EQ-VAS value obtained in this study (84.3) is comparable 
with EQ-VAS estimated for the general population in 2009 (79.2)(23), although based on the 
reported characteristics of the sample representing the general population it is difficult to 
explain why the self-reported quality of life in the patients of CORSAR is higher than that of the 
general population. 
This study shows the dimensions of quality of life that are the most affected are 
“anxiety/depression” and “pain/physical discomfort”, while “mobility” and “self-care” are minor 
problems. This supports the preliminary results from Investigation on Antiretroviral Therapy 
(IANUA) and highlights the need to improve specific psychological and social support for 
PLWHA(24). 
In order to distinguish effects of different patient characteristics we conducted a regression 
analysis using a GLM with beta-inflated distributions. The estimation of the coefficients of 
sigma parameter indicates which variables are associated with the variance of health utilities 
in HIV patients. The estimated coefficients suggest that the variance is not associated with 
age, but that the variance is smaller for transsexual and female patients, i.e. male patients 
show a greater variance in their utility values than those two groups. Living with HIV for a 
longer time also seems to be associated with a lower variance. On the contrary, having a CD4 
cell count above the mean seems to lead to a higher variance of utility values of the patients 
and the patients with symptomatic HIV infection (CDC-B) and AIDS (CDC-C) also seem to be 
more different with regard to the utility values than the patients with asymptomatic HIV infection 
(CDC-A).The nu-parameter was only estimated for the VAS model, as there were no zero 
values obtained using the TTO method. This parameter reflects the probability of having a 
HRQoL score of zero. The only factor that is significantly associated with this probability is the 
time living with HIV. A longer period of time with HIV is thereby associated with a significantly 
higher probability of VAS score of zero. The probability of having utility value of 1 (i.e. being in 
perfect health) is estimated via the tau-parameter. For the utility model, a higher age, a longer 
period of living with HIV, a higher CD4-cell count and having symptomatic HIV (CDC B) or 
AIDS (CDC C) are associated with a lower probability of being in perfect health. The gender 
of patients seems to have no significant effect on having utility value of 1. 
Investigation of HRQoL can help us to provide means for its improvement, necessitating 
examination of influential factors. This research can contribute to the development of better 
HIV management programs. Our findings confirm previous research which found that time 
since diagnosis and disease stage to be negatively related to HRQoL, even in those treated 
anti-retrovirally for a longer duration with the recently available options of cART(25–27). 
Hence, our study support the recent development of treatment guidelines, which recommend 
the initiation of cART even in asymptomatic patients with normal CD4-T cell counts (28), 
because it appears that HRQoL will remain impaired for a longer period in those with more 
 
 
progressed stages of disease or immunodeficiency. This concept is intuitive due to untreated 
HIV infection which progresses to a further stage will diminish physical health. Indeed, the 
poorest physical health is observed in people whose HIV has progressed to AIDS(29). 
However, in contrast to our study, Jia et al showed that while a higher CD4-T cell count was 
associated with worse HRQoL at baseline, the same CD4-T cell counts were predictive of 
higher HRQoL scores 12 months later(30). Though this finding may be counter-intuitive, it is 
possible that the initial psychological impact of a high CD4-T cell count is significant but that 
over time, PLWHA more readily accept a high CD4-T cell count by several coping strategies 
and hence are less likely to experience changes in HRQoL based on this specific factor. Our 
regression analysis showed a statistically significant negative impact of time living with on the 
quality of life, which may support the previously stated assumption that people who live with 
HIV over long time periods experience accumulated negative effects in HRQoL(25, 26). 
This study did not reveal a differential impact of the use standardized antiretroviral regimen but 
lower impairment of HRQoL in the patients receiving PI-individualized regimen, supporting the 
national guidelines of the German AIDS Association(Deutsche AIDS Gesellschaft, DAIG)(22), 
which allows physicians to choose between a broad spectrum of available options of cART. 
The German policy is distinct from most foreign guidelines, giving physicians the opportunity 
to personalize the treatment, adapting cART regimens based on individual patients’ reactions. 
An administrative database analysis of approximately four million beneficiaries showed that 
German physicians use this flexibility and are more likely to prescribe patients who are in a 
more advanced disease state (CDC class C) with a PI/r based regimen than with a NNRTI 
based regimen(31). The same result was obtained in another observational study in 
Germany(32). 
Limitations 
This study has several limitations that need to be addressed. This observational study did not 
pre-define endpoints and is not statistically powered for more extensive subgroup-analyses. 
Further, we utilized the EQ-5D questionnaire, which is a “non-disease-specific instrument”. 
Although it allowed estimating quality of life weights applicable for economic evaluations, it 
may be relatively insensitive tool for measuring the specific HRQoL in PLWHA. Future studies 
should test the robustness of our results with alternative instruments such as HIV-specific 
questionnaires like the WHOQOL-HIV Instrument(33). Finally, the study period occurred 
before the integrase strand transfer inhibitors (INSTI) elvitegravir and dolutegravir became 
available, which are meanwhile widely used as components of cART in Germany.  
Conclusions 
As long as HRQoL in PLWHA shows wide variations across the socio-demographic and the 
clinical characteristic of individuals, measuring HRQoL and determining factors affecting 
 
 
HRQoL can help to understand to what extent HRQoL is affected by the infection and cART 
treatment. This analysis used the EQ-5D-3L measurement of utility values (quality of life 
weights) and determined the factors which influence on HRQoL. The results of this study can 
inform development and evaluation of HIV-related intervention strategies to improve health-
related quality of life in people living with HIV and AIDS in Germany.  
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Table S1: Socio-demographic characteristics of the patients in CORSAR. (n=participants who completed EQ-5D-3L questionnaires) 
Characteristic 
at Visit 0 
(Baseline) 
(n=1056) 
at Visit 1 
(12 weeks) 
(n=808) 
at Visit 2 
(24 weeks) 
(n=754) 
at Visit 3 
(36 weeks) 
(n=707) 
at Visit 4 
(48 weeks) 
(n=682) 
at Visit 5 
(60 weeks) 
(n=672) 
at Visit 6 
(72 weeks) 
(n=669) 
at Visit 7 
(84 weeks) 
(n=667) 
at Visit 8 
(96 weeks) 
(n=721) 
Age (mean. SD) 47.6 11.0 - - - - - - - - - - - - - - - - 
Age (n.%)                   
<20 years old 1 0.1 - - - - - - - - - - - - - - - - 
20-29 years old 43 4.1 - - - - - - - - - - - - - - - - 
30-39 years old 207 19.6 - - - - - - - - - - - - - - - - 
40-49 years old 444 42 - - - - - - - - - - - - - - - - 
50-59 years old 223 21.1 - - - - - - - - - - - - - - - - 
>60 years old 138 13.1 - - - - - - - - - - - - - - - - 
Gender (n.%)                   
Male 938 88.8 - - - - - - - - - - - - - - - - 
Female 112 10.6 - - - - - - - - - - - - - - - - 
Transsexual 6 0.6 - - - - - - - - - - - - - - - - 
Education level (n.%)                   
No qualifications 88 8.3 52 6.4 42 5.6 38 5.4 27 4 26 3.9 25 3.7 27 4 33 4.6 
Secondary school leaving certificate 
(leaving after 9th grade) 243 23 202 25 176 23.3 165 23.3 170 24.9 165 24.6 165 24.7 171 25.6 185 25.7 
Intermediate school-leaving certificate 
(leaving after 9th grade) 308 29.2 232 28.7 221 29.3 198 28 197 28.9 190 28.3 196 29.3 195 29.2 181 25.1 
School diploma corresponding to university 
entrance level 195 18.5 139 17.2 142 18.8 136 19.2 139 20.4 131 19.5 132 19.7 128 19.2 142 19.7 
Professional training 86 8.1 84 10.4 78 10.3 85 12 69 10.1 65 9.7 68 10.2 67 10 93 12.9 
University  115 10.9 79 9.8 80 10.6 65 9.2 67 9.8 76 11.3 71 10.6 63 9.4 73 10.1 
Other 3 0.3 5 0.6 1 0.1 7 1 3 0.4 3 0.4 4 0.6 3 0.4 3 0.4 
No response 88 8.3 52 6.4 42 5.6 38 5.4 27 4 26 3.9 25 3.7 27 4 33 4.6 
Employment status (n. %)                   
Full-time employed 418 39.6 323 40 310 41.1 268 37.9 280 41.1 271 40.3 271 40.5 268 40.2 304 42.2 
Part-time employed 77 7.3 58 7.2 52 6.9 58 8.2 50 7.3 48 7.1 54 8.1 61 9.1 70 9.7 
 
 
Self-employed 73 6.9 43 5.3 43 5.7 53 7.5 44 6.5 45 6.7 50 7.5 46 6.9 50 6.9 
Unemployed 95 9 71 8.8 70 9.3 53 7.5 56 8.2 47 7 42 6.3 46 6.9 51 7.1 
Retired 241 22.8 202 25 190 25.2 192 27.2 189 27.7 189 28.1 187 28 179 26.8 178 24.7 
House 17 1.6 15 1.9 16 2.1 16 2.3 12 1.8 12 1.8 12 1.8 12 1.8 13 1.8 
In study 10 0.9 6 0.7 5 0.7 4 0.6 4 0.6 7 1 8 1.2 7 1 6 0.8 
Other 17 1.6 13 1.6 10 1.3 8 1.1 12 1.8 15 2.2 14 2.1 12 1.8 11 1.5 
No response 108 10.2 77 9.5 58 7.7 55 7.8 35 5.1 38 5.7 31 4.6 36 5.4 38 5.3 
 
 
Table S2: Health-related and clinical characteristics of the patients in CORSAR. 
Characteristic 
at Visit 0 
(Baseline) 
(n=1056) 
at Visit 1 
(12 weeks) 
(n=808) 
at Visit 2 
(24 weeks) 
(n=754) 
at Visit 3 
(36 weeks) 
(n=707) 
at Visit 4 
(48 weeks) 
(n=682) 
at Visit 5 
(60 weeks) 
(n=672) 
at Visit 6 
(72 weeks) 
(n=669) 
at Visit 7 
(84 weeks) 
(n=667) 
at Visit 8 
(96 weeks) 
(n=721) 
Years since diagnosis of HIV (mean. SD) 10.7 7.0 - - - - - - - - - - - - - - - - 
HIV infection stage (CDC classification) (n. %)                   
Asymptomatic (Category A)  302 28.6 - - - - - - - - - - - - - - - - 
Symptomatic (Category B) 443 42 - - - - - - - - - - - - - - - - 
AIDS-Indicator (Category C) 286 27.1 - - - - - - - - - - - - - - - - 
Not recorded 25 2.4                 
CD4+ cell count (n. %)                    
<200 cells/µL 65 6.2 49 6.1 33 4.4 32 4.5 24 3.5 29 4.3 23 3.4 19 2.8 23 3.2 
200-499 cells/µL 402 38.1 301 37.3 283 37.5 259 36.6 235 34.5 224 33.3 230 34.4 218 32.7 236 32.7 
≥500 cells/µL 585 55.4 448 55.4 435 57.7 412 58.3 420 61.6 417 62.1 416 62.2 429 64.3 462 64.1 
Not recorded 4 0.4 10 1.2 3 0.4 4 0.6 3 0.4 2 0.3 0 0 1 0.1 0 0 
HIV viral load (different grouping) (n. %)                   
Below quantification limit 949 89.9 727 90 694 92 660 93.4 645 94.6 641 95.4 642 96 638 95.7 677 93.9 
<10.000 90 8.5 64 7.9 57 7.6 41 5.8 31 4.5 25 3.7 22 3.3 26 3.9 38 5.3 
10.000-100.000 7 0.7 5 0.6 0 0 3 0.4 3 0.4 2 0.3 4 0.6 0 0 5 0.7 
≥100.000 6 0.6 1 0.1 0 0 0 0 0 0 2 0.3 1 0.1 2 0.3 1 0.1 
Not recorded 4 0.4 11 1.4 3 0.4 3 0.4 3 0.4 2 0.3 0 0 1 0.1 0 0 
 
 
Comorbidity (n. %)                   
Presence of comorbidity  872 82.6 592 73.3 568 75.3 556 78.6 544 79.8 547 81.4 521 495 74.2 559 77.5 872 
1-4 conditions 655 62 440 54.5 402 53.3 379 53.6 394 57.8 380 56.5 363 54.3 352 52.8 403 55.9 
>5conditions  216 20.5 151 18.7 165 21.9 176 24.9 146 21.4 164 24.4 154 23 139 20.8 151 20.9 
Allergy 188 17.8 113 14 125 16.6 123 17.4 97 14.2 108 16.1 95 14.2 99 14.8 100 13.9 
Dermatological  286 27.1 204 25.2 191 25.3 199 28.1 181 26.5 186 27.7 176 26.3 162 24.3 175 24.3 
Respirational 183 17.3 150 18.6 137 18.2 142 20.1 119 17.4 129 19.2 133 19.9 130 19.5 146 20.2 
Cardiovascular 248 23.5 165 20.4 170 22.5 174 24.6 159 23.3 172 25.6 156 23.3 143 21.4 159 22.1 
Endocrine  134 12.7 82 10.1 99 13.1 98 13.9 84 12.3 92 13.7 83 12.4 67 10 84 11.7 
Gastro-intestinal  249 23.6 183 22.6 175 23.2 173 24.5 158 23.2 159 23.7 157 23.5 151 22.6 176 24.4 
Haematological 89 8.4 58 7.2 57 7.6 61 8.6 48 7 52 7.7 49 7.3 44 6.6 50 6.9 
Neurological 145 13.7 83 10.3 78 10.3 84 11.9 71 10.4 83 12.4 75 11.2 68 10.2 65 9 
Psychiatric 209 19.8 126 15.6 144 19.1 134 19 128 18.8 143 21.3 128 19.1 115 17.2 135 18.7 
Other. including :   601 56.9 415 51.4 407 54 423 59.8 399 58.5 420 62.5 387 57.8 370 55.5 426 59.1 
Lipodystrophy  58 5.5 34 4.2 37 4.9 42 5.9 39 5.7 40 6 42 6.3 40 6 36 5 
Diabetes mellitus 13 1.2 10 1.2 9 1.2 10 1.4 7 1 10 1.5 5 0.7 6 0.9 7 1 
Hepatitis C 35 3.3 25 3.1 22 2.9 23 3.3 24 3.5 22 3.3 26 3.9 21 3.1 28 3.9 
Hepatitis B 52 4.9 36 4.5 29 3.8 34 4.8 26 3.8 32 4.8 33 4.9 23 3.4 24 3.3 




Table S3. Therapy characteristics in patients of CORSAR (n=1034).  
Characteristics  n % 
Prescribed regimen at baseline 1034  
PI based regimen:   
regimen “PI stand”, most prescribed PIs + NRTIs regimen included: 408 100 
Atazanavir/Emtricitabin&Tenofovir/Ritonavir/ 81 19.9 
Darunavir/Emtricitabin&Tenofovir/Ritonavir/ 51 12.5 
Emtricitabin&Tenofovir/Lopinavir(tbl)/ 34 8.3 
Emtricitabin&Tenofovir/Lopinavir(cps)/ 29 7.1 
Emtricitabin&Tenofovir/Fosamprenavir /Ritonavir/ 23 5.6 
Emtricitabin&Tenofovir/Ritonavir/Saquinavir-Invirase/ 16 3.9 
Abacavir&Lamivudin/Atazanavir/Ritonavir/ 18 4.4 
Abacavir&Lamivudin/Fosamprenavir /Ritonavir/ 13 3.2 
Abacavir&Lamivudin/Darunavir/Ritonavir/ 10 2.5 
regimen “PI ind”. most prescribed regimen included 106  
Lopinavir (Tbl.)/Saquinavir-Invirase/ 6 5.7 
NNRTI based regimen   
regimen “NNRTI stand”, most prescribed NNRTIs+NRTIs regimen included: 280 100 
Emtricitabin&Tenofovir/Nevirapin/ 103 36.8 
Abacavir&Lamivudin/Nevirapin/ 34 12.1 
Abacavir&Lamivudin/Efavirenz/ 31 11.1 
Efavirenz/Emtricitabin&Tenofovir/ 32 11.4 
Efavirenz/Lamivudin&Zidovudin/ 8 2.9 
Lamivudin&Zidovudin/Nevirapin/ 22 7.9 
regimen “NNRTI ind”, most prescribed regimen included: 12  
Efavirenz/Emtricitabin&Tenofovir&Efavirenz/ 2 16.7 
NRTI based regimen 228 100 
Emtricitabin&Tenofovir&Efavirenz/ (NRTIs+NNRTI) 157 68.9 
Abacavir&Lamivudin&Zidovudin/ (NRTIs) 15 6.6 
Emtricitabin&Tenofovir/Raltegravir/ (NRTIs + INSTI) 13 5.7 
Abacavir&Lamivudin&Zidovudin/Tenofovir/ (NRTIs) 5 2.2 



































Table S3.1: cART substances and class.   
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Table S4: Records of measurement of quality of life of the patients in CORSAR. 
Characteristic 
at Visit 0 
(Baseline) 
(n=1056) 
at Visit 1 
(12 weeks) 
(n=808) 
at Visit 2 
(24 weeks) 
(n=754) 
at Visit 3 
(36 weeks) 
(n=707) 
at Visit 4 
(48 weeks) 
(n=682) 
at Visit 5 
(60 weeks) 
(n=672) 
at Visit 6 
(72 weeks) 
(n=669) 
at Visit 7 
(84 weeks) 
(n=667) 
at Visit 8 
(96 weeks) 
(n=721) 
Most reported health states at baseline (n.% of 
total) 
                  
11111 479 45.4 356 44.1 344 45.6 337 47.7 306 44.9 312 46.4 308 46 311 46.6 339 47 
11112 111 10.5 88 10.9 71 9.4 65 9.2 66 9.7 62 9.2 68 10.2 57 8.5 57 7.9 
11121 96 9.1 89 11 86 11.4 69 9.8 74 10.9 68 10.1 65 9.7 70 10.5 86 11.9 
11122 96 9.1 66 8.2 72 9.5 69 9.8 67 9.8 60 8.9 63 9.4 63 9.4 63 8.7 
11212 13 1.2 5 0.6 6 0.8 7 1 7 1 5 0.7 4 0.6 6 0.9 7 1 
11221 16 1.5 16 2 16 2.1 6 0.8 11 1.6 11 1.6 7 1 7 1 5 0.7 
11222 46 4.4 35 4.3 22 2.9 18 2.5 26 3.8 19 2.8 22 3.3 21 3.1 23 3.2 
21121 26 2.5 20 2.5 18 2.4 25 3.5 22 3.2 22 3.3 22 3.3 19 2.8 26 3.6 
21122 21 2 19 2.4 9 1.2 17 2.4 15 2.2 18 2.7 22 3.3 19 2.8 11 1.5 
21221 20 1.9 13 1.6 7 0.9 7 1 11 1.6 15 2.2 13 1.9 6 0.9 9 1.2 
21222 36 3.4 28 3.5 29 3.8 19 2.7 20 2.9 24 3.6 21 3.1 28 4.2 29 4 
EQ-5D-3L domains (n.%)                   
Mobility problems                    
None  885 83.8 679 84 645 85.5 595 84.2 574 84.2 551 82 548 81.9 548 82.2 603 83.6 
Some 171 16.2 128 15.8 108 14.3 112 15.8 108 15.8 121 18 121 18.1 119 17.8 117 16.2 
Severe 0 0 1 0.1 1 0.1 0 0 0 0 0 0 0 0 0 0 1 0.1 
Problems with self-care                   
None  1032 97.7 782 96.8 733 97.2 678 95.9 656 96.2 643 95.7 642 96 638 95.7 693 96.1 
Some 23 2.2 22 2.7 19 2.5 28 4 23 3.4 28 4.2 26 3.9 28 4.2 28 3.9 
Severe 1 0.1 4 0.5 2 0.3 1 0.1 3 0.4 1 0.1 1 0.1 1 0.1 0 0 
Problems performing usual activities                   
None  857 81.2 659 81.6 620 82.2 596 84.3 563 82.6 550 81.8 560 83.7 558 83.7 601 83.4 
Some 187 17.7 145 17.9 127 16.8 107 15.1 116 17 119 17.7 107 16 107 16 118 16.4 
Severe 12 1.1 4 0.5 7 0.9 4 0.6 3 0.4 3 0.4 2 0.3 2 0.3 2 0.3 
Pain/discomfort                   
None  632 59.8 471 58.3 444 58.9 433 61.2 398 58.4 390 58 393 58.7 387 58 421 58.4 
 
 
Some 395 37.4 320 39.6 291 38.6 262 37.1 269 39.4 267 39.7 259 38.7 264 39.6 286 39.7 
Severe 29 2.7 17 2.1 19 2.5 12 1.7 15 2.2 15 2.2 17 2.5 16 2.4 14 1.9 
Anxiety/depression                    
None  664 62.9 520 64.4 492 65.3 464 65.6 446 65.4 441 65.6 428 64 431 64.6 484 67.1 
Some 366 34.7 265 32.8 242 32.1 222 31.4 219 32.1 216 32.1 227 33.9 221 33.1 212 29.4 
Severe 26 2.5 23 2.8 20 2.7 21 3 17 2.5 15 2.2 14 2.1 15 2.2 25 3.5 
TTO utility value (n.%)                   
Mean. SD 0.912 0.154 0.911 0.153 0.91 0.157 0.917 0.142 0.913 0.15 0.911 0.149 0.911 0.153 0.911 0.149 0.91 0.152 
0.0-0.2  7 0.7 8 1 4 0.5 4 0.6 6 0.9 8 1.2 7 1 6 0.9 6 0.8 
0.2-0.4  26 2.5 13 1.6 23 3.1 10 1.4 13 1.9 8 1.2 13 1.9 11 1.6 14 1.9 
0.4-0.6  19 1.8 17 2.1 16 2.1 14 2 8 1.2 11 1.6 7 1 10 1.5 15 2.1 
0.6-0.8  121 11.5 94 11.6 73 9.7 87 12.3 80 11.7 98 14.6 95 14.2 91 13.6 90 12.5 
0.8-0.9  257 24.3 210 26 200 26.5 168 23.8 183 26.8 162 24.1 160 23.9 166 24.9 181 25.1 
0.9-1.0  626 59.3 466 57.7 438 58.1 424 60 392 57.5 385 57.3 387 57.8 383 57.4 415 57.6 
VAS score (n.%)                   
Mean. SD 84.32 18.55 84.45 18.26 84.76 18.63 85.39 18.08 84.92 17.95 84.97 18.2 84.83 18.17 84.93 18.22 85.28 18.47 
0-20 5 0.5 6 0.7 4 0.5 5 0.7 7 1 4 0.6 4 0.6 4 0.6 3 0.4 
20-40 43 4.1 29 3.6 31 4.1 21 3 16 2.3 21 3.1 21 3.1 16 2.4 28 3.9 
40-60 21 2 15 1.9 19 2.5 19 2.7 14 2.1 20 3 18 2.7 26 3.9 16 2.2 
60-80 373 35.3 283 35 239 31.7 224 31.7 237 34.8 222 33 228 34.1 215 32.2 215 29.8 
80-90 39 3.7 30 3.7 31 4.1 32 4.5 28 4.1 25 3.7 25 3.7 25 3.7 34 4.7 
90-100 575 54.5 445 55.1 430 57 406 57.4 380 55.7 380 56.5 373 55.8 381 57.1 425 58.9 
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Abstract
Background: In lung cancer screening, a nodule management protocol describes nodule assessment and
thresholds for nodule size and growth rate to identify patients who require immediate diagnostic evaluation or
additional imaging exams. The Netherlands-Leuvens Screening Trial and the National Lung Screening Trial used
different selection criteria and nodule management protocols. Several modelling studies have reported variations in
screening outcomes and cost-effectiveness across selection criteria and screening intervals; however, the effect of
variations in the nodule management protocol remains uncertain. This study evaluated the effects of the eligibility
criteria and nodule management protocols on the benefits, harms and cost-effectiveness of lung screening
scenarios in a population-based setting in Germany.
Methods: We developed a modular microsimulation model: a biological module simulated individual histories of
lung cancer development from carcinogenesis onset to death; a screening module simulated patient selection,
screening-detection, nodule management protocols, diagnostic evaluation and screening outcomes. Benefits
included mortality reduction, life years gained and averted lung cancer deaths. Harms were costs, false positives
and overdiagnosis. The comparator was no screening. The evaluated 76 screening scenarios included variations in
selection criteria and thresholds for nodule size and growth rate.
Results: Five years of annual screening resulted in a 9.7–12.8% lung cancer mortality reduction in the screened
population. The efficient scenarios included volumetric assessment of nodule size, a threshold for a volume of
300 mm3 and a threshold for a volume doubling time of 400 days. Assessment of volume doubling time is essential
for reducing overdiagnosis and false positives. Incremental cost-effectiveness ratios of the efficient scenarios were
16,754–23,847 euro per life year gained and 155,287–285,630 euro per averted lung cancer death.
Conclusions: Lung cancer screening can be cost-effective in Germany. Along with the eligibility criteria, the nodule
management protocol influences screening performance and cost-effectiveness. Definition of the thresholds for
nodule size and nodule growth in the nodule management protocol should be considered in detail when defining
optimal screening strategies.
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Background
The National Lung Screening Trial (NLST) in the USA
[1] has shown that lung screening with low-dose com-
puted tomography (LDCT) can reduce lung cancer mor-
tality by 20%, but it also can induce harms that the
screened population may experience, i.e. false-positive
findings, overdiagnosed cases, radiation-related deaths
and interval cancers [2–5]. The largest lung screening
trial in Europe, the Netherlands-Leuvens Screening Trial
(NELSON) [6], used less stringent selection criteria and
a different approach to patient management and has re-
ported a reduced number of false positives compared to
NLST [7]. The nodule management protocols of NLST
and NELSON differ in applied measurement techniques
(diametric vs volumetric assessment), follow-up algo-
rithms and the definition of a cut-off nodule size indicat-
ing a cancer-positive result [8]. However, other differences
between the studies (e.g. screened cohort, screening inter-
vals) make it difficult to recognise the potential of nodule
management approaches to succeed in the reduction of
harms of screening.
Designing a screening program with an optimal balance
between the benefits, harms and/or cost-effectiveness has
become a major challenge for healthcare decision-makers
who manage development of a lung screening program
and decide on population selection strategies and screen-
ing intervals [7, 9, 10] as well as for clinicians who decide
how to manage a screening-detected lung nodule [7].
Several modelling studies have examined trade-offs be-
tween the benefits and harms of LDCT screening and
contributed to comprehension of the effects that eligibil-
ity criteria and screening intervals might have on its
long-term screening performance and cost-effectiveness
[11–18]. However, the effects of nodule management
strategies have not been investigated in detail, and our
understanding of how to proceed with a screening-de-
tected nodule remains limited [19]. An algorithm for
nodule assessment and management determines ways
to prognosticate malignancy, defines core procedures of
a screening program and may strongly influence the
screening outcomes [20].
In this modelling study, we aimed to investigate the ef-
fects of the eligibility criteria and nodule management
on the benefits, harms and cost-effectiveness of lung
screening with LDCT in a population-based setting.
Methods
Microsimulation model
We developed a stochastic modular microsimulation
model that simulated individual life histories focusing on
the development of lung cancer and its progression from
the onset of the first malignant cell to death from lung
cancer.
The model consists of the following structural modules:
population, natural history, clinical detection, survival,
screening and life history (Fig. 1). The model was popu-
lated with 10% of the German population aged 40 years
and older. Data on smoking behaviour was obtained
from the German Health Update (GEDA) survey (years
2009–2012) [21], and the demographic structure of 2012
was obtained from the German statistical office [22].
The natural history module contains a biological two-
stage clonal expansion (TSCE) model [23] and a tumour
growth component and simulates a complete flow of
events in the development of lung cancer (details are
available in Additional file 1: Section 1.1.2). The TSCE
model defines the individual age at the onset of the first
malignant cell and the histologic cancer type: small cell,
large cell, squamous cell carcinoma, adenocarcinoma or
adenocarcinoma in situ (AIS). The progression of lung
cancer is described via tumour growth, lymph nodes in-
volvement and metastasis. The tumour growth is defined
by a Gompertz function [24] (Additional file 1: Section
1.1.4.2). This function describes the relation between
time and the tumour volume. For a specific tumour vol-
ume the function gives the time needed to reach this
volume and vice versa. The module uses the age at the
onset of the first malignant cell and the time to reach
the stage-specific volume and gives the age at different
stages of the progression of the disease. Threshold
tumour volumes at the stages of nodal involvement, dis-
tant metastases and clinical diagnosis are randomly
drawn from log-normal distributions (Additional file 1:
Table S5), and the tumour growth model is applied to
calculate the corresponding ages of the individual. The
clinical detection module determines the stage of lung
cancer (I, II, III, IV) according to the tumour-node-
metastasis (TNM) staging system based on the tumour
volume and spread (local, nodal involvement, distant
metastasis) at the age of diagnosis (Additional file 1:
Section 1.1.3).
The lung cancer survival is modelled as long-term sur-
vival, which lets the individual live until death from
other causes, and short-term survival in years, which fol-
lows the Weibull distribution [25]. The parameters vary
over the histological classes and stages at the time of
diagnosis (Additional file 1: Table S1, Section 1.1.3) [25].
The screening module (Additional file 1: Section 1.1.5)
contains several structural components: eligibility assess-
ment, screening-detection, nodule management (including
follow-up), diagnostic work-up and lung cancer survival.
For each individual it creates a screening schedule based
on eligibility criteria and nodule management protocol. At
each screening exam, the module checks for presence of a
lung nodule and determines its volume using the tumour
growth function, the individual’s age and the age at the on-
set of the first malignant cell. Screening-detection depends
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on the location and volume of the tumour and the sensi-
tivity of the CT scan (Additional file 1: Section 1.1.5.2,
Table S7). Individuals with a detected nodule proceed with
a nodule management algorithm. The nodule manage-
ment algorithm defines the threshold values of the nodule
size and tumour growth and indicates the patients who re-
quire immediate diagnostic work-up or undergo additional
imaging exams (follow-up course).
Two nodule management algorithms were designed
based on those used in the NELSON and NLST trials.
Schematic representations of the algorithms are given in
Figs. 2 and 3. The modelled NELSON-like nodule man-
agement algorithm includes volumetric assessment of
the nodule size. Based on the nodule volume, the patients
undergo either the next screening round (if negative), a
follow-up exam 3 months later (if indeterminate) or an
immediate diagnostic evaluation (if positive) [6, 26]. At the
follow-up examination, tumour growth and tumour vol-
ume doubling time (VDT [6]) are assessed as an additional
malignancy predictor.
The NLST-like nodule management algorithm includes
diametric assessment of the nodule size and defines three
categories of screening results: negative, positive intermedi-
ate and positive (Fig. 3). In contrast to the NELSON-like
nodule management algorithm, individuals with positive
intermediate initial results undergo a course of follow-up
chest imaging exams where tumour growth is assessed as a
change (%) in the nodule diameter relative to the result at
the initial screening. The follow-up can occur with a fixed
periodicity: at 3, 6 and 12 months after the initial screening.
Additional details on the modelled nodule management
protocols are available in Additional file 1: Section 1.1.5.3.
Individuals with lung cancer, defined in the management
algorithm, undergo the diagnostic work-up component
(Additional file 1: Section 1.1.5.4), and the tumour is staged
according to TNM classification based on the volume and
spread. These patients are withdrawn from the regular
screening schedule.
We assume that individuals with screen-detected lung
cancer live at least as long as they would in the no
screening scenario. In the screening module lung cancer,
survival component alters the age of death from lung
cancer for the persons with a screen-detected lung can-
cer at stages I and II: if they die from lung cancer in the
no screening scenario, they receive 40% probability of
long-term survival [25]. The screening module sums up
imaging exams, work-ups, complications and treatments.
The life history module computes false positives and
interval cancers and calculates overdiagnosed cases and
deaths from radiation-induced cancer (Additional file 1:
Section 1.1.6). Figure 4 gives a schematic representation
of the modelling of the tumour growth and interaction
between the natural history, screening, clinical diagnosis
and survival modules.
Fig. 1 Structural modules of the microsimulation model. * refers to the case in which the patients would die from lung cancer in the no
screening scenario
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Fig. 3 Schematic representation of modelled NLST-like nodule management protocol. *Growth is calculated as a percentage increase in the diameter
vs the diameter at the initial screening. Dcut and Growthcut indicate the threshold values of the diameter and percentage increase in the diameter that
indicate a cancer positive result. Dfup represents low threshold diameter for a follow-up examination
Fig. 2 Schematic representation of modelled NELSON-like nodule management protocol. Vcut and VDTcut indicate the threshold values of the
volume and volume doubling time which indicate a cancer positive result. Vfup represents low threshold volume for a follow-up examination
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Screening scenarios
At base case, a 5-year LDCT annual lung screening
program with perfect adherence was evaluated. Over-
all, 76 scenarios were constructed using variations of
the eligibility criteria (four different screened popula-
tions) and nodule management protocol (defined as
the NELSON-like or NLST-like protocol) (Table 1).
The outcomes were projected over the course of a life-
time. Lung cancer-specific mortality reduction and
false-positive cases were calculated for the screened
cohort.
Health economics
Costs included LDCT exams, staging tests and lifetime
treatment (Additional file 1: Table S8). Expenditures of
lifetime treatment, due to limitations of available cost
data for Germany, were calculated via application of cost
variations across cancer stages obtained from the UK
cost data [27] compared with the German cost data [28]
(Additional file 1: Section 1.3). The lifetime treatment
costs for patients with early-stage and advanced cancers
were 45,803 euro for stages I/II and 30,101 euro for
stages III/IV.
Fig. 4 Schematic representation of modelled tumour growth and interaction between the natural history, screening, clinical diagnosis and
survival modules. NMP nodule management protocol. The curve schematically represents the tumour growth. Figure does not reflect the scales.
The natural history module contains a biological two-stage clonal expansion (TSCE) model and a tumour growth component and simulates for
each individual the age at the onset of carcinogenesis, its histological features, the age and tumour size at the lymph nodes involvement and
distant metastasis. The TSCE model simulates age at the cancer onset for each histological class. The final histological class for the individual
is determined based on the competing risk (the lowest age at onset). The tumour growth component applies a Gompertz function which
describes the relation between time (age) and the tumour volume. The clinical diagnosis model determines the age at lung cancer diagnosis
and stage of the tumour according to TNM classification using the tumour growth model and information on the tumour progression from
the natural history module. The screening module simulates an individual screening schedule based on the eligibility criteria. It applies the
tumour growth module to determine the tumour volume at age of screening and uses information on the tumour progression for staging
the screen-detected tumour according to TNM classification. The survival model determines the age of death based on the tumour stage and
histological class. The figure illustrates a case where an individual in the no screening scenario develops a lung cancer tumour and is eventually
symptomatically diagnosed with lung cancer at stage IV. The patient dies from lung cancer in the no screening scenario. In the screening scenario, a
nodule (tumour) is detected in the first round of screening. The screen-detected nodule is small for the patient to undergo an immediate diagnostic
evaluation. The patient undergoes a follow-up exam, where the growth is assessed according to the NMP. The growth and/or the volume doubling
time meet the definition of cancer according to the NMP. The screen-detected tumour is at the local stage, and the patient is diagnosed with
lung cancer at stage I in the screening scenario. The patient is cured and dies from other causes. The model calculates life years gained for
each individual in the screened cohort
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Cost-effectiveness was represented by average and in-
cremental cost-effectiveness ratios (ACER and ICER,
respectively). Life years gained (LYG) and averted lung
cancer deaths constituted the main benefits of the
screening. We applied equal (3%) and differential (3% for
costs and 1.5% for LYG) annual discounting. A health in-
surance perspective was used.
Sensitivity analyses
One-way sensitivity analyses were performed to assess
variations of the cost-effectiveness after altering assump-
tions about LDCT sensitivity parameters, parameters of
long-term survival after screening, attendance rate cost
per CT exam and lifetime treatment costs (Additional
file 1: Section 1.4).
Results
Benefits and harms of screening
Annual screening led to a 9.7–12.8% reduction in lung
cancer mortality in the screened cohorts. Relative to
usual care, where 79% of cancers were diagnosed at
stages III and IV, a screening program shifted the majority
of diagnoses towards the early-staged cancers (stages I/II
accounted for 66.4–71.7%). Adenocarcinomas (around




Values arranged as (eligibility criteria of the NLST clinical trial)
age at begin smoking - age at quit smoking - minimum pack years - maximum
years since quitting smoking
55-80-30-15
(as recommended by the US Preventive Services Task Force
(USPSTF) for lung screening with LDCT [2])
50-75-15-9
(less restrictive eligibility criteria, similar to the NELSON trial)
55-75-40-10
(more restrictive eligibility criteria) [18]
Nodule management algorithm
NELSON-like VDTcut = 400 days – Vcut = 500 mm
3
Scenario is characterised by the threshold value of the volume doubling time
(VDTcut) and the cut-off volume (Vcut) for cancer positive
(values of the NELSON clinical trial)
VDTcut = 400 days – VDTcut = 300 mm
3
VDTcut = 400 days – VDTcut = 400 mm
3
VDTcut = 400 days – VDTcut = 750 mm
3
VDTcut = 300 days – VDTcut = 500 mm
3
VDTcut = 600 days – VDTcut = 500 mm
3
VDTcut = 300 days – omitting VDTcut
a
VDTcut = 400 days – omitting VDTcut
a
VDTcut = 600 days – omitting VDTcut
a
Vfup = 80 mm
3
– VDTcut = 400 days – VDTcut = 500 mm
3b
NLST-like Growthcut = 10% – Dcut = 10 mm
Scenario is characterised by the threshold value of the tumour growth and the
diameter (Dcut) for cancer positive
(values of the NLST clinical trial)
Growthcut = 10% – Dcut = 9 mm
Growthcut = 10% – Dcut = 11 mm
Growthcut = 7.5% – Dcut = 10 mm
Tumour growth (threshold growth, Growthcut) is defined as a percentage increase
in diameter
Growthcut = 12.5% – Dcut = 10 mm
Growthcut = 7.5% – omitting Dcut
a
Growthcut = 10% – omitting Dcut
a
Growthcut = 12.5% – omitting Dcut
a
Dfup = 5 mm – Growth = 10% – Dcut = 10 mm
b
aIn these scenarios nodule growth is taken as a single malignancy predictor
bIn these scenarios a higher nodule size for the follow-up exams (Vfup; Dfup) is used according to the British Thoracic Society guidelines [29]. In other scenarios the
value of nodule size for follow-up exams is applied according to the trials as 4 mm (NLST-like) and 50 mm3 (NELSON-like)
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50%), squamous cell carcinomas (around 23.4%) and AIS
(around 18.2%) constituted the majority of screening-
detected cancers. Around 77.2% of screening-diagnosed
AIS were overdiagnosed cases. Overdiagnoses constituted
9–21.5% of all screening-detected lung cancers. Small cell
carcinomas were rarely detected at screening (around
5.35%) but constituted 56% of all interval cancers. False-
positive diagnoses constituted 59.4–96% of all screening
findings.
Eligibility criteria have a considerable influence on the
main outcomes of a large-scale screening program. Eval-
uated scenarios with a selection of people similar to the
eligibility criteria of the NLST clinical trial (55-74-30-15)
gained 192,147–240,626 life years (ranged over the varia-
tions of the nodule management protocol) and 20,335–
25,467 averted deaths due to lung cancer and induced
3780–5069 million euro costs additional to no screening.
The scenarios with the increased threshold of exposure
to smoking (40 pack-years and maximum 10 years since
quitting) limited the screened population and yielded
around 31% less LYG (133,222–164,864) and 29% less
averted deaths (14,373–17,889) and induced 37% fewer
costs (2231–3178 million euro). Increasing the stopping
age to 80 (55-80-30-15) yielded around 8.3% additional
LYGs (207,468–260,807) and 14.4% more averted lung
cancer deaths (23,029–29,165) compared to the 55-74-
30-15 scenarios and a slightly increased reduction in
lung cancer mortality (12.4%); however, it induced around
13.5% more costs (4159–5811 million euro) and the
highest rate of overdiagnosis. Scenarios with the least
restrictive eligibility criteria, 50-75-15-9, resulted in
50.5% more LYGs (295,093–362,039) and 45.6% more
averted lung cancer deaths (30,147–37,075) vs the 55-
74-30-15 scenarios; however, they led to 57% more
healthcare costs (6447–8026 million euro additional to
no screening) and a higher number of CT scans.
Generally, the scenarios with the NELSON-like nodule
management protocol resulted in 1.1–1.3% fewer lung
cancer findings, but around 2.3% more findings of can-
cer at an early stage, 3.3–3.4% more cases of averted lung
cancer deaths, around 3% more LYGs, 0.1–0.9% fewer
overdiagnosed cases and around 3% more interval cancers
than the NLST-like strategies. The NLST-like scenarios
yielded around 51–57.4% more follow-ups of malignant
nodules and considerable additional costs.
Overall, across the evaluated 76 scenarios, a few tenden-
cies in the effects of the nodule management protocols
could be seen: (1) increasing the threshold for nodule size
for a cancer-positive diagnosis slightly decreased overdiag-
nosis, LYG and averted lung cancer deaths; (2) decreasing
the cut-off size yielded more overdiagnosed cases but did
not improve numbers of LYG and averted lung cancer
deaths; (3) altering threshold values for a cancer indicating
nodule growth when the cut-off volume stayed the same
did not appreciably change the rates of LYG and averted
lung cancer deaths; (4) application of VDT or an increase
in diameter as a single malignancy predictor in the two-
step framework remarkably reduced the accuracy of lung
cancer diagnosis, but it also notably decreased rates of
overdiagnosis. Increasing the threshold nodule size for a
follow-up in the NELSON-like scenarios from a volume of
50 mm3 to 80 mm3 and in the NLST-like scenarios from a
diameter of 4 mm to 5 mm, as recommended by the
British Thoracic Society [29], led to a 5% and 4% de-
crease in overdiagnosis and a 3.7–5% decline in LYG
and averted lung cancer deaths.
Cost-effectiveness of screening
ACER ranged from 16,754 to 24,160 euro/LYG (Fig. 5)
and from 155,287 to 230,678 euro/averted lung cancer
death (Fig. 6). Out of the 76 evaluated scenarios, three
scenarios were judged to be efficient based on their cost/
LYG ratio and five scenarios based on their cost per
averted lung cancer death ratio (Table 2).
The scenarios that featured NELSON and NLST
clinical trials were less efficient (Figs. 4 and 5, NLST-
and NELSON-resembling scenarios). Compared to the
NELSON-like scenarios, NLST-based screening over
5 years of annual screening would result in considerably
more total costs (around 450 million euro) while yielding
around 800 fewer averted deaths. Considering the cost per
life year gained ratio, characteristics of the not-dominated
scenario included the most restrictive eligibility criteria
(55-74-40-10) and the NELSON-like nodule management
protocol which applies the assessment of VDT 3 months
after the initial screening as a sole malignancy predictor
(Scenario 65, Table 2). The scenario yielded an ICER of
16,754 euro/LYG. The second efficient scenario (Scenario
60, Table 2) combined the threshold VDT of 400 days and
a cut-off nodule volume of 300 mm3. This scenario gained
31,642 additional life years for an incremental cost of
19,707 euro/LYG. The third efficient scenario (Scenario
41, Table 2) applied the same nodule management proto-
col and less stringent eligibility criteria (50-75-15-9). It
gained an additional 197,174 life years for an incremental
cost of 23,837 euro/LYG.
Two of the five scenarios, which were judged to be
efficient based on averted cancer deaths, included the
most restrictive selection criteria (55-75-40-10) and as-
sessment of VDT 3 months later than the initial screen-
ing as a sole malignancy predictor for individuals with
initial findings over 50 mm3 in volume (Scenarios 64
and 65, Table 2). The scenario with the lowest ICER of
155,287 euro per averted death (Scenario 65 with
threshold VTD of 300 days) yielded 14,373 averted
deaths. Increasing the threshold value of VDT to 400 days
gained an additional 1000 averted deaths for an incremen-
tal cost of 161,124 euro (Scenario 64). The inclusion of the
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cut-off volume of 300 mm3 (Scenario 60) into the nodule
management algorithm yielded 2500 more averted deaths
for an incremental cost of 184,009 euro. The scenario with
less restrictive selection criteria of exposure to smoking
and the increased stopping age (55-80-30-15, Scenario 22)
yielded 11,276 more averted lung cancer deaths for an
ICER of 216,454 vs the previous efficient scenario. The
scenario with the largest number of LYG (Scenario 41) is
also the scenario with the largest yield of averted cancer
deaths (37,075) for an ICER of 285,630 euro per averted
death.
Sensitivity analyses
Figure 7 illustrates the discounted life years and additional
costs (vs no screening) for the three efficient scenarios
(Scenarios 65, 60 and 41) and for their variations in the
sensitivity analyses. The main cost-effectiveness drivers
are cost per CT exam, treatment costs and lung cancer
long-term survival probability in screening. Relative to the
baseline long-term survival probability (40%), its reduction
to 20% led to a more than 50% reduction in LYG and
averted deaths with a more than 100% increase in cost/
LYG. Increase in cost per CT exam would have a stronger
adverse effect on the cost-effectiveness if the less restrict-
ive eligibility criteria were used. More expensive treatment
with innovative targeted medication at a lifetime cost of
77,702 euro [28] would increase the ACER by 65%. An in-
crease of the CT sensitivity for smaller nodules would
slightly improve the cost-effectiveness; a 20% decrease of
the sensitivity would lead to a more than 10% increase in
Fig. 5 The cost-effectiveness (cost per life year gained) of all evaluated scenarios and the scenarios that constitute an efficient frontier. The figure
illustrates three scenarios judged to be efficient based on the cost per life year gained ratio. These scenarios constitute the efficient frontier. The
other 73 evaluated scenarios are illustrated according to the population selection criteria and applied nodule management protocol (NMP). The
figure illustrates the four evaluated eligibility criteria in different colours: 55-75-40-10 is given in green, 55-74-30-15 is given in violet, 55-80-30-15 is
given in orange and 50-75-15-9 is given in dark blue. The scenarios which apply the NLST-like nodule management are illustrated with a circular
shape. The scenarios which apply the NELSON-like nodule management are illustrated with a triangular shape. The figure does not specify in
colour or a shape the evaluated variations of the threshold values for the tumour size and growth in the NELSON-like and NLST-like scenarios.
The scenarios which resemble the eligibility criteria and nodule management protocols of the NLST and NELSON clinical trials are illustrated in
light blue. Descriptions of the scenarios are given in Table 1. Main outcomes and cost-effectiveness of the 76 baseline screening scenarios are
given in Additional file 1: Table S12
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ACER. Compared with perfect adherence (100%), decreas-
ing adherence to 85% for the years following the initial
screening led to a modest decline of ACER (around 1%).
Screening strategy 60 (55-75-40-10-NELSON-VDT400-
V300) becomes inefficient in the scenarios of the de-
creased adherence, decreased cost per CT exam and
increased treatment cost (i.e. innovative treatment
scenario). Due to high rates of detection and overdiag-
nosis, factors that increase ratio of treatment relative
to the costs of screening have adverse effects on ICER
compared to the previous efficient scenario. Scenario
65 (55-75-40-10-NELSON-VDT300-only) in turn becomes
inefficient under conditions of increased screening costs.
Expanding the period of the screening to 10 years did
not considerably influence the cost-effectiveness. Detailed
results of baseline and sensitivity analyses are available in
Additional file 1: Sections 2.2–2.4.
Discussion
The microsimulation analysis shows that lung cancer
screening of the high-risk population in Germany can be
cost-effective. A program with less restrictive eligibility
criteria would be more effective but would induce a
higher ICER due to screening of people with a lower risk
of lung cancer development. The selection of heavier
smokers and limitation of the screened population yields
the lowest cost-effectiveness ratio compared with the no
screening scenario. Increasing the stopping age, i.e. follow-
ing the recommendations of the USPSTF [2], prevents
additional deaths from lung cancer but also leads to con-
siderable additional costs and increased overdiagnosis.
Overall, if decision-making is based on the results of esti-
mation of efficiency of an intervention, the scenarios that
constitute an efficient frontier should be considered for
implementation because other scenarios are proven to be
Fig. 6 The cost-effectiveness (cost per averted lung cancer death) of all evaluated scenarios and the scenarios that constitute an efficient frontier.
The figure illustrates five scenarios judged to be efficient based on the cost per averted lung cancer death ratio. These scenarios constitute the
efficient frontier. The other 71 evaluated scenarios are illustrated according to the population selection criteria and applied nodule management
protocol (NMP). The figure illustrates the four evaluated eligibility criteria in different colours: 55-75-40-10 is given in green, 55-74-30-15 is given in
violet, 55-80-30-15 is given in orange and 50-75-15-9 is given in dark blue. The scenarios which apply the NLST-like nodule management are illustrated
with a circular shape. The scenarios which apply the NELSON-like nodule management are illustrated with a triangular shape. The figure does not
specify in colour or a shape the evaluated variations of the threshold values for the tumour size and growth in the NELSON-like and NLST-like
scenarios. The scenarios which resemble the eligibility criteria and nodule management protocols of the NLST and NELSON clinical trials are
illustrated in light blue. Descriptions of the scenarios are given in Table 1. Main outcomes and cost-effectiveness of the 76 baseline screening
scenarios are given in Additional file 1: Table S12
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less efficient. The efficiency frontier itself is shaped by the
applied measure of efficiency.
Our study provides two efficiency frontiers based on
weighting two major benefits of screening (LYG and
averted lung cancer deaths) against the resulting costs
(additional costs relative to the no screening scenario).
The comparative modelling study by de Koning et al. for
the USPSTF [2] in turn used “screenings per lung cancer
death averted” as a measure of the efficiency. Based on
this measure, the authors concluded that the eligibility
criteria 55-80-30-15 are more efficient than the original
NLST criteria. Considering their results for the screen-
ings per LYG as the efficiency measure, the 55-80-30-15
scenario is still more effective but less efficient than the
55-75-30-15 scenario. Although we applied the additional
cost in the numerator of the cost-effectiveness ratio, our
findings are consistent with those by de Koning et al.: the
selection criteria 55-80-30-15 are more efficient than 55-
74-30-15 if the efficiency is estimated using the cost per
averted lung cancer death ratio but less efficient based on
the cost per life year gained ratio. Overall, both efficient
frontiers outlined in our study do not include scenarios
with the 55-74-30-15 population selection criteria.
Additionally, the efficiency measure “screenings per
lung cancer death averted” used by the USPSTF to give
the recommendation for screening does not include the
harms of overdiagnosis. In our study, the cost side of
the cost-effectiveness ratio includes the costs (related
to screening and treatment) of the overdiagnosed cases
and by that the overdiagnosis is incorporated into the
measure of efficiency. In screening for lung cancer,
overdiagnosis is thought to be “the most extreme form
of length-time bias” [30]. These cases include patients
with tumours that would never have caused symptoms
or been diagnosed in clinical settings. Stopping screen-
ing at age 80 leads to substantially higher numbers of
overdiagnosed cases. This also has been shown in the
studies by ten Haaf et al. [18] and de Koning et al. [2].
In our analysis, the costs of the overdiagnosed cases ac-
count for about 30% of the difference in costs between
the 55-80-30-15 and 55-74-30-15 scenarios. If the im-
pact of overdiagnosis on the quality of life was included
into estimation of the efficiency, it would be expected
to further reduce the effectiveness and efficiency of the
screening of an older population.
Ideally, all benefits and harms which are considered to
be relevant for the identification of an optimal screening
strategy should be included into the measure of effective-
ness and efficiency. However, this would require a defined
efficiency threshold [31] or prioritisation and weighting of
the benefits and harms made by decision-makers. The aim
of our study was to evaluate strategies for an introduction
Fig. 7 The cost-effectiveness of the efficient scenarios (cost/LYG) in the sensitivity analyses. Scenario 60 is not efficient under conditions of
decreased adherence, innovative treatment and cost per CT exam of 100 euro. Scenario 65 is not efficient when cost per CT exam is 200 euro
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of a large-scale lung screening in Germany and to outline
and discuss efficient scenarios rather than provide a solid
recommendation.
Patient management strategy has a strong influence on
long-term performance and cost-effectiveness of lung
screening. The NELSON- and NLST-like nodule man-
agement protocols are comparably effective in reducing
lung cancer mortality; however, the NELSON-like strat-
egy is more successful in detection of early-stage lung
cancers, yields fewer follow-up exams, and saves costs,
and therefore may be preferable in clinical practice. The
efficient screening scenarios highlight the combinations
of the eligibility criteria and NELSON-like nodule man-
agement protocols, which may yield additional benefits
without increasing the ICER. The cut-off volume for
immediate diagnostic evaluation is a key element of the
nodule management strategy. In the NELSON trial, the
cut-off volume was defined as 500 mm3 and higher.
Our results show that a decrease to 300 mm3 would be
a more cost-effective strategy and may be justified for
clinical practice. From the health economics perspective,
our findings support previous inferences made by Horeweg
and colleagues, who assessed probabilities of cancer de-
velopment based on the NELSON data and concluded
that patients with a screen-detected nodule of volume
of 300 mm3 or more should undergo immediate diagnos-
tic work-up [20]. Additionally, variations of the nodule
management elements show that the assessment of VDT
at follow-up becomes more important if the threshold
nodule volume is less restrictive (more than 500 mm3).
It is important to note that a decreased cut-off volume
may lead to an increased number of overdiagnosed cases.
In our analysis, the majority of the overdiagnosed cases
were patients with slowly growing adenocarcinomas and
AIS. Due to their slow growth, these are rarely symptom-
atically diagnosed [32] but may be detected by screening.
Our results also suggest that scenarios which exclude the
threshold nodule volume as the indicator for immediate
diagnostic evaluation and apply the assessment of VDT (at
the follow-up exam 3 months later) as a sole malignancy
predictor can considerably reduce overdiagnosis; however,
this can come at a high price of missing LYG and averted
lung cancer deaths. Although a number of cases and the
costs of overdiagnosis can be calculated in model settings,
their effects on the health outcomes and quality of life
need to be further investigated and quantified.
In this study, the effect of screening on quality of life
could not be included in the analysis due to lack of
German data on values of quality-adjusted life years
(QALYs) across the lung cancer stages, sexes and age
groups. The cost-effectiveness ratios in terms of costs per
QALY gained would be expected to be notably higher than
the estimated cost/LYG ratios [7]. As long as the screening
shifts the major part of diagnoses towards the early-stage
cancers, more patients are likely to receive a resection op-
eration. These patients are reported to have a considerably
impaired quality of life during the first 2 years after lung
resection but it may improve later [33, 34]. Additionally,
with the application of QALYs, the negative effects of
overdiagnosis and false positives would considerably
increase [35, 36].
Several limitations are worth noting. Tumour growth
is simulated using a Gompertzian growth model which
does not capture abrupt changes in the development
(growth) of the tumour. However, other studies have
shown that cancer tumour growth can be well approxi-
mated by a Gompertz function [37]. Our approach to
modelling of false positives is rather simplified and does
not allow for a comprehensive analysis of the false-
positive outcomes at screening. The question of how to
decrease the number of false-positive cases remains
unanswered and requires additional information, which
clinical trials may provide in the future. The limitations
form a direction for further research into lung screening
in Germany. There is a need to collect detailed data on tu-
mours at time of diagnosis about their size, stage, smoking
habits of the patients, treatment costs and quality of life
of German patients with lung cancer, along with factors
affecting screening uptake among the target groups.
The cost-effectiveness of a combination of a smoking
cessation intervention with a screening program is worth
investigating.
Despite the limitations, the present study contributes
insights on the impacts of the nodule management
protocol on the effectiveness and cost-effectiveness of
the introduction of a large-scale lung screening program.
Additionally, this work is the first modelling study of
microsimulation design which examines cost-effectiveness
of the introduction of a large-scale lung screening pro-
gram in a European country. The presented findings are
comparable to the results reported in NLST [38] and pre-
vious modelling studies [2, 14, 18]. Because the developed
model contains very little input obtained from the NLST
data, comparison with the outcomes of NLST may serve
as validation of the model. Outcomes of the model for the
scenario most similar to NLST (Additional file 1: Section
2.2, Table S10) show a resembling distribution of histo-
logic classes and stages of lung cancers detected at screen-
ing and interval cancers [1]. NLST reports lung cancer
mortality outcomes relative to radiography for a median
follow-up of 6.5 years [38]. We could compare these with
the outcomes of our microsimulation model for 7 years of
follow-up (Additional file 1: Table S14). In our analysis
lung cancer mortality is considerably higher in the no
screening settings and in the NLST-resembling scenario
than reported in the trial; however, the differences be-
tween mortality rates in the screening and no screening
scenarios are close to the differences in mortality rates
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between LDCT screening and radiography observed in
NLST. Considering lung cancer mortality reduction as a
ratio, due to the higher mortality rates the model reports a
lower percentage (around 16%) in comparison to NLST
(21%) [38]. However, it still falls into the range given by
confidence interval calculations in NLST. Our model
also predicts a higher all-cause mortality rate than ob-
served in NLST. The higher mortality may be caused by
an older population and a larger proportion of current
smokers in the screened cohorts; additionally, the settings
of a clinical study and a possible “healthy-volunteer” effect
[38] may positively affect the mortality outcomes of the
clinical trial.
Overall, reduction in lung cancer mortality calculated
over a lifetime course ranges from 9.7 to 12.8% and stays
similar to the values reported in previous studies [2, 18].
Furthermore, the difference in the mortality rates be-
tween the no screening and screening arms is the basis
for the economic evaluation, and it is very similar to that
of the NLST trial. We therefore suggest that application
of survival data other than that reported in NLST has a
limited influence on the presented findings.
The cost-effectiveness has been analysed in modelling
studies in the USA [14] and Canada [18]. Due to the
application of QALYs in the study by McMahon et al.
(USA), the obtained cost-effectiveness ratios cannot be
compared. Comparing the findings to the study by the
Canadian team, the cost-effectiveness ratios obtained in
this study lie within the range given by ten Haaf et al.,
despite differences in the applied cost inputs [18].
Overall, applicability of the presented results for other
countries depends on the similarity of the cost structure
and heavy smoker prevalence between the countries.
The sensitivity analyses show that cost-effectiveness ratio
is driven by cost per CT exam and other screening-
related costs. The cost per CT exam taken in our study
is not Germany-specific and is varied in the sensitivity
analyses, giving an opportunity to transfer the results to
other countries. The costs of lung cancer treatment tend
to be higher in Germany, as in other European countries
[39]. Pharmaceutical companies continue to keep prices
higher in Germany based on the expectation that German
prices will become reference prices for the pharmaceuticals
in other European countries [40]. Lower costs of screening
and lung cancer treatment in other countries may decrease
the cost-effectiveness ratio and make population-based lung
screening more cost-effective.
Due to differences in exposure to smoking in popula-
tions, cost structures and approaches to lung cancer treat-
ment, efficient scenarios of lung screening can vary
between the European countries. However, the main find-
ings on the impacts of the nodule management protocol
and population selection criteria on the cost-effectiveness
of the screening can be applied to other countries.
Conclusions
This study quantifies the effect of nodule management
approaches on the benefits, harms and cost-effectiveness
of lung screening. Our analysis shows that the nodule
management protocol has a considerable effect on
screening performance and should be considered in
greater detail when defining optimal screening strategies.
It is the first cost-effectiveness analysis of lung cancer
screening using a microsimulation design performed in a
population-based setting in Germany. These results can
support decision-making processes in lung cancer pre-
vention and direct creation of guidelines for LDCT lung
cancer screening to benefit the German population.
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1. Methods  
1.1. Modules of the microsimulation model 
The model is of modular design and comprises of the following structural modules: Population, Natural History, 
Clinical Detection and Survival, Screening and Life History. 
 
1.1.1. Population module 
Population module creates a screening population with the given demographic structure and smoking patterns. 
The individuals in the simulated population were characterized by gender, age at model entry point and then 
defined by the age at the point of initial smoking, age at smoking cessation and the average number of cigarettes 
consumed per day. Smoking history determines the exposure to cigarette smoke (first hand), which along with 
age and gender governs age of death from other causes.  
Smoking behaviour data were obtained from two national health surveys conducted between 2008 and 2012: the 
German Health Interview and Examination Survey for Adults (DEGS) and the German Health Update (GEDA)
1
. 
Due to the data availability, the demographic structure was taken from the year of 2012 
2
. Based on the smoking 
behaviour data and demographic structure, the population for the simulation was obtained via  bootstrapping 10% 
of the German population. Smoking behaviours of current smokers were extrapolated over the course of a 
lifetime and during the modelled years the current smokers could quit smoking. The smoking cessation age was 
calculated by using the smoking cessation probabilities , which were assigned according to estimates obtained 
based on the data from the national health surveys. 
1.1.1.1. Other-cause mortality 
In the Population module an individual age of death from other causes than lung cancer is simulated based on 
age at entry the model, gender and the smoking status: never-, current- or former smoker. Five-year survival 
probabilities across age, gender and the smoking status were constructed based on the estimates obtained by 
Woloshin et al 
3
 and extrapolated using the recent life tables for the German population
2
. Other-cause mortality 
was introduced into the model as a competing risk and computed by applying the probability estimates and two 
random numbers (for each individual) which defined a five-year age interval in which the person may die from 
other causes and then the exact age of death within this interval. 
 
1.1.2. Natural History module 
The Natural History module simulates the development of lung cancer during individual life course. The 
sequence of events starts with onset of the first malignant cell, evolves through the progressive stages of lung 
cancer and ends with the death from the cancer.  
The onset of the first malignant cell is simulated by using the biological two-stage clonal expansion (TSCE) 
model described by Moolgavkar and Luebeck 
4
, where age, gender and personal exposure to cigarette smoke are 
translated into the piecewise constant parameters of the hazard functions. Onset lung cancer is modelled as a 




each histological type, we drew an individual age at onset of carcinogenesis from a respective survival function. 
The histologic type that develops first is defined as the active cancer. We assume that 20% of adenocarcinomas 
are of type adenocarcinoma in situ
5
. Additionally, if the onset of cancer takes place, we assume a single 
malignant nodule per person. 
The progression of the cancer is characterised by its growth, nodal involvement and occurrence of distant 
metastases. Threshold values of tumour volumes at the stages of nodal involvement and distant metastases 
depend on the histologic cancer type and are randomly drawn from log-Normal distributions. We applied a 
Gompertz function to model tumour growth over time
5
. This function determines the individual age at every 
stage of disease progression given the respective threshold volumes are reached (see section  Modelling details of 
the Natural History, Clinical detection and Survival modules ). 
 
1.1.3. Clinical detection and Survival module 
Clinical detection and Survival module simulates symptomatic detection of lung cancer, which includes age and 
tumour volume at the time of diagnosis, and age of death from lung cancer. The distribution of the tumour 
volumes at time of diagnosis is given by the log-Normal distribution; age at the time of diagnosis is analogously 
calculated by using the tumour growth function. Persons with clinical detection undergo diagnostic procedures 
which include PET CT, EBUS bronchoscopy and head MRI 
6
. The diagnosis is assigned according to the TNM 
Classification of Malignant Tumours (TNM) by the Union for International Cancer Control (UICC). Treatment 
is not explicitly modelled, however, its effects are implicitly included in lung cancer survival function. The 
survival depends on the histological class and stage at the time of  diagnosis and follows the Weibull 
distribution
7
 (see Table 1). It is assumed that death from lung cancer occurs after the time of clinical diagnosis. 
Table S1: Parameters for the long-term survival probability and the Weibull distributions for time period 
from clinical diagnosis to lung cancer death by cell type and stage at diagnosis  
7
. 




Squamous cell- carcinoma I , II 0.180 2.419 0.573 
Squamous cell-carcinoma III , IV 0.060 0.752 0.641 
Adeno- and Large cell-
carcinoma 
I , II 0.290 4.783 0.676 
Adeno- and Large cell-
carcinoma 
III , IV 0.050 0.674 0.607 
Small cell-carcinoma I , II 0.080 1.049 0.727 
Small cell-carcinoma III , IV 0.010 0.507 0.738 
 
1.1.4. Modelling details of the Natural History, Clinical detection and Survival modules  
1.1.4.1. Onset of the first malignant cell: 
Onset of the first malignant cell of each histological class  is expressed by the biological two-stage clonal 
expansion (TSCE) model. The hazard rates and the survival probabilities are given by the equations  below which 
were adopted from an R package “MIcrosimulation Lung Cancer (MILC) model” by Chrysanthopoulou AS. 8 






h(t) = υμX (e(γ  + 2B)t  - 1)
γ + B (e(γ  + 2B)t  + 1)
 
where X is total number of normal cells , υ is the normal cell initiation rate, μ is the malignant transformation 
rate, γ and B are piecewise constant parameters which are determined by: 
 γ = α - β – μ and B = 1
2
 (- γ + √γ2  + 4αμ) 
where α the cell division rate and β is the rate of programmed cell death.  






 * (- t + 1
B
 * log (γ + B + B * e(γ  + 2B)t )) 
with  
α = α0  (1 +  α1 q(t)α2 ) and γ = γ0  (1 +  α1 q(t)α2) ,  
where q(t) is the average number of cigarettes consumed per day at age t and α0 and γ0 represent coefficients for 
never smokers. The parameters are given in Table 2.  
Table S2: Parameters for the cumulative hazard functions  
Parameter  Males Females Reference 









Division rate of initiated cells  
non-smokers(α0) 
smokers: α1 ; α2 
 
7.7 
0.6 ; 0.22 
 
15.82 
0.5 ; 0.32 
Piecewise constant parameters non-smokers (γ0) 0.09 0.071 
The normal cell initiation rate non-smokers (ν0) = μ = μ 
The normal cell initiation rate smokers (ν1) 0 0.02 
 
For each histological class, the cumulative hazard functions are transformed into the survival functions which 
describe the time of the onset of lung cancer and are given by 
8
:  
S(𝑡) = exp {- H(t)} = exp {- ∫  h(x)  dxt
0
} 
For each individual with onset carcinogenesis, the ages of onset of the first malignant cell of each histological 
type are drawn from the respective survival functions . The type of the active cancer and age of onset of 
carcinogenesis are modelled through competing risks between the four histological types  and are determined by 
the histological type of the earliest cancer. 
The life course is segmented into periods which are defined by age, gender and smoking status. Table 3 
describes the division. The periods are bounded by age given by a and b, 0 < a < b< 𝑡𝑑 , where 𝑡𝑑  depicts the 
age of death. Over these periods the survival functions are differently parameterized to express  differences in the 
risk of onset of carcinogenesis. The parameters for the survival functions are given in Table 4 and are constant 




Table S3: Age boundaries ("a and b") for parametrization of age-dependent risk of the onset of the first 











Age1 (a) 50.88 50.31 49.75 50.41 
Age2 (b) 64.54 66.09 62.62 66.37 
Female 
Age1 (a) 56.88 56.61 57.05 56.07 
Age2 (b) 79.46 79.28 79.89 79.19 
* adenocarcinoma in situ 











0 - a 2.13E-08 1.12E-08 2.70E-08 5.64E-08 
a - b 2.67E-08 1.05E-08 4.14E-08 8.58E-08 
b - 100 5.84E-08 2.07E-08 9.90E-08 1.26E-07 
Female 
0 - a 4.51E-08 2.00E-08 3.96E-08 1.27E-07 
a - b 7.37E-08 2.08E-08 7.46E-08 1.70E-07 
b - 100 5.26E-08 1.71E-08 5.91E-08 4.60E-08 
* The parameters were fitted using data on lung cancer incidence by Eberle 2015 and the German cancer registry  
10,11
. 
Depending on the smoking status an individual life course can be divided into periods as follows. The periods 
are denoted by T1, T2,T3  and T4 .  
Never smoker: 
For never smokers a life course is divided into three periods in which the survival function is parametrized with 
different malignant conversion rates (Table 4). 
S(t) = exp { - ∫  h(x) dx -  ∫  h(x)  dxT2T1T10  - ∫ h(x)  dx𝑡𝑑T2 }, 
with T1 = 𝑎 and T1 = 𝑏 
Current smoker:  
For current smokers a life course is divided into four periods which are defined by the age boundaries (as for 
never smokers) and age at start smoking. The age at smoking initiation can fall into any of the three periods and 
alter the parameterization for the hazard and survival functions over the periods following the time at smoking 
initiation as follows:  
S(t) = exp {- ∫  h(x) dx - ∫  h(x)  dxT2T1 - ∫  h(x) dxT3T2 − ∫  h(x) dx𝑡𝑑T3T10 }, 
with T𝑠𝑡  is age at start smoking, 0 < 𝑎 < 𝑏 < 𝑡; 0 < T𝑠𝑡  < 𝑡𝑑  , and: 




T2 = { 𝑎,                 𝑇𝑠𝑡 ≤ 𝑎𝑇𝑠𝑡 , 𝑎 < 𝑇𝑠𝑡 < 𝑏𝑏,                 𝑇𝑠𝑡 ≥ 𝑏  
T3 = {𝑇𝑠𝑡 , 𝑇𝑠𝑡 ≥ 𝑏𝑏, 𝑇𝑠𝑡 < 𝑏  
Former smoker: 
For former smokers a life course is divided into five periods given by the age boundaries (as for non-smokers), 
age at smoking initiation and age at smoking cessation. The hazard and survival functions are respectively 
parameterized over the pre-smoking, smoking and post-smoking periods. 
The survival functions for former smokers are described as follows:  
S(t) = exp {- ∫  h(x) dx - ∫  h(x)  dxT2T1 - ∫  h(x) dxT3T2 − ∫  h(x) dxT4T3 − ∫  h(x)  dx𝑡𝑑T4T10 }, 
with 𝑇𝑠𝑡  age at initial cigarette smoking and 𝑇𝑞  age of cessation, 0 < 𝑎 < 𝑏 < 𝑡𝑑 ;0 < 𝑇𝑠𝑡 < 𝑇𝑞 < 𝑡𝑑 , 
and:  
T1 = {𝑇𝑠𝑡 , 𝑇𝑠𝑡 ≤ 𝑎𝑎, 𝑇𝑠𝑡 > 𝑎  
T2 = {𝑇𝑞 ,                  𝑇𝑞 < 𝑎𝑎, 𝑇𝑠𝑡 < 𝑎 and 𝑇𝑞 ≥ 𝑎𝑇𝑠𝑡 , 𝑎 < 𝑇𝑠𝑡 < 𝑏  
T3 = { 
 𝑎,                                  𝑇𝑞 ≥ 𝑎𝑏, 𝑇𝑠𝑡 < 𝑏 𝑎𝑛𝑑 𝑇𝑞 ≥ 𝑏𝑇𝑞, 𝑇𝑠𝑡 < 𝑏 𝑎𝑛𝑑 𝑇𝑞 < 𝑏𝑇𝑠𝑡 ,                             𝑇𝑠𝑡 ≥ 𝑏  
T4 = {𝑏,            𝑇𝑞 < 𝑎𝑇𝑞 , 𝑇𝑠𝑡 ≥ 𝑏  
1.1.4.2. Tumour growth 
The following Gompertz function for tumour growth is applied: 
𝑉(𝑡) = 𝑉0 ∙ 𝑒𝛽𝛼∙(1−𝑒−𝛼∙𝑡) 
Where 𝑉0  and  𝑉(𝑡)  represent initial tumour volume and 𝑉(𝑡) tumour volume at time 𝑡, 𝛼 and 𝛽 are the location 
and scale parameters of the Gompertz distribution. 
Maximum tumour volume Vmax in the Gompertz function is given by: 
𝑉𝑚𝑎𝑥 = 𝑉0 ∙ 𝑒𝛽𝛼  
With a given 𝑉𝑚𝑎𝑥  , the volume of the tumour developed over time 𝑡 is expressed by:  





and time needed to reach volume 𝑉(𝑡) can be computed as:  
𝑡 = ln(log 𝑉0𝑉𝑚𝑎𝑥 𝑉(𝑡)𝑉𝑚𝑎𝑥)−𝛼 , 
where 𝛼 is the growth rate which is drawn from lognormal distributions parameterized according to the 
histological class (see Table 5) 
5
.  
Relationship between 𝑉𝑚𝑎𝑥  and a set diameter is described by:  𝑉𝑚𝑎𝑥  = π6 (𝐷) 3 
where D is a given diameter. 
Limits of diameters for 𝑉𝑚𝑎𝑥  are fixed to 277 mm for all histological types except adenocarcinoma in situ for 
which the limit of diameter for 𝑉𝑚𝑎𝑥  is set to 30 mm. 



















logN(-7.765, 0.5504) 187(160) 227(194) 260(222) 
Large cell- 
carcinoma 
logN(-6.59942, 0.68862) 61(61) 74(74) 85(85) 
Small cell- 
carcinoma 
logN(-5.44357, 0.611485) 19(16) 23(20) 26(23) 
Squamous cell- 
carcinoma 
logN(-6.6111, 0.7935) 65(72) 79(87) 90(100) 
 
 
1.1.4.3.  Modelling regional and distant stages of the disease progression 
The disease progression is featured via tumour growth, nodal involvement (regional stage) and metastases 
(distant stage). It has been previously shown that with a Gompertzian tumour growth function, the disease 
progression through advanced stages over time are characterized by specific tumour volumes, location and 
presence of metastases can be well described by applying log-Normal distributions 
8
. 
Threshold tumour volumes for regional and distant stages are drawn from log-Normal distributions constructed 
for each histological class 𝑖 (𝑖 = 1,2,3,4) and stage 𝑗 (𝑗=regional, distant, clinical diagnosis) as 
lognormal(𝜇𝑖,𝑗, 𝜎𝑖 ,𝑗2 ). If a person’s threshold volume exceeds computed for her 𝑉𝑚𝑎𝑥 , the corresponding cancer 
stage will not be reached during the lifetime of this person. 
The threshold volumes across the histological classes and progression stages are given in the Table 6 below. The 
log-Normal distributions are constructed by transforming these volumes to mean and standard deviations of the 




Table S6: Threshold values for volumes in mm
3
 used to construct the log-Normal distributions in modelling 









the regional stage 
Mean (SD) 
Diagnosis after 




610* (650) 4,710* (4,140) 4,787 (4,787) 9,031 (9,031) 
Large cell- 
carcinoma 
2,299 (2,299) 18,482 (18,482) 8,262 (8,262) 25,144 (25,144) 
Squamous cell- 
carcinoma 
8,466 (8,466) 74,610 (74,610) 24,458 (24,458) 56,418 (56,418) 
Adeno/AIS- 
carcinoma 
3,038 (3,038) 17,376 (17,376) 9,899 (9,899) 27,304 (27,304) 




1.1.5. Screening module 
Screening module contains several structural components: eligibility assessment, screen -detection, nodule 
management (includes follow-up), diagnostic work-up and lung cancer survival.  
1.1.5.1. Eligibility assessment 
The eligibility criteria include qualifying age range, accumulated pack-years and number of years since cigarette 
cessation. Once eligible an individual undergoes a screen chest exam with LDCT. 
1.1.5.2. Screen-detection 
The probability of a screen-detection of a nodule depends on the presence of lung cancer and  the sensitivity of 
the LDCT-test. The sensitivity of CT varies with nodule size and its location (Table 7). The location is 
considered of two types, central and peripheral, and varies with histological classes
5
. In the case of screen-
detection of a nodule, the person proceeds through the nodule management algorithm. In the case of no 
detection, the person is scheduled for the next screening round. 
1.1.5.3.  Nodule management algorithms 
The nodule management includes the nodule size assessment, classification of the screening test results and 
follow-up scans. The output of the nodule management predetermines whether the person goes through the 
work-up component or is scheduled for the next screening round. During simulation only one of the NLST and 
NELSON nodule management is switched depending on the screening scenario under evaluation. 
See Figures 2 and 3 in the main text.  
In the NELSON-line nodule management protocol, based on the assessed volume (𝑉), the screening-detected 
nodule is classified as a negative (𝑉<𝑉𝑓𝑢𝑝 ), positive (𝑉≥𝑉𝑐𝑢𝑡 ) or indeterminate result (𝑉𝑓𝑢𝑝 ≤ 𝑉 <𝑉𝑐𝑢𝑡 ). 
Individuals with the negative initial results continue with annual screening. Individuals with the positive initial 
results undergo immediate diagnostic work-up. Persons with the indeterminate results undergo a follow-up 
imaging exam at three months after the initial screening. Results of the follow-up exam are determined by the 




doubling time (VDT) 
121
. At the follow-up the initial results are reclassified as positive if the nodule volume 
reaches or exceeds the cut-off volume (𝑉𝑐𝑢𝑡 ) and/or with VDT less than the threshold value (𝑉𝐷𝑇𝑐𝑢𝑡 ) defined by 
the scenario. The person with these results undergoes the work-up diagnostic procedures. If VDT is more than 
the threshold value, the person proceeds with the annual periodicity follow-up till the requirements for the 
positive result are met. Volumes at the follow-ups are compared with the volume of the initial screen-finding. 
The NLST-like nodule management algorithm includes diametric assessment of the nodule size and a sequence 
of follow-up procedures where tumour growth is estimated as a change (%) in the nodule diameter relative to the 
result at the initial screening. Based on the assessed diameter (D) the nodule is placed into one of the three 
categories: negative (𝐷<𝐷𝑓𝑢𝑝 ), positive intermediate (𝐷𝑓𝑢𝑝 ≤𝐷 < 𝐷𝑐𝑢𝑡) and positive (𝐷 ≥ 𝐷𝑐𝑢𝑡)13. People with 
negative initial results proceed to the next screening round. People with the positive initial results undergo 
diagnostic evaluation. Individuals with the intermediate initial results undergo a course of follow-up chest 
imaging exams with LDCT. The follow-up can occur with the fixed periodicity: at three, six and twelve months 
after the initial screening. The number of follow-up scans is managed according to the diameter of the nodule 
and its growth during the time between the initial screening and the follow-up exam. The growth is defined as a 
percentage increase in diameter and determined in screening scenario (𝐺𝑟𝑜𝑤𝑡ℎ𝑐𝑢𝑡 ). Measurement of growth is 
based on the comparison between the actual diameter and the diameter of the nodule found at the initial screen. 
In the follow-up course the diameter of 7 mm is the threshold diameter to undergo diagnostic evaluation. If at the 
first follow-up (at 3 months after the initial screening) no growth is detected , the person continues with an annual 
periodicity follow-up till the requirements for the positive result are met (𝐷  ≥7 mm) 13. If the growth is present, 
the diameter is assessed. In case the diameter does not exceed the threshold, the person undergoes the next 
follow-up round within 6 month after the initial screening with assessment of the diameter. If the diameter of the 
nodule at the second follow-up (6 months) is over 7 mm, the person proceeds with the diagnostic work-up. In 
case the nodule size does not reach the thres hold the person continues with the annual periodicity follow-up till 
the requirements for the positive result are met (𝐷  ≥7 mm). The cancer-indicating values for nodule size 
(𝑉𝑐𝑢𝑡 , 𝐷𝑐𝑢𝑡) and tumour growth (𝑉𝐷𝑇𝑐𝑢𝑡 , 𝐺𝑟𝑜𝑤𝑡ℎ𝑐𝑢𝑡 ) were taken from the trials and varied in the screening 
scenarios.   
1.1.5.4. Diagnostic work-up 
The diagnostic work-up component models a one-month long period when a patient undergoes a CT-supported 
biopsy to determine malignancy of the nodule and a head MRI (magnetic resonance imaging) and proceed with 
diagnosis. Screen-detected nodules are staged according to the TNM system based on the tumour 
diameter/volume and the progression state at time of diagnosis. During the diagnostic work-up a complication 
(pneumothorax) may occur, which is modelled as an age-dependent probability (see Table 7). 
1.1.5.5.  Lung cancer survival 
Description is given in the main text. 
                                                                 
1
 𝑉𝐷𝑇 = ln (2)∆𝑡ln(𝑉2)−ln(𝑉1)  , 




1.1.6.  Life history module 
For the screening and no screening scenarios , the Life History module calculates the final life scenario for each 
individual, providing the chronological sequence of events and final age of death along with the cause of death. 
The module also calculates events of false-positive cases, overdiagnosed cases, interval cancers  and radiation 
induced cancer and deletes obsolete cases.  
1.1.6.1. False-positive findings  
False-positive findings of different sizes are simulated for people without lung cancer based on the outcomes of 
the clinical trials. For the NLST-based on nodule management algorithm, the number of follow-up scans and 
work-up of false-positive findings are estimated using the ratio of true positive to all positive findings obtain ed 
from the NLST trial results. For the NELSON nodule management follow-ups and work-ups of false-positive 
findings are estimated relative to the number of CT scans. The respective rates are calculated based on the results 
of the NELSON trial. Diagnostic work-up of false-positive finding includes a CT-supported biopsy, which may 
induce pneumothorax as a complication with the age-dependent probability (see Table 7). The false-positive 
findings are retroactively included into the model.  
1.1.1.1. Overdiagnosed cases 
A case of overdiagnosis is defined as an individual whose lung cancer is expected to be clinically diagnosed after 
her age of death from other causes but whose cancer is screen-detected before this age (de Koning, Harry J. et al. 
2014).  
1.1.1.2. Interval lung cancer 
Interval lung cancer is defined as a cancer which is not initially screen-detected but is diagnosed in the time 
between scheduled screening exams 
14
. The module incorporates two sources of interval lung cancer occurrence. 
The first is false-negative screening results, which can occur due to the nodule size-dependent sensitivity of CT 
scan. The second is the truly interval lung cancer, which develops and is diagnosed within the time interval 
between two screenings. 
1.1.1.3. Radiation-induced cancer 
Radiation-induced cancer death may occur in a 10–20-year period after the screening program. The risk is 
calculated as one radiation-induced cancer death per 2500 screened individuals who received 8 mSv in a 3-year 




1.1.7. Screening scenarios 
Based on Table 1 in the main paper, name of a scenario contained specified population, nodule management 
protocol, thresholds for nodule size and nodule growth. The scenarios were additionally numbered from 1 to 76.  
The scenarios that simulated NELSON-like and NLST-like nodule management protocols were 50-75-15-9-




1.1.8. Screening module: Parameters overview 
Table S7: Parameters of the screening component 
Parameter NLST NELSON  Reference 
Sensitivity of screening CT exam for peripheral 
lesions. 
Sensitivities for a central lesion of the same diameter 
are 25% lower (Probability of detection) 
0.63 for D≥1mm  
0.77 for D≥4mm 
1.00 for D≥8mm 
16
 
Specificity of screening CT exam 0.98 





Rate of “Stage II” at diagnosis: parameter for a 
binomial function which randomly defines whether 
the person at regional stage* is diagnosed with 
“Stage II” 
at screening: 








Complication rate at work up: 
malignant nodule: D≤2cm 
malignant nodule: 2<D≤4cm 
malignant nodule: D>4cm 








Long-term survival probability for stages I and II 
in the case the patients would die from lung cancer in 




*people at regional stage of cancer progression can be diagnosed either with stage II or stage III of TNM system.  
 
1.2. Model calibration 
The calibration process was performed in two steps. Firstly, for each lung cancer type mean and standard 
deviation of the log-Normal distributed threshold volumes of lymph nodes involvement (regional), distant 
metastases (distant) and clinical diagnosis were simultaneously calibrated to fit the German UICC data on 
diseases stage at time of diagnosis 
11
. The parameters for the log-Normal distribution of the tumour volumes at 
time of clinical diagnosis differed depending on the disease stage progression: before and after the lymph nodes 
involvement (regional stage). Table 6 (section 1.1.4.3) presents the applied parameters in the columns “diagnosis 
before the regional stage” and “diagnosis after the regional stage”. Data limitations allowed for the calibration of 
a limited number of parameters per cancer type. Therefore, we assumed that the mean and standard deviations of 
the threshold volumes are equal (see “Tumour growth” section).  
Secondly, we simultaneously calibrated the age- and cancer type-dependent malignant conversion rates and age 
boundaries of the survival functions (derived from the hazard functions, see section 1.1.4.1). The outcomes of 
the microsimulation model (no screening scenario) were fitted to German age and cancer type specific annual 
incidental lung cancer cases of the period 2010-2012
11
. The second calibration step was done separately for 
males and females. 
The Nelder-Mead Simplex method implemented in  the R package “FME”18 was used to minimize squared 





1.3. Health economics  
The costs per unit were obtained using EBM (Unit assessment scale applied in the German healthcare) or DRG 
(Diagnosis Related Groups) codes and are summarized in Table 8. The model includes CT-guided needle 
biopsy-induced pneumothorax as a complication that leads to increased costs of the staging tests. 
Table S8: Cost per unit: screening and no screening 
 Procedure Code EBM* or 
DRG** 














Values for the sensitivity 
analyses: 


























  CT-guided needle biopsy 
 
Complication 











Histology (pathology)  EBM code 19310 8.41€ 20 
Head magnetic resonance imaging 
(MRI)  
EBM code 34410 126.59€ 20 

























Positron emission tomography 
(PET) 
EBM code 34701 589.95€  20 
Endobronchial ultrasound-guided 
trans bronchial needle aspiration 
(EBUS-TBNA) 
EBM code 13662 or 
09315 
988.00€ 20 
Histology (pathology)  EBM code 19310 8.41€ 20 
Head MRI EBM code 34410 126.59€ 20 
Medical contrast medium for MRT EBM code 34452 46.55€ 20 
* Unit assessment scale applied in the German healthcare 
** Diagnosis Related Groups 
 
In the calculations of the total cost of screening we did not include lifetime lung cancer treatment costs and the 
costs for pharmaceuticals. The reason of omitting these expenditures is that there is partly available German data 
on life time costs stratified across ages and cancer stages and histology. Therefore we made the assumptions 
based on the literature. We based these assessments on data given by Mc Guire et al. 
23
 who calculated the costs 
of non-small cell lung cancer for Germany, France and England.  
The average treatment costs for patients with metastatic disease were 27,932€ for the first year and 22,909€ for 
the second year after the diagnoses. We used these values to calculate costs for people with the advanced cancers 
in our model output. For that we calculated the mean survival of the patients with stage III and IV which is 
1.100702 years (50-75-15-9-NELSON-VDT400-V500). Based on the mean survival and the average costs for 
each year (Mc. Guire) we calculated treatment costs of 26,698€ for advanced cancers (stage III and IV).  
Mc Guire et al.
23
 do not provide cost data for people with the early-staged cancers. In order to determine relevant 
costs for the early-staged cancers we took data on the lifetime costs for people with the early-staged cancers in 
the UK calculated by the British Department of Health 
24
. Based on their estimates we calculated the ratio 
between the costs given for I-II and III-IV stages: (i) ratio of costs between III and I stages is used to define a 




and IV 45,808€ (example for 50-75-15-9-NELSON-VDT400-V500). In order to obtain the costs for people with 
early-stage cancer in our model we applied these ratios to the costs calculated based on the mean survival and the 
average costs for late cancers 
23
. The same calculations were performed for each of the six evaluated scenarios  
and scenarios of the sensitivity analys is.  
 
1.4. Sensitivity analysis 
Parameter uncertainty: 
We varied the nodule size-dependent sensitivity parameters of LDCT exam within a range of ±20%. The long 
term survival probability for the screened individuals – who were diagnosed at screening with lung cancer in 
stage I or II and who would die of the cancer in the non-screening scenario – was tested for the range of values: 
20%, 30%, 50% and 60%. We decreased adherence for the next years after the initial screening to 85%. 
Additional scenarios:  
We prolonged the period of the screening program and simulated ten years of annual screening for each of the 
evaluated scenarios. The cost per LDCT unit varied across three different scenarios (Table 8). Additionally, the 
total costs were analyzed for a hypothetical scenario (scenario 4) when staging tests at screening were the same 
as at clinical settings in no screening scenario.  
Because treatment costs are based on different assumptions we tested possible impacts of the treatment costs in 
the sensitivity analyses. In the pessimistic scenario the costs for Stage I and II are based on the ratio of costs 
between stage IV and I (see Table 9, example is given for 50-75-15-9-NELSON-VDT400-V500). In the last 
years a few cost inducing pharmaceutical drugs for lung cancer treatment have been developed and introduced to 
the market 
25
. It is possible that they were not taken into the calculations by Mc Guirre et al. To account for that 
we added the third scenario with lifetime costs for the patients with the advanced cancer of 77,702€ 26 (see Table 
9).  
Table S9: Lifetime treatment costs for patients diagnosed with lung cancer by cancer stages calculated for 
50-75-15-9-NELSON-VDT400-V500. 






Max Scenario  
(Cost Ratio IV / I) 
Min Scenario (Cost 
Ratio III / I) 
Scenario with new 
treatment options 
Stage I 7,135.00 ₤ 45,803.38 €** 31,960.12 €** 118,234.97 €** 
Stage II 7,135.00 ₤ 45,803.38 €** 31,960.12 €** 118,234.97 €** 
Stage III 6,720.00 ₤ 30,101.20 €* 30,101.20 €* 77,702.00 € 
Stage IV 4,689.00 ₤ 30,101.20 €* 30,101.20 €* 77,702.00 € 
*calculated based on the mean survival and the average costs for late cancers 
23
 







2.1. Calibration  
  


























































































































































































































































































































































































































































































































































































































































2.2. Benefits and harms of lung cancer screening for the baseline scenarios   














Number of people screened 7,431,345 4,373,484 7,431,345 4,373,484 
Screening outcomes  
Lung Cancer Findings 179,504 126,910 181,468 128,484 
Screen detection Stage I 114,379 79,598 109,608 76,595 
Screen detection Stage II 13,254 9,583 14,774 10,633 
Screen detection Stage III 31,447 22,698 34,879 25,024 
Screen detection Stage IV 20,424 15,031 22,207 16,232 
Stage III, % 17.52 17.89 19.22 19.48 
Stage IV, % 11.38 11.84 12.24 12.63 
Total Cases Detected at an Early Stage 127,633 89,181 124,382 87,228 
Total Cases Detected at an Early Stage, % 71.10 70.27 68.54 67.89 
Small-cell carcinoma 10,048 6,601 10,528 6,915 
Large-cell carcinoma 5,003 3,490 5,106 3,560 
Squamous-cell carcinoma 42,688 29,549 43,182 29,873 
Adenocarcinoma 92,003 64,423 91,697 64,209 
Adenocarcinoma in situ 29,762 22,847 30,955 23,927 
Small-cell carcinoma, % 5.60 5.20 5.80 5.38 
Large-cell carcinoma, % 2.79 2.75 2.81 2.77 
Squamous-cell carcinoma, % 23.78 23.28 23.80 23.25 
Adenocarcinoma, % 51.25 50.76 50.53 49.97 
Adenocarcinoma in situ, % 16.58 18.00 17.06 18.62 
False-Positive Findings 262,311 185,356 4,531,519 3,208,432 
False-Positive Findings of all screen detected findings 59.37 59.36 96.15 96.15 
Interval cancer: False Negative Detection 33,111 21,763 32,101 21,106 
Small-cell carcinoma 15,894 10,275 15,464 9,994 
Large-cell carcinoma 1,576 1,044 1,520 1,005 
Squamous-cell carcinoma 11,449 7,676 11,097 7,440 
Adenocarcinoma 4,174 2,754 4,006 2,660 
Adenocarcinoma in situ 18.00 14.00 14.00 7.00 
Interval Cancer Stage I 5,363 3,556 5,147 3,413 
Interval Cancer Stage II 1,810 1,211 1,765 1,182 
Interval Cancer Stage III 8,745 5,619 8,467 5,439 
Interval Cancer Stage IV 17,193 11,377 16,722 11,072 
True Interval cancer 10,232 6,638 10,232 6,638 
Small-cell carcinoma 8,494 5,504 8,494 5,504 
Large-cell carcinoma 201 142 201 142 
Squamous-cell carcinoma 1,517 981 1,517 981 
Adenocarcinoma 20.00 11.00 20.00 11.00 
Adenocarcinoma in situ 0.00 0.00 0.00 0.00 
Interval Cancer Stage I 818 535.00 818 535 
Interval Cancer Stage II 389 263 389 263 
Interval Cancer Stage III 2,594 1,683 2,594 1,683 
Interval Cancer Stage IV 6,431 4,157 6,431 4,157 
Small-cell carcinoma, % of interval cancers 56.27 55.56 56.59 55.86 
Stage IV, % of interval cancers  54.50 54.70 54.69 54.89 
Clinical Detection 771,760 435,763 770,918 435,228 
Clinical Detection: onset of cancer before the end of screening 208,902 137,329 208,060 136,794 
All detected cancers: onset of cancer before the end of screening 388,406 264,239 389,528 265,278 
Overdiagnosis 31,005 23,772 31,385 24,260 
Overdiagnosis, % of screening detected cases 17.27 18.73 17.30 18.88 
Small-cell carcinoma 51.00 33.00 52.00 35.00 
Large-cell carcinoma 147 110.00 144 105 
Squamous-cell carcinoma 1,683 1,201 1,606 1,155 
Adenocarcinoma 6,429 4,795 5,934 4,461 
Adenocarcinoma in situ 22,695 17,633 23,649 18,504 
Adenocarcinoma in situ, % 73.20 74.18 75.35 76.27 
Overdiagnosis Stage I 19,722 14,434 19,282 14,369 
Overdiagnosis Stage II 2,368 1,919 2,603 2,090 
Overdiagnosis Stage III 5,613 4,573 6,141 4,916 
Overdiagnosis Stage IV 3,302 2,846 3,359 2,885 
Radiation-induced Lung Cancer Deaths 2,390 1,329 2,388 1,328 
No screening scenario  
Clinical Detection no screening 919,585 538,385 919,585 538,385 
Clinical Detection Stage 1 132,312 77,379 132,312 77,379 
Clinical Detection Stage 2 56,328 33,417 56,328 33,417 
Clinical Detection Stage 3 235,578 138,090 235,578 138,090 
Clinical Detection Stage 4 495,367 289,499 495,367 289,499 




















Clinical detection during the first five years: Histological class 152,040 102,786 152,040 102,786 
Small-cell carcinoma 35,472 23,234 35,472 23,234 
Large-cell carcinoma 6,265 4,321 6,265 4,321 
Squamous-cell carcinoma 48,009 32,720 48,009 32,720 
Adenocarcinoma 59,673 40,630 59,673 40,630 
Adenocarcinoma in situ 2,621 1,881 2,621 1,881 
Clinical Detection Stage 1 22,129 15,039 22,129 15,039 
Clinical Detection Stage 2 9,129 6,247 9,129 6,247 
Clinical Detection Stage 3 38,797 26,004 38,797 26,004 
Clinical Detection Stage 4 81,985 55,496 81,985 55,496 
Deaths from lung cancer  
Death from lung cancer: screening 763,653 442,246 764,847 443,061 
Death from lung cancer: onset of cancer before the end of screening 275,110 184,150 276,304 184,965 
Death from lung cancer: no screening 800,040 467,246 800,040 467,246 
Death from lung cancer: no screening (onset of cancer before the end of 
screening) 311,497 209,150 311,497 209,150 
Mortality reduction vs no screening, %  11.68 11.95 11.30 11.56 
Benefits of screening vs no screening  
Averted death vs no screening 36,387 25,000 35,193 24,185 
Life years gained vs no screening 541,697 356,262 525,811 345,918 
Life years gained vs no screening: 3% discount 355,348 236,371 346,100 230,284 
Life years gained vs no screening: 1.5% discount  435,161 288,028 423,115 280,136 
Healthcare resources for the screening program      
Number of Screen exams 29,969,925 16,660,175 29,955,605 16,650,031 
Number of Follow-up scans 2,781,924 1,525,291 4,011,903 2,839,342 
Number of Follow-up scans: malignant nodules 100,296 71,876 157,843 110,595 
Number of Work-ups 441,815 312,266 945,678 669,564 
Number of Work-ups: malignant nodules 171,637 121,317 173,250 122,633 
Number of Complications 117,474 82,898 233,375 165,097 
Efficiency of screening  
Detected cancer per 1000 scans 5.99 7.62 6.06 7.72 
Interval cancers per 1000 screen-scans 1.45 1.70 1.41 1.67 
Lung cancer deaths per 1000 screen-scans: onset of cancer before the end of 
screening 9.18 11.05 9.22 11.11 
Averted lung cancer deaths vs no screening per 1000 screen-scans 1.21 1.50 1.17 1.45 
Life years gained (3% discount) vs no screening per 1000 screen-scans 11.86 14.19 11.55 13.83 
Health economics outcomes of screening vs no screening  
Total costs (discounted) 29363651302 17776335686 29885787583 18223237851 
Total costs: no screening(discounted) 21900234274 13183590963 21900234274 13183590963 
Additional costs vs. no screening (discounted) 7463417028 4592744723 7985553310 5039646887 
ACER: Costs (including life time treatment costs) per Life Year Gained 
(uniform discounting) vs no screening  21,003 19,430 23,072 21,884 
Cost categories (Discounted 3%) 
Screening scans 4,243,729,151 2,355,013,913 4,241,738,728 2,353,604,382 
Work-up total malignant  211,365,526 149,013,209 212,913,711 150,313,048 
Complication 178,066,109 125,439,507 179,259,484 126,453,389 
Without complication 33,299,417 23,573,702 33,654,226 23,859,659 
Follow-up malignant  15,044,522 10,781,399 23,676,532 16,589,331 
False-Positive Work-up total 201,146,272 142,104,689 580,683,348 411,030,986 
Complication 179,465,545 126,787,810 518,093,885 366,727,652 
Without complication 21,680,726 15,316,878 62,589,462 44,303,334 
False-Positive Follow-up 385,177,551 208,247,816 550,582,775 389,724,592 
Interval cancer: False-Negative Detection 55,046,074 36,158,088 53,381,576 35,078,201 
True Interval cancer 16,964,750 10,988,952 16,964,750 10,988,952 




Figure S7: Accumulated lung cancer death cases 50-75-15-9-NELSON-VDT400-V500 vs. 50-75-15-9-NLST-
GR10-D10 
 















































2.3. Main outcomes and Cost-effectiveness of the 76 baseline screening scenarios.  
 
Table S12: Main outcomes and Cost-effectiveness of the 76 baseline screening scenarios. 
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Scenario 65 55-75-40-10-NELSON-VDT300-none 67.31 9.95 14,373 133,222 23,057 6,733 9.48 10,892,118,387 2,231,946,546 16,754 155,287 16,754 155,287 
Scenario 64 55-75-40-10-NELSON-VDT400-none 67.95 10.65 15,395 140,490 21,367 9,184 11.73 11,056,787,394 2,396,615,552 17,059 155,675 not efficient 161,124 
Scenario 66 55-75-40-10-NELSON-VDT600-none 68.25 11.00 15,891 143,763 20,406 12,036 14.35 11,211,978,121 2,551,806,280 17,750 160,582 not efficient not efficient 
Scenario 75 55-75-40-10-NLST-GR12.5-none 67.50 11.37 16,430 147,652 19,629 15,341 17.20 11,716,673,226 3,056,501,385 20,701 186,032 not efficient not efficient 
Scenario 73 55-75-40-10-NLST-GR10-none 67.91 11.52 16,638 149,484 19,570 16,074 17.75 11,766,309,036 3,106,137,195 20,779 186,689 not efficient not efficient 
Scenario 74 55-75-40-10-NLST-GR7.5-none 68.20 11.63 16,798 150,829 19,514 16,812 18.34 11,811,094,697 3,150,922,856 20,891 187,577 not efficient not efficient 
Scenario 76 55-75-40-10-NLST- Dfup5 67.08 11.26 16,270 151,944 20,278 16,476 18.90 11,712,212,808 3,052,040,967 20,087 187,587 not efficient not efficient 
Scenario 67 55-75-40-10-NELSON-Vfup80 68.43 11.49 16,604 154,199 20,558 16,389 18.92 11,381,642,165 2,721,470,324 17,649 163,905 not efficient not efficient 
Scenario 72 55-75-40-10-NLST-GR12.5-D10 66.61 11.48 16,594 154,561 19,424 17,268 19.07 11,789,031,396 3,128,859,555 20,243 188,554 not efficient not efficient 
Scenario 70 55-75-40-10-NLST-GR10-D11 66.84 11.59 16,741 155,308 19,429 17,366 19.11 11,800,360,566 3,140,188,725 20,219 187,575 not efficient not efficient 
Scenario 68 55-75-40-10-NLST- GR10-D10  67.69 11.75 16,976 157,701 19,409 17,467 19.19 11,817,384,038 3,157,212,197 20,020 185,981 not efficient not efficient 
Scenario 59 55-75-40-10-NELSON-VDT400-V750 68.73 11.90 17,201 158,585 19,883 16,598 18.63 11,416,918,590 2,756,746,749 17,383 160,267 not efficient not efficient 
Scenario 71 55-75-40-10-NLST-GR7.5-D10 68.35 11.90 17,200 159,297 19,404 17,647 19.30 11,838,944,522 3,178,772,681 19,955 184,812 not efficient not efficient 
Scenario 69 55-75-40-10-NLST-GR10-D9 68.50 11.91 17,212 159,963 19,392 17,575 19.27 11,834,207,265 3,174,035,423 19,842 184,408 not efficient not efficient 
Scenario 62 55-75-40-10-NELSON-VDT300-V500 69.95 12.14 17,542 161,967 19,866 17,162 19.09 11,459,390,353 2,799,218,512 17,283 159,572 not efficient not efficient 
Scenario 58 55-75-40-10-NELSON-VDT400-V500 70.07 12.16 17,564 162,073 19,862 17,221 19.14 11,465,748,287 2,805,576,446 17,311 159,734 not efficient not efficient 
Scenario 63 55-75-40-10-NELSON-VDT600-V500 70.30 12.19 17,608 162,281 19,857 17,656 19.49 11,491,382,892 2,831,211,051 17,446 160,791 not efficient not efficient 
Scenario 61 55-75-40-10-NELSON-VDT400-V400 70.71 12.27 17,726 163,470 19,857 17,573 19.42 11,491,130,432 2,830,958,591 17,318 159,707 not efficient not efficient 
Scenario 60 55-75-40-10-NELSON-VDT400-V300 71.35 12.38 17,889 164,864 19,854 17,892 19.69 11,515,704,974 2,855,533,133 17,321 159,625 19,707 184,009 
Scenario 8 55-74-30-15-NELSON-VDT300-none 67.41 9.72 20,335 192,747 33,009 9,106 9.12 16,964,229,032 3,780,638,069 19,615 185,918 not efficient not efficient 
Scenario 7 55-74-30-15-NELSON-VDT400-none 68.13 10.47 21,908 204,456 30,527 12,562 11.37 17,202,833,077 4,019,242,114 19,658 183,460 not efficient not efficient 
Scenario 27 55-80-30-15-NELSON-VDT300-none 67.52 10.10 23,029 207,468 38,212 11,724 10.14 17,709,501,637 4,159,369,822 20,048 180,614 not efficient not efficient 
Scenario 9 55-74-30-15-NELSON-VDT600-none 68.49 10.82 22,633 209,464 29,157 16,599 14.01 17,425,676,762 4,242,085,799 20,252 187,429 not efficient not efficient 
Scenario 18 55-74-30-15-NLST-GR12.5-none 67.86 11.21 23,437 215,599 28,049 21,270 16.88 18,086,156,020 4,902,565,056 22,739 209,181 not efficient not efficient 
Scenario 16 55-74-30-15-NLST-GR10-none 68.21 11.35 23,747 218,277 27,972 22,232 17.39 18,153,904,252 4,970,313,288 22,771 209,303 not efficient not efficient 
Scenario 17 55-74-30-15-NLST-GR7.5-none 68.46 11.46 23,962 220,191 27,900 23,237 17.96 18,215,134,331 5,031,543,367 22,851 209,980 not efficient not efficient 
Scenario 26 55-80-30-15-NELSON-VDT400-none 68.24 10.93 24,917 220,616 35,048 16,282 12.62 18,002,132,447 4,452,000,631 20,180 178,673 not efficient not efficient 
Scenario 19 55-74-30-15-NLST- Dfup5 67.28 11.07 23,152 221,728 28,955 22,938 18.63 18,078,388,416 4,894,797,453 22,076 211,420 not efficient not efficient 
Scenario 10 55-74-30-15-NELSON-Vfup80 68.62 11.29 23,620 224,880 29,359 22,740 18.59 17,662,309,284 4,478,718,321 19,916 189,616 not efficient not efficient 
Scenario 15 55-74-30-15-NLST-GR12.5-D10 66.85 11.31 23,646 225,756 27,773 24,000 18.76 18,184,707,034 5,001,116,071 22,153 211,499 not efficient not efficient 
Scenario 28 55-80-30-15-NELSON-VDT600-none 68.57 11.35 25,871 226,617 33,118 21,861 15.63 18,293,791,730 4,743,659,914 20,932 183,358 not efficient not efficient 
Scenario 13 55-74-30-15-NLST-GR10-D11 67.05 11.39 23,831 226,640 27,773 24,145 18.81 18,200,613,216 5,017,022,253 22,136 210,525 not efficient not efficient 




Scenario 2 55-74-30-15-NELSON-VDT400-V750 68.89 11.69 24,442 231,099 28,431 22,874 18.22 17,705,725,213 4,522,134,250 19,568 185,015 not efficient not efficient 
Scenario 14 55-74-30-15-NLST-GR7.5-D10 68.57 11.72 24,512 232,766 27,736 24,493 18.99 18,253,498,654 5,069,907,690 21,781 206,834 not efficient not efficient 
Scenario 37 55-80-30-15-NLST-GR12.5-none 67.77 11.72 26,719 232,797 31,764 28,055 18.78 19,112,331,877 5,562,200,062 23,893 208,174 not efficient not efficient 
Scenario 12 55-74-30-15-NLST-GR10-D9 68.72 11.73 24,527 233,603 27,721 24,418 18.97 18,247,633,560 5,064,042,597 21,678 206,468 not efficient not efficient 
Scenario 35 55-80-30-15-NLST-GR10-none 68.13 11.89 27,092 235,833 31,657 29,431 19.39 19,199,988,990 5,649,857,174 23,957 208,543 not efficient not efficient 
Scenario 5 55-74-30-15-NELSON-VDT300-V500 70.15 11.94 24,973 236,226 28,407 23,689 18.68 17,767,037,281 4,583,446,318 19,403 183,536 not efficient not efficient 
Scenario 1 55-74-30-15-NELSON-VDT400-V500  70.27 11.95 25,000 236,371 28,401 23,772 18.73 17,776,335,686 4,592,744,723 19,430 183,710 not efficient not efficient 
Scenario 6 55-74-30-15-NELSON-VDT600-V500 70.52 11.98 25,059 236,665 28,392 24,434 19.12 17,814,338,122 4,630,747,159 19,567 184,794 not efficient not efficient 
Scenario 36 55-80-30-15-NLST-GR7.5-none 68.34 12.00 27,350 238,024 31,556 30,922 20.08 19,284,015,000 5,733,883,184 24,090 209,648 not efficient not efficient 
Scenario 4 55-74-30-15-NELSON-VDT400-V400 70.90 12.06 25,223 238,424 28,393 24,278 19.03 17,812,380,227 4,628,789,264 19,414 183,515 not efficient not efficient 
Scenario 3 55-74-30-15-NELSON-VDT400-V300 71.58 12.18 25,467 240,626 28,389 24,767 19.32 17,849,042,023 4,665,451,059 19,389 183,196 not efficient not efficient 
Scenario 38 55-80-30-15-NLST- Dfup5 66.76 11.67 26,589 240,683 32,739 31,090 21.03 19,160,111,768 5,609,979,952 23,309 210,989 not efficient not efficient 
Scenario 29 55-80-30-15-NELSON-Vfup80 68.00 11.89 27,104 244,027 33,178 30,722 20.93 18,625,060,345 5,074,928,530 20,797 187,239 not efficient not efficient 
Scenario 34 55-80-30-15-NLST-GR12.5-D10 66.35 11.89 27,105 244,796 31,380 32,411 21.15 19,281,610,562 5,731,478,747 23,413 211,455 not efficient not efficient 
Scenario 32 55-80-30-15-NLST-GR10-D11 66.56 11.98 27,308 245,671 31,391 32,590 21.19 19,299,330,176 5,749,198,361 23,402 210,532 not efficient not efficient 
Scenario 30 55-80-30-15-NLST- GR10-D10  67.37 12.16 27,706 249,634 31,348 32,764 21.27 19,325,894,027 5,775,762,212 23,137 208,466 not efficient not efficient 
Scenario 21 55-80-30-15-NELSON-VDT400-V750 68.19 12.28 27,987 250,445 32,125 30,739 20.47 18,661,518,852 5,111,387,037 20,409 182,634 not efficient not efficient 
Scenario 33 55-80-30-15-NLST-GR7.5-D10 68.04 12.31 28,062 252,243 31,338 33,098 21.40 19,361,758,630 5,811,626,814 23,040 207,100 not efficient not efficient 
Scenario 31 55-80-30-15-NLST-GR10-D9 68.18 12.32 28,080 253,130 31,313 32,991 21.38 19,354,607,603 5,804,475,788 22,931 206,712 not efficient not efficient 
Scenario 24 55-80-30-15-NELSON-VDT300-V500 69.49 12.55 28,596 256,006 32,094 31,929 21.02 18,741,364,602 5,191,232,786 20,278 181,537 not efficient not efficient 
Scenario 20 55-80-30-15-NELSON-VDT400-V500 69.61 12.56 28,625 256,159 32,086 32,050 21.08 18,752,973,157 5,202,841,342 20,311 181,759 not efficient not efficient 
Scenario 25 55-80-30-15-NELSON-VDT600-V500 69.89 12.59 28,694 256,478 32,077 32,983 21.53 18,803,698,202 5,253,566,386 20,483 183,089 not efficient not efficient 
Scenario 23 55-80-30-15-NELSON-VDT400-V400 70.25 12.67 28,877 258,339 32,076 32,752 21.42 18,798,713,288 5,248,581,472 20,317 181,756 not efficient not efficient 
Scenario 22 55-80-30-15-NELSON-VDT400-V300 70.95 12.80 29,165 260,807 32,071 33,473 21.76 18,846,402,156 5,296,270,341 20,307 181,597 not efficient 216,454 
Scenario 46 50-75-15-9-NELSON-VDT300-none 67.40 9.68 30,147 295,093 48,838 13,432 9.09 28,347,809,378 6,447,575,105 21,849 213,871 not efficient not efficient 
Scenario 45 50-75-15-9-NELSON-VDT400-none 68.06 10.27 31,994 308,862 45,891 17,943 11.18 28,650,791,510 6,750,557,237 21,856 210,994 not efficient not efficient 
Scenario 47 50-75-15-9-NELSON-VDT600-none 68.37 10.54 32,825 314,731 44,293 22,752 13.41 28,917,092,962 7,016,858,689 22,295 213,766 not efficient not efficient 
Scenario 56 50-75-15-9-NLST-GR12.5-none 68.06 10.95 34,122 325,575 42,717 28,483 15.84 29,748,996,225 7,848,761,952 24,107 230,021 not efficient not efficient 
Scenario 54 50-75-15-9-NLST-GR10-none 68.40 11.08 34,525 329,167 42,610 29,643 16.29 29,830,458,906 7,930,224,633 24,092 229,695 not efficient not efficient 
Scenario 55 50-75-15-9-NLST-GR7.5-none 68.64 11.16 34,757 331,214 42,520 30,791 16.76 29,902,320,995 8,002,086,722 24,160 230,229 not efficient not efficient 
Scenario 57 50-75-15-9-NLST- Dfup5 68.05 10.83 33,738 333,574 44,213 29,610 17.04 29,682,843,414 7,782,609,141 23,331 230,678 not efficient not efficient 
Scenario 48 50-75-15-9-NELSON-Vfup80 69.39 11.02 34,317 337,355 44,808 29,451 17.05 29,191,246,090 7,291,011,817 21,612 212,461 not efficient not efficient 
Scenario 53 50-75-15-9-NLST-GR12.5-D10 67.49 11.05 34,418 339,475 42,368 30,993 17.17 29,828,497,218 7,928,262,945 23,355 230,352 not efficient not efficient 
Scenario 51 50-75-15-9-NLST-GR10-D11 67.69 11.13 34,673 340,726 42,383 31,253 17.24 29,854,521,936 7,954,287,663 23,345 229,409 not efficient not efficient 
Scenario 49 50-75-15-9-NLST- GR10-D10  68.54 11.30 35,193 346,100 42,333 31,385 17.30 29,885,787,583 7,985,553,310 23,073 226,907 not efficient not efficient 
Scenario 40 50-75-15-9-NELSON-VDT400-V750 69.77 11.43 35,603 347,754 43,379 29,951 16.83 29,273,891,072 7,373,656,799 21,204 207,108 not efficient not efficient 
Scenario 52 50-75-15-9-NLST-GR7.5-D10 69.17 11.44 35,622 349,465 42,322 31,706 17.41 29,926,417,893 8,026,183,620 22,967 225,315 not efficient not efficient 
Scenario 50 50-75-15-9-NLST-GR10-D9 69.37 11.45 35,669 350,891 42,301 31,560 17.37 29,918,079,355 8,017,845,082 22,850 224,785 not efficient not efficient 
Scenario 43 50-75-15-9-NELSON-VDT300-V500 71.00 11.67 36,352 355,128 43,349 30,891 17.22 29,351,505,809 7,451,271,536 20,982 204,976 not efficient not efficient 
Scenario 39 50-75-15-9-NELSON-VDT400-V500 71.10 11.68 36,387 355,348 43,343 31,005 17.27 29,363,651,302 7,463,417,029 21,003 205,112 not efficient not efficient 
Scenario 44 50-75-15-9-NELSON-VDT600-V500 71.30 11.71 36,465 355,742 43,335 31,770 17.60 29,408,338,707 7,508,104,434 21,105 205,899 not efficient not efficient 
Scenario 42 50-75-15-9-NELSON-VDT400-V400 71.72 11.78 36,709 358,394 43,334 31,596 17.52 29,409,436,683 7,509,202,410 20,952 204,560 not efficient not efficient 
Scenario 41 50-75-15-9-NELSON-VDT400-V300 72.39 11.90 37,075 362,039 43,331 32,183 17.78 29,455,834,679 7,555,600,405 20,870 203,792 23,837 285,630 






2.4. Cost-effectiveness of the efficient screening scenarios in the sensitivity analyses  
 
Table S13: Cost-effectiveness of the efficient screening scenarios in the sensitivity analyses . 
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Decreased adherence (85%) 
55-75-40-10-NELSON-VDT300-only 67.88 11.04 15,951 147,905 18,266 14,241 17.51 11,128,381,492 2,468,209,650 16,687.80 154,736.99 
55-75-40-10-NELSON-VDT400-V300 70.48 11.71 16,926 154,633 17,939 17,447 19.99 11,327,266,138 2,667,094,296 17,247.89 157,573.81 
50-75-15-9-NELSON-VDT400-V300 71.59 11.20 34,885 339,158 39,059 31,360 18.12 28,876,917,490 6,976,683,217 20,570.59 199,990.92 
Decreased CT sensitivity 
55-75-40-10-NELSON-VDT300-only 65.91 8.51 12,290 113,926 28,728 5,822 9.40 10,769,522,882 2,109,351,040 18,515.04 171,631.49 
55-75-40-10-NELSON-VDT400-V300 69.81 10.75 15,538 142,709 25,783 16,697 20.53 11,362,508,546 2,702,336,704 18,935.96 173,917.92 
50-75-15-9-NELSON-VDT400-V300 70.76 10.31 32,114 312,327 55,624 30,160 18.61 29,154,812,658 7,254,578,384 23,227.53 225,900.80 
Increased CT sensitivity 
55-75-40-10-NELSON-VDT300-only 68.97 10.42 15,061 139,346 22,429 7,189 9.82 10,946,629,549 2,286,457,708 16,408.45 151,813.14 
55-75-40-10-NELSON-VDT400-V300 72.33 12.81 18,507 170,216 19,258 18,347 19.72 11,566,774,883 2,906,603,041 17,075.97 157,054.25 
50-75-15-9-NELSON-VDT400-V300 73.41 12.34 38,450 375,036 41,991 33,020 17.80 29,561,115,978 7,660,881,704 20,427.06 199,242.70 
Survival 20% 
55-75-40-10-NELSON-VDT300-only 67.31 4.90 7,073 64,976 23,057 6,733 9.48 10,892,118,388 2,231,946,546 34,350.47 315,558.68 
55-75-40-10-NELSON-VDT400-V300 71.35 6.15 8,886 81,476 19,854 17,892 19.69 11,515,704,975 2,855,533,133 35,047.54 321,351.92 
50-75-15-9-NELSON-VDT400-V300 72.39 5.90 18,383 179,031 43,331 32,183 17.78 29,455,834,680 7,555,600,406 42,202.87 411,010.19 
Survival 30% 
55-75-40-10-NELSON-VDT300-only 67.31 7.39 10,671 98,141 23,057 6,733 9.48 10,892,118,388 2,231,946,546 22,742.13 209,160.02 
55-75-40-10-NELSON-VDT400-V300 71.35 9.25 13,372 122,191 19,854 17,892 19.69 11,515,704,975 2,855,533,133 23,369.47 213,545.70 
50-75-15-9-NELSON-VDT400-V300 72.39 8.85 27,577 268,594 43,331 32,183 17.78 29,455,834,680 7,555,600,406 28,130.18 273,981.96 
Survival 50% 
55-75-40-10-NELSON-VDT300-only 67.31 12.31 17,788 163,572 23,057 6,733 9.48 10,892,118,388 2,231,946,546 13,645.04 125,474.85 
55-75-40-10-NELSON-VDT400-V300 71.35 15.38 22,218 203,495 19,854 17,892 19.69 11,515,704,975 2,855,533,133 14,032.47 128,523.41 
50-75-15-9-NELSON-VDT400-V300 72.39 14.76 45,972 448,474 43,331 32,183 17.78 29,455,834,680 7,555,600,406 16,847.36 164,352.22 
Survival 60% 
55-75-40-10-NELSON-VDT300-only 67.31 17.34 21,349 196,872 23,057 6,733 9.48 10,892,118,388 2,231,946,546 11,337.03 104,545.72 
55-75-40-10-NELSON-VDT400-V300 71.35 22.64 26,676 245,212 19,854 17,892 19.69 11,515,704,975 2,855,533,133 11,645.18 107,045.03 
50-75-15-9-NELSON-VDT400-V300 72.39 21.69 55,518 541,052 43,331 32,183 17.78 29,455,834,680 7,555,600,406 13,964.66 136,092.81 
Cost per CT 200 Euro  
55-75-40-10-NELSON-VDT300-only 67.31 9.95 14,373 133,222 23,057 6,733 9.48 11,348,079,792 2,687,907,951 20,176.16 187,010.92 
55-75-40-10-NELSON-VDT400-V300 71.35 12.38 17,889 164,864 19,854 17,892 19.69 11,971,666,380 3,311,494,538 20,086.20 185,113.45 
50-75-15-9-NELSON-VDT400-V300 72.39 11.90 37,075 362,039 43,331 32,183 17.78 31,003,818,424 9,103,584,150 25,145.34 245,545.09 
Cost per CT 500 Euro  
55-75-40-10-NELSON-VDT300-only 67.31 9.95 14,373 133,222 23,057 6,733 9.48 14,083,848,222 5,423,676,380 40,711.57 377,351.73 
55-75-40-10-NELSON-VDT400-V300 71.35 12.38 17,889 164,864 19,854 17,892 19.69 14,707,434,810 6,047,262,968 36,680.28 338,043.66 
50-75-15-9-NELSON-VDT400-V300 72.39 11.90 37,075 362,039 43,331 32,183 17.78 40,291,720,874 18,391,486,601 50,799.80 496,061.68 
Cost per CT 100 Euro  
55-75-40-10-NELSON-VDT300-only 67.31 9.95 14,373 133,222 23,057 6,733 9.48 10,436,156,983 1,775,985,141 13,331.02 123,563.98 
55-75-40-10-NELSON-VDT400-V300 71.35 12.38 17,889 164,864 19,854 17,892 19.69 11,059,743,569 2,399,571,727 14,554.84 134,136.72 
50-75-15-9-NELSON-VDT400-V300 72.39 11.90 37,075 362,039 43,331 32,183 17.78 27,907,850,938 6,007,616,665 16,593.86 162,039.56 
Innovative Treatment Cost 
55-75-40-10-NELSON-VDT300-only 67.31 9.95 14,373 133,222 23,057 6,733 9.48 25,486,357,786 3,539,339,140 26,567.23 246,249.16 
55-75-40-10-NELSON-VDT400-V300 71.35 12.38 17,889 164,864 19,854 17,892 19.69 27,055,830,817 5,108,812,172 30,988.01 285,584.00 










Follow-up after end of annual screening  median 6.5 years 7 years* 
Screen exams per person 2.8 3.8 
Lung Cancer specific mortality rate per 100,000 person-years:    
LDCT 247 332 
Radiography/no screening 309 394 
Difference in mortality rates 62 62 
Lung cancer mortality reduction, % 20.1 15.8 
All-cause mortality rate per 100,000 person-years   
LDCT 1,303 1,930 
Radiography/no screening 1,395 1,986 
Mortality reduction absolute 92 56 
Screen detected Lung Cancer: 
Proportion of all detected cancer, % 61.2 67.9 
Stage I, % 63.0 59.6 
Stage II, % 7.2 8.3 
Stage III, % 17.0 19.5 
Stage IV, % 12.8 12.6 
Small-cell carcinoma, % 7.6 5.4 
Large-cell carcinoma, % 4.3 2.8 
Squamous-cell carcinoma, % 21.1 23.2 
Adenocarcinoma, % 39.9 50.0 
Adenocarcinoma in situ, % 14.7 18.6 
Non-small-cell carcinoma or other, % 11.6 n/a 
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Background: Pneumococci (Pnc) are among the main causes of infectious disease-related mortality 
and morbidity, especially in the elderly. Two Pnc vaccines are available to prevent pneumococcal 
disease in adults: a 13-valent conjugate vaccine (PCV13) and a 23-valent polysaccharide vaccine 
(PPSV23) that protects against 13 and 23 of the 94 Pnc serotypes, respectively. The Standing 
Committee on Vaccination (STIKO) recommends PCV vaccination for infants and standard vaccination 
(currently with PPSV23) for people over 60. The aim of the study is to evaluate a variety of vaccination 
scenarios in adults aged 60 and over in the German healthcare context. 
Methods: Asymptomatically colonized children are the main pathogen reservoir for Pnc. To illustrate 
the impact of infant vaccination on Pnc epidemiology, a dynamic transmission model was developed 
that forecasts the future incidence and serotype mix in Pnc cases in the over-60 age group. 
Replacement effects were simulated by grouping the serotypes (in accordance with the vaccines) into 
five groups that compete with each other in colonization. The primary outcome of the model is 
additional cost per QALY gained. Clinical, epidemiological and health economics parameters are 
based on German primary data or German and international studies. Parameter uncertainty was 
tested in sensitivity and scenario analyses. 
Results: Sequential vaccination (PCV13 + PPSV23) prevented the largest number of Pnc infections 
and deaths in all the scenarios tested. In contrast, PPSV23 is considerably more efficient in most 
scenarios on the number needed to vaccinate in order to prevent one Pnc infection or one death. 
Furthermore, use of PPSV23 on its own is associated with substantially lower cost. PPSV23 is more 
economical and mostly more effective than vaccination with PCV13 on its own (exception: PPSV23 is 
not effective against noninvasive Pnc pneumonia and PCV13 is just as effective against serotype 3 as 
against the other PCV13 serotypes, whereas PPSV23 is only half as effective against serotype 3 as 
against the other PPSV23 serotypes). In all the scenarios tested, revaccination is more effective than 
single vaccination on the number of prevented infections as well as being more efficient on the number 
needed to vaccinate. The most effective strategy is multiple revaccination with PPSV23 every 6 years 
following sequential initial vaccination at age 60. However, in all the scenarios tested, this strategy is 
economically inferior to multiple revaccination with PPSV23 every 6 years after initial vaccination with 
PPSV23 at age 60. 
Conclusion: For single vaccination, PPSV23 is preferable to other vaccination strategies from the 
point of view of efficiency. If the budget impact of multiple revaccination is acceptable, multiple 
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1 Status quo of research 
1.1 Pneumococcal infections 
Pneumococci (Streptococcus pneumoniae, Pnc) are Gram-positive encapsulated bacteria. The 
polysaccharide capsule gives the pathogenic bacteria an element of protection from phagocytosis and 
adds to their virulence. Pneumococci are grouped into 94 capsule types known as serotypes based on 
the type of capsular polysaccharides involved. Manifestations of pneumococcal disease may be local. 
Examples include ear infections (otitis media) sinusitis and pneumonia. However, pneumococci can 
also cause invasive disease (IPDs) with manifestations including purulent meningitis, bacteremia and 
sepsis. IPD has an average lethality of approximately 10%, rising to more than 30% in high-risk 
groups. IPD mainly affects immunocompromised individuals, young children (immature immune 
system) and elderly people (immunosenescence).[1] The major reservoir of pneumococci is the 
nasopharynx of healthy carriers. About 50% of young children and 5-10% of adults have 
pneumococcal colonization of the nasopharynx.[2–4] 
1.2 Public health 
Pneumococci have significant public health relevance as a major cause of many serious diseases that 
are associated with high morbidity and mortality as well as a high cost of treatment. In Europe, for 
instance, pneumonia engenders annual costs to the tune of EUR 10.1 billion, EUR 5.7 billion of which 
goes for inpatient treatment, EUR 0.5 billion for non-hospital treatment and EUR 0.2 billion for 
medicines. The indirect cost due to lost labor input amounts to EUR 3.6 billion.[5] 
1.3 Vaccines for immunization of adults against pneumococcal disease 
Two types of Pnc vaccines are currently available which work by inducing the formation of antibodies 
against bacterial capsular polysaccharides. The older vaccine is a purely polysaccharide vaccine 
containing the purified capsular polysaccharide antigens of 23 of the 94 known Pnc serotypes 
(PPSV23). In Pnc conjugate vaccines (PCVs), the capsular polysaccharides are coupled – or 
conjugated – to a highly immunogenic protein (e.g., diphtheria toxin). Conjugation generates an 
additional T cell response compared with pure polysaccharide vaccines, which in turn results in the 
formation of memory cells, changes in antibody response and avidity maturation. The mucosal 
immunity conferred by the conjugate vaccine results in a reduction in the serotypes covered by the 
vaccine in asymptomatic carriers. If the immunization rate in a population is high enough, the 
serotypes covered by the vaccine can be reduced in the overall population as a result of indirect herd 
effects. 
At present, immunization with PPSV23 is the standard-of-care vaccination schedule for over-60s 
recommended by the Standing Committee on Vaccination (STIKO).[6–8] In the presence of certain 
underlying diseases, STIKO says that immunization can take place either with PPSV23, a 13-valent 






In addition, revaccination every five years in individuals with congenital or acquired immunodeficiency 
or immunosuppression or chronic kidney disease/nephrotic syndrome is under consideration.[6–8] 
 
PCV13 has been approved in Germany since 2009 for children and since the end of 2011 for adults 
over 50 and superseded the 7-valent Pnc conjugate vaccine (PCV7) for infant vaccination at the start 
of 2010. 
1.4 Impact of universal infant vaccination with conjugate vaccines on the epidemiology 
of pneumococcal infections in adults 
The implementation of a universal vaccination program to vaccinate infants with PCV7 has led in many 
countries to a major decline in the incidence of invasive and noninvasive Pnc infections attributable to 
vaccine serotypes in (unvaccinated) adults.[9–13] Conversely, epidemiological data also showed a 
definite increase in diseases attributable to non-vaccine serotypes in the same period (in some cases 
with a 1-2 year delay).[14] Reduction of the PCV7 vaccine serotypes created an ecological niche that 
non-vaccine serotypes were able to occupy (serotype replacement). Both indirect herd effects and 
replacement effects have been observed in invasive pneumococcal diseases in Germany.[15, 16] 
PCV13 includes one of the main replacement serotypes to date (19A) along with another five 
serotypes. Apart from a further reduction in PCV7 serotypes, the switch from PCV7 to PCV13 for 
infant immunization also produced indirect herd effects in invasive and noninvasive Pnc infections 
attributable to the other vaccine serotypes, while replacement effects of non-vaccine serotypes 
persisted.[17–21] 
Germany too has seen indirect herd effects in vaccine serotypes and sustained replacement effects by 
non-vaccine IPD serotypes following the switch from PCV7 to PCV13.[22, 23] In contrast to the other 
PCV13 serotypes, a significant reduction in case numbers has not been observed to date for serotype 
3 in adults (see Fig. 1). However, nor are there indications of a definite increase (such as observed for 








Figure 1: Invasive pneumococcal disease trends in the 60+ population 
 
Source: van der Linden et al. 2015[22] 
Some western European countries are also seeing signs of persistence of serotype 3 in adults, but 
other western European studies are observing a definite decline.[19] 
Recent studies of PCV13 also diverge in their presentation of PCV13's efficacy against serotype 3. 
While two studies [24, 25] point to reduced or no efficacy of the conjugate vaccine, the CAPITA study 
provides no indications of reduced effectiveness against serotype 3 in noninvasive Pnc 
pneumonia.[26] The evidence on PPSV23's efficacy against serotype 3 is similarly inconclusive.[27] 
1.5 Health economics evaluation 
Various health economics models investigating the cost effectiveness of Pnc vaccinations for adult 
immunization already exist on an international level. A systematic review [28] identified 11 studies that 
compared various PPSV23 vaccination programs with no vaccination. The polysaccharide vaccine 
was found to be cost effective in most studies. Some even identified a cost-saving effect. More recent 
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A systematic review of PCV13 vaccination programs in adults [35] identified 10 studies. Four of them 
[36–39] compared PCV13 with no vaccination and six [32, 40–44] compared PCV13 with PPSV23. 
Three [37–39] of the four studies showed the evaluated PCV13 vaccination programs to be cost 
effective compared with no vaccination. PCV13 vaccination programs were cost effective compared 
with PPSV23 in all six studies [32, 40–44]. 
Another four studies comparing PCV13 are available, three of which compared PCV13 with 
PPSV23[29, 45, 46] and one with no vaccination [47]. In two of the studies, PCV13[45, 46] was cost 
effective versus PPSV23. One study produced the opposite result [29]. In the comparison with no 
vaccination, PCV13 was found to be cost effective.[47] 
Two studies [33, 40] additionally analyzed sequential vaccination programs (PCV13+PPSV23). While 
one study concluded that sequential vaccination was not cost effective [40], the other study [33] found 
it to be preferable in immunosuppressed adults, also from an economic point of view. 
Two models exist to date for the German healthcare context.[30, 48] One model [48] compared 
PPSV23 with PCV13. Vaccination with PCV13 dominated pure polysaccharide vaccination in this 
model. However, it needs to be borne in mind that the vaccines were evaluated in one scenario with 
PCV7 infant vaccination. In the other study [30], the potential indirect effects (indirect herd effects + 
replacement effects) of PCV13 vaccination in infants as a function of cumulative vaccination rates 
based on US data were projected to Germany. In this scenario, adult vaccination with PPSV23 was 
shown to be cost effective versus no vaccination. 
Interstudy variability in outcome was high overall. There are many reasons for this. 
1) Differences in the incidence and serotype mix of Pnc diseases in the countries investigated 
2) Different cost structures in the countries investigated 
3) Uncertain effectiveness of PPSV23 vaccination against noninvasive Pnc pneumonia 
4) Uncertain effectiveness of PV13 vaccination in adults prior to publication of the results of the 
CAPITA study [26] (only one analysis so far [47] is based on the CAPITA results) 
5) No conclusive data on long-term protection with PCV13 and PPSV23 
6) Different vaccination programs in children (PCV7 vs. PCV10 vs. PCV13) 
7) A precise estimation of the extent of indirect effects of PCV10 and PCV13 infant vaccination is 
not yet possible. 
Nonetheless, the various results do indicate clear trends. If PCV infant vaccination produced just a 
small decline in the PCV13 serotypes not contained in PCV7 (or no decline) in the adult population, 
then adult vaccination with PCV13 would be cost effective or dominant versus no vaccination.[37–39, 
47, 48] If at the same time PPSV23 were not effective against noninvasive Pnc pneumonia, then 
vaccination programs with PCV13 would also be cost effective or dominant versus PPSV23.[32, 40–






Even if PPSV23 were effective against noninvasive Pnc pneumonia, PCV13 would still be cost 
effective as long as the conjugate vaccine displays significantly slower waning of efficacy.[48] 
If there were a very strong decline in all PCV13 serotypes in adults (similar to the decline in PCV7 
serotypes), then the cost effectiveness of PCV13 vaccination programs in the over-60 population 
versus no vaccination would be questionable.[36] If at the same time PPSV23 were effective against 
noninvasive Pnc pneumonia, then PCV13 would be dominated by PPSV23.[29] In this epidemiological 
scenario, PPSV23 would be cost effective versus no vaccination provided the effectiveness against 
noninvasive Pnc pneumonia were significant.[30] 
 
Objectives and rationale 
The previous sections (1.4 and 1.5) show that the body of evidence from studies so far is insufficient to 
define the optimum vaccination program for prevention of Pnc diseases in Germany in people over 60. 
This requires the most precise possible prediction of incidences and serotype mixes in Pnc infections 
in this age group. The latest data on the efficacy of the available vaccines should also feed into the 
analysis. 
The aim of this model analysis is to provide a health economics evaluation of various scenarios for the 
prevention of Pnc infections in standard-of-care vaccination schedules in people over 60, in 
consideration of the epidemiological impact of infant vaccination and the specific epidemiology of 
serotype 3. The evaluation starts at the beginning of 2016. The effects of adult vaccination are 
followed in immunized individuals until the end of their lives. 
The following vaccination strategies are compared in the study: 
A) No vaccination 
B) Single vaccinations 
 PCV13: single vaccination with PCV13 in the 2016-2030 period 
 PPSV23: single vaccination with PPSV23 in the 2016-2030 period 
 SEQ: sequential vaccination with one dose of PCV13 + a PPSV23 booster six months later 
(called sequential vaccination in the following) 
 SEQ_5J: sequential vaccination in the 2016-2020 period/single vaccination with PPSV23 in 
the 2021-2030 period 
C) Revaccinations 
 PPSV23_W: initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at 
specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period 
 SEQ_W: sequential initial vaccination + lifelong revaccinations with PPSV23 at specified 
intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination 
in the 1996-2015 period 
 SEQ_5J_W: vaccination strategy SEQ_5J + lifelong revaccinations with PPSV23 at specified 
intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination 
in the 1996-2015 period 





 What are the long-term epidemiological effects of the vaccination programs (incidence, 
disease-related deaths)? 
 How many vaccinations are required to prevent one case/death, i.e., what is the "number 
needed to vaccinate" (NNV)? 
 How cost effective are the vaccination strategies? 
 What are the effects of initial vaccination age on outcomes? 
 What are the effects of revaccination frequency on outcomes? 
 
2 Methods 
2.1 Selection of model type, model structure and methodology framework 
A fundamental goal of modeling is to forecast the epidemiology of Pnc infections as precisely as 
possible. It is therefore essential to include childhood vaccination in the model in order to address its 
effects on the incidence and serotype mix of Pnc infections in adults. Two empirically established 
epidemiological effects need to be implemented in the model in this regard (see section 1.4). 
 Herd effects: The conjugate vaccine prevents the carriage and hence the transmission of 
vaccine serotypes, such that unvaccinated individuals also benefit from indirect protection. 
 Replacement effects: The replacement of vaccine serotypes by the conjugate vaccine creates 
an ecological niche that is penetrated by non-vaccine serotypes, resulting in an increase in 
carriage prevalence of these serotypes. 
A mathematical model on the basis of differential equations was developed. The model covers five 
groups of Pnc serotypes that compete with each other to colonize the host. 
 GS1: 4, 6B, 9V, 14, 18C, 19F, 23F (PCV7) 
 GS2: 1, 5, 6A, 7F, 19A (PCV13/not PCV7 without serotype 3) 
 GS3: 3 
 GS4: 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F (PPSV23/not PCV13) 
 GS5: other serotypes 
The model includes 16 possible carriage states: 
A) No carriage 
B) Carriers of one group of serotypes 
 SC1: GS1carriers 
 SC2: GS2 carriers 
 SC3: GS3 carriers 
 SC4: GS4 carriers 
 SC5: GS5 carriers 
C) Carriers of two different groups of serotypes 
 DC12: GS1+GS2 carriers 
 DC13: GS1+GS3 carriers 
 DC14: GS1+GS4 carriers 





 DC23: GS2+GS3 carriers   
 DC24: GS2+GS4 carriers 
 DC25: GS2+GS5 carriers 
 DC34: GS3+GS4 carriers 
 DC35: GS3+GS5 carriers 
 DC45: GS4+GS5 carriers 
The model is divided into 400 age groups (0, 3 months, 6 months, …, 99 years and 9 months). Three 
Pnc diseases are addressed: 
 Invasive Pnc diseases (IPD: e.g., sepsis, meningitis) 
 Hospitalized community-acquired noninvasive Pnc pneumonia (Pnc CAPin) 
 Community-treated community-acquired noninvasive PNc pneumonia (Pnc CAPout) 
Figure 2: Phases of the epidemiological submodel 
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  PPSV23_W 
  SEQ_W/SEQ_W_5J 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one dose of PCV13 + PPSV23 booster six months later; SEQ_5J: sequential 
vaccination in the 2016-2020 period/single vaccination with PPSV23 in the 2021-2030 period; PPSV23_W: Initial vaccination 
with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who 
received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination + lifelong revaccinations with 
PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; SEQ_5J_W: vaccination strategy SEQ_5J + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period 
The model comprises an epidemiological, a demographic and a health economics submodel. The 
epidemiological submodel forms the core of the model and simulates pneumococcal transmission in 












 Burn-in: The burn-in phase simulates pneumococcal transmission over a 25-year period. 
The aim is to generate a steady state prior to universal introduction of the conjugate 
vaccine for childhood vaccination as no longitudinal data are available on the incidence of 
IPD in Germany prior to the introduction of childhood vaccination. 
 Childhood vaccination: The second phase simulates the effects of childhood vaccination 
between 2004 and 2015: 
o 2004-2009 childhood vaccination with PCV7 (vaccination recommendation for 
PCV7 in August 2006) 
o 2010-2015 childhood vaccination with PCV13 
 Evaluation: The evaluation phase simulates the effects of adult vaccination in the years 
between 2016 and 2035 with maintenance of childhood vaccination with PCV13. The 






o No adult vaccination 
Each of the 400 age groups in the epidemiological submodel comprises 100,000 individuals, all of 
whom age by a quarter year at the same point in time. At the start of each quarter, 100,000 newborns 
enter the model and 100,000 99.75 year olds leave it. Mortality is not addressed in the epidemiological 
submodel. Given the complexity of the epidemiological model, the simplified population structure is 
required in order to create a steady state with a reasonable computing effort. The transmission risk is 
weighted with the "real-life" population structure. The outcome of the epidemiological submodel is age- 
and serotype-specific Pnc carrier prevalences and incidences of Pnc infection as a function of time. 
The demographic submodel is designed to forecast the real-life German population structure up to the 
year 2070. It is based on extrapolated birth and mortality rates published by the Federal Statistical 
Office and given in the Human Mortality Database. The estimated size of the over-60 population is 
slightly above the Federal Statistical Office forecast (Variant 1 AG). 
The health economics submodel links the results of the epidemiological and demographic submodel 
and health economics parameters. Finally, the following outcomes are calculated: 
 Absolute number of Pnc cases 
 Absolute number of disease-related deaths 
 Overall cost of Pnc infections 
 Overall cost of adult vaccination 
 Years of life gained 






 Incremental cost effectiveness ratios 
 Number of vaccinations needed per prevented case/hospitalization/disease-related death 
 
Figure 3: Projected population trends in the over-60 population (2005-2035) 
 
 
Figure 4: Demographic and health economics submodel 
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2.2 Transmission risk 
The transmission risk has four determinants: 
 Number of Pnc carriers in the population 
 Number of physical contacts with carriers per unit of time 
 Probability of transmission per physical contact 
 Existing carriage of another serotype group 
The physical contact rate between two age groups and age- and serotype-dependent transmission 
probability per contact make up the effective contact rate. The physical contact rate is estimated on 
the basis of social contact data in the POLYMOD study [49]. Close contacts play a key role in 
pneumococcal transmission.[50, 51] Age- and serotype-dependent transmission probability per 
contact is estimated on the basis of epidemiological data. This is done when calibrating the models 
(see section 3.5). 
In children protected with a Pnc conjugate vaccine, the risk of colonization by vaccine serotypes 
additionally depends on vaccine effectiveness against carriage as a fifth determinant. This reduces the 
risk of colonization.  
 
Figure 5: Transmission risk in an unvaccinated population for two groups of serotypes [51] 
 
GS1: Group of serotypes 1; GS2:  Group of serotypes 2; SC1: GS1 carriers; SC2: GS2 carriers; DC12: Carriers of GS1 + GS2 
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2.3 Dynamic effects 
Dynamicity in the model comes from the continually changing number of Pnc carriers in the population 
until a steady state is obtained. Infant vaccination with a conjugate vaccine reduces the risk of 
colonization of the nasopharynx with vaccine serotypes. This lowers the carrier prevalence of these 
serotypes among vaccinated individuals. As a result, the transmission risk declines in the 
unvaccinated population as well. 
The decline in vaccine serotypes creates an ecological niche that is occupied by non-vaccine 
serotypes, whose transmission risk rises as a result. To address this effect in the model, it is assumed 
that the five groups of serotypes compete with each other to colonize the nasopharynx. This 
"competition" has no effect on the duration of carriage.[52] If the nasopharynx has already been 
colonized by a group of serotypes, this makes it harder for another serotype group to colonize the 
area. The model has twenty competition parameters (c21, c31, c41, c51, c12, c32, c42, c52, c13, c23, 
c43, c53, c14, c24, c34, c54, c15, c25, c35, c45) that reduce the risk of dual carriage in Pnc carriers. 
The assumption is that colonization by no more than two different groups of serotypes is possible. 
The regression of the vaccine serotypes eliminates "rivals" in the quest to colonize the nasopharynx, 
resulting in an increased probability of transmission of the non-vaccine serotypes. 
Figure 6: Structure of the entire epidemiological submodel in the burn-in phase 
 
Si: Susceptible at age i; GS1-GS5: Serotype groups 1-5; SC1i-SC5i: GS1-GS5 carriers at age i; DC12i-DC45i: carriers of two 
different serotype groups at age i; λ1i- λ5i: age-dependent transmission risk of the different serotype groups; c12-c54: competition 






2.4 Model parameters 
2.4.1 Carriage 
Carrier prevalence 
There are no useful studies on pneumococcal carrier prevalence in Germany. International studies 
that might provide suitable data for modeling are very rare. Such studies would need to include a 
broad range of ages and should have been conducted before the introduction of childhood vaccination 
with PCV. If the protection the vaccine provides against infection is higher than against carriage – 
which is the current understanding based on the available evidence - then vaccination influences the 
case-carrier ratio (CCR) of the vaccine serotypes in vaccinated children. CCRs are key model 
parameters and should be determined in the most bias-free manner possible. Another issue is whether 
Pnc carrier prevalences from other countries are valid in Germany. Table 1 summarizes the main 
studies on pneumococcal carrier prevalence. 
Table 1: Pnc carrier studies with a broad age range 
Authors Title Country Period Population Description 
Hussain et al 
2005[3] 
 
UK 2001-2002 Children + adults 
121 families (489 
participants) over 10 
months, 3752 
samples; longitudinal 
Leino et al 
2008[4] 
 
Finland 2001-2002 Children + adults 
213 participants over 9 
months, 1941 
samples; longitudinal 
Flasche et al 
2011[53] 
 
UK 2008-2009 Children + adults 






Van Hoek at 
al. 2014[54] 
 
UK 2012/2013 Children + adults 
683 participants, 683 
samples; cross-
sectional; after 
transition to PCV13 for 
childhood vaccination 
Case-carrier ratio (CCR) 
Brueggeman et al.[55]'s systematic analysis of Pnc carrier studies reports that the CCRs of individual 
Pnc serotypes are stable in geography and time. This suggests that generalizability is more likely here 
than with carrier prevalences. Extensive serotype-specific data on CCRs are available in Trotter et 
al.[56] and Flasche et al.[53], but CCRs were calculated for only two or three age groups. Melegaro et 
al.[51] and Choi et al.[50, 57] estimated age-stratified CCRs for serotype groups based on carrier 







Figure 7: Case-carrier ratios in invasive pneumococcal disease 
 
Authors' own calculations based on Choi et al.[57]; IPD: invasive pneumococcal disease 
Carrier prevalence is determined from the transmission risk and duration of carriage. The latter was 
taken from the Högberg et al.[58] study. The assumption is that the duration of carriage depends 
solely on age. The age- and serotype-dependent transmission risk is estimated using German IPD 
incidences when calibrating the models (see section 3.5). The CCRs determine how many carriers are 
needed to induce the observed IPD incidences. 
Table 2: Duration of Pnc carriage according to Högberg et al.[58] 
Age <1 year 1-2 years 3-4 years 5-17 years >18 years 
Duration of Pnc carriage 74 days 47 days 34 days 26 days 25 days 
2.4.2 Pneumococcal infections 
Invasive Pnc disease 
The IPD incidence in children in Germany is calculated using the capture-recapture method. The data 
are from the two surveillance systems ESPED and Pneumoweb. Incidence data in the age groups 
under 2, 2 to 4 and 5-15 years of age are available for the 1997-2001 period and the period from 2007 
to 2012.[23, 59] To obtain incidences for the relevant serotype groups, incidence data and the 
























Serotyping is conducted by the National Reference Center for streptococci, which provided the 
relevant data. Estimates of the incidence in adults are available only from a cross-sectional study in 
North Rhine-Westphalia[60] for the 2001-2003 period. Apart from this, only serotype distributions are 
known. 
IPD incidences were adjusted to compensate for underestimation of case numbers due to the practice 
of collecting blood cultures in community-acquired pneumonia.[60] 
 
Figure 8: Adjusted IPD incidence in the 1997-2003 period 
 
Authors’ own calculations based on Kries et al.[59], Reinert et al.[60] and National Reference Center for Streptococci;  
IPD: invasive pneumococcal disease 
Noninvasive community-acquired pneumonia 
Age-stratified Pnc-CAPin and Pnc-CAPout incidences were calculated on the basis of case numbers 
and prescription volumes for ICD-10 codes J12-J18 in the Federal Health Report[61] and IMS 
Health[62]. The assumption was that 20% of all CAP cases were caused by pneumococci [26, 63] and 
that the serotype mix in Pnc-CAP is similar to that in IPD. 
The age- and serotype-related CCRs for noninvasive pneumonias were calculated using the following 
formula: 
























PCV13 serotypes/non-PCV7 without serotype 3 
PPSV23 serotypes/non-PCV13 






Figure 9: Case-carrier ratios for hospitalized Pnc- CAP (20% of all CAP cases) 
 
Authors' own calculations based on Federal Health Report [61], adjusted IPD incidence, IPD case-carrier ratios; Pnc-CAPin: 
hospitalized noninvasive Pnc pneumonia 
 
Figure 10: Case-carrier ratios for community-treated Pnc-CAP (20% of all CAP cases) 
 
Authors' own calculations based on IMS Health[62], adjusted IPD incidence, IPD case-carrier ratios; Pnc-CAPout: community-
























































Pnc infection lethality is shown in Table 3. 
Table 3: Lethality in Pnc infections 
Age IPD GS1 IPD GS2 IPD GS3 IPD GS4 Pnc-CAPin Pnc-CAPout 
<1 year 3.15% 2.94% 3.11% 3.55% 0.15% 0.00% 
1-4 years 3.15% 2.94% 3.11% 3.55% 0.09% 0.00% 
5-14 years 10.99% 9.40% 14.69% 13.13% 0.26% 0.00% 
15-24 years 10.99% 9.40% 14.69% 13.13% 0.84% 0.00% 
25-44 years 10.99% 9.40% 14.69% 13.13% 1.42% 0.00% 
45-64 years 10.99% 9.40% 14.69% 13.13% 6.02% 0.40% 
65-74 years 32.48% 29.33% 28.56% 31.51% 9.99% 0.40% 
75-84 years 32.48% 29.33% 28.56% 31.51% 14.23% 0.40% 
85+ years 32.48% 29.33% 28.56% 31.51% 20.13% 0.40% 
Source 




GS1: PCV7 serotypes; GS2: PCV13 serotypes/non-PCV7 without serotype 3; GS3: serotype 3; GS4: PPSV23 serotypes/non- 
PCV13; GS5: non-vaccine serotypes; IPD: invasive pneumococcal disease; Pnc-CAPin: hospitalized noninvasive Pnc 
pneumonia; Pnc-CAPout: community-treated noninvasive Pnc pneumonia; NRC: National Reference Center 
2.4.3 Vaccination 
Vaccination rates 
In August 2006 the Standing Committee on Vaccination at the Robert Koch Institute recommended 
universal vaccination of infants with PCV7 in accordance with the 3+1 vaccination schedule. The 
vaccination rate soared in consequence. In January 2010, PCV7 was superseded by PCV13. Age-
stratified vaccination rates in children were calculated quarterly on the basis of data provided by 
statutory health insurance physician associations (KV data). The records go back to January 2004. 
Infants who had received at least two doses of PCV vaccine were considered vaccinated. A 
vaccination rate of 30% was assumed for adult vaccination.[65] 
Effectiveness 
It was assumed that the vaccinations were effective only against vaccine serotypes (VTs) (and not 
against vaccine-related serotypes). It was also assumed that the protection conferred by vaccination 
declined continually over time (an effect called waning). As the effects reported in the studies relate to 







A fixed waning rate was imputed for pediatric vaccination that corresponds to the inverse of the 
expected duration of immunity. Effectiveness (at the time of vaccination) against vaccine serotype 
carriage and the expected duration of PCV immunity in children were estimated when calibrating the 
models (see section 3.5). It was assumed that pediatric vaccination against VT-IPD has 100% 
effectiveness at the time of vaccination. 
A time-dependent waning rate was imputed in adult vaccination, with waning of immunity in just a few 
individuals during the first years after vaccination. After this period, however, the number of protected 
individuals declines rapidly. A time-dependent rate could not be used for infant vaccination because 
the model lacks the necessary memory with regard to the exact vaccination age of the infants 
concerned. 
Figure 11: Expected anti-VT-IPD effectiveness of PPSV23 for various periods of time * 
 
RKI meta-analysis of RCTs[66]: 73% vaccine effectiveness 
with an average study duration of 2.5 years 
Cohort study, Ochoa-Gondar et al.[67]: 64% vaccine 
effectiveness with an average follow-up of 5 years 
* The expected effectiveness for a specific interval of time is calculated from the area under the curve divided by the length of 
time. 
VT-IPD: Invasive pneumococcal cases caused by vaccine serotypes 
 
When calibrating the models, an expected duration of immunity of 8.2 years (IPD and CAP) in children 
was estimated for the PCV vaccine. This value is very close to the results in a study by Melegaro et 
al.[68]. The same duration of immunity was imputed for adult vaccination with PCV13. Effectiveness at 
the time of vaccination was then calculated on the basis of the results of the CAPITA study [26] and 
the duration of immunity. An expected duration of immunity with PPSV23 was calculated both for IPD 
(4.67 years) and for CAP (3.75 years). This was calculated to achieve the effectiveness levels for 
randomized controlled trials calculated in a meta-analysis by the Robert Koch Institute [66] and the 
levels seen in the non-interventional study by Ochoa-Gondar[67], taking the respective study durations 
into account. Figure 11 shows the trends for IPD, by way of example. Figures 12 and 13 present a 
comparison of the effectiveness of PCV13 and PPSV23 as a function of time. 
  

















Ø 64% over 5 
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It was assumed that the efficacy of revaccination with PPSV23 declines by 0%-25% versus the initial 
vaccination with PPSV23. 
 
Figure 12: Effectiveness of adult vaccination against VT-IPD 
 
VT-IPD: Invasive pneumococcal disease caused by vaccine serotypes 
 
Figure 13: Effectiveness of adult vaccination against VT-Pnc-CAP 
 
VT-Pnc-CAP: Noninvasive Pnc pneumonia caused by vaccine serotypes 
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Cost was determined in accordance with German recommendations on "Evaluation of resources in the 
healthcare system from the perspective of the German social security system"[69] and indirect cost 
due to lost labor input was added. 
Vaccination prices 
The cost of pneumococcal vaccination is made up of the drug price and the vaccination fee. It was 
assumed that the insurance flat rate has fallen due and that pneumococcal vaccination coincides with 
other vaccinations (such as influenza vaccination). The drug prices were taken from the official 
German price list for prescription medicines (Lauer-Taxe[70]). Pharmacy retail prices were adjusted for 
pharmaceutical industry and pharmacy rebates. The result was a dose price of EUR 60.24 for PCV13 
and EUR 29.08 for PPSV23. The vaccination fee was calculated as weighted average of current 
vaccination agreements in the federal states, resulting in a price of EUR 7.19. 
Direct cost of illness 
The cost of treating a Pnc case was defined as direct cost of illness. A weighted average across 
various G-DRG flat fees was calculated for IPD and Pnc-CAPin. The cost of treatment of a Pnc-
CAPout case was determined by adding the health insurance flat fee for a primary care physician and 
the cost of antibiotic drug therapy. The pricing year is 2014 (2015 for PCV13 and PPSV23 prices). 
Table 4: Direct cost of illness per Pnc case 
Disease  Cost per case Reference 
IPD  EUR 8,581 
87% weighted average 
T60A,C; B72B + 13% weighted average  
A07C-D; A09C-E; A11C,E-F; A13B-C,E-F[71] 
Pnc-CAPin  EUR 3,178 
95% weighted average E77B-F,I + 5% weighted 







EUR 23.91  
03004 EBM 2014[72] 
03005 EBM 2014[72] 
IMS HEALTH 2009[62] 
IPD: Invasive pneumococcal disease; Pnc-CAPin: hospitalized noninvasive Pnc pneumonia; Pnc-CAPout: community treated 






Indirect cost/productivity loss 
Productivity loss due to Pnc cases was calculated on the basis of the friction cost approach. Friction 
time was 77 days in 2014.[73] This value was used for the production loss associated with one 
disease-related death. In 2014, employee salary was EUR 104 per day per capita.[74] Employment 
rates for the age groups of 60-64, 65-74 and 75+ were 46.36%, 5.93% and 0%.[75] The average 
number of days off work in the 60+ age group was 39.30 per IPD case and 18.65 per CAP case.[76] 
2.4.5 Quality of life 
The quality of life values and losses used in the model are presented in Table 5. Age-specific values 
were calculated for the five serotype groups in IPD. Any late complications were discounted on the 
Pnc date. 
Table 5: Quality of life and quality of life losses in Pnc cases 



















Bacteremia/sepsis All Case -0.0079 
Empyema All Case -0.0232 
Pnc-CAPin All Case -0.0060 
Pnc-CAPout All Case -0.0040 
Late 
complications* 
All Year -0.2550 
*Probability of late complications of meningitis: 31.7%[78] 
QALY: quality-adjusted life years; Pnc-CAPin: hospitalized noninvasive Pnc pneumonia; Pnc-CAPout: community treated 
noninvasive Pnc pneumonia 
2.4.6 Discounting 
Cost and life years gained / QALYs were discounted at a rate of 3% in accordance with IQWiG 






2.5 Calibrating the models 
50 parameters were fitted when calibrating the models. Eight age-dependent transmission probabilities 
per social contact were estimated for each serotype group. Six (c21, c31, c41, c51, c42, c52) of the 
twenty competition parameters were also calibrated (the other competition parameters were fixed at a 
value of 0.5) and effectiveness of the conjugate vaccination against pneumococcal carriage, expected 
duration of immunity and reduction of effectiveness against serotype 3 (in carriage and Pnc cases). All 
parameters were calibrated simultaneously with a direct optimization method. For this purpose, the 
sum of squared differences between the logarithmized IPD incidences and serotype distributions of 
the model and the logarithmized empirical data was minimized. 
Both the Nelder-Mead algorithm and the Levenberg-Marquardt algorithm were used as optimization 
methods. As the Nelder-Mead method did not converge after 10,000 iteration steps, the results of the 
Levenberg-Marquardt algorithm were used. 
 
2.6 Summary of input parameters and model assumptions 
Table 6: Summary of input parameters and model assumptions in the base case 
Parameter Value Source 
Vaccination rate among seniors 30% DEGS study 
Effectiveness of PPSV23 
Against VT-Pnc-CAP 67% (0%;83%)  
Against VT-IPD 75% (38%;95%) Calculated on the basis of the RKI meta-analysis [66]; 
see section 3.4.3 Immunity duration VT-IPD 4.7 years 
Immunity duration VT-Pnc-CAP  3.8 years  
 
against Serotype 3  Assumption: PPSV23 is only half as effective against 
serotype 3 as against the other vaccine serotypes 
(ineffective; equal effectiveness) 
VT-Pnc-CAP 34% (0%;83%) 
VT-IPD 38% (0%;95%) 
Effectiveness of PPSV23 
revaccination 
75%-100% of initial 
PPSV23 vaccination 
Assumption; see section 3.4.3 
Effectiveness of PCV13   
against VT-Pnc-CAP 46% (15%;67%) Calculated on the basis of the CAPITA study [26] and 
results of calibrating PCV childhood vaccination models; 
see section 3.4.3 
against VT-IPD 77% (42%;93%) 
Immunity duration  8.2 years  
against serotype 3 
 Assumption: PCV13 is only have as effective against 
serotype 3 as against the other vaccine serotypes 
(ineffective; equal effectiveness) 
VT-Pnc-CAP 23% (0%;67%) 
VT-IPD 39% (0%;93%) 
IPD incidences 
The age- and serotype-specific incidences are the result of the dynamic transmission 
model for Pnc carriage based on infant vaccination since 2006. The model was 
calibrated on the basis of German data on IPD incidence [15, 23, 59] and the 
serotype mix [22]. See sections 3.4.2, 3.5. 
Pnc-CAP incidences 
The age- and serotype-specific incidences are the result of the dynamic transmission 
model for Pnc carriage based on infant vaccination since 2006. Incidence rates 
before the introduction of PCV childhood vaccination are from the Federal Health 
Report [61] and IMS Health[62]. The assumption was that the serotype mix in Pnc-
CAP and IPD is similar and that Pnc-CAP accounts for 20% of all CAP cases [26, 
63] See section 3.4.2. 
Lethality 
IPD 2.9%-32.5% Age- and serotype-specific data from the UK [64], 
adjusted to serotype mix and age structure in Germany 
[22]. See section 3.4.2. 
Pnc-CAPin 0.2%-20.1% Age-dependent; Federal Health Report [61]. See section 
3.4.2. 
Pnc-CAPout 0%-0.4% Age-dependent; CAPNETZ. See section 3.4.2. 
QALY loss per case (including deaths) 
IPD 0.51-4.04 Age- and serotype-specific data from the UK [64], 
adjusted to serotype mix and age structure in Germany 
[22]. See section 3.4.5. 
CAP, hospital treated 0.28-1.27 Age-dependent. See section 3.4.5. 





Cost of illness per case 
IPD EUR 8581 DRG browser 2012/2014[71]. See section 3.4.4. 
Pnc-CAPin EUR 3178 DRG browser 2012/2014[71]. See section 3.4.4. 
Pnc-CAPout EUR 40-45 Age-dependent; EBM Catalogue 2014[72], IMS 
Health[62]. See section 3.4.4. 
Absence from work (per day) EUR 104 Federal Statistical Office 2014[74]. See section 3.4.4. 
Vaccine prices (per dose from a pack of 10) 
PPSV23 EUR 29.08 Lauer-Taxe [official drug price list in Germany] 
15 Oct 2015[70]. See section 3.4.4. 
PCV13 EUR 60.24 Lauer-Taxe 15 Oct 2015[70]. See section 3.4.4. 
Vaccination fee EUR 7.19 Average from current vaccination agreements. See 
section 3.4.4. 
Discount 3% IQWiG[79]. See section 3.4.6. 
VT-IPD: Invasive pneumococcal disease caused by vaccine serotypes; VT-Pnc-CAP: Non-invasive Pnc pneumonia caused by 
vaccine serotypes; Pnc-CAPin: hospitalized noninvasive Pnc pneumonia; Pnc-CAPout: community-treated noninvasive Pnc 
pneumonia; QALY: quality-adjusted life years 
 
2.7 Model analyses 
Two epidemiological scenarios were calibrated: 
 Scenario A: Persistence of serotype 3 at level of Pnc season 2013/2014 
 Scenario B: Delayed elimination of serotype 3 
In addition, four scenarios on the effectiveness of adult vaccinations were established. These explore 
the effectiveness of PCV13 and PPSV23 against serotype 3 and the effectiveness of PPSV23 against 
VT-Pnc-CAP: 
 Scenario A1/B1 
o PPSV23 effective against Pnc-CAP 
o Reduced effectiveness against serotype 3 with PCV13 and PPSV23 (compared with 
the other vaccine serotypes) 
 Scenario A2/B2 
o PPSV23 effective against Pnc-CAP 
o Reduced effectiveness against serotype 3 only with PPSV23 (compared with the other 
vaccine serotypes) 
 Scenario A3/B3 
o PPSV23 not effective against Pnc-CAP 
o Reduced effectiveness against serotype 3 with PCV13 and PPSV23 (compared with 
the other vaccine serotypes) 
 Scenario A4/B4 
o PPSV23 not effective against Pnc-CAP 
o Reduced effectiveness against serotype 3 only with PPSV23 (compared with the other 
vaccine serotypes) 
Each of the eight scenarios that emerged was run with base case analysis with the most probable set 
of parameters and sensitivity analyses on the effectiveness of the vaccinations (lower limit; upper 
limit), age at initial vaccination and frequency of revaccinations. The assumptions on vaccination 
effectiveness in the various scenarios are outlined in Table 7. Variations of scenarios A1/B1 are 
highlighted in bold. 





 Absolute number of pneumococcal disease cases/disease-related deaths 
 Overall cost of pneumococcal disease cases 
 Overall cost of adult vaccination 
 Years of life gained 
 Quality-adjusted life years (QALY) gained  
 Incremental cost effectiveness ratios 
 Number needed to vaccinate per prevented case/hospitalization/disease-related death 
 
Table 7: Effectiveness of adult vaccinations in the various scenarios 
 Epidemiology of serotype 3 
Persistence (at the level of the 
2013/2014 Pnc season) 









serotype 3 with 
PCV13 and 
PPSV23  
Scenario A1 Scenario B1 
Effectiveness PPSV23 
against VT-Pnc-CAP 67% (0%;83%) 
RKI meta-analysis[66]** 
against VT-IPD 75% (38%;95%) 
against serotype 3   
VT-Pnc-CAP 34% (0%;83%)* Assumption: effectiveness 
against serotype 50% reduced VT-IPD 38% (0%;95%)* 
Effectiveness PCV13 
against VT-Pnc-CAP 46% (15%;67%) 
CAPITA[26]** 
against VT-IPD 77% (42%;93%) 
against serotype 3   
VT-Pnc-CAP 23% (0%;67%)* Assumption: effectiveness 




serotype 3 only 
with PPSV23 
Scenario A2 Scenario B2 
Effectiveness PPSV23 
against VT-Pnc-CAP 67% (0%;83%) 
RKI meta-analysis[66]** 
against VT-IPD 75% (38%;95%) 
against Serotype 3   
VT-Pnc-CAP 34% (0%;83%)* Assumption: effectiveness 
against serotype 50% reduced VT-IPD 38% (0%;95%)* 
Effectiveness PCV13 
against VT-Pnc-CAP 46% (15%;67%) 
CAPITA[26]** 
against VT-IPD 77% (42%;93%) 
against Serotype 3   
VT-Pnc-CAP 46% (15%;67%) Assumption: no reduced 
effectiveness against 
serotype 3 








serotype 3 with 
PCV13 and 
PPSV23 
Scenario A3 Scenario B3 
Effectiveness PPSV23 
against VT-Pnc-CAP 0% (0%;0%) Moberley[80], Huss[81] 
against VT-IPD 75% (38%;95%) RKI meta-analysis[66]** 
against Serotype 3   
VT-Pnc-CAP 0% (0%;0%)* Assumption: effectiveness 
against serotype 50% reduced VT-IPD 38% (0%;95%)* 
Effectiveness PCV13 
against VT-Pnc-CAP 46% (15%;67%) 
CAPITA[26]** 
against VT-IPD 77% (42%;93%) 
against Serotype 3   
VT-Pnc-CAP 23% (0%;67%)* Assumption: effectiveness 




serotype 3 only 
with PPSV23 
Scenario A4 Scenario B4 
Effectiveness PPSV23 
against VT-Pnc-CAP 0% (0%;0%) Moberley[80], Huss[81] 
against VT-IPD 75% (38%;95%) RKI meta-analysis[66]** 
against Serotype 3   
VT-Pnc-CAP 0% (0%;0%)* Assumption: Effectiveness 
against serotype 0% reduced VT-IPD 38% (0%;95%)* 
Effectiveness PCV13 





against VT-IPD 77% (42%;93%) 
against Serotype 3   
VT-Pnc-CAP 46% (15%;67%) Assumption: no reduced 
effectiveness against 
serotype 3 
VT-IPD 77% (42%;93%) 
VT-IPD: Invasive pneumococcal disease caused by vaccine serotypes; VT-Pnc-CAP: Noninvasive Pnc pneumonia caused by 
vaccine serotypes 
*In parentheses: lower limit; upper limit 
** Authors' own calculations: see section 3.4.3. 
 
3 Results 
The main results of Scenario A are presented in the following, as Scenario A was assumed to be the 
more probable case. In Scenario B, the results for PCV13 and sequential vaccination versus 
vaccination with PPSV23 alone are much poorer. Detailed results of both scenarios were sent to the 
RKI in separate documents. A vaccination rate of 30%[65] in seniors was assumed for all scenarios. 
The results for the base case are given in each case, along with the results for the upper and lower 
limits of vaccination effectiveness in parentheses (see section 3.7, Table 7). 
3.1 Impact of pediatric vaccination on the epidemiology of pneumococci in Germany 
3.1.1 Impact of pediatric vaccination on pneumococcal carrier prevalence 
Figure 14 shows the Pnc carrier prevalences for various age groups as a function of time as simulated 
by the model. Graph 14a) (4th quarter 2003) shows the steady state before the STIKO 
recommendation for infant vaccination with PCV7. Due to the case carrier ratios, the serotype mix in 
asymptomatic carriers differs from the serotype mix in invasive Pnc cases. Because of the higher case 
carrier ratios of PCV7 serotypes, they account for a smaller percentage of total carrier prevalence than 
IPD incidence (see Figures 8, 14). The percentage of non-PCV13 serotypes in overall carrier 
prevalence is much higher than with IPD because of the lower case carrier ratios. The difference in the 
invasiveness of the various serotypes is a decisive factor in determining indirect net effects of infant 
vaccination (indirect herd effects minus replacement infections). Even if replacement is complete on 
the level of carriage, lower case carrier ratios of the non-vaccine serotypes would lead to positive 
effects as regards Pnc infections. 
Elimination of PCV7 serotypes in particular favors the spread of the additional serotypes contained in 
PCV13 (Fig. 14b). The introduction of pediatric vaccination with PCV13 in the 1st quarter of 2010 
however then leads to a decline in the additional PCV13 serotypes (except serotype 3). The process is 
initially slower than with the PCV7 serotypes because the additional PCV13 serotypes have not yet 
achieved a new steady state at the introduction of the higher-valency conjugate vaccine and were still 
in the process of rising, a process favored among other things by the sustained elimination of the last 
remaining PCV7 serotypes. 
The prevalence of serotype 3 carriers continues to increase slightly in most age groups in Scenario A 
between 2016-2020 (by -1.5% – 5.7% until 2020 depending on age group) because of the sustained 
replacement of the other PCV13 serotypes and the reduced protection conferred by the pediatric 
vaccination against colonization by serotype 3. The model predicts that the prevalence of serotype 3 
will decline again by just under 10% by the year 2030 compared with the levels in the 4th quarter of 







Figure 14: Predicted Pnc carrier prevalence for various age groups 
 
SC1: Carriers of PCV7 serotypes; SC2: Carriers of PCV13 serotypes without PCV7 serotypes and serotype 3; SC3: Carriers of 
serotype 3; SC4: Carriers of PPSV23 serotypes without PCV13 serotypes; SC5: Carriers of non-vaccine serotypes; DC12- 
DC45: Dual carriers of the relevant serotype groups. 
3.1.2 Impact of pediatric vaccination on the incidence of invasive pneumococcal disease 
in adults >= 60 years of age 
The impact of infant vaccination on the prevalence and serotype mix in Pnc colonizations of the 
nasopharynx is changing the epidemiology of Pnc infections. 
  
a) Q4 2003 b) Q4 2009 
c) Q4 2014 d) Q4 2019 





The model predicts almost complete disappearance of PCV13 serotypes except serotype 3 by the 
year 2020. Vaccine serotypes are being replaced in part by non-PCV13 serotypes. Despite positive 
indirect net effects of infant vaccination, demographic effects are driving a sharp increase in IPD cases 
in the over-60 population (see section 3.1, Fig. 3 for demographic trends in the 60+ population). 
Without PCV13 pediatric vaccination, the model would predict about 25%-30% more cases by 2055.  
Figure 15: Predicted number of invasive Pnc cases in the 60+ population 
 
GS1: PCV7 serotypes; GS2: PCV13 serotypes without PCV7 serotypes and serotype 3; GS3: Serotype 3; GS4: PPSV23 
serotypes without PCV13 serotypes; GS5: non-vaccine serotypes. 
3.2 Results of single pneumococcal vaccination 
3.2.1 Scenario A1: PPSV23 effective against noninvasive Pnc-CAP / reduced effectiveness 
against serotype 3 with PPSV23 and PCV13 
3.2.1.1 Epidemiological results 
Immunization of 60 year olds in the 2016-2030 period with PCV13 vaccination could prevent 712 (34-
1649) IPD episodes, 1194 (33-3316) Pnc-CAPin episodes and 279 (6-713) disease-related deaths 
over the lifetime of vaccine recipients, compared with no vaccination. 2286 (982-3322) IPD, 4583 (0-
6583) Pnc-CAPin episodes and 831 (163-1.222) disease-related deaths could be preventable with 
PPSV23 vaccination. The most effective strategy is sequential vaccination, which could prevent 2595 
(989-4.027) IPD, 5125 (33-8234) Pnc-CAPin episodes and 970 (168-1581) disease-related deaths. 
PPSV23 is the most efficient vaccination in terms of the NNV to prevent one hospitalization or one 
disease-related death (see Figures 17, 18). With sequential vaccination, 6721 (2428-144,365) 
individuals would need to be vaccinated additionally with PCV13 in order to prevent one 
hospitalization, and 41,283 (15,954-1,116,813) additional people to prevent one disease-related 







Figure 16: Single vaccination - Scenario A1: prevented cases 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period /Single vaccination with PPSV23 in the 2021-2030 period; Age: Age at initial vaccination 
 
Figure 17: Single vaccination – Scenario A1:  NNV to prevent one hospitalization 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J:  Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
the 2021-2030 period; k. I.: no vaccination; Age: Age at initial vaccination 
  
Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 























































Figure 18: Single vaccination – Scenario A1:  NNV to prevent one death 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J:  Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
the 2021-2030 period; k. I.: no vaccination; Age: Age at initial vaccination 
3.2.1.2 Health economics results 
The PCV13 vaccination strategy is dominated by PPSV23 in the base case. The incremental cost 
effectiveness ratio of PPSV23 versus no vaccination is EUR 15,079-16,398 per QALY gained, 
depending on the age at vaccination. A sequential vaccination strategy would require additional 
spending of about EUR306,411-406,482 versus PPSV23 per QALY gained. 
Table 8: Single vaccination - Scenario A1: Incremental cost effectiveness (additional cost per QALY 
gained) 




SEQ vs. PPSV23 SEQ_5J vs. 
PPSV23 
60 EUR 15,079 dominated EUR 406,482 EUR 366,499 
65 EUR 16,398 dominated EUR 355,525 EUR 318,812 
70 EUR 16,130 dominated EUR 338,779 EUR 306,411 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period/Single vaccination with PPSV23 in the 2021-2030 period 
  





















































3.2.2 Scenario A2: PPSV23 effective against noninvasive Pnc-CAP / reduced effectiveness 
against serotype 3 with PPSV23 only 
3.2.2.1 Epidemiological results 
Immunization of 60 year olds in the 2016-2030 period with PCV13 vaccination could prevent 1362 
(752-1649) IPD episodes, 2285 (721-3316) Pnc-CAPin episodes and 544 (246-713) disease-related 
deaths over the lifetime of vaccine recipients, compared with no vaccination. With PPSV23 
vaccination, 2286 (982-3322) IPD episodes, 4583 (0-6583) Pnc-CAPin episodes and 831 (163-1222) 
disease-related deaths would be preventable. The most effective strategy is sequential vaccination, 
which could prevent 3245 (1706-4027) IPD episodes, 6086 (721-8234) Pnc-CAPin episodes and 1222 
(409-1581) disease-related deaths. 
PPSV23 is the most efficient vaccination in terms of the NNV to prevent one hospitalization or one 
disease-related death (see Figure 20 and 21). With sequential vaccination, 2323 (2428-3955) 
individuals would need additional vaccination with PCV13 in order to prevent one hospitalization, and 
14,626 (15,954-23,277) additional vaccinations would be required to prevent one disease-related 
death. Changing the vaccination age to 65 or 70 would improve the efficiency of the vaccinations. 
Figure 19: Single vaccination - Scenario A2: prevented cases 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period/Single vaccination with PPSV23 in the 2021-2030 period; Age: Age at initial vaccination 
  
Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 Age 60 Age 65 Age 70 






Figure 20: Single vaccination - Scenario A2: NNV to prevent one hospitalization 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J: Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
the 2021-2030 period; k. I.: no vaccination; Age: Age at initial vaccination 
 
Figure 21: Single vaccination - Scenario A2: NNV to prevent one death 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J: Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
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3.2.2.2 Health economics results 
The PCV13 vaccination strategy is dominated by PPSV23 in the base case. The incremental cost 
effectiveness ratio of PPSV23 compared with no vaccination is EUR15,079-16,398 per QALY gained, 
depending on the age at vaccination. A sequential vaccination strategy would require additional 
spending of about EUR 85,310-107,252 versus PPSV23 per QALY gained. 
Table 9: Single vaccination - Scenario A2: Incremental cost effectiveness (additional cost per QALY 
gained) 




SEQ vs. PPSV23 SEQ_5J vs. 
PPSV23 
60 EUR 15,079 dominated EUR 107,252 EUR 101,032 
65 EUR 16,398 dominated EUR 96,538 EUR 90,647 
70 EUR 16,130 dominated EUR 90,479 EUR 85,310 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period/Single vaccination with PPSV23 in the 2021-2030 period 
3.2.3 Scenario A3: PPSV23 not effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 with PPSV23 and PCV13 
3.2.3.1 Epidemiological results 
Immunization of 60 year olds in the 2016-2030 period with PCV13 vaccination could prevent 712 (34-
1649) IPD episodes, 1194 (33-3316) Pnc-CAPin episodes and 279 (6-713) disease-related deaths 
over the lifetime of vaccination recipients, compared with no vaccination. With PPSV23 vaccination, 
2286 (982-3322) IPD episodes, 0 Pnc-CAPin episodes and 400 (163-604) disease-related deaths 
would be preventable. The most effective strategy is sequential vaccination, which could prevent 2595 
(989-4027) IPD episodes, 1194 (33-3316) Pnc-CAPin episodes and 600 (168-1118) disease-related 
deaths. 
PPSV23 is the most efficient vaccination in terms of the NNV to prevent one hospitalization or one 
disease-related death (see Figure 23 and 24). With sequential vaccination, 3805 (1422- 144,365) 
individuals would need additional vaccination with PCV13 in order to prevent one hospitalization, and 
28,704 (11,125-1,116,813) additional vaccinations would be required to prevent one disease-related 






Figure 22: Single vaccination – Scenario A3: prevented cases 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period/Single vaccination with PPSV23 in the 2021-2030 period; Age: Age at initial vaccination 
Figure 23: Single vaccination - Scenario A3: NNV to prevent one hospitalization 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J: Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
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Figure 24: Single vaccination - Scenario A3: NNV to prevent one death 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J: Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
the 2021-2030 period; k. I.: no vaccination; Age: Age at initial vaccination 
 
3.2.3.2 Health economics results 
The PCV13 vaccination strategy is dominated by PPSV23 in the base case. The incremental cost 
effectiveness ratio of PPSV23 compared with no vaccination is EUR 37,673-38,860, depending on the 
age at vaccination. A sequential vaccination strategy would require additional spending of about 
EUR153,893-211,112 versus PPSV23 per QALY gained. 
Table 10: Single vaccination - Scenario A3: Incremental cost effectiveness (additional cost per QALY 
gained) 




SEQ vs. PPSV23 SEQ_5J vs. 
PPSV23 
60 EUR 38,613 dominated EUR 211,112 EUR 178,595 
65 EUR 37,673 dominated EUR 192,552 EUR 163,370 
70 EUR 38,860 dominated EUR 178,843 EUR 153,893 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 























































3.2.4 Scenario A4: PPSV23 not effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 only with PPSV23 
3.2.4.1 Epidemiological results 
Immunization of 60 year olds in the 2016-2030 period with PCV13 vaccination could prevent 1362 
(752-1649) IPD episodes, 2285 (721-3316) Pnc-CAPin episodes and 544 (246-713) disease-related 
deaths over the lifetime of vaccination recipients, compared with no vaccination. With PPSV23 
vaccination, 2286 (982-3322) IPD episodes, 0 Pnc-CAPin episodes and 400 (163-604) disease-
related deaths would be preventable. The most effective strategy is sequential vaccination, which 
could prevent 3245 (1706-4027) IPD episodes, 2285 (721-3316) Pnc-CAPin episodes and 864 (409-
1118) disease-related deaths. 
PCV13 is the most efficient vaccination in terms of the NNV to prevent one hospitalization or one 
disease-related death (see Figure 26 and 27). Changing the vaccination age to 65 or 70 would 
improve the efficiency of the vaccinations. 
 
Figure 25: Single vaccination – Scenario A4: prevented cases 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period/Single vaccination with PPSV23 in the 2021-2030 period; Age: Age at initial vaccination 
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Figure 26: Single vaccination - Scenario A4: NNV to prevent one hospitalization 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J: Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
the 2021-2030 period; k. I.: no vaccination; Age: Age at initial vaccination 
Figure 27: Single vaccination - Scenario A4: NNV to prevent one death 
 
■Results for the base case; ▄Results for upper and lower limit of vaccination effectiveness (see section 3.6, Table 6) 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; SEQ: Sequential vaccination with one PCV13 dose + 
PPSV23 booster six months later; SEQ_5J: Sequential vaccination in the 2016-2020 period/Single vaccination with PPSV23 in 
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3.2.4.2 Health economics results 
The PCV13 vaccination strategy is dominated by PPSV23 in the base case. The incremental cost 
effectiveness ratio of PPSV23 compared with no vaccination is EUR 37,673-38,860, depending on the 
age at vaccination. A sequential vaccination strategy would require additional spending of about 
EUR63,604-81,775 versus PPSV23 per QALY gained. 
Table 11: Single vaccination - Scenario A4: Incremental cost effectiveness (additional cost per QALY 
gained) 




SEQ vs. PPSV23 SEQ_5J vs. 
PPSV23 
60 EUR 38,613 EUR 245,553 EUR 81,775 EUR 74,203 
65 EUR 37,673 EUR 160,074 EUR 74,929 EUR 68,106 
70 EUR 38,860 EUR 104,968 EUR 69,500 EUR 63,604 
PCV13: Single vaccination with PCV13 in the 2016-2030 period; PPSV23: Single vaccination with PPSV23 in the 2016-2030 
period; SEQ: Sequential vaccination with one PCV13 dose + PPSV23 booster six months later; SEQ_5J: Sequential 
vaccination in the 2016-2020 period/Single vaccination with PPSV23 in the 2021-2030 period 
3.3 Results for revaccination 
3.3.1 Scenario A1: PPSV23 effective against noninvasive Pnc-CAP / reduced effectiveness 
against serotype 3 with PPSV23 and PCV13 
3.3.1.1 Epidemiological results 
3.3.1.1.1 Initial vaccination with PPSV23 and revaccinations with PPSV23 
Multiple lifelong revaccination with PPSV23 of individuals initially vaccinated in the 1996-2030 period 
could prevent an additional 7029-21,032 IPD episodes, 36,462-101,193 Pnc-CAPin episodes and 
9117-24,745 disease-related deaths over the lifetime of vaccine recipients versus single vaccination 
with PPSV23, depending on revaccination frequency and age at initial vaccination. The most effective 
of the analyzed strategies is initial vaccination at age 60 with revaccination every six years (see Figure 
28). This vaccination strategy is also the most inefficient option in terms of the NNV to prevent one 







Figure 28: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A1: Additionally prevented cases 
 
▄Results for reduction of effectiveness of revaccination by 25% and 0% versus initial PPSV23 vaccination (see section 3.6, 
Table 6)  
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period; Age: Age at initial vaccination; RV: revaccination 
 
Figure 29: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A1: NNV to prevent one additional 
hospitalization 
 
▄Results for reduction of effectiveness of revaccination by 25% and 0% versus initial PPSV23 vaccination (see section 3.6, 
Table 6)  
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
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Figure 30: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A1: NNV to prevent one additional 
death 
 
Results for reduction of effectiveness of revaccination by 25% and 0% versus initial PPSV23 vaccination (see section 3.6, Table 
6)  
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period; Age: Age at initial vaccination; RV: revaccination 
3.3.1.1.2 Sequential initial vaccination and revaccinations with PPSV23 
Initial administration of sequential vaccination instead of PPSV23 in the 2016-2030 period could 
prevent an additional 48-297 IPD episodes, 128-688 Pnc-CAPin episodes and 29-177 disease-related 
deaths over the lifetime of the vaccination recipients depending on the frequency of vaccination and 
age at initial vaccination. The most effective of the analyzed strategies is sequential initial vaccination 
at age 60 with revaccination every six years (see Figure 31). However, this vaccination strategy 
provides the smallest effectiveness gain versus revaccination with initial PPSV23 vaccination (see 
Figure 32 and 33) as the higher effectiveness of sequential vaccination is due in particular to the 
longer duration of immunity with PCV13. This benefit of sequential vaccination is lost in large part with 
revaccination after six years unless the effectiveness of the revaccination falls below a certain 
threshold. This is not the case in the presence of 25% lower efficacy of revaccinations with PPSV23, 
so a graph has not been provided (but see Tables 12-14 on incremental cost effectiveness). 
  














































































Figure 31: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A1: additionally prevented 
cases 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
Figure 32: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A1: NNV to prevent one 
additional hospitalization 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
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Figure 33: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A1: NNV to prevent one 
additional death 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
 
3.3.1.2 Health economics results 
3.3.1.2.1 Initial vaccination with PPSV23 and revaccinations with PPSV23 
If PPSV23 revaccination is as effective as initial PPSV23 vaccination, then the incremental cost 
effectiveness ratio is EUR 8990 – 11,150 per QALY gained, depending on age at initial vaccination 
and frequency of revaccination. If revaccination is 25% less effective than the initial vaccination, then 
the ICER rises to EUR 13,731-16,585 per QALY gained. With the frequencies analyzed, the interval of 
time between vaccinations has little impact on the incremental cost effectiveness ratio. 
  































































































Table 12: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A1: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 11,150 EUR 10,502 EUR 10,234 
65 EUR 10,515 EUR 10,066 EUR 9,793 
70 EUR 9,819 EUR 9,399 EUR 8,990 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 16,585 EUR 15,697 EUR 15,346 
65 EUR 15,775 EUR 15,154 EUR 14,778 
70 EUR 14,864 EUR 14,293 EUR 13,731 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period 
3.3.1.2.2 Sequential initial vaccination and PPSV23 revaccinations 
If PPSV23 revaccination is as effective as initial PPSV23 vaccination, then the incremental cost 
effectiveness ratio is EUR 413,750-5,009,010 per QALY gained, depending on age at initial 
vaccination and frequency of revaccination. The incremental cost effectiveness ratio rises with a 
reduction in the interval between initial vaccination and revaccination. If revaccination is 25% less 
effective than the initial vaccination, then the additional cost per QALY gained declines marginally with 
sequential initial vaccination strategies. 
Table 13: Vaccination strategy SEQ_W vs. PPSV23_W - Scenario A1: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 4,823,633 EUR 686,869 EUR 476,626 
65 EUR 1,715,852 EUR 537,524 EUR 413,750 
70 EUR 5,009,010 EUR 597,985 EUR 414,911 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 4,689,881 EUR 686,679 EUR 476,624 
65 EUR 1,693,985 EUR 537,315 EUR 413,748 
70 EUR 4,731,080 EUR 597,646 EUR 414,910 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 






Table 14: Vaccination strategy SEQ_5J_W vs. PPSV23_W - Scenario A1: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 2,810,187 EUR 598,592 EUR 425,785 
65 EUR 1,270,467 EUR 468,585 EUR 367,358 
70 EUR 2,645,213 EUR 519,401 EUR 370,209 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 2,758,938 EUR 598,443 EUR 425,783 
65 EUR 1,257,226 EUR 468,422 EUR 367,357 
70 EUR 2,560,204 EUR 519,143 EUR 370,208 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential initial 
vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period 
3.3.2 Scenario A2: PPSV23 effective against noninvasive Pnc-CAP / reduced effectiveness 
against serotype 3 only with PPSV23 
3.3.2.1 Epidemiological results 
3.3.2.1.1 Initial vaccination with PPSV23 and PPSV23 revaccinations 
The results are as given for Scenario A1 as the PPSV23 parameters are the same as for Scenario A1. 
3.3.2.1.2 Sequential initial vaccination and revaccinations with PPSV23 
Initial administration of sequential vaccination instead of PPSV23 in the 2016-2030 period could 
prevent an additional 531-950 IPD episodes, 734-1809 Pnc-CAPin episodes and 198-504 disease-
related deaths over the lifetime of the vaccine recipients depending on the frequency of vaccination 
and age at initial vaccination. The most effective of the analyzed strategies is sequential initial 
vaccination at age 60 with revaccination every six years (see Figure 34). However, this vaccination 
strategy is associated with the smallest effectiveness gain versus revaccination with initial PPSV23 
vaccination (see Figure 35 and 36) as the higher effectiveness of sequential vaccination is due in 
particular to the longer duration of immunity with PCV13. This benefit of sequential vaccination is lost 
in large part with revaccination after six years unless the effectiveness of the revaccination falls below 
a certain threshold. This is not the case in the presence of 25% lower efficacy of revaccinations with 








Figure 34: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A2: Additionally prevented 
cases 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
Figure 35: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A2: NNV to prevent one 
additional hospitalization 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
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Figure 36: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A2: NNV to prevent one 
additional death 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
3.3.2.2 Health economics results 
3.3.2.2.1 Initial vaccination with PPSV23 and revaccinations with PPSV23 
The results are as given for Scenario A1 as the PPSV23 parameters are the same as for Scenario A1. 
3.3.2.2.2 Sequential initial vaccination and revaccinations with PPSV23 
If PPSV23 revaccination is as effective as initial PPSV23 vaccination, then the incremental cost 
effectiveness ratio is EUR 101,012-191,548 per QALY gained, depending on age at initial vaccination 
and frequency of revaccination. The incremental cost effectiveness ratio rises with reduction of the 
interval between initial vaccination and revaccination. If revaccination is 25% less effective than the 
initial vaccination, then the additional cost per gained QALY of the strategies with sequential initial 
vaccination declines marginally or remains constant. 
  































































































Table 15: Vaccination strategy SEQ_W vs. PPSV23_W - Scenario A2: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 191,548 EUR 137,998 EUR 116,810 
65 EUR 158,678 EUR 119,263 EUR 104,983 
70 EUR 168,408 EUR 119,461 EUR 101,012 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 169,886 EUR 136,387 EUR 116,810 
65 EUR 143,648 EUR 118,168 EUR 104,982 
70 EUR 149,015 EUR 118,392 EUR 101,012 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period 
Table 16: Vaccination strategy SEQ_5J_W vs. PPSV23_W - Scenario A2: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 179,637 EUR 129,773 EUR 109,942 
65 EUR 148,210 EUR 111,732 EUR 98,449 
70 EUR 157,547 EUR 112,209 EUR 95,035 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 159,486 EUR 128,267 EUR 109,942 
65 EUR 134,322 EUR 110,716 EUR 98,449 
70 EUR 139,653 EUR 111,217 EUR 95,035 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential initial 
vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 







3.3.3 Scenario A3: PPSV23 not effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 with PPSV23 and PCV13 
3.3.3.1 Epidemiological results 
3.3.3.1.1 Initial vaccination with PPSV23 and PPSV23 revaccinations 
Multiple lifelong revaccination with PPSV23 of individuals first vaccinated in the 1996-2030 period 
could prevent 7029-21,032 IPD episodes, 0 Pnc-CAPin episodes and 2714-7524 disease-related 
deaths in the 60+ age group versus single vaccination with PPSV23, depending on the frequency of 
vaccination and age at initial vaccination. The most effective of the analyzed strategies is initial 
vaccination at the age of 60 years with revaccination every six years (see Figure 37). This vaccination 
strategy is also the most inefficient option in terms of the number needed to vaccinate to prevent one 
hospitalization or one disease-related death, but the differences are marginal (see Figure 38 and 39). 
 
Figure 37: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A3: additionally prevented cases 
 
▄Results for reduction of effectiveness of revaccination by 25% and 0% versus initial PPSV23 vaccination (see section 3.6, 
Table 6)  
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
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Figure 38: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A3: NNV to prevent one additional 
hospitalization 
 
▄Results for reduction of effectiveness of revaccination by 25% and 0% versus initial PPSV23 vaccination (see section 3.6, 
Table 6)  
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period; Age: Age at initial vaccination; RV: revaccination 
 
Figure 39: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A3: NNV to prevent one additional 
death 
 
▄Results for reduction of effectiveness of revaccination by 25% and 0% versus initial PPSV23 vaccination (see section 3.6, 
Table 6)  
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period; Age: Age at initial vaccination; RV: revaccination  


























































































































































































3.3.3.1.2 Sequential initial vaccination and revaccinations with PPSV23 
 
Initial administration of sequential vaccination instead of PPSV23 in the 2016-2030 period could 
prevent an additional 48-297 IPD episodes, 1194-1534 Pnc-CAPin episodes and 134-282 
disease-related deaths over the lifetime of the vaccination recipients, depending on the frequency of 
vaccination and age at initial vaccination. The most effective of the analyzed strategies is sequential 
initial vaccination at age 60 with revaccination every six years (see Figure 40). However, this 
vaccination strategy provides the smallest effectiveness gain versus revaccination with initial PPSV23 
vaccination, as the higher effectiveness of sequential vaccination is due in particular to the longer 
duration of immunity with PCV13. This benefit of sequential vaccination is lost in large part with 
revaccination after six years unless the effectiveness of the revaccination falls below a certain 
threshold (see Figure 41 and 42). This is not the case in the presence of 25% lower effectiveness of 
revaccinations with PPSV23, so a graph has not been provided (but see Tables 17-19 on incremental 
cost effectiveness). 
 
Figure 40: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A3: Additionally prevented 
cases 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
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Figure 41: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A3: NNV to prevent one 
additional hospitalization 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
 
Figure 42: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A3: NNV to prevent one 
additional death 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
  


























































































































































































3.3.3.2 Health economics results 
3.3.3.2.1 Initial vaccination with PPSV23 and revaccinations with PPSV23 
If PPSV23 revaccination is as effective as initial PPSV23 vaccination, then the incremental cost 
effectiveness ratio is EUR 37,646-40,777 per QALY gained, depending on age at initial vaccination 
and frequency of revaccination. If revaccination is 25% less effective than the initial vaccination, then 
the ICER rises to EUR 52,035-56,338 per QALY gained. With the frequencies analyzed, the interval of 
time between vaccinations has little impact on the incremental cost effectiveness ratio. 
Table 17: Vaccination strategy PPSV23_W vs. PPSV23 - Scenario A3: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 40,741 EUR 38,449 EUR 38,156 
65 EUR 40,777 EUR 38,858 EUR 38,329 
70 EUR 40,346 EUR 38,451 EUR 37,646 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 56,241 EUR 53,043 EUR 52,662 
65 EUR 56,338 EUR 53,634 EUR 52,908 
70 EUR 55,773 EUR 53,118 EUR 52,035 
PPSV23: Single vaccination with PPSV23 in the 2016-2030 period; PPSV23_W: Initial vaccination with PPSV23 + lifelong 
revaccinations with PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial 
vaccination in the 1996-2015 period 
3.3.3.2.2 Sequential initial vaccination and revaccinations with PPSV23 
If PPSV23 revaccination is as effective as initial PPSV23 vaccination, then the incremental cost 
effectiveness ratio is EUR 186,257-297,556 per QALY gained, depending on age at initial vaccination 
and frequency of revaccination. The incremental cost effectiveness ratio rises with a reduction in the 
interval between initial vaccination and revaccination. If revaccination is 25% less effective than the 
initial vaccination, then the additional cost per QALY gained declines marginally with sequential initial 






Table 18: Vaccination strategy SEQ_W vs. PPSV23_W - Scenario A3: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 297,556 EUR 242,729 EUR 221,234 
65 EUR 256,859 EUR 215,087 EUR 200,469 
70 EUR 233,102 EUR 198,850 EUR 186,257 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 297,443 EUR 242,729 EUR 221,234 
65 EUR 256,775 EUR 215,087 EUR 200,469 
70 EUR 233,034 EUR 198,850 EUR 186,257 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period 
 
Table 19: Vaccination strategy SEQ_5J_W vs. PPSV23_W - Scenario A3: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 241,218 EUR 202,174 EUR 186,205 
65 EUR 210,545 EUR 180,295 EUR 169,339 
70 EUR 194,841 EUR 169,265 EUR 159,594 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 241,115 EUR 202,174 EUR 186,205 
65 EUR 210,467 EUR 180,295 EUR 169,339 
70 EUR 194,776 EUR 169,265 EUR 159,594 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential initial  
vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals; plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period 
3.3.4 Scenario A4: PPSV23 not effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 only with PPSV23 
3.3.4.1 Epidemiological results 
3.3.4.1.1 Initial vaccination with PPSV23 and revaccinations with PPSV23 






3.3.4.1.2 Sequential initial vaccination and revaccinations with PPSV23 
Initial administration of sequential vaccination instead of PPSV23 in the 2016-2030 period could 
prevent an additional 531-950 IPD episodes, 2285-2985 Pnc-CAPin episodes and 134-282 disease-
related deaths in the 60+ age group, depending on the frequency of vaccination and age at initial 
vaccination. The most effective of the analyzed strategies is sequential initial vaccination at age 60 
with revaccination every six years (see Figure 43). 
Figure 43: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A4: Additionally prevented 
cases 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one dose of PCV13 + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
This vaccination strategy however provides the smallest effectiveness gain versus revaccination with 
initial PPSV23 vaccination as the higher effectiveness of sequential vaccination is due in particular to 
the longer duration of immunity with PCV13. This benefit of sequential vaccination is lost in large part 
with revaccination after six years unless the effectiveness of revaccination falls below a certain 
threshold. (see Figure 44 and 45). This is not the case in the presence of 25% lower effectiveness of 
revaccinations with PPSV23, so a graph has not been provided (but see Tables 17, 20 and 21 on 
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Figure 44: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A4: NNV to prevent one 
additional hospitalization 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one dose of PCV13 + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
Figure 45: Vaccination strategy SEQ_W/SEQ_5J_W vs. PPSV23_W - Scenario A4: NNV to prevent one 
additional death 
 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one dose of PCV13 + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 
revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential 
initial vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 
PPSV23 at specified intervals, plus revaccinations with PPSV23 for individuals who received the initial vaccination in the 1996-
2015 period; Age: Age at initial vaccination; RV: revaccination 
  



























































































































































































3.3.4.2 Health economics results 
3.3.4.2.1 Initial vaccination with PPSV23 and revaccinations with PPSV23 
The results are as given for Scenario A3 as the PPSV23 parameters are the same as for Scenario A3. 
3.3.4.2.2 Sequential initial vaccination and revaccinations with PPSV23 
If PPSV23 revaccination is as effective as initial PPSV23 vaccination, then the incremental cost 
effectiveness ratio is EUR 71,871-101,814 per QALY gained, depending on age at initial vaccination 
and frequency of revaccination. The incremental cost effectiveness ratio rises with reduction of the 
interval between initial vaccination and revaccination. If revaccination is 25% less effective than the 
initial vaccination, then the additional cost per gained QALY of the strategies with sequential initial 
vaccination declines marginally or remains constant. 
Table 20: Vaccination strategy SEQ_W vs. PPSV23_W - Scenario A4: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 101,814 EUR 91,293 EUR 84,962 
65 EUR 90,201 EUR 81,833 EUR 77,441 
70 EUR 82,643 EUR 75,687 EUR 71,871 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 97,193 EUR 90,573 EUR 84,962 
65 EUR 86,736 EUR 81,323 EUR 77,441 
70 EUR 79,731 EUR 75,264 EUR 71,871 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_W: Sequential initial vaccination 
with one PCV13 dose + PPSV23 booster six months later + lifelong revaccinations with PPSV23 at specified intervals; plus 






Table 21: Vaccination strategy SEQ_5J_W vs. PPSV23_W - Scenario A4: Incremental cost effectiveness 
(additional cost per QALY gained) 
Vaccination 
age 
Revaccination every 6 
years 
Revaccination every 8 
years 
Revaccination every 10 
years 
Effectiveness of revaccination: 100% of initial vaccination 
60 EUR 91,544 EUR 82,488 EUR 76,977 
65 EUR 81,368 EUR 74,127 EUR 70,291 
70 EUR 75,124 EUR 69,039 EUR 65,677 
Effectiveness of revaccination: 75% of initial vaccination 
60 EUR 87,558 EUR 81,862 EUR 76,977 
65 EUR 78,363 EUR 73,682 EUR 70,291 
70 EUR 72,572 EUR 68,667 EUR 65,677 
PPSV23_W: Initial vaccination with PPSV23 + lifelong revaccinations with PPSV23 at specified intervals; plus revaccinations 
with PPSV23 for individuals who received the initial vaccination in the 1996-2015 period; SEQ_5J_W: Sequential initial 
vaccination in the 2016-2020 period/initial vaccination with PPSV23 in the 2021-2030 period + lifelong revaccinations with 




3.4 Short-term results (initial vaccination in the 2016-2020 period) 
Tables 22-25 show the results for individuals reaching the defined vaccination age in the 2016-2020 
period (lifelong follow-up). The strategies involving revaccination only include cohorts who received the 
initial vaccination in the 2016-2020 period. 
Table 22: Short-term results, Scenario A1: PPSV23 effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 with PPSV23 and PCV13 
 

















PPSV23 vs. no vaccination 
60 years 1,505 748 270 801 6,690 EUR 18,838 EUR 14,383 
65 years 1,440 700 298 725 5,208 EUR 19,634 EUR 15,670 
70 years 1,357 627 303 648 4,247 EUR 17,056 EUR 15,436 
PCV13 vs. no vaccination 
60 years 454 271 101 2,490 17,931 EUR 149,338 EUR 112,606 
65 years 463 265 119 2,134 13,026 EUR 129,327 EUR 100,829 
70 years 519 236 137 1,703 9,411 EUR 102,370 EUR 96,372 
Sequential vaccination vs. PPSV23 
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
60 years 186 110 47 6,072 38,024 EUR 375,498 EUR 366,499 
65 years 212 113 56 4,762 27,438 EUR 293,721 EUR 318,812 
70 years 273 90 71 3,521 17,960 EUR 216,506 EUR 306,411 
Initial vaccination with PPSV23 at the age of 60 years + revaccinations with PPSV23 vs. no vaccination 
every 6 years 17,898 4,271 4,272 398 2,064 EUR 6,690 EUR 12,839 
every 8 years 13,734 3,424 3,267 396 2,077 EUR 6,685 EUR 12,294 
every 10  
years 
11,026 2,826 2,650 403 2,104 EUR 6,880 EUR 12,195 
Sequential vaccination at the age of 60 years + revaccinations withPPSV23 vs. PPSV23  
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
every 6 years 47 24 11 25,038 167,139 EUR 1,561,739 EUR 2,810,187 
every 8 years 120 70 29 9,471 61,333 EUR 587,983 EUR 598,592 
every 10  
years 
160 95 40 7,052 45,011 EUR 436,714 EUR 425,785 






Table 23: Short-term results, Scenario A2: PPSV23 effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 only with PPSV23 
 




Cost per quality 
adjusted life year 








PPSV23 vs. no vaccination 
60 years 1,505 748 270 801 6,690 EUR 18,838 EUR 14,383 
65 years 1,440 700 298 725 5,208 EUR 19,634 EUR 15,670 
70 years 1,357 627 303 648 4,247 EUR 17,056 EUR 15,436 
PCV13 vs. no vaccination 
60 years 813 485 188 1,391 9,613 EUR 80,499 EUR 59,102 
65 years 841 480 221 1,175 7,029 EUR 69,128 EUR 53,717 
70 years 962 430 256 924 5,014 EUR 53,584 EUR 50,582 
Sequential vaccination vs. PPSV23 
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
60 years 502 324 130 2,175 13,788 EUR 130,323 EUR 101,032 
65 years 546 327 153 1,768 10,077 EUR 106,065 EUR 90,647 
70 years 672 284 186 1,335 6,870 EUR 79,447 EUR 85,310 
Initial vaccination with PPSV23 at the age of 60 years + revaccinations with PPSV23 vs. no vaccination 
every 6 years 17,898 4,271 4,272 398 2,064 EUR 6,690 EUR 12,839 
every 8 years 13,734 3,424 3,267 396 2,077 EUR 6,685 EUR 12,294 
every 10  
years 
11,026 2,826 2,650 403 2,104 EUR 6,880 EUR 12,195 
Sequential vaccination at the age of 60 years + revaccinations withPPSV23 vs. PPSV23  
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
every 6 years 246 183 66 4,191 27,101 EUR 255,020 EUR 179,637 
every 8 years 372 246 95 2,910 18,913 EUR 175,743 EUR 129,773 
every 10  
years 
450 294 116 2,415 15,533 EUR 145,118 EUR 109,942 
*Number needed to vaccinate; **hospitalized Pnc-CAP; *** Pnc-CAP or IPD 
Table 24: Short-term results, Scenario A3: PPSV23 not effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 with PPSV23 and PCV13 
 




Cost per quality 
adjusted life year 








PPSV23 vs. no vaccination 
60 years 0 748 128 2,413 14,063 EUR 72,085 EUR 37,746 
65 years 0 700 146 2,217 10,627 EUR 67,244 EUR 36,344 
70 years 0 627 144 2,051 8,903 EUR 61,403 EUR 37,549 
PCV13 vs. no vaccination 
60 years 454 271 101 2,490 17,931 EUR 149,338 EUR 112,606 
65 years 463 265 119 2,134 13,026 EUR 129,327 EUR 100,829 
70 years 519 236 137 1,703 9,411 EUR 102,370 EUR 96,372 
Sequential vaccination vs. PPSV23 
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
60 years 454 110 72 3,187 24,889 EUR 192,859 EUR 178,595 
65 years 463 113 83 2,684 18,681 EUR 163,898 EUR 163,370 
70 years 519 90 99 2,098 12,854 EUR 127,421 EUR 153,893 
Initial vaccination with PPSV23 at the age of 60 years + revaccinations with PPSV23 vs. no vaccination 
every 6 years 0 4,271 1,359 2,064 6,485 EUR 43,657 EUR 40,730 
every 8 years 0 3,424 1,076 1,982 6,308 EUR 42,600 EUR 38,642 
every 10  
years 
0 2,826 868 1,974 6,426 EUR 43,186 EUR 38,338 
Sequential vaccination at the age of 60 years + revaccinations withPPSV23 vs. PPSV23  
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
every 6 years 454 24 66 3,761 27,087 EUR 234,936 EUR 247,730 
every 8 years 454 70 77 3,433 23,262 EUR 213,880 EUR 207,647 
every 10  
years 
454 95 84 3,275 21,472 EUR 203,719 EUR 191,253 






Table 25: Short-term results, Scenario A4: PPSV23 not effective against noninvasive Pnc-CAP / reduced 
effectiveness against serotype 3 only with PPSV23 
 




Cost per quality 
adjusted life year 








PPSV23 vs. no vaccination 
60 years 0 748 128 2,413 14,063 EUR 72,085 EUR 37,746 
65 years 0 700 146 2,217 10,627 EUR 67,244 EUR 36,344 
70 years 0 627 144 2,051 8,903 EUR 61,403 EUR 37,549 
PCV13 vs. no vaccination 
60 years 813 485 188 1,391 9,613 EUR 80,499 EUR 59,102 
65 years 841 480 221 1,175 7,029 EUR 69,128 EUR 53,717 
70 years 962 430 256 924 5,014 EUR 53,584 EUR 50,582 
Sequential vaccination vs. PPSV23 
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
60 years 813 324 159 1,582 11,287 EUR 92,372 EUR 74,203 
65 years 841 327 184 1,321 8,379 EUR 78,315 EUR 68,106 
70 years 962 284 219 1,024 5,824 EUR 60,081 EUR 63,604 
Initial vaccination with PPSV23 at the age of 60 years + revaccinations with PPSV23 vs. no vaccination 
every 6 years 0 4,271 1,359 2,064 6,485 EUR 43,657 EUR 40,730 
every 8 years 0 3,424 1,076 1,982 6,308 EUR 42,600 EUR 38,642 
every 10  
years 
0 2,826 868 1,974 6,426 EUR 43,186 EUR 38,338 
Sequential vaccination at the age of 60 years + revaccinations with PPSV23 vs. PPSV23  
(additionally preventable cases and additionally required vaccinations with PCV13 versus vaccination with PPSV23 alone) 
every 6 years 813 183 123 1,806 14,642 EUR 106,436 EUR 91,544 
every 8 years 813 246 138 1,699 13,000 EUR 99,677 EUR 82,488 
every 10  
years 
813 294 151 1,625 11,927 EUR 95,051 EUR 76,977 




In all four scenarios studied, sequential vaccination of the 60+ population prevents the largest number 
of Pnc infections and deaths. Depending on scenario and vaccination age, short-term analysis 
(vaccination in the 2016-2020 period only) indicates that sequential vaccination prevents an additional 
90-327 IPD cases, 186-962 noninvasive Pnc cases and 47-219 deaths (cumulative over the lifetime of 
vaccination recipients) compared with the PPSV23 vaccination strategy. 
The resources required with combined vaccination (PCV13 + PPSV23) to prevent one additional 
hospitalization or one additional disease-related death versus vaccination with PPSV23 on its own are 
relatively high, however. The NNVs to prevent one hospitalization or one death are smaller than for 
PPSV23 only if PPSV23 is ineffective against noninvasive Pnc-CAP and PCV13 is as effective against 
serotype 3 as against the other PCV13 serotypes (assumption for PPSV23: only half as effective as 
against the other PPSV23 serotypes). Given the higher price of the PCV13 vaccine, vaccination with 
PPSV23 on its own would still be the preferred option from an economics point of view (approx. 
EUR36,000-38,000 / QALY vs. EUR77,000-92,000per QALY). 
In Scenarios A1-A3, PPSV23 saves costs and is more effective (in terms of years of life and QALYs 
gained) than vaccination with PCV13 on its own. In Scenario A4 (PPSV23 not effective against 
noninvasive Pnc-CAP / reduced effectiveness against serotype 3 only with PPSV23), vaccination with 
PCV13 on its own is more effective. From the point of view of cost effectiveness, PPSV23 would be 
preferable in this scenario too. 
Assuming that vaccine effectiveness does not depend on age at vaccination, immunization strategies 
become more efficient as the age at vaccination increases, in terms of the number of vaccinations 





involving revaccinations are not only more effective (in preventing additional Pnc infections and 
deaths) but also more efficient with regard to the NNVs to prevent one hospitalization or one death 
than single, one-off vaccinations, provided the interval between revaccinations is long enough. This 
still applies if the effectiveness of revaccinations is 25% lower than that of the initial vaccinations. The 
most effective vaccination strategy of all the strategies studied is repeated immunization every six 
years, with the initial vaccination taking place at the age of 60. Any losses of efficiency versus other 
revaccination strategies are marginal. From the point of view of efficiency, initial vaccination with 
PPSV23 would be preferable to sequential initial vaccination. 
It should be noted that the results presented here are based on the assumption that the incidence of 
serotype 3 will persist at the level of the 2013/2014 Pnc season. If pediatric vaccination eventually also 
eliminates serotype 3 (albeit with some delay versus the other PCV13 serotypes), then vaccination of 
the 60+ population with PCV13 alone, and sequential vaccination, would have to be rejected based on 
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The Role of decision-analytic modelling in
German health technology assessments
Alexander Kuhlmann1*, Marina Treskova1, Sebastian Braun2 and J-Matthias Graf von der Schulenburg1
Abstract
Background: Decision-analytic modelling (DAM) has become a widespread method in health technology assessments
(HTA), but the extent to which modelling is used differs among international HTA institutions. In Germany, the use of
DAM is optional within HTAs of the German Institute of Medical Documentation and Information (DIMDI). Our study
examines the use of DAM in DIMDI HTA reports and its effect on the quality of information provided for health policies.
Methods: A review of all DIMDI HTA reports (from 1998 to September 2012) incorporating an economic assessment
was performed. All included reports were divided into two groups: HTAs with DAM and HTAs without DAM. In both
groups, reports were categorized according to the quality of information provided for healthcare decision making.
Results: Of the sample of 107 DIMDI HTA reports, 17 (15.9%) used DAM for economic assessment. In the group
without DAM, conclusions were limited by the quality of economic information in 51.1% of the reports, whereas we
did not find limited conclusions in the group with DAM. Furthermore, 24 reports without DAM (26.7%) stated that
using DAM would likely improve the quality of information of the economic assessment.
Conclusion: The use of DAM techniques can improve the quality of HTAs in Germany. When, after a systematic review
of existing literature within a HTA, it is clear that DAM is likely to positively affect the quality of the economic
assessment DAM should be used.
Keywords: Health technology assessment; Health economic evaluation; Health economic modelling;
Cost-effectiveness; Cost-utility; Decision analysis
Background
In the process of health technology assessment, decision-
analytic modelling serves as an assessment approach for
economic evaluation. Performing economic evaluation in
the HTA has become a standard requirement of health-
care systems in many countries (e.g. the UK, Canada,
Australia), and DAM has been accepted as a valid analyt-
ical approach. The method is applied to synthesize existing
evidence on the costs and effectiveness of healthcare op-
tions and to determine an optimal strategy among them.
In recent years, the use of DAM for HTA has significantly
increased [1,2], and several studies providing good practice
guidelines for the use of DAM in HTA have been con-
ducted [2]. In particular, guidelines issued by HTA insti-
tutes in the UK and Canada provide detailed descriptions
of the required elements of HTAs and the appropriate
methods for decision modelling.
In Germany, HTA was introduced in the 1990s. In 1995,
the German Federal Ministry of Health assembled a re-
search group and assigned it to review, assess and prepare
the implementation of data collection and to evaluate
medical procedures and technologies in Germany [3].
HTA was formally approved in Germany with the health-
care reform in 2000. The German Agency for Health
Technology Assessment (DAHTA) was established within
the German Institute of Medical Documentation and
Information (DIMDI). It was commissioned to implement
and operate a database, an information system and a
scientific working program on HTA [4,5]. The HTAs pub-
lished by DIMDI aim to primarily inform health policy and
not to provide recommendations for the benefits catalogue
of the Statutory Health Insurance (SHI) [5]. These HTA re-
ports include medical, economic, ethical, social and juridical
aspects [6]. Following the SHI Modernization Act in 2004,
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HTA gained increasing importance in Germany. The Insti-
tute for Quality and Efficiency in Health Care (IQWiG) was
established as an independent scientific body to perform
technology assessments on behalf of the Federal Joint Com-
mittee (G-BA; a supreme decision making body of the self-
governing healthcare system in Germany) or the Federal
Ministry of Health. The technology assessments serve to in-
form the decision making by the G-BA [5], and the reports
by IQWiG were limited to medical technology assessments.
Since 2007, with the German Act on reinforcing SHI compe-
tition, IQWiG may also be commissioned to perform cost-
benefit assessments.
The guidelines of both DIMDI and IQWiG indicate
that DAM may be necessary for economic assessment
of a technology [6,7]; however, the incorporation of a
model is not a requirement for developing an HTA for
publication by DIMDI, and DAM has become an op-
tional tool in practice. IQWiG sees modelling as essen-
tial for economic assessment and requires it in the
absence of comprehensive economic data [7]. Thus,
IQWiG has released detailed information on the
methods applied in modelling [8]. The DIMDI guide-
lines, which are summarized in its handbook, do not
provide specific methodological recommendations for
the development of DAM.
Considering the growing importance of performing sys-
tematic assessments of health technologies in Germany, it
is desirable to continue working on the development of
HTA methodologies, which may improve the quality of
HTA reports. One important direction may be to enhance
the application of decision models in German HTAs.
Therefore, in our study, we review the use of DAM in
German HTAs and analyse the effects of the use of DAM
on the quality of information provided for healthcare deci-
sion making. We also study decision models applied to
German settings and consolidate the main characteristics
of the models developed by the German HTAs. Because
IQWiG did not provide economic assessments by the time
of our analysis, we based our work on the HTA reports
published by DIMDI.
Methods
Search strategy and exclusion criteria
Using the DAHTA database, we identified and extracted
all DIMDI HTA reports conducted during the period
from 1998 to September 2012. HTAs that did not
undertake economic assessments were excluded from
the analysis. The resulting sample of HTAs was divided
into two groups: HTAs that performed a systematic litera-
ture review and HTAs that developed a new decision-
analytic model (designed for the characteristics of the
German healthcare system) in addition to the literature
review for the economic assessment.
Assessing the informativeness of HTA reports for decision
making
In order to analyse the informativeness of HTAs for de-
cision making, we developed an HTA classification based
on the quality of information provided in each HTA re-
port. We reviewed all included HTAs, focusing on the
following sections: the summary, the conclusion and the
answers provided to the research questions. Additionally,
we checked for consistency between these sections. We
defined three aggregate types that described the levels of
informativeness of the HTA report.
‘Conclusion’: The HTA provides a clear conclusion
regarding the medical effectiveness or cost-effectiveness
of the health technology (technologies) under assess-
ment. Uncertainty is low and further research is unlikely
to affect the given conclusion.
‘Limited conclusion’: Authors on an HTA formulate a
general suggestion regarding the medical effectiveness/cost-
effectiveness of the health technology (technologies) under
assessment, but the conclusion is limited because of the
limitations of the reviewed evidence. Major limitations of
the study are explained through either the low quality of
the reviewed studies or the difficulties of applying the exist-
ing evidence to the German health care system. The latter
generally occurs when conducting an economic assessment
because of the differences in the healthcare structures and/
or resource prices. In addition, the uncertainty is significant,
and further research is likely to have a considerable effect
on the results and may change the provided inferences.
‘No conclusion’: Authors of an HTA cannot provide an
assessment of medical effectiveness and cost-effectiveness
of the health technology (technologies) because of the lack
of scientific evidence in the reviewed literature.
Assessing the impact of decision-analytic modelling on
the informativeness of HTA reports
The medical effectiveness of interventions is a key input
parameter in decision-analytic models. The evidence of
medical effectiveness affects the quality of information pro-
vided in health economic evaluations. Low-quality medical
evidence can be a barrier for conducting economic ana-
lysis. Consequently, the existing medical evidence has to be
taken into account when assessing the impact of decision-
analytic modelling on the informativeness of HTA reports.
Therefore, we reviewed the medical part and the economic
part of each HTA separately. Using the three types of in-
formativeness, six categories (CAT I-VI) were formed to
classify the HTA reports. Table 1 shortly sketches these
categories. The first row and column of the table provide
the level of information related to the medical and eco-
nomic assessments, respectively. Combinations between
the type of the medical part and the type the economic
part constitute the six categories shown in the intersection
cells of the table.
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In order to evaluate the impact of using DAM on the
quality of information given in the economic portions
of the HTAs, we compared medical and economic as-
sessments of each report in the sample and analysed the
difference between their levels of informativeness. HTA re-
ports in CAT VI were excluded from the analysis, since the
reports in this category provide insufficient medical evi-
dence for progressing to economic evaluation. For each of
the groups, ‘HTA with a model’ and ‘HTA without a model’,
we determined the percentage of HTAs in which the eco-
nomic assessment provides significantly lower quality of in-
formation than the medical assessment (CATs II, III and
V). We compared “with-” and “without a model” groups
based on these percentages to reduce potential bias, in case
both groups are not comparable with respect to the re-
ported level of information in the medical assessment.
The review and the classification of the reports were
undertaken by two researchers independently, and any
distinctions were discussed and clarified. The HTA re-
ports with new model development were further ana-
lysed with respect to the applied modelling methods.
The aim of the further analyses was to characterize and
compare the techniques used that focused on the se-
lected key components of modelling: the economic
evaluation type, the model type, the time horizon, the
perspective, the primary medical outcome, the dis-
count factor and the type of sensitivity analyses. These
components were extracted according to the individual
descriptions provided in the HTA reports.
Results
Sample size
In the period from 1998 to September 2012, 158 DIMDI–
HTA reports were conducted, published and indexed in the
DAHTA database. Of these, 20 methodological reports
were excluded during the screening process. Another 31 re-
ports did not meet the inclusion criterion of an economic
assessment of the health technology. The resulting sample
of 107 HTA reports was divided into reports that include
the development of a new model for the German health-
care system and those that only performed a systematic lit-
erature review for economic assessment. In total, 17 HTA
reports (approximately 16%) developed such a model,
whereas the other 90 reports did not. Figure 1 summarizes
the selection procedure (A list of all identified reports is
presented in the Additional file 1: Table S2 to Table S5).
Informativeness of DAHTA reports
The medical and economic parts of the 107 HTAs in our
sample are grouped into the three aggregate types. Of our
sample, 29 reports (27.1%) state a clear conclusion regard-
ing the medical effectiveness of a technology in the assess-
ment, and 15 reports (14%) provide a conclusion regarding
cost-effectiveness in the economic section. Another 44 re-
ports (41.1%) state a general suggestion on medical effect-
iveness. The conclusion on cost-effectiveness is significantly
limited in 36 reports (33.6%). In 34 reports (31.8%), it is
not possible to conduct a medical assessment because of
the lack of scientific evidence in the reviewed literature.
An economic conclusion could not be drawn in 56 reports
(52.3%), either because of the lack of economic evidence
or because the results of the international studies are not
applicable to the German setting. Figure 2 shows the re-
sults of the division of the reports into the types for the
groups of ‘HTAs with a model’ and ‘HTAs without a
model’. In the sample of HTAs with a model, a higher per-
centage of reports provide information for decision mak-
ing in the medical assessment compared to the sample of
HTAs without a model (conclusion is given in 52.9% vs.
22.2%; conclusion is limited in 41.2% vs. 41.1%). Of the re-
ports that applied DAM, 94.1% provide either a clear con-
clusion (32.2%) or a limited conclusion (61.1%) on the
cost-effectiveness of the technology/technologies under
assessment compared with 38.9% in the group without a
model (conclusion: 6.7%; limited conclusion: 32.2%).
Overall, the proportion of HTA reports that provide infor-
mation on the assessed health technology for decision mak-
ing (CAT I–V) is 68.2% (73 out of 107 reports), of which 15
reports draw a clear conclusion on both the medical and
economic assessments (CAT I). Another 14 reports either
draw a clear conclusion on effectiveness but provide only a
general suggestion on cost-effectiveness (CAT II; seven re-
ports), or they are not able to provide a conclusion on cost-
effectiveness based on the reviewed evidence (CAT III; seven
reports). Of the 44 reports that provide a general suggestion
on medical effectiveness, 29 reports also provide a general
suggestion on cost-effectiveness (CAT IV) and 15 are not
able to assess the cost-effectiveness because of a lack of evi-
dence (CAT V). In addition, 31.8% (34 of 107 reports) of the
reports are grouped in CAT VI, because they cannot draw a
conclusion on medical effectiveness or cost-effectiveness.
Among the 90 HTAs without a new model 57 (63.3%) give
information for decision making (CAT I–V). The majority of
these (51 reports) provide only a general opinion on the
medical effectiveness or cost-effectiveness of the health tech-
nology (technologies) under assessment (CAT II–V); thus,
further research is likely to have an important effect and may
Table 1 Categorization of HTA conclusions based on the








Conclusion I II III
Limited
conclusion
not applicable IV V
No conclusion not applicable not applicable VI
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change the conclusion. The number of the reports in CATs
II, III, IV and V are 7, 7, 22 and 15, respectively.
The HTA reports with a developed model provide in-
formation for decision making (CAT I–V) in 16 out of
the 17 cases (94.1%). Of these, nine HTAs draw a clear
conclusion and provide high-quality information in both
the medical and economic assessment (CAT I), and
seven HTAs provide a general suggestion on both effect-
iveness and cost-effectiveness (CAT IV).
Impact of decision-analytic modelling on informativeness
of DAHTA reports
Of the HTA reports that did not develop a decision-
analytic model for the German healthcare system, 51.1%
provide significantly less information in the economic as-
sessment compared with the medical assessment. Of the
20 reports that provide a conclusion in the medical assess-
ment, 7 provide suggestions in the economic assessment
and another 7 cannot draw a conclusion. Of the 37 reports
with a limited conclusion on effectiveness in the medical
assessment, 15 reports provide no information on cost-
effectiveness in the economic assessment. In the group of
HTAs that apply DAM techniques, no report provides sig-
nificantly less information in the economic assessment
compared with the medical assessment. Figure 3 illustrates
the results for both groups.
Additionally, we reviewed the proportion of HTAs that
reported a requirement for further economic research. The
majority of these reports (86 of 107) conclude that add-
itional economic evidence is required in the literature. Of
the 90 reports that conduct only an economic systematic
literature research, 26.7% (24 reports) state that the
development of a model is likely to improve the quality of
information of the economic assessment. Six of the HTAs
that used DAM provide recommendations to update the
models as soon as new medical evidence is available.
Economic evaluations for the German settings are re-
trieved in 36 of 107 HTA reports; however, none of
these evaluations significantly affected the level of infor-
mation in the economic assessments, mainly because of
either the low quality of the evaluation or the use of out-
dated economic or medical data.
Characteristics of decision-analytic models
Seventeen of the HTA reports in our sample developed
new decision-analytic models for the German settings.
Here, we provide a review of these and focus on the se-
lected key components of health economic modelling.
Table 1 in the supplements summarizes the results. One
model was not completed because of the lack of medical
evidence of important input parameters, and this model
is excluded from the following review.
Type of economic evaluation
Overall, 10 cost-effectiveness analyses and 2 cost-utility
analyses were conducted within the 16 HTAs. Three
HTA reports include examination of costs, and one re-
port includes both a cost-effectiveness analysis and a
cost-utility analysis.
Model type
The applied DAM techniques are identified in 63% (10
of 16) of the HTAs. In six HTAs, economic evaluations
are based on Markov models. Three HTA reports apply
Figure 1 Selection process for report inclusion. *As of September 2012.
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decision trees. One report uses combinations of a deci-
sion tree and the Markov model. Another report pre-
sents a Markov chain Monte Carlo simulation in which,
in contrast with common cohort modelling, virtual pa-
tients are simulated on an individual level with the im-
plication of a stochastic process (i.e. a micro-simulation).
The remaining six HTAs calculate results on the basis of
simple calculations.
Discount factor
Overall, 11 of the 16 models apply a discount rate in the
economic evaluations. Of these, six models use a 3% an-
nual discount rate and five models use a 5% discount rate
for both health effects and costs. In one model, it is un-
necessary to discount because the economic evaluation is
performed for a short time horizon (1 year). One model
omits discounting of the costs and benefits, albeit it per-
forms the economic evaluation for a time horizon of
3 years. The other three models report no discount rate.
Perspective
Of the 16 reviewed models, four state a social perspec-
tive. Three models describe the perspective as a nar-
rowed social perspective. The perspective of two models
is that of the German statutory health insurance. One
model uses the scope of a healthcare provider and in-
cludes additional costs in its evaluation. Five models
state no perspective; however, the outcomes of the
models probably reflect the perspective of the statutory
health insurance. One model uses the perspective of the
German healthcare system.
Primary medical outcome
Three models use life years to value health outcomes and
two models use QALYs. One model bases the economic
evaluation on both life years and QALYs. The rest of the
models calculate health outcomes specific to the character
of the disease or the technology under assessment.
Figure 2 Results of the division of HTA reports into the types.
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Type of sensitivity analysis
All 16 models conduct sensitivity analyses. All models
apply a one-way sensitivity analysis; in addition, three re-
ports also perform a multi-way analysis and two perform
a probabilistic sensitivity analysis.
Discussion
Following the objective of this work, we searched for evi-
dence that developing a new decision-analytical model im-
proves the quality of information of HTAs for decision
making in the German healthcare sector.
Therefore, we reviewed all HTAs published from DIMDI
that included economic assessments and classified them
according to the quality level of the information provided
for decision making. The results of this study suggest
that HTAs perform better when they build a new deci-
sion model for economic evaluation. Particularly, the
review showed that all HTAs with developed models
were capable of providing economic evidence for deci-
sion making with the quality of the information at least
equivalent to that provided by the medical portion. In
contrast, over 50% of HTA reports without model gave
a lower level of information in the economic assess-
ments than in the medical assessment. Moreover, ap-
proximately 80% of the reviewed HTAs concluded that
there is a need for further economic research, and 27%
(24 reports) of the HTAs without a model stated that
the development of a decision-analytic model might im-
prove the quality of the information of the economic as-
sessment. These findings indicate that using DAM in
DAHTA reports is not related to the need for additional
economic information.
In our analysis, we also found differences between the
models in their quality and complexity. The review of
HTAs with models indicated that cost-effectiveness ana-
lysis with Markov models was the preferred type of eco-
nomic evaluation. Although the majority of the selected
HTAs with models incorporated the key elements of mod-
elling, some differences in the applied methods were ob-
served. These differences occurred in valuing medical
outcomes, the stated perspectives and the applied annual
discount rate. Not all the applied methods were up-to-
date. For example, for addressing uncertainty, a one-way
sensitivity analysis but no probabilistic sensitivity analysis
was mostly conducted.
Current shortcomings of the HTA reports and the
differences between the applied methods might com-
plicate decision making processes and might decrease
the role of HTAs as sources of information in health-
care. Elaboration of official standards and recommen-
dations on the use of decision-analytic models in HTA
might solve the discrepancies in the applied methods.
Imposing a requirement of justifying and clarifying the
necessity for modelling seems to be useful. Thus, re-
quiring DAM is necessary when, after conducting a
systematic literature review, it is justified that a model
would improve the results of assessment in terms of
informing decision making.
The current description of the HTA methods by DIMDI
lacks guidance on both, methods for conducting decision
modelling and for assessment of cost-effectiveness (e.g.
ICER vs. the Efficiency Frontier of the IQWiG [7]). Since
these aspects are interconnected, they are both essential
for the production of consistent results among HTAs.
For instance, if the assessment of cost-effectiveness
Figure 3 Impact of decision-analytic modelling on the conclusion of HTA reports.
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allows for comparisons between health outcomes, a
generic measure such as QALY should be applied in
modelling. When developing a guide on decision mod-
elling in HTA, both the modelling methods and the as-
sessment of outcomes must be considered. Additionally,
it is desirable to consider the requirements and needs of
the users of HTA reports. For instance, requests by deci-
sion makers may determine the applied perspective (e.g.
societal or sickness funds).
Some limitations of this study should be considered
when contemplating the results. First, because of the di-
versity and complexity of the HTAs conclusions pro-
vided, the types and categories of our classifications are
broadly defined. A more precise grouping might change
the results of the classifications, but it would unlikely
affect the overall conclusion of our study. Second, the
classifications were performed based on the concluding
statements provided by the authors of the HTAs; there-
fore, we did not conduct an assessment of the evidence
reviewed in the reports. Among the HTA researchers,
distinctions in valuing the existing evidence may exist.
These differences might in turn bias our work.
Despite the limitations, this study provides new infor-
mation on conducting HTA in Germany regarding the
use of DAM. It also indicates the lack of economic re-
search in the German HTAs as well as the need for in-
creased and improved economic evaluations conducted
for HTAs.
Conclusion
Our review shows that it is necessary to improve eco-
nomic evaluations for HTAs produced in Germany. The
results of the analysis suggest that the use of modelling
improves the quality of economic assessment and
thereby the overall performance of an HTA, however,
the number of HTAs that conduct modelling is small.
In order to enhance the quality of HTAs in Germany, it
is desirable to develop a procedure for incorporating
decision-analytic models in the economic assessments
of reports. As long as the application of modelling is
not necessary for every HTA study, it seems reasonable
to develop a model on request after a systematic literature
review clarifies that DAM is likely to have a positive im-
pact on the economic assessment quality. In order to
guarantee good modelling quality and consistency of
the applied methods, designing and expanding the good
practices guide for the use of DAM for DIMDI–HTAs
is required.
Additional file
Additional file 1: Technology reports with economic assessment
based on systematic literature review.
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Table S2: Technology reports with economic assessment based on systematic literature review 
(n=90); included 
Document 
Number Authors Year Titel 
DAHTA023 Perleth M; Kochs G 1999 Stenting versus Ballondilatation bei koronarer Herzkrankheit. Systematische Übersichten zur medizinischen Effektivität und zur Kosten-Effektivität 
DAHTA016 Bitzer EM; Greiner W 2000 Hochdosis-Chemotherapie mit autologer Stammzelltransplantation zur Therapie des metastasierenden Mammakarzinoms 
DAHTA019 Siebert U; Mühlberger N; Behrend C; Wasem J 2001 PSA-Screening beim Prostatakarzinom - systematischer gesundheitsökonomischer Review 
DAHTA020 Müller A; Stratmann-Schöne D; Klose T; Leidl R 2001 Ökonomische Evaluationen der Positronen-Emissions-Tomographie 
DAHTA021 
Perleth M; Leyen U von der; Schmitt 
H; Dintsios CM; Felder S; Schwartz 
FW; Teske S 
2003 Das Schlaf-Apnoe-Syndrom - systematische Übersichten zur Diagnostik, Therapie und Kosten-Effektivität 
DAHTA028 Kulp W; Garrido Velasco M; Greiner W; Schulenburg JM Graf von der 2003 Die Verwendung des Excimer Lasers in der refraktiven Augenchirurgie 
DAHTA032 Kulp W; Greiner W; Schulenburg JM Graf von der 2003 Bewertung der Möglichkeiten und Verfahren zur Aufbereitung medizinischer Einwegprodukte 
DAHTA033 Olbrich A; Felder S 2003 Knochen- und Knochenersatzmaterialien zur parodontalen Regeneration oder zum Knochenaufbau für Implantate 
DAHTA064 Felder S; Meyer FP 2003 Glycoprotein IIb/IIIa-Rezeptorantagonisten in der Therapie akuter koronarer Syndrome - ein gesundheitsökonomischer HTA-Bericht 
DAHTA066 
Siebert U; Aidelsburger P; Peeters 
J; Regar E; Mühlberger N; Klauss 
V; Rieber J; Corzillius M; Wasem J 
2003 
Wertigkeit des Einsatzes der intravaskulären Ultraschallbildgebung (IVUS) im Rahmen von 
diagnostischen und therapeutischen Herzkatheteruntersuchungen - ein 
gesundheitsökonomischer HTA-Bericht 
DAHTA076 Gerhardus A; Jalilvand N; Heintze C; Krauth C 2003 
Ein Vergleich verschiedener chirurgischer Verfahren zur elektiven Leistenhernienoperation bei 
Erwachsenen - ein Health Technology Assessment 
DAHTA077 
Gorenoi V; Siebert U; Perleth M; 
Brundobler M; Dintsios CM; Klauss 
V; Rieber J; Wasem J; Leidl R 
2003 Stenting versus Ballondilatation bei koronarer Herzkrankheit 
DAHTA075 
Kulp W; Corzillius M; Greiner W; 
Pientka L; Siebert U; Schulenburg 
JM Graf von der; Wasem J 
2005 Wertigkeit von Tumor-Nekrose-Faktor-alpha-Antagonisten in der Behandlung der Rheumatoiden Arthritis 
DAHTA084 
Vauth C; Englert H; Fischer T; Kulp 
W; Greiner W; Willich SN; Stroever 
B; Schulenburg JM Graf von der 
2005 Sonographische Diagnostik beim akuten Abdomen bei Kindern und Erwachsenen 
DAHTA108 Lühmann D; Burkhardt-Hammer T; Borowski C; Raspe H 2005 Minimal-invasive Verfahren zur Behandlung des Bandscheibenvorfalls 
DAHTA109 Habl C; Bodenwinkler A; Stürzlinger H 2005 Wurzelbehandlung an Molaren 
DAHTA111 Gorenoi V; Kulp W; Greiner W; Schulenburg JM Graf von der 2005 
Thrombozytenaggregationshemmer zur Primär- und Sekundärprävention des ischämischen 
Schlaganfalls 
DAHTA114 Antony K; Pichlbauer E; Stürzlinger H 2005 
Medizinische und ökonomische Effektivität der Pneumokokkenimpfung für Säuglinge und 
Kleinkinder 
DAHTA115 Frank W; Konta B 2005 Bluthochdruckleitlinien und ihre Auswirkungen auf das Gesundheitssystem 
DAHTA116 
Braun S; Behrens T; Kulp W; Eberle 
A; Greiner W; Ahrens W; 
Schulenburg JM Graf von der 
2005 Neuraminidasehemmer in der Therapie und Postexpositionsprohylaxe der Influenza 
DAHTA119 
Hessel F; Grabein K; Schnell-
Inderst P; Siebert U; Caspary W; 
Wasem J 
2005 Extrakorporale artifizielle Leberunterstützungssysteme bei akutem Leberversagen oder einer akuten Dekompensation eines chronischen Leberleidens 
DAHTA123 Frank W; Konta B 2005 Kognitives Training bei Demenzen und andere Störungen mit kognitiven Defiziten 
DAHTA128 
Eberhardt S; Heinemann A; Kulp W; 
Greiner W; Leffmann C; 
Leutenegger M; Anders J; Pröfener 
F; Balmaceda U; Cordes O; 
Zimmermann U; Schulenburg JM 
Graf von der 
2005 Dekubitusprophylaxe und -therapie 
DAHTA130 Carvalho Gomes H de; Velasco-Garrido M; Busse R 2005 Screening auf urogenitale Chlamydia trachomatis-Infektionen 
DAHTA118 Frank W; Konta B; Seiler G 2006 Therapie des unspezifischen Tinnitus ohne Ursache 
DAHTA120 
Eidt D; Roll S; Kulp W; Müller-
Nordhorn J; Vauth C; Greiner W; 
Willich SN; Schulenburg JM Graf 
von der 
2006 Bypassmaterialien in der Gefäßchirugie 
DAHTA121 Aidelsburger P; Grabein K; Huber A; Hertlein H; Wasem J 2006 Die elastisch stabile intramedulläre Nagelung bei instabilen kindlichen Unterarmschaftfrakturen 
DAHTA124 Stürzlinger H; Antony K; Pichlbauer E 2006 Koronarkalkbestimmung mit CT-Verfahren bei asymptomatischen Risikopatienten 
DAHTA125 Heinen-Kammerer T; Wiosna W; 2006 Monitoring von Herzfunktionen mit Telemetrie 
 
Nelles S; Rychlik R 
DAHTA129 
Claes C; Kulp W; Greiner W; 
Schulenburg JM Graf von der; 
Werfel T 
2006 Therapie der mittelschweren und der schweren Psoriasis 
DAHTA132 Frank W; Konta B; Prusa N; Raymann C 2006 Bedeutung der intensivierten Pflege 
DAHTA133 Rosian I; Pichlbauer E; Stürzlinger H 2006 Einsatz von Statinen in der Primärprävention 
DAHTA134 Lühmann D; Burkhardt-Hammer T; Stoll S; Raspe H 2006 
Prävention rezidivierender Rückenschmerzen- Präventionsmaßnahmen in der 
Arbeitsplatzumgebung 
DAHTA135 Schnell-Inderst P; Kossmann B; Fischereder M; Klauss V; Wasem J 2006 
Antioxidative Vitamine zur Prävention kardiovaskulärer Erkrankungen nach 
Nierentransplantation und bei chronischer Niereninsuffizienz 
DAHTA136 Walter U; Krauth C; Wienold M; Dreier M; Bantel S; Droste S 2006 Verfahren zur Steigerung der Teilnahmerate an Krankheitsfrüherkennungsprogrammen 
DAHTA140 Rohde V; Grabein K; Hessel F; Siebert U; Wasem J 2006 
Orchiektomie versus medikamentöse Therapie mit LH-RH-Analoga zur Behandlung des 
fortgeschrittenen Prostatakarzinoms 
DAHTA141 Frank W; Konta B 2006 Bypassoperation am schlagenden Herzen im Vergleich zur Operation mit Unterstützung durch die Herz-Lungen-Maschine 
DAHTA142 Werfel T; Claes C; Kulp W; Greiner W; Schulenburg JM Graf von der 2006 Therapie der Neurodermitis 
DAHTA145 Bockelbrink A; Rasch A; Roll S; Willich SN; Greiner W 2006 
Welche Auswirkung hat die Kataraktoperation auf das Entstehen oder das Fortschreiten einer 
altersbedingten Makuladegeneration (AMD)? 
DAHTA127 
Eberhardt S; Keil T; Kulp W; 
Greiner W; Willich SN; Schulenburg 
JM Graf von der 
2007 Hormone zur Therapie von Beschwerden im Klimakterium und zur Primärprävention von Erkrankungen in der Postmenopause 
DAHTA138 Rosian-Schikuta I; Fröschl B; Habl C; Stürzlinger H 2007 Die Masern-Mumps-Röteln-Impfung aus gesundheitspolitischer und ökonomischer Sicht 
DAHTA144 Antony K; Genser D; Fröschl B 2007 Erkennungsgüte und Kosteneffektivität von Screeningverfahren zur Erfassung von primären Offenwinkelglaukomen 
DAHTA146 Busch M; Haas S; Weigl M; Wirl C; Horvath I; Stürzlinger H 2007 Langzeitsubstitutionsbehandlung Opioidabhängiger 
DAHTA147 Schumacher H; Müller-Nordhorn J; Roll S; Willich SN; Greiner W 2007 Drotrecogin alfa (aktiviert) bei der Behandlung der schweren Sepsis 
DAHTA149 Stürzlinger H; Fröschl B; Genser D 2007 Wertigkeit der optischen Kohärenztomographie im Vergleich zur Fluoreszenzangiographie in der Diagnostik der altersbedingten Makuladegeneration (AMD) 
DAHTA187 Gorenoi V; Schönermark MP; Hagen A 2007 Nutzen und Risiken hormonaler Kontrazeptiva bei Frauen 
DAHTA189 Angermayr L; Velasco Garrido M; Busse R 2007 Künstliche Ventrikel bei fortgeschrittener Herzinsuffizienz 
DAHTA195 Lühmann D; Schramm S; Raspe H 2007 Wie ist der derzeitige Stellenwert der Homozysteinbestimmung im Blut als Risikofaktor für die koronare Herzkrankheit (KHK)? 
DAHTA198 
Nocon M; Mittendorf T; Roll S; 
Greiner W; Willich SN; Schulenburg 
JM Graf von der 
2007 Welchen medizinischen und gesundheitsökonomischen Nutzen hat die Kolposkopie als primäres Screening auf das Zervixkarzinom? 
DAHTA199 
Mittendorf T; Nocon M; Roll S; 
Mühlberger N; Sroczynski G; 
Siebert U; Willich SN; Schulenburg 
JM Graf von der 
2007 HPV-DNA-Diagnostik zur Zervixkarzinomfrüherkennung 
DAHTA206 Gorenoi V; Schönermark MP; Hagen A 2007 
Maßnahmen zur Verbesserung der Compliance bzw. Adherence in der Arzneimitteltherapie mit 
Hinblick auf den Therapieerfolg 
DAHTA143 
Friedrich M; Müller-
Riemenschneider F; Roll S; Kulp W; 
Vauth C; Greiner W; Willich SN; 
Schulenburg JM Graf von der 
2008 Vergleich der laparoskopischen Narbenhernioplastik und der konventionellen Operation mit und ohne Netzeinlage – Effektivität und Kostennutzenrelation 
DAHTA186 Fröschl B; Arts D; Leopold C 2008 Topische antientzündliche Behandlung der Neurodermitis im Kindesalter 
DAHTA203 Bockelbrink A; Stöber Y; Roll S; Vauth C; Willich SN; Greiner W 2008 
Medizinische und ökonomische Beurteilung der bariatrischen Chirurgie (Adipositaschirurgie) 
gegenüber konservativen Strategien bei erwachsenen Patienten mit morbider Adipositas 
DAHTA204 Konta B; Frank W 2008 Die Therapie der Parkinsonerkrankung mit Dopaminagonisten 
DAHTA205 Frank W; Pfaller K; Konta B 2008 Mundgesundheit nach kieferorthopädischer Behandlung mit festsitzenden Apparaten 
DAHTA213 Clar C; Velasco-Garrido M; Gericke C 2008 Interferone und Natalizumab in der Behandlung der multiplen Sklerose (MS) 
DAHTA224 Antony K; Hiebinger C; Genser D; Windisch F 2008 Haltbarkeit von Zahnamalgam im Vergleich zu Kompositkunststoffen 
DAHTA232 
Müller-Riemenschneider F; Rasch 
A; Bockelbrink A; Vauth C; Willich 
SN; Greiner W 
2008 Wirksamkeit und Wirtschaftlichkeit von verhaltensbezogenen Maßnahmen zur Prävention des Zigarettenrauchens 
DAHTA215 
Rieckmann N; Schwarzbach C; 
Nocon M; Roll S; Vauth C; Willich 
SN; Greiner W 
2009 Pflegerische Versorgungskonzepte für Personen mit Demenzerkrankungen 
DAHTA216 
Schnell-Inderst P; Schwarzer R; 
Göhler A; Grandi N; Grabein K; 
Stollenwerk B; Klauss V; Wasem J; 
2009 Stellenwert des hochsensitiven C-reaktiven Proteins (hs-CRP) als Marker für Herzinfarktgefährdung 
 
Siebert U  
DAHTA217 Stürzlinger H; Genser D; Hiebinger C; Windisch F 2009 
ffektivität und Effizienz der CT-Koloskopie im Vergleich zur konventionellen Koloskopie in der 
Dickdarmkrebsdiagnose und -früherkennung 
DAHTA225 
Müller-Riemenschneider F; 
Schwarzbach C; Bockelbrink A; 
Ernst I; Vauth C; Willich SN; 
Schulenburg JM Graf von der 
2009 Medizinische und gesundheitsökonomische Bewertung der Radiochirurgie zur Behandlung von Hirnmetastasen 
DAHTA228 Stürzlinger H; Hiebinger C; Pertl D; Traurig P 2009 
Computerized Physician Order Entry – Wirksamkeit und Effizienz elektronischer 
Arzneimittelverordnung mit Entscheidungsunterstützungssystemen 
DAHTA234 Damm O; Nocon M; Roll S; Vauth C; Willich SN; Greiner W 2009 
Impfung gegen humane Papillomaviren (HPV) zur Prävention HPV 16/18 induzierter 
Zervixkarzinome und derer Vorstufen 
DAHTA236 Brunner-Ziegler S; Fröschl B; Hiebinger C; Wimmer A; Zsifkovits J 2009 Effektivität und Kosteneffizienz von Phosphatbindern in der Dialyse 
DAHTA242 Fröschl B; Haas S; Wirl C 2009 Prävention von Adipositas bei Kindern und Jugendlichen (Verhalten- und Verhältnisprävention) 
DAHTA248 
Weinmann S; Schwarzbach C; 
Begemann M; Roll S; Vauth C; 
Willich SN; Greiner W 
2009 Verhaltens- und fertigkeitenbasierte Frühinterventionen bei Kindern mit Autismus 
DAHTA257 
Nocon M; Kuhlmann A; Leodolter A; 
Roll S; Vauth C; Willich SN; Greiner 
W 
2009 
Medizinischer und gesundheitsökonomischer Nutzen der Untersuchung auf Helicobacter pylori-
Besiedlung mittels 13C-Harnstoff-Atemtest in der Primärdiagnostik im Vergleich zu invasiven 
und nichtinvasiven diagnostischen Verfahren 
DAHTA261 
Müller-Riemenschneider F; Damm 
K; Meinhard C; Bockelbrink A; 
Vauth C; Willich SN; Greiner W 
2009 Nichtmedikamentöse Sekundärprävention der koronaren Herzkrankheit (KHK) 
DAHTA254 Hagen A; Gorenoi V; Schönermark MP 2010 Spezifische Immuntherapie (SIT) zur Behandlung der allergischen Rhinitis 
DAHTA256 Tinnemann P; Stöber Y; Roll S; Vauth C; Willich SN; Greiner W 2010 
Zahnmedizinische Indikationen für standardisierte Verfahren der instrumentellen 
Funktionsanalyse unter Berücksichtigung gesundheitsökonomischer Gesichtspunkte 
DAHTA258 Grimm C; Köberlein J; Wiosna W; Kresimon J; Kiencke P; Rychlik R 2010 Diabetesneuentstehung unter antihypertensiver Therapie 
DAHTA262 Buchberger B; Follmann M; Freyer D; Huppertz H; Ehm A; Wasem J 2010 
Bedeutung von Wachstumsfaktoren für die Behandlung von chronischen Wunden am Beispiel 
des diabetischen Fußulcus  
DAHTA263 Korczak D; Schöffmann C 2010 Medizinische Wirksamkeit und Kosten-Effektivität von Präventions- und Kontrollmaßnahmen gegen Methicillin-resistente Staphylococcus aureus (MRSA)-Infektionen im Krankenhaus 
DAHTA267 Benkert D; Krause KH; Wasem J; Aidelsburger P 2010 
Medikamentöse Behandlung der ADHS (Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung) im 
Erwachsenenalter in Deutschland 
DAHTA268 Geiseler J; Karg O; Börger S; Becker K; Zimolong A 2010 Invasive Heimbeatmung insbesondere bei neuromuskulären Erkrankungen 
DAHTA278 Korczak D; Kister C; Huber B 2010 Differentialdiagnostik des Burnout-Syndroms 
DAHTA279 Korczak D; Huber B; Steinhauser G; Dietl M 2010 
Versorgungssituation und Wirksamkeit der ambulanten im Vergleich mit der stationären 
pneumologischen Rehabilitation 
DAHTA280 
Schnell-Inderst P; Hunger T; 
Hintringer K; Schwarzer R; Seifert-
Klauss V; Gothe H; Wasem J; 
Siebert U 
2011 Individuelle Gesundheitsleistungen 
DAHTA299 
Buchberger B; Heymann R; 
Huppertz H; Friepörtner K; Pomorin 
N; Wasem J 
2011 Effektivität von Maßnahmen der betrieblichen Gesundheitsförderung (BGF) zum Erhalt der Arbeitsfähigkeit von Pflegepersonal 
DAHTA300 Korczak D; Steinhauser G; Dietl M 2011 Effektivität von Maßnahmen im Rahmen primärer Prävention am Beispiel kardiovaskulärer Erkrankungen und des metabolischen Syndroms 
DAHTA301 Dietl M; Korczak D 2011 Versorgungssituation in der Schmerztherapie in Deutschland im internationalen Vergleich hinsichtlich Über-, Unter- oder Fehlversorgung 
DAHTA309 Korczak D; Steinhauser G; Dietl M 2011 Prävention des Alkoholmissbrauchs von Kindern, Jugendlichen und jungen Erwachsenen 
DAHTA255 Balzer K; Bremer M; Schramm S; Lühmann D; Raspe H 2012 Sturzprophylaxe bei älteren Menschen in ihrer persönlichen Wohnumgebung 
DAHTA281 Hagen A; Gorenoi V; Schönermark MP 2012 Knochenersatzmaterialien zur Behandlung von traumatischen Frakturen der Extremitäten 
DAHTA307 Aidelsburger P; Schauer S; Grabein K; Wasem J 2012 Alternative Methoden zur Behandlung postmenopausaler Beschwerden 
DAHTA329 Neusser S; Bitzer EM; Mieth I; Krauth C 2012 
Medizinische Wirksamkeit und Kosteneffektivität von Minocyclin/Rifampicin-beschichteten 
zentralvenösen Kathetern zur Prävention von Blutbahninfektionen bei Patienten in 
intensivmedizinischer Betreuung 
DAHTA331 Korczak D; Steinhauser G; Kuczera C 2012 
Effektivität der ambulanten und stationären geriatrischen Rehabilitation bei Patienten mit der 
Nebendiagnose Demenz 





Table S3: Technology reports with economic assessment based on DAM (n=17); included 
Document 
Number Authors Year Titel 
DAHTA024 Aidelsburger P; Hessel F; Wasem J 2003 Stellenwert von Ultraschallverfahren im Rahmen der Osteoporoseversorgung (Früherkennung des Frakturrisikos). Ökonomischer Kurz-HTA 
DAHTA067 
Siebert U; Muth C; Sroczynski G; 
Velasco-Garrido M; Gerhardus A; 
Gibis B 
2003 
Dünnschichtpräparationen und computergestützte Untersuchungen von Zervixabstrichen - 
Medizinische Effektivität, gesundheitsökonomische Evaluation und systematische 
Entscheidungsanalyse 
DAHTA069 Siebert U; Sroczynski G 2003 
Antivirale Therapie bei Patienten mit chronischer Hepatitis C in Deutschland - medizinische und 
ökonomische Evaluation der initialen Kombinationstherapie mit Interferon / Peginterferon und 
Ribavirin 
DAHTA071 
Corzillius M; Mühlberger N; 
Sroczynski G; Peeters J; Siebert U; 
Jäger H; Wasem J 
2003 Wertigkeit des Einsatzes der genotypischen und phänotypischen HIV-Resistenzbestimmung im Rahmen der Behandlung von HIV-infizierten Patienten 
DAHTA063 
Kunze S; Schnell-Inderst P; Hessel 
F; Grill E; Nickisch A; Siebert U; 
Voß von H; Wasem J 
2004 Hörscreening für Neugeborene - ein Health Technology Assessment der medizinischen Effektivität und der ökonomischen Effizienz 
DAHTA110 Frank W; Konta B; Peters-Engl C 2004 Pap-Test zum Screening auf Zervixkarzinom. Einfluss verschiedener Untersuchungsintervalle 
DAHTA126 Gorenoi V; Dintsios CM; Hagen A 2005 
Senkung der Restenoserate durch Einsatz beschichteteter Stents bei koronarer Herzkrankheit. 
Systematische Übersicht zur medizinischen Wirksamkeit und gesundheitsökonomische 
Bewertung zum Vergleich von beschichteten gegenüber unbeschichteten Stents 
DAHTA131 
Zahn J von; Schnell-Inderst P; 
Gothe H; Häussler B; Menke D; 
Brüggenjürgen B; Willich S; Wasem 
J 
2006 Episiotomie bei der vaginalen Geburt 
DAHTA137 
Schnell-Inderst P; Kunze S; Hessel 
F; Grill E; Siebert U; Nickisch A; 
Voss H von; Wasem J 
2006 Hörscreening für Neugeborene - Update 
DAHTA148 Gorenoi V; Dintsios CM; Schönermark MP; Hagen A 2006 
Laparoskopische vs. offene Appendektomie - Systematische Übersicht zur medizinischen 
Wirksamkeit und gesundheitsökonomische Analyse 
DAHTA193 
Siebert U; Bornschein B; Schnell-
Inderst P; Rieber J; Pijls N; Wasem 
J; Klauss V 
2008 Messung der fraktionierten Flussreserve zur Indikationsstellung der perkutanen Koronarintervention 
DAHTA218 Gorenoi V; Dintsios CM; Schönermark MP; Hagen A 2008 Intravaskuläre Brachytherapie bei peripherer arterieller Verschlusskrankheit (PAVK) 
DAHTA219 Gorenoi V; Dintsios CM; Schönermark MP; Hagen A 2008 
Medikamente freisetzende Stents im Vergleich zu Bypass-Operationen bei koronarer 
Herzkrankheit 
DAHTA229 
Schmieder K; Engelhardt M; 
Wawrzyniak S; Börger S; Becker K; 
Zimolong A 
2010 
Stellenwert der Radiochirurgie von Meningeomen im Vergleich mit der fraktionierten 
stereotaktischen Bestrahlung, der konventionellen 3D-geplanten konformalen Bestrahlung und 
der mikrochirurgischen Operation 
DAHTA265 
Sroczynski G; Schnell-Inderst P; 
Mühlberger N; Lang K; Aidelsburger 
P; Wasem J; Mittendorf T; Engel J; 
Hillemanns P; Petry KU; Krämer A; 
Siebert U 
2010 
Entscheidungsanalytische Modellierung zur Evaluation der Langzeit-Effektivität und Kosten-
Effektivität des Einsatzes der HPV-DNA-Diagnostik im Rahmen der 
Zervixkarzinomfrüherkennung in Deutschland 
DAHTA297 Gorenoi V; Schönermark MP; Hagen A 2011 
Perkutane Koronarinterventionen zusätzlich zur optimalen medikamentösen Therapie bei 
stabiler Angina Pectoris 
DAHTA308 Gorenoi V; Schönermark MP; Hagen A 2012 













Table S4: Technology reports without economic assessment (n=31); excluded 
Document 
Number Authors Year Titel 
DAHTA002 Lühmann D; Kohlmann T; Raspe H 1998 Die Evaluation von Rückenschulprogrammen als medizinische Technologie 
DAHTA003 Gibis B; Busse R; Reese E; Richter K; Schwartz FW; Köbberling J 1998 Das Mammographie-Screening zur Brustkrebsfrüherkennung 
DAHTA005 Pientka L 1998 PSA-Screening beim Prostatakarzinom 
DAHTA006 Gibis B; Busse R; Schwartz FW 1999 Verfahrensbewertung der Magnet-Resonanz-Tomographie (MRT) in der Diagnostik des Mamma-Karzinoms 
DAHTA007 Pientka L 1999 Minimal-invasive Therapie der benignen Prostatahyperplasie (BPH-Syndrom) 
DAHTA008 Röseler S; Duda L; Schwartz FW 1999 Evaluation präoperativer Routinediagnostik (Röntgenthorax, EKG, Labor) vor elektiven Eingriffen bei Erwachsenen 
DAHTA011 Perleth M; Jakubowski E; Busse R 1999 Bewertung von Verfahren zur Diagnostik der akuten Sinusitis maxillaris bei Erwachsenen 
DAHTA012 Gernreich C 1999 Spezifische Hyposensibilisierung mit Allergenextrakten bei extrinsischem Asthma bronchiale und Insektengiftallergie 
DAHTA013 Lühmann D; Kohlmann T; Lange S; Raspe H 2000 
Die Rolle der Osteodensitometrie im Rahmen der Primär-, Sekundär- und 
Tertiärprävention/Therapie der Osteoporose 
DAHTA014 Röseler S; Schwartz FW 2000 Evaluation arthroskopischer Operationen bei akuten und degenerativen Meniskusläsionen 
DAHTA015 Fritze J 2000 Die Evaluation von Stroke Units als medizinische Technologie 
DAHTA017 Perleth M 2000 Vergleichende Effektivität und Differentialindikation von Ballondilatation (PTCA) versus Bypasschirurgie bei Ein- und Mehrgefäßerkrankungen der Herzkranzgefäße 
DAHTA018 Lühmann D; Hauschild B; Raspe H 2000 Hüftgelenkendoprothetik bei Osteoarthrose 
DAHTA004 Droste S; Brand A 2001 Biochemisches Screening für fetale Chromosomenanomalien und Neuralrohrdefekte - eine Verfahrensbewertung 
DAHTA022 Lühmann D 2001 Stellenwert der Magnet-Resonanz-Tomographie im Rahmen der Versorgung von Patienten mit Rückenschmerzen - Kurz-HTA: Update einer Best-Evidence-Synthese 
DAHTA061 Corzillius M; Pientka L; Siebert U; Wasem J 2002 
Wertigkeit von Tumor-Nekrose-Faktor alpha-Antagonisten in der Behandlung der rheumatoiden 
Arthritis (Medizinischer Teil) 
DAHTA068 Gorenoi V; Dintsios CM; Perleth M 2002 Stenting versus Ballondilatation bei koronarer Herzkrankheit - systematische Übersicht zur medizinischen Effektivität 
DAHTA010 Lühmann D; Raspe H 2003 Operative Eingriffe an der lumbalen Wirbelsäule bei bandscheibenbedingten Rücken- und Beinschmerzen - eine Verfahrensbewertung 
DAHTA026 Dettenkofer M; Merkel H; Mutter J 2003 Bewertung unterschiedlicher Hygienekonzepte zur Kontrolle von MRSA (Methicillin-resistente Staphylococcus aureus) 
DAHTA029 Schroeder A; Reese E; Richter K; Köbberling J 2003 
Die Wertigkeit der Streßechokardiographie in der Primärdiagnostik der koronaren 
Herzkrankheit 
DAHTA030 Wild C; Frank W; Konta B; Huber K 2003 Medizinische Effektivität beim Einsatz von GP- IIb / IIIa-Rezeptorantagonisten in der Therapie von akuten Koronarsyndromen 
DAHTA060 Perleth M; Gerhardus A; Velasco M 2003 Positronen-Emissions-Tomographie - systematische Übersichten zur Wirksamkeit bei ausgewählten Indikationen 
DAHTA065 
Peeters J; Siebert U; Aidelsburger 
P; Regar E; Rieber J; Wasem J; 
Klauss V 
2003 
Wertigkeit des Einsatzes der intravaskulären Ultraschallbildgebung (IVUS) im Rahmen von 
diagnostischen und therapeutischen Herzkatheteruntersuchungen - ein HTA-Bericht zur 
medizinischen Effektivität 
DAHTA073 Mand P 2003 Verfahrensbewertung der CT-Angiographie, MR-Angiographie, Doppler-Sonographie und Szintigraphie bei der Diagnose von Nierenarterienstenosen 
DAHTA078 Gernreich NC; Gerhardus A; Velasco-Garrido M 2003 
Knochen- und Knochenersatzmaterialien zur parodontalen Regeneration und zum 
Knochenaufbau für Implantate - eine systematische Bewertung der medizinischen Wirksamkeit 
DAHTA072 Rosery H; Maxion-Bergemann S; Rosery B; Bergemann R 2004 
Ultraschall in der Schwangerschaft. Beurteilung der routinemäßigen 
Schwangerschaftsultraschalluntersuchungen unter Maßgabe der Mutterschaftsrichtlinien 
DAHTA074 Schroeder A; Heiderhoff M; Köbberling J 2004 
Stroke Units - Update des HTA Berichts "Die Evaluation von Stroke Units als medizinische 
Technologie" 
DAHTA113 Schroeder A; Heiderhoff M; Köbberling J 2005 
Bestimmung der Albuminausscheidung im Urin bei Diabetikern zur Vorsorge und Kontrolle der 
diabetischen Nephropathie 
DAHTA117 Lange-Lindberg AM; Velasco-Garrido M; Busse R 2006 
Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie 
maligner Erkrankungen 
DAHTA233 Rasch A; Müller-Riemenschneider F; Vauth C; Willich SN; Greiner W 2008 
 Föderale Strukturen und damit verbundene verhaltensbezogene Maßnahmen zur Prävention 
des Zigarettenrauchens 






Table 5: Methodological reports (n=20); excluded 
Document 
Number Authors Year Titel 
DAHTA1 
Bitzer E; Busse R; Dörning H; Duda 
L; Köbberling J; Kohlmann T; 
Lühmann D; Pasche S; Perleth M; 
Raspe H; Reese E; Richter K; 
Röseler S; Schwartz FW 
1998 Bestandsaufnahme, Bewertung und Vorbereitung der Implementation einer Datensammlung "Evaluation medizinischer Verfahren und Technologien" in der Bundesrepublik 
DAHTA9 
Behrend C; Greiner W; Hessel F; 
Hoffmann C; Leidl R; Mühlberger N; 
Schulenburg JM Graf von der; 
Siebert U; Wasem J; Welte R 
1999 Ansätze und Methoden der ökonomischen Evaluation - eine internationale Perspektive 
DAHTA25 Raum E; Perleth M 2003 Methoden der Metaanalyse von diagnostischen Genauigkeitsstudien 
DAHTA27 Aidelsburger P; Felder S; Siebert U; Wasem J 2003 
Gesundheitsökonomische "Kurz-HTA-Berichte" - eine systematische Übersichtsarbeit zur 
Methodik und Implementation 
DAHTA34 Ekkernkamp M; Lühmann D; Raspe H 2003 
Methodenmanual für "HTA-Schnellverfahren" und Exemplarisches "Kurz-HTA": Die Rolle der 
quantitativen Ultraschallverfahren zur Ermittlung des Risikos für osteoporotische Frakturen 
DAHTA62 Droste S; Gerhardus A; Kollek R 2003 Methoden zur Erfassung ethischer Aspekte und gesellschaftlicher Wertvorstellungen in Kurz-HTA-Berichten - eine internationale Bestandsaufnahme 
DAHTA122 Zentner A; Velasco-Garrido M; Busse R 2005 Methoden zur vergleichenden Bewertung pharmazeutischer Produkte 
DAHTA99 Siebert U 2005 Entscheidungsanalytische Modelle zur Sicherung der Übertragbarkeit internationaler Evidenz von HTA auf den Kontext des deutschen Gesundheitssystems 
DAHTA31 Gerhardus A; Dintsios CM 2006 Der Einfluss von HTA-Berichten auf die gesundheitspolitische Entscheidungsfindung - eine systematische Übersichtsarbeit 
DAHTA210 Neumann U; Hagen A; Schönermark MP 2007 
Regulation der Aufnahme von innovativen nichtmedikamentösen Technologien in den 
Leistungskatalog solidarisch finanzierter Kostenträger 
DAHTA194 Siebert U; Zietemann V; Sroczynski G 2008 
Pharmacogenomics-Bias - Systematische Verzerrungen in Studienergebnissen durch 
genetische Heterogenität 
DAHTA214 Kossmann B; Ulle T; Kahl KG; Wasem J; Aidelsburger P 2008 
Nichtmedikamentöse verhaltensbezogene Adipositastherapie unter Berücksichtigung der 
zugelassenen Arzneimittelbehandlung 
DAHTA243 Schöttker B; Lühmann D; Boulkhemair D; Raspe H 2009 Indirekte Vergleiche von Therapieverfahren 
DAHTA250 Mangiapane S; Velasco Garrido M 2009 Surrogatendpunkte als Parameter der Nutzenbewertung 
DAHTA251 Gorenoi V; Schönermark MP; Hagen A 2009 Instrumente zur Risikoprädiktion für kardiovaskuläre Erkrankungen 
DAHTA259 Gorenoi V; Schönermark MP; Hagen A 2009 Gelenkendoprothesenregister für Deutschland 
DAHTA272 
Bartelmes M; Neumann U; 
Lühmann D; Schönermark MP; 
Hagen A 
2009 Methoden zur frühen entwicklungsbegleitenden Bewertung innovativer medizinischer Technologien 
DAHTA260 Dreier M; Borutta B; Stahmeyer J; Krauth C; Walter U 2010 
Vergleich von Bewertungsinstrumenten für die Studienqualität von Primär- und 
Sekundärstudien zur Verwendung für HTA-Berichte im deutschsprachigen Raum 
DAHTA264 Gorenoi V; Schönermark MP; Hagen A 2010 Infektionsschutz in der Knieendoprothetik 
DAHTA220 Brettschneider C; Lühmann D; Raspe H 2011 
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Abstract
Background Previous systematic reviews concluded that pneumococcal vaccination in the elderly was cost effective. How-
ever, recently published economic evaluations state that it may not be cost effective when children are vaccinated with 
higher-valent pneumococcal conjugate vaccines. The literature suggests that the outcomes of vaccination in the elderly are 
strongly influenced by the vaccine effectiveness (VE) against the vaccine-type pneumococcal diseases (PD) and the impact 
of childhood vaccination on the vaccine-type PD incidence in the elderly, but the extent remains unclear.
Methods We conducted a systematic literature search of cost-effectiveness studies on vaccination in the elderly in the 
PubMed database starting from 2006. We included studies that consider the presence of a childhood vaccination with 
pneumococcal conjugate vaccine (PCV) 10 and PCV13. We focus on methods and assumptions used in modeling VE and 
epidemiology of PD over time.
Results Twenty-eight economic evaluations underwent full-text review and data extraction. Thirteen were selected for qual-
ity assessment. The studies with a higher quality score provide evidence that vaccinating the elderly with PCV13 is not cost 
effective, when an ongoing rapid decline in the incidence of PCV13-type PD is modeled. A moderate persistence of PCV13 
serotypes, in particular due to PCV10 childhood vaccination, makes vaccination of the elderly with PCV13 more attractive. 
There is no agreement that combining PCV13 with polysaccharide vaccine PPSV23 is cost effective. PPSV23 is attractive 
when it is effective against non-invasive PD.
Conclusion Methodological approaches and assumptions in modeling VE and the indirect effects of childhood vaccina-
tion have a major impact on outcomes of decision-analytic models and cost-effectiveness estimates. Considering recently 
observed trends in the epidemiology of pneumococcal serotypes, there is currently inconclusive evidence regarding the cost 
effectiveness of pneumococcal vaccination of the elderly due to lack of studies that model key serotypes such as serotype 3 
separately from other groups of serotypes.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-019-00805 -5) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Vaccination of susceptible groups is the most effective meas-
ure to fight diseases caused by Streptococcus pneumoniae (S. 
pneumoniae) on a population level. Pneumococcal conjugate 
vaccination of infants and young children has been estab-
lished in many developed countries and indisputably has 
proven to be an effective preventive measure [1]. Following 
the 7-valent pneumococcal conjugate vaccine (PCV7), the 
introduction of higher valent conjugate vaccines (PCV10 
and PCV13) has further reduced the burden of the pneumo-
coccal diseases (PD) [1, 2]. The vaccination of the elderly 
in the presence of routine childhood vaccination with the 
higher valent pneumococcal conjugate vaccines (PCVs) 
still poses questions on general cost effectiveness, optimal 
age of vaccine administration, and which vaccine should be 
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Key Points for Decision Makers 
Understanding of the methods and assumptions to model 
the vaccine effects and predict epidemiology of pneumo-
coccal diseases can help to rationally interpret obtained 
conclusions about the cost effectiveness of pneumococ-
cal vaccination in the elderly.
It is important to look at the modeling of the key fac-
tors that majorly drive the outcomes of the vaccination; 
these include the applied vaccine effectiveness, the 
assumptions about the waning of vaccine protection, the 
prior-vaccination incidence of invasive and non-invasive 
pneumococcal diseases in the targeted population, and 
the indirect impact of the childhood pneumococcal 
vaccination with higher valent pneumococcal conjugate 
vaccines on the epidemiology of the diseases.
Due to the country-specific differences in the major eco-
nomic factors (e.g., vaccination strategy, vaccine price, 
cost per disease case and discount rates) and epidemio-
logical patterns, any comparisons between the outcomes 
of the different economic evaluations should be made 
with caution.
Trial in Adults) [7]. CAPiTA has become a milestone in the 
current debates and triggered reassessments of cost effec-
tiveness of PCV13 versus PPSV23 in view of its findings. 
Recently, Porchia et al. [6] conducted a review of 31 eco-
nomic evaluations including the studies that informed the 
parameters based on the CAPiTA findings [7]. The authors 
concluded that both PPSV23 and PCV13 programs in the 
elderly were cost-effective and should be seen as a priority 
by decision makers [6]. Although the authors conducted a 
substantial review of the economic parameters, they did not 
address the uncertainty around vaccine effectiveness (VE) 
and epidemiological changes in pneumococcal diseases 
originated from the childhood vaccination with PCV13 and/
or PCV10. By doing so, in our opinion, the authors limited 
their summarization of the current evidence for decision 
makers. In addition, since their publication a number of eco-
nomic evaluations have been published that concluded that 
under the influence of the herd effect induced by childhood 
vaccination with a higher valent conjugate vaccine, vaccina-
tion of the elderly was unlikely to be cost effective [8–10].
In contrast to Porchia et al. [6], we investigated the cost 
effectiveness of vaccination strategies for the elderly in 
the presence of childhood pneumococcal vaccination with 
PCV10 and PCV13. We focus on the methods, assumptions, 
and data used to model the vaccine effects in order to ensure 
that input VE was consistent with the current knowledge 
and that potential epidemiological effects stemming from the 
childhood vaccination were not neglected or oversimplified.
2  Methods
2.1  Constituents of Vaccination Effects
The direct outcomes of a pneumococcal vaccination cam-
paign in the elderly are determined by VE in preventing 
PD caused by the serotypes contained in the pneumococcal 
vaccine (and cross-protective serotypes [11]) as well as the 
disease incidence in the targeted population.
2.1.1  Vaccine Effectiveness Among the Elderly
The pneumococcal vaccine protection is expected to decline 
over time. PPSV23 protection has been shown to wane dur-
ing and also after the first 5 years [12–15]. PCV13 is thought 
to provide longer protection than PPSV23 because it triggers 
a stronger immune response [16]. The CAPiTA results [7] 
show that PCV13 protection is stable over 4–5 years but its 
waning is still uncertain [11, 17]. Therefore, overall VE over 
the period of its protection can be composed of the initial VE 
at the time of administration and a waning pattern (see elec-
tronic supplementary material [ESM] file S1). We used the 
initial VE at administration and the waning of the vaccine 
used. Conclusions of previously published systematic litera-
ture reviews [3–6] suggest that the polysaccharide vaccine 
PPSV23 and the conjugate vaccine PCV13 can be consid-
ered cost effective for vaccinating the elderly against pneu-
mococcal diseases. Ogilvie et al. [3] reviewed 11 economic 
evaluations of vaccination of the elderly with PPSV23 and 
concluded that the vaccination could be cost effective com-
pared with no program for individuals older than 65 years. 
These findings were supported by Nishikawa et al. [5] in a 
recently published review. Dirmesropian et al. [4] reviewed 
ten economic evaluations of usage of PCV13 in adults and 
the elderly and concluded that the conjugate vaccine was 
also cost effective [4]. However, the authors stated that the 
drawn estimates of the cost effectiveness should be inter-
preted with caution in respect to key factors that influenced 
the cost effectiveness, which were uncertain at that time. 
These included the effectiveness of PCV13 against invasive 
pneumococcal diseases (IPD) and non-bacteremic pneumo-
coccal pneumonia (NBPP) in the elderly, the effectiveness 
of PPSV23 and the indirect effects of higher-valent PCV 
childhood immunization programs on the epidemiology of 
PD in the elderly [4].
Since the publication of the review by Dirmesropian et al. 
[4], new clinical evidence on PCV13 effectiveness against 
IPD and NBPP in the elderly has been generated in the CAP-
iTA trial (Community-Acquired Pneumonia Immunization 
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protection reported in the studies to plot the decline of VE 
over time and to calculate the area under the resulting curve. 
This area under the curve represents the expected vaccine 
protection over time (EVPOT); that is, integration of the 
years of protection adjusted for VE at a given point in time 
(see ESM file S1: section 1.1). We applied a cut-off point of 
20 years since vaccination when a longer period of waning 
was assumed. The expected vaccine protection over time is 
measured in efficacy-adjusted protection years (EAPY) and 
enables a comparative analysis of the assumptions about VE 
and duration of protection across the studies.
2.1.2  Incidence of Disease Due to S. pneumoniae Among 
the Elderly
Currently, over 90 different strains (serotypes) of S. pneu-
moniae have been identified, with certain strains having a 
higher potential to cause the disease and a higher preva-
lence in the susceptible groups [18]. The currently avail-
able pneumococcal vaccines contain a limited number of the 
serotypes; that is, PCV13 covers 13 antigens and PPSV23 
includes the PCV13 serotypes, except for serotype 6A, and 
11 additional antigens. Therefore, in the case of S. pneumo-
niae, VE could be interpreted as the proportionate reduc-
tion in occurrence of the disease caused only by the strains 
contained in this vaccine and included as such in the cost-
effectiveness analyses.
In addition, in the countries where children are rou-
tinely vaccinated with PCV, childhood vaccination has 
indirect effects on pneumococcal infection caused by the 
vaccine strains among the elderly. The observed indirect 
effects include the herd effect (i.e., the indirect reduction 
in vaccine-type disease incidence as an effect of the child-
hood vaccination) and replacement disease (i.e., an indirect 
increase in non-vaccine-type PD incidence) [1]. The type of 
PCV vaccine (PCV7, PCV10, or PCV13) implemented in 
the infant vaccination programs plays a crucial role in the 
evolution of vaccine-type PD incidence among the elderly. 
Furthermore, the sequence of PCV infant vaccination pro-
grams (for instance PCV7 replaced by PCV13 or PCV7 fol-
lowed by PCV13 and then PCV10) can also have an impact 
on the cost effectiveness of pneumococcal vaccination of 
the elderly.
Therefore, the vaccine-type PD incidence in the target 
population over time is determined by vaccine-serotype dis-
ease incidence before the implementation of the PCV child-
hood vaccination and the indirect effects on the epidemiol-
ogy of S. pneumonia in this population. The key factors that 
determine the performance of the elderly pneumococcal vac-
cination, are illustrated in Fig. 1 and are described in greater 
detail in the ESM (file S1: section 1). Due to the complex 
dynamics seen in the strains of S. pneumonia, an accurate 
projection of vaccine-type PD incidences is challenging and 
subject to major assumptions. Therefore, we reviewed the 
assumptions and methodological choices applied in the mod-
eling of vaccine-type IPD and NBPP incidences.
2.2  Review Strategy
We conducted an extensive search in the PubMed database 
to find studies for full-text review. The identified studies 
were subject to the full-text review with data extraction and 
selection for the following assessment of quality of eco-
nomic evaluation. The search syntax, inclusion criteria for 
the full-text review and data extraction are described in the 
ESM (file S1: section 2). In accordance with the goal of this 
review, we defined inclusion criteria for the assessment of 
quality of the selected studies as follows:
1. VE parameters are obtained (i) for PCV13—from or 
based on the CAPiTA trial [7]; (ii) for PPSV23—from 
a meta-analysis, a randomized clinical trial (RCT) or 
an observational study. These criteria are in accordance 
with the guidelines of the World Health Organization 
(WHO) for economic evaluations of vaccination pro-
grams [19].
2. Childhood pneumococcal conjugate vaccination with the 
higher-valent vaccines is included in baseline scenarios. 
Post-PCV data are used to project the burden of pneu-
mococcal diseases in the targeted population.
Quality of economic evaluations of the studies that met 
both selection criteria was assessed using the “Evidence and 
Value: Impact on DEcisionMaking” (EVIDEM) instrument: 
“assessment of quality of economic evaluations” [20]. In 
compliance with the EVIDEM instrument, we developed a 
form consisting of two parts: (i) completeness and consist-
ency of reporting of economic evaluation, and (ii) relevance 
and validity of economic evaluation. The instrument allowed 
a sequential and structured assessment of economic evalu-
ations across 11 dimensions and provided a way of trans-
parent reporting ensuring full traceability of the reviewers’ 
work. We placed a particular focus on completeness, consist-
ency and relevance of the assumptions and methods applied 
in modeling VE and the indirect effects of the childhood 
PCV vaccination. Two evaluators (MT, SMS) selected the 
studies and independently completed the developed form 
and assigned a score (between one for low and four for 
high relevance/validity) for each study with a summarizing 
rationale for the given score. The decisions were compared, 
and any disagreement was resolved under arbitration by the 
third reviewer (AK). The studies excluded from the assess-
ment of quality are summarized in the ESM, including the 
reason for their exclusion.
The assessed economic evaluations were further sum-
marized in a comparative analysis of the assumptions and 
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the methods applied to model the VE among the elderly, 
the incidence of invasive and non-invasive diseases due to 
S. pneumoniae, and the indirect effects of the vaccination 
programs with higher valent conjugate vaccines in children 
on the PD incidence in the elderly population. Thereafter, 
the cost effectiveness of the elderly vaccination programs 
was described using the findings of the studies that were 
evaluated with an EVIDEM score of three or higher for rel-
evance and validity of economic evaluation. To facilitate the 
comparison of incremental cost-effectiveness ratio (ICER) 
estimates between the studies, the reported ratios were firstly 
time-adjusted to the year 2017 by applying the country-spe-
cific consumer price indices from the organisation for eco-
nomic co-operation and development (OECD) [21]. After-
wards, the 2017 country-specific values were standardized 
to 2017 US dollars using the purchasing power parity (PPP) 
index [22] and exchange rates for 2017 from the OECD [23].
3  Results
3.1  Literature Search and Selection
The search was conducted on 18 October 2017 and updated 
twice on 2 March 2018 and 28 May 2018 to identify recently 
published studies. Overall, it resulted in 28 studies selected 
for the full-text review (see Fig. 2). Of these, 13 economic 
evaluations were selected for the assessment of quality 
[8–10, 24–33], and the remaining 15 studies [34–46] were 
excluded from further analysis and are summarized in the 
ESM (file S2).
The extracted data from the selected studies are summa-
rized in three tables. Table 1 gives the extracted data on 
base-case VE parameters and calculated EVPOT; Table 2 
gives an overview of the applied methods and the quality 
assessment scores of the economic evaluations; and Table 3 
describes the main characteristics of the health economic 
evaluations, the reported ICERs, and the conclusions given 
in the evaluations. The sources for VE cited in the reviewed 
studies as well as the extracted incidence rates with their 
sources are summarized in the ESM (files S3 and S4, respec-
tively). The results of the quality assessment of economic 
evaluation with EVIDEM are given in the ESM (file S5).  
3.2  Assumptions and Methods Used to Model 
the Vaccine Effects Over Time
3.2.1  Initial Vaccine Effectiveness
Although we included only the evaluations that had obtained 
the initial PCV13 VE from the CAPiTA trial [7], the 
reported values varied between the studies (see Table 1). 
For instance, in the age group 65–74 years, the average ini-
tial PCV13 VE against IPD ranged from 75 to 84.5%. The 
main reasons for this variation are methodological differ-
ences in the application of vaccine-age-interaction effects 
and in the estimates of effect of age on the initial VE. Eight 
[8–10, 25, 27, 30, 31, 33] of 12 studies (which evaluated 
PCV13) applied age-interaction effects of the initial VE. Of 
them, five studies [8–10, 25, 30] derived estimates of the 
vaccine-age-interaction effect from a post-hoc analysis of 
the CAPiTA data [50, 51] (see Table 2). Another study [33] 
assumed that the age-vaccine-interaction effect for PCV13 is 
50% lower than the effect for PPSV23. Two studies [27, 31] 
applied age-group-specific variations of the initial PCV13 
VE. Heo et al. [31] adjusted VE assumptions by Smith et al. 
[40]. Rodriguez Gonzalez-Moro et al. [27] did not describe 
the methods for the calculation of age-group-specific VE 
parameters.
Fig. 1  Constituents of the vaccination effects over time: a graphical 
representation. The outcomes of the elderly pneumococcal vaccina-
tion depend on the initial vaccine effectiveness against vaccine-type 
PD and its protection over time (illustrated in b) and the PD incidence 
caused by vaccine-type serotypes over time, which is also influenced 
by the indirect effects of a childhood vaccination with PCV (illus-
trated in a). Asterisk: vaccination rate 100% and vaccine effectiveness 
according to b. PD pneumococcal diseases
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We found a great variation in the applied values of the ini-
tial PPSV23 VE with two major sources of the variation of 
the VE values: the application of the vaccine-age-interaction 
effects and sources of the initial VE (see Tables 1, 2). In the 
age group 65–74 years, the average PPSV23 VE against IPD 
ranged from 55 to 82% (see Table 1). In eight studies [8, 9, 
26–28, 30, 31, 33], PPSV23 VE against NBPP was assumed 
to be 0% based on the findings of several reviews and 
observational studies [53, 54, 59, 60] (see Table 2 for VE 
sources). Three studies applied VE of 39% [24], 30.8% [10], 
and 19.6% [32] based on other empirical studies [48, 57]. 
Four studies [27, 30, 31, 33] applied vaccine-age-interac-
tion effects for PPSV23. Only Kuchenbecker et al. [33] and 
Dirmesropian et al. [30] reported single-age-specific initial 
VE for PPSV23. Dirmesropian et al. [30] applied a logistic 
function that was calibrated for ≥ 75 year-olds based on data 
from the study by Andrews et al. [15]. Kuchenbecker et al. 
[33] calculated the initial PPSV23 VE using a linear interpo-
lation of VE estimates for 50-, 65- and 80-year-olds reported 
by Smith et al. [61]. In order to facilitate comparison of the 
initial VE assumptions between the studies, we defined four 
age groups and reported the extracted VE values in Table 1 
according to these groups. For the studies that apply func-
tions to calculate VE, Table 1 gives the unweighted average.
3.2.2  Vaccine Protection Over Time
Figure 3 gives an overview of the protection waning patterns 
among the reviewed evaluations. Applied waning patterns 
varied in their structure and, hence, showed different shapes 
of the curves. It resulted in differences of the calculated 
expected vaccine protection over time. The most common 
waning pattern included a period of stable VE followed by 
a step-wise linear decline of VE to 0% [8, 9, 25, 29, 30, 32, 
33]. Three studies [27, 28, 31] applied age-group-specific 
waning patterns and one study [33] used single-age-specific 
patterns. We calculated EVPOT for the generic age groups 
to enable comparison between the studies. Figure 4 shows 
the resulting values. In this section we focus on the resulting 
EVPOT for immunocompetent people aged 65–74 years. For 
Fig. 2  Literature search, study 
inclusion, and selection for the 
assessment of quality of eco-
nomic evaluation. PPV pneumo-
coccal polysaccharide vaccine, 
VE vaccine effectiveness
Records identified through PubMED database search:  n=494 
Records excluded: n= 23 
• systematic review: n=4 
• no economic evaluation: n=1 
• budget impact analyses: n=4 
• PPV vaccine is not explicitly stated: n=4 
• vaccination with other vaccines: n=2 
• targeted population is not relevant: n=4 
• evaluation of no vaccination strategy: n=1 
• other language of the main text: n=2
• no full text published: n=1     
Records excluded from assessment of quality of economic 
evaluation: n=15
• No childhood vaccination program: n=2 
• PCV13 VE is not based on CAPITA: n=4 
• Indirect effects of childhood vaccination are not 
applied: n=5 
• Both VE and indirect effects do not meet the selection 
criteria: n=4                                          
Records screened:  n=51
Records selected for the full text review and data extraction: n=28 
Records selected for assessment of quality of economic evaluation and 
reporting results: n=13 
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PPSV23, the calculated EVPOT against IPD ranges from 1.5 
to 5.6 EAPY depending on both initial VE parameter and 
the waning of protection. The commonly applied period of 
constant protection was 1–5 years. In five studies [8, 9, 26, 
30, 32], VE declined to 0% within 5–6 years of vaccination, 
while in the other four studies [27, 28, 31, 33] there was a 
(small) protective effect at least until the ninth year after 
vaccination. EVPOT for PCV13 is commonly larger than for 
PPSV23 and ranges from 3.8 to 12.6 EAPY due to a longer 
duration of stable protection and the slower decline of the 
VE afterwards. Nine [8, 9, 25–27, 30, 32, 33] of the 12 stud-
ies that model PCV13 protection apply a 4- to 5-year period 
of stable vaccine protection. Other assumptions include 
9 years of stable protection [29] and a shorter period with 
waning starting in the second year after the initial vaccine 
administration [28, 31]. Blommaert et al. [26] is the only 
study that applied in the base-case scenario an equal dura-
tion of protection for PCV13 and PPSV23. Furthermore, the 
study was unique in assuming an instant drop to 0% VE after 
a stable period of protection for 5 years.
In the Australian studies, Dirmesropian et al. [30] and 
Chen et al. [8, 9] applied 5 years of waning after the stable 
protection. In the studies by Rodriguez Gonzalez-Moro 
et al. [27], Heo et al. [31], Thorrington et al. [32], and 
Willem et al. [10], the waning to 0% was modeled over 
10 years with different waning rates. Mangen et al. [25] 
and Kuchenbecker et al. [33] applied a 15-year period of 
waning to 0%. Van Hoek and Miller [29] and Stoecker 
et al. [28] assumed remaining PCV13 VE even after year 
20, with Stoecker et al. [28] assuming very low waning 
rates compared with all other studies. Due to the assump-
tions of a longer period of waning, the resulting EVPOT 
for the studies by Mangen et  al. [25], Kuchenbecker 
et al.[33], van Hoek and Miller [29], and Stoecker et al. 
[28] lies above 8.5 EAPY. In contrast, the assumption of 
no waning period by Blommaert et al. [26] resulted in 
EVPOT of 3.7 EAPY.
In contrast to the common linear decline of protection 
over time, Willem et al. [10] applied parametric functions of 
waning after the period of constant protection; these include 
logistic waning of PCV13 protection and an exponential 
decay for PPSV23. The calculation of EVPOT with the 
reported parameterization of these functions led to values 
similar to other studies: PCV13 against IPD of 7.2 EAPY 
and PPSV23 against IPD of 2.3 EAPY. The duration of vac-
cine protection against non-invasive PD was modeled analo-
gously with the lower initial VE. The EVPOT values range 
from 2.1 to 7.6 EAPY.
3.2.3  Modeling Incidence Over Time (Indirect Herd 
and Replacement Effects)
To model the PD incidence over time, pneumococcal sero-
types were typically summarized into groups according to 
the considered pneumococcal vaccines. Only the study by 
Thorrington et al. [32] included individual serotypes that 
are covered in PCV13 and not in PCV10 into the projection, 
with an assumption about the stable incidence for serotypes 
3 and 6A and an indirect reduction in the incidence due to 
serotype 19A caused by the replacement of PCV10 with 
PCV13 in the childhood vaccination.
3.2.3.1 Indirect Effects of Childhood Vaccination with PCV13 
on IPD Incidence Among the Elderly Out of the 13 included 
studies, 11 [8–10, 25–31, 33] evaluated pneumococcal vac-
cination of the elderly in the presence of a PCV13 program 
in children, which had replaced the PCV7 program.
We found different methods to project the epidemiologi-
cal development of the serotype groups in the presence of 
routine childhood vaccination with PCV13. The Australian 
studies by Dirmesropian et al. [30] and Chen et al. [8, 9] 
started with an epidemiological steady state based on the 
national surveillance data and kept the future serotype-spe-
cific PD burden constant. Chen et al. [8] also looked into 
the potential changes in the PCV13-serotype epidemiology.
Other method to project indirect effects of PCV13 infant 
vaccination was to simulate an ongoing gradual decline of 
infections due to six additional (contained in PCV13 but not 
in PCV7) serotypes until elimination or near-elimination is 
reached, and include an increase of infections due to the non-
PCV13 strains. In the Belgian studies, Blommaert et al. [26] 
and Willem et al. [10] applied an annual indirect reduction 
in PD incidence preventable by vaccination with PCV13 and 
did not report post-vaccination stabilization of the serotype 
distribution. Blommaert et al. [26] modeled the herd effect 
of the childhood PCV13 vaccination as an exponential decay 
with a 24% annual decrease in circulation of the PCV13-
type serotypes and the vaccine-induced replacement effect 
was applied as a compensation of the reduction in incidence 
originating from the herd effect by 50% in the base case. 
The values were based on the observed PCV7-serotype cir-
culation in Belgian children. Willem et al. [10] applied the 
indirect reduction of PD incidence in adults as an annual 
16% decline of PCV13 serotypes in PCV13-serotype IPD 
incidence. Of this decline, 76.3% was compensated with 
occurrence of non-PCV13 serotypes in IPD incidence as 
the vaccine-induced serotype replacement. Stoecker et al. 
[28] and van Hoek and Miller [29] projected a decline of 
the six PCV13-minus-PCV7 serotypes, similar to the indi-
rect reduction of PCV7 serotypes in IPD incidence in the 
elderly observed in the national epidemiological data, with a 
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The study by Mangen et al. [25] was the only analysis 
that evaluated pneumococcal vaccination of the elderly in 
a scenario with PCV10 infant vaccination present, which 
had replaced PCV7 vaccination program. The study applied 
equilibrium of PCV13 serotypes assuming no indirect effects 
of PCV10 vaccination. In addition, no projections of sero-
types 3, 6A, and 19A were made.
In an additional scenario, Willem et al. [10] analyzed the 
impact of replacing PCV13 with PCV10 infant vaccination 
on the cost effectiveness of pneumococcal vaccination in 
the elderly. For this scenario, a relapse of PCV13 serotype 
incidence within 7 or 15 years was assumed and modeled by 
applying a logistic curve.
3.2.3.3 Indirect Effects of  PCV Childhood Vaccination 
on Non‑bacteremic Pneumococcal Pneumonia (NBPP) Inci‑
dence Among the Elderly Nine studies [8–10, 25, 26, 28–
30, 32] assumed the same serotype-specific dynamics in 
NBPP incidence as for IPD. Jiang et al. [24] did not describe 
the effects of infant vaccination on NBPP in the elderly. We 
also identified three studies [27, 31, 33] that used all-cause 
and all-serotype approaches (described in ESM file S1: sec-
tion  1.2.2) to project indirect effects on NBPP incidence 
among the elderly. The all-cause approach assumes a perfect 
correlation between percentage changes in all-cause non-
bacteremic pneumonia (NBP) and serotype-specific NBPP 
(i.e., a 2% reduction in all-cause NBP results in a 2% reduc-
tion of PCV13-NBPP). Both approaches are not valid and 
misrepresent possible real evolution of the serotype-specific 
PD incidences as described in the ESM in detail (file S1: 
section 1.2.2).
3.2.4  Selection of Studies for Reporting the Cost 
Effectiveness
The selected studies were evaluated on 11 dimensions of 
economic evaluation for consistency in reporting and rel-
evance to decision making, and the scores were classified 
as low (≤ 2), middle (3), and high (4) (see Table 2). A short 
summary and the complete assessment of the quality of the 
economic evaluation can be found in the ESM (file S5). For 
the studies by Jiang et al. [24], Rodriguez Gonzalez-Moro 
et al. [27], Heo et al. [31], and Kuchenbecker et al. [33] 
we found weaknesses in the reporting and in the applied 
methods of modeling the VE and the indirect effects and 
hence considered them of low validity for decision making. 
These studies were excluded from the reporting of the cost-
effectiveness estimates in this review.
In the Korean study by Heo et al. [31], the main limita-
tions were seen using the all-serotype approach in the mod-
eling of the indirect effects of the childhood vaccination, 
which may have led to the contrastingly low ICER estimates. 
Weaknesses were also found for other dimensions of the 
post-vaccination stabilization during the modeled time hori-
zon comparable to the remaining PCV7 PD disease burden.
Jiang et al. [24] estimated the PD incidence from the Ger-
man surveillance data and modeled the indirect effects of a 
PCV13 program in children on the IPD incidence among 
adults to follow the PCV7 effects observed in the USA. The 
authors applied stabilization of serotypes in 2012, 7 years 
after the introduction of the PCV7 vaccination and only 
2 years after the replacement of PCV7 with PCV13. The 
evaluated vaccination of the elderly started in 2011; there-
fore, the cost effectiveness was evaluated under the assump-
tions that IPD incidence had stabilized after 1 year since the 
start of the program in the elderly. Therefore, the projection 
applied by Jiang et al. [24] can be considered to resemble 
the steady-state scenarios in the Australian studies [8, 30].
Thorrington et al. [32] analyzed a scenario in which 
PCV13 replaced PCV10 in the infant vaccination. It was 
assumed that the low PCV7 PD incidence remained stable. 
The indirect effects of higher valent PCV immunization of 
infants were projected based on the (historical) observed 
herd and replacement effects of PCV7 childhood vaccina-
tion. Under the PCV10 childhood vaccination, the incidence 
of IPD caused by the three additional serotypes included 
in PCV10 among the elderly was projected to decline 
over 5 years while the incidence of PCV13-minus-PCV10 
serotypes remained stable. PCV13 infant vaccination was 
assumed to have the same effects on PCV10 serotypes. 
Additionally, the impact of PCV13 on vaccine serotypes 3, 
19A, and 6A was analyzed based on the post-PCV13 sero-
type epidemiology observed in other countries. Based on 
this data, the authors projected a 40% decrease in the 19A 
serotype and no impact of PCV13 on serotypes 3 and 6A. 
The IPD incidences caused by PPSV23-minus-PCV13 and 
non-vaccine serotypes were projected to increase with the 
same rate as the observed serotype replacement induced by 
PCV7 but over a longer period in case of a replacement of 
PCV10 by PCV13.
Three studies [27, 31, 33] applied an all-serotype 
approach (described in ESM file S1: section 1.2.2) to project 
the indirect effects in IPD among the elderly. This approach 
assumes a perfect correlation between all-serotype PD inci-
dence and serotype-specific PD incidence (i.e., a 2% reduc-
tion in IPD of pneumococcal origin results in a 2% reduction 
of IPD caused by PCV13 serotypes).
3.2.3.2 Indirect Effects of Childhood Vaccination with PCV10 
on IPD Incidence Among the Elderly One study [25] assessed 
the cost effectiveness of PCV13 vaccination in the elderly 
in the presence of PCV10 infant vaccination, which had 
replaced the PCV7 program. Two studies [10, 32] analyzed 
the possible impact of changing one higher-valent PCV with 
another; that is, replacement of PCV10 with PCV13 [32] 
and replacement of PCV13 with PCV10 [10].














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cost Effectiveness of Elderly Pneumococcal Vaccination
economic evaluation such as calculation of the indirect costs, 
time horizon, discounting, and sensitivity analysis (SA). In 
the Spanish study by Rodriguez Gonzalez-Moro et al. [27], 
vaccination with PCV13 of adults with chronic obstruc-
tive pulmonary disease (COPD) aged 50 years was evalu-
ated, however, the φ with the population of the CAPiTA 
trial [7], which was used for definition of PCV13 VE. The 
authors applied a reduction in all-cause NBP incidence when 
modeling the herd effect of PCV13 childhood vaccination 
in NBPP. The all-cause approach was also used in mod-
eling PCV13 VE against NBPP. The same methodologi-
cal choices in modeling the vaccine effects in NBPP were 
seen in a recent German study by Kuchenbecker et al. [33]. 
The authors applied PCV13 VE of 3.9% against all-cause 
NBP and, in addition, used a longer duration of PCV13 and 
PPSV23 protection demonstrating high values of EVPOT. 
The herd effect for all-cause NBP was calculated based on 
the data from the study by Pletz et al. [64], who reported 
serotype distributions in NBPP. Kuchenbecker et al. [33] 
used the data on the serotype distributions for the calculation 
of the herd effect for both IPD and NBPP incidence, how-
ever, the authors did not report the methods for translation of 
the serotype distribution into the incidence of PD. We also 
excluded the German study by Jiang et al. [24] because of 
their assumption about the rapid stabilization of the vaccine-
type serotypes in the PD incidence among the elderly in 
2012 and absence of the indirect effects on NBPP incidence 
among the elderly.
3.2.5  Funding Source
Nine [8–10, 26, 28–32] of the 13 included studies reported 
industry-independent funding sources and the other four [24, 
25, 27, 33] were funded by the industry. Three [24, 27, 33] 
of the industry-funded evaluations and one [31] of the stud-
ies with industry-independent funding were considered of 
Stoecker Thorrington vanHoek Willem
Heo Jiang Kuchenbecker Mangen
Blommaert Chen_A Dirmesropian Gonzales−Moro




























































Fig. 3  Representation of constructed waning patterns reported in 
the selected studies by the first author, vaccine and age group (when 
reported). For the study by Stoecker et  al. [28], for the age group 
50–64 years, the plot represents the unweighted average curve due to 
the assumption of no waning for adults aged 50–64 years, and each 
single age cohort from 50 to 64 years had a different length of time 
with stable vaccine protection. The graph for Blommaert et  al. [26] 
illustrates the assumption of the same waning pattern for both PCV13 
and PPSV23
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low validity for the decision-making because of the flaws 
in modeling the indirect effects of the childhood vaccina-
tion. These studies are likely to underestimate the indirect 
PD reduction due to the PCV13 program in children. The 
assumptions about the duration of the vaccine protection 
seem to vary among the studies irrespectively of the funding 
source (see Fig. 4).
3.3  Cost Effectiveness of the Elderly Pneumococcal 
Vaccination in the Presence of a Routine 
Childhood Pneumococcal Conjugate 
Vaccination
In order to facilitate a comparative analysis of the findings 
on cost effectiveness of the adult vaccination, we included 
nine studies [8–10, 25, 26, 28–30, 32] that were considered 
relevant for decision making. We summarize the results by 
grouping the studies according to the vaccine used for the 
childhood vaccination and its effects on the PD incidence 
among the elderly. The results are summarized accordingly 
in Table 3. All reported prices and ICERs in this section 
are converted to 2017 US dollars (see ESM file S6 for the 
original and converted values of ICERs).
3.3.1  Childhood Vaccination with PCV13
3.3.1.1 Ongoing Indirect Effects Five [8, 10, 26, 28, 29] 
studies projected a future decline of PCV13 preventable PD 
incidence among the adult population due to the herd effect 
of the childhood vaccination with PCV13.
Adult vaccination with PPSV23 compared with no vac-
cination In the presence of ongoing effects of the childhood 
vaccination with PCV13, only the study by Blommaert et al. 
[26] reported the cost effectiveness of vaccinating the elderly 
with PPSV23 compared with no vaccination program. The 
authors investigated vaccinating different age groups of the 
Belgian adult population and stated that the vaccination with 
PPSV23 (75% coverage) might be considered cost effective 
with US$88,415/QALY for adults aged 65–74 years and 
with US$65,468/QALY for those 75–90 years old. The 
authors further state that the vaccine is cost effective (with 
willingness to pay [WTP] of US$46,062/QALY) for the 65- 
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Fig. 4  Dot plot of the calculated expected vaccine protection over 
time (for details about the methods for the calculation see electronic 
supplementary material [ESM] file S1: section  1). EAPY efficacy-
adjusted protection years, EVPOT expected vaccine protection over 
time, IPD invasive pneumococcal diseases, y.o. years old
Cost Effectiveness of Elderly Pneumococcal Vaccination
IPD incidence in the population and the stable vaccine pro-
tection lasts longer than 5 years. Of note, the authors applied 
a conservatively low PPSV23 effectiveness against IPD of 
55% taken as the lower value of the given confidence inter-
val reported in the review by Moberley et al. [47].
Adult vaccination with PCV13 compared with no vaccina-
tion The studies by Blommaert et al. [26] and Chen et al. [8] 
evaluated vaccinating adults with PCV13 compared with no 
vaccination. Both studies showed that PCV13 was unlikely 
to be cost effective in the presence of the ongoing herd 
effects of the routine PCV13 childhood vaccination. Most 
of the ICER estimates reported in these studies lie above 
US$100,000/QALY. The results reported by Blommaert 
et al. [26] suggest that vaccinating the elderly ≥ 75 years can 
be potentially cost effective with an ICER of US$88,842/
QALY compared with no vaccination. However, the authors 
point out that price reductions are required to keep it pos-
sibly cost effective when PCV13-preventable PD incidence 
decreases (24% annually) due to the herd effect. Vaccinat-
ing adults aged 50–64 years (ICER of US$287,917/QALY) 
or 65–74 years (ICER of US$131,104/QALY) was unlikely 
to be cost effective (with WTP of US$46,062/QALY) at 
the current prices (PCV13: US$100) unless no herd effect 
was present and the duration of stable PCV13 protection 
exceeded 6 years. In the base-case scenario, Blommaert 
et al. [26] assumed a constant protection for 5 years, which 
ceased to exist afterwards, and varied the duration of PCV13 
protection in relation to the vaccine price in the sensitivity 
analysis. The results show the distributions of the vaccine 
prices, which allow keeping the ICER equal to US$46,062/
QALY (original €35,000/QALY) with the given duration 
of protection with and without waning. The results suggest 
that with a longer duration of protection the vaccine price 
can be increased.
Chen et al. [8] analyzed the implication of the decline 
of PCV13 serotype circulation in the adult population in 
greater detail. The authors investigated a scenario of the 
indirect reduction in the six additional PCV13 serotypes as 
it has been observed for the PCV7 serotypes and compared 
the cost-effectiveness outcomes in this scenario with the 
estimates obtained under the assumption of potential sta-
bilization seen in the national data. The authors show that 
compared with the conditions of the stabilization of the indi-
rect effects of the childhood vaccination, ongoing decline of 
the additional six serotypes covered by PCV13 substantially 
worsens the cost effectiveness of vaccination for the elderly 
with PCV13 (US$50,359/QALY vs US$121,288/QALY). 
The authors emphasize that changes in the serotype distribu-
tion caused by the PCV13 childhood programs are critical 
to the cost effectiveness of PCV13 programs in the elderly.
Adult vaccination with PCV13 compared with vaccina-
tion with PPSV23 Stoecker et al. [28] and Willem et al. [10] 
compared PPSV23 with PCV13 for vaccinating the elderly. 
The estimated ICER for vaccinating 65-year-olds reported 
by Stoecker et al. [28] is slightly above US$50,000/QALY. 
However, Willem et al. [10] showed contrasting ICERs that 
lie well above US$100,000/QALY.
It is important to note that Stoecker et al. [28] showed that 
vaccinating at 65 years old was only cost effective (ICER of 
US$50,891/QALY) in a short period after the introduction of 
the PCV13 childhood vaccination. The authors analyzed the 
replacement of PPSV23 with PCV13 for the elderly vaccina-
tion in the US and evaluated cost effectiveness of this strat-
egy for the cohort of the year 2013 with PCV13 introduced 
for the childhood program in 2010. The authors used a sin-
gle-cohort model and looked at three scenarios of vaccinat-
ing the population of 2013 at 50, 60, and 65 years old. They 
showed that the ICER values rose substantially after 2013, 
reaching over US$400,000/QALY in 2015, and the PCV13 
strategy was dominated. This increase of ICERs after 2015 
suggests that a mid- or a long-term vaccination program 
with PCV13 is unlikely to be cost effective (> US$100,000/
QALY). In addition, the authors applied a step-wise waning 
of PCV13 protection at a rate of 10% every 5 years, resulting 
in the highest EVPOT in this review.
Willem et al. [10] estimated an ICER for vaccinating 
65-year-olds of US$221,970/QALY that can be consid-
ered unlikely to be cost effective (relative to a WTP of 
US$64,773/QALY). The authors performed extensive anal-
yses of different vaccination strategies considering uncer-
tainty surrounding VE, the duration of the protection, vac-
cine uptake, and initial PD incidence in adults. The authors 
applied age-specific PCV13 VE obtained from CAPiTA [7], 
but set it to zero for ≥ 85-year-olds. Comparably to several 
other studies [8, 9, 26, 30], PPSV23 VE was 56% against 
IPD but, in contrast, PPSV23 was also assumed to be effec-
tive against NBPP with VE of 30.8%. The authors examined 
different scenarios of VE against NBPP (i.e., when both vac-
cines are either effective or not effective against NBPP and 
when only PPSV23 is ineffective). The cost effectiveness 
of PCV13 was estimated compared with several strategies 
involving PPSV23: the current program with a low uptake 
(0.79–3.01%) and a program with an increased PPSV23 
uptake (15–25%). The cost effectiveness was analyzed 
contrasting ICER with different thresholds of WTP (up to 
US$453,411/QALY). The authors pointed out that PCV13 
could become cost effective for people < 75 years of age if a 
combination of favorable changes around PCV13 occurred, 
including a substantial (75%) reduction of the vaccine price, 
an increased duration of protection, and a lower herd effect 
caused by PCV13 childhood vaccination (i.e., increased dis-
ease burden caused by PCV13 serotypes). For the people 
aged ≥ 75 years, PCV13 remained unlikely to be cost effec-
tive in comparison with PPSV23 (ICER of US$438,072/
QALY). The higher uptake of PPSV23 would be considera-
bly more efficient relative to the current vaccination situation 
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with ICERs of US$107,282, US$74,116, and US$67,554 
per QALY for the age groups 50–64 years, 65–74 years, and 
75–84 years, respectively.
Adult vaccination with a combination of PCV13 and 
PPSV23 (sequential vaccination) The cost effectiveness of 
adding PCV13 to PPSV23 in vaccinations for the elderly 
was analyzed in four selected studies [10, 26, 28, 29]. All of 
them showed that this strategy was efficacious in reducing 
the number of cases of IPD and NBPP and related deaths. 
Blommaert et al. [26], van Hoek and Miller [29] and Wil-
lem et al. [10] showed that it was above US$100,000/QALY 
and was not cost effective. Stoecker et al. [28] showed that 
the sequential vaccination could possibly be cost effective 
(with WTP of US$50,000–US$100,000/QALY) in a short 
period (around 6 years) after the introduction of the PCV13 
childhood vaccination.
Stoecker et al. [28] showed an ICER of US$68,078/QALY 
for the addition of PCV13 to PPSV23 at age 65 years and 
higher ICERs for vaccinating at age 50 and 60 years with 
estimates of US$365,482/QALY and US$261,307/QALY, 
respectively. Similar to the strategy of replacing PPSV23 
with PCV13, the ICER for adding PCV13 to PPSV23 was 
demonstrated to reach over US$250,000/QALY by 2018 for 
the modeled cohort ≥ 65-year-olds and to be cheaper than 
the replacement strategy after the first year of the modeling 
horizon. The dramatic increase in ICER of both strategies 
over time was driven by the herd effect in the single cohort.
The Belgian studies by Blommaert et al. [26] and Willem 
et al. [10] showed that the addition of PCV13 to a vaccina-
tion scheme with PPSV23 was generally effective but not 
cost effective at any age. Blommaert et al. [26] stated that 
this strategy might be cost effective for 65- to 74-year-olds 
at a WTP of US$46,062/QALY, when the stable PCV13 
protection lasted 15 years. Willem et al. [10] concluded that 
the addition of PCV13 would bring less gain than a high 
uptake of PPSV23 and would become an expensive strategy 
with a high ICER. The ICER estimates are US$218,776, 
US$171,765, and US$201,380 per QALY for the age groups 
50–64, 65–74, and 75–84 years, respectively.
Van Hoek and Miller [29] evaluated the cost effective-
ness of adding one PCV13 dose to the vaccination with 
PPSV23 for the elderly aged ≥ 65 years for one cohort of 
65-year-olds in England. The authors simulated the disease 
burden in the cohort from 2016 until death comparing the 
outcomes of the addition of PCV13 to the current vaccina-
tion policy with an uptake of 69% in comparison with the 
current program without PCV13. They assumed the long-
est constant duration of PCV13 VE (9 years) among the 
selected studies, which resulted in a relatively long EVPOT 
for PCV13, and PPSV23 VE was not reported. The esti-
mated cost-effectiveness ratio for adding PCV13 to PPSV23 
was US$375,622/QALY. The authors pointed out that the 
PCV13 price should be below zero for ICER to be below the 
threshold of US$29,144/QALY (original £20,000/QALY).
3.3.1.2 PCV13 Serotypes Reached a  New Post‑vaccination 
Equilibrium in  PD Incidence The Australian studies [8, 9, 
30] explored the expected protective impact of PCV13 on 
PD incidence in the elderly ≥ 65 years and its cost effective-
ness when the six additional serotypes included in PCV13 
reached stabilization. The new post-vaccination equilibrium 
was assumed based on the Australian national surveillance 
data, which showed that after a rapid indirect reduction, the 
PCV13-type PD incidence among the elderly had stabilized 
[8, 30]. In these studies, the PCV13-serotype incidence was 
kept constant.
Adult vaccination with PPSV23 compared with no vac-
cination The cost-effectiveness of vaccinating the elderly 
with PPSV23 compared with no program was reported only 
by Dirmesropian et al. [30], who concluded that the strat-
egy (60% uptake) was not cost effective with an ICER of 
US$210,800/QALY (vs WTP of US$42,557/QALY). The 
researchers applied age-specific PPSV23 VE and assumed 
that the initial constant protection of PPSV23 lasted for 
2 years and thereafter linearly declined to zero over 3 years.
Adult vaccination with PCV13 compared with no 
vaccination The cost effectiveness of vaccinating the 
elderly with PCV13 was reported to be in the range of 
US$50,000–US$100,000/QALY and the program could be 
considered to be potentially cost effective compared with no 
vaccination. The studies used similar methods in calculation 
of age effects on VE, waning of the vaccine immunity, and 
most of the input parameters in the economic evaluation 
(price, discount rate).
Dirmesropian et  al. [30] estimated an ICER of 
US$62,417/QALY, which is similar to the estimate obtained 
by Chen et al. [8] for the scenarios with the post-vaccination 
PCV13-serotype equilibrium (ICER of US$50,359/QALY). 
Nevertheless, Dirmesropian et al. [30] concluded that the 
strategy was not cost effective relative to the WTP level of 
US$42,557/QALY. The authors stated that vaccination with 
PCV13 could be cost effective when either the vaccine price 
was below US$33 (A$46) or the duration of PCV13 protec-
tion exceeds 15 years.
In another study, Chen et al. [9] demonstrated the impor-
tance of modeling the actual age of the vaccine recipients 
rather than assuming a certain cohort to be vaccinated all at 
once at a recommended age. The first approach was shown 
to provide more accurate estimates of the cost effectiveness 
and the optimal age of vaccine administration (US$59,252/
QALY [recommended age scenario] vs US$46,294/QALY 
[actual age scenario]).
Adult vaccination with PCV13 compared with vaccina-
tion with PPSV23 Dirmesropian et al. [30] also concluded 
that PCV13 was cost effective versus PPSV23 with an 
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ICER of US$25,038/QALY (vs WTP of $42,557/QALY). 
The authors pointed out that PCV13 was favored due to the 
longer duration of protection and higher VE against IPD 
and NBPP. The assumption that PPSV23 has no efficacy 
against non-invasive PD was tested in the sensitivity analy-
ses, which resulted in larger benefits of PPSV23 and a sub-
stantial reduction in differences between ICERs.
3.3.2  Childhood Vaccination: PCV10 is Replaced 
with PCV13
Thorrington et al. [32] specified a hypothetical scenario of 
switching from PCV10 to PCV13 in the infant vaccination 
program and evaluated adult vaccination with PCV13 and/
or PPSV23 in the Netherlands. The authors examined dif-
ferent scenarios of vaccinating 50% of adults over 60 years 
of age in combination with infant vaccination with PCV13 
in comparison to the current vaccination scheme of no adult 
vaccination and PCV10 infant immunization. The authors 
projected the evolution of serotype epidemiology of IPD in 
Dutch adults with a routine infant vaccination with PCV10 
and with PCV13, respectively. Thorrington et  al. [32] 
showed that the strategies of vaccinating the elderly with 
PPSV23 with or without re-vaccination were cost effective 
relative to WTP of US$25,560/QALY, with vaccinating 
at age 70 being the most cost-effective scenario (ICER of 
US$7925/QALY). Vaccinating the elderly with PCV13 was 
shown to be more expensive, generating a higher ICER. The 
authors pointed out that switching to PCV13 for the infant 
vaccination was a rather inexpensive strategy having a ben-
eficial health impact for the elderly as well.
3.3.3  Childhood Vaccination with PCV10
The earliest study was conducted by Mangen et al. [25] in 
2015 for the Netherlands, where PCV7 had been replaced 
with PCV10 in the childhood pneumococcal vaccination 
program in 2011. The authors evaluated age- and risk-group-
specific strategies of vaccinating adults aged 65–74 years 
with PCV13 in comparison with no vaccination from a 
societal perspective. Vaccination coverage varied with the 
health-risk group (63.9% for low-risk groups; 81.5% for 
medium- and high-risk groups). The resulting ICER was 
US$12,003/QALY for vaccinating those aged 65–74 years 
with a single dose of PCV13. Relative to the WTP level of 
US$105,900/QALY, the authors inferred that vaccination 
strategies with PCV13 were cost effective and vaccinating 
65- to 74-year-old high-risk individuals was cost saving in 
the Netherlands.
3.3.4  Childhood Vaccination: PCV13 is Replaced 
with PCV10
Willem et al. [10] also investigated the potential impact of 
replacing PCV13 with PCV10 in the infant vaccination on 
serotype distribution. Motivation for this analysis was that 
PCV10 had been introduced in two regions of the country, 
which potentially could induce reoccurrence of three PCV13 
serotypes not included in PCV10 in the elderly population. 
The authors analyzed a ‘quick’ (within 7 years) and a ‘slow’ 
(within 15 years) scenario of the potential return of PCV13 
serotype incidence to the level of 2015 (current state). When 
PCV13 is replaced with PCV10 in the childhood vaccina-
tion, the relapse of PCV13-minus-PCV10 serotype incidence 
can make adult vaccination with PCV13 more beneficial.
4  Discussion
In this study, we analyzed the methods applied to model 
vaccine effectiveness over time as well as the indirect effects 
of PCV infant vaccination. In addition, we summarized the 
evidence of the cost effectiveness of the elderly pneumococ-
cal vaccination in the presence of the childhood vaccination 
with the higher-valent PCVs. We applied very strict inclu-
sion criteria on the assumptions and methodological choices 
made in the modeling of the vaccine effects. Overall, out of 
the 28 full-text economic evaluations that were reviewed, 
we selected 13 for the quality assessment with EVIDEM 
and included nine evaluations of the higher quality group to 
present the cost-effectiveness estimates.
4.1  Initial Vaccine Effectiveness
Despite our strict selection criteria regarding the input 
parameters for VE, we found substantial heterogeneity in 
the values used in the selected studies. In the case of PCV13, 
in order to restrain variation in the applied VE parameters 
we only selected studies that referred to the CAPiTA trial 
[7] to inform VE parameters. For PPSV23, we observed a 
greater variation originating from the chosen sources and 
applied age and health effects. Studies referencing Shapiro 
et al. [58] and Moberley et al. [47, 53] were seen to apply a 
higher PPSV23 effectiveness against IPD. In contrast to the 
majority of these studies, Blommaert et al. [26] applied the 
lowest value (55%) of the confidence interval provided by 
Moberley et al. [47]. This value was considerably lower but 
similar to VE of 56–58% used in the models referencing the 
review by Andrews et al. [15]. A few studies also included 
PPSV23 effectiveness against NBPP either in their baseline 
or sensitivity analyses informing the VE parameter with the 
data from cohort studies conducted in Spain [48, 57, 65, 
66]. We found between- and (in some cases) within-study 
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differences in the magnitude of applied age effects on the 
VE.
So far, the study of van Werkhoven et al. [50, 51] is the 
only analysis that explored vaccine-age-interaction effects 
of PCV13 among the elderly. The authors report statistically 
significant interaction effects for pneumococcal pneumonia 
(including invasive and non-invasive diseases). However, the 
applied statistical model showed a relatively poor fit for the 
age group ≥ 85 years, in which very few disease episodes 
occurred [25, 51]. Excluding this age group from the analy-
sis, the vaccine-age-interaction was not statistically signifi-
cant [25, 51]. Several observational studies [12, 15, 66–68] 
indicate vaccine-age interaction effects for PPSV23 but these 
have not been further investigated, although Djennad et al. 
[67] reported that differences in PPSV23 VE against vac-
cine-type IPD were significant between different age groups. 
Based on the current evidence about the vaccine-age-interac-
tion effects for PCV13 and PPSV23, both age-dependent and 
age-independent approaches to VE can be justified and both 
scenarios should be evaluated in cost-effectiveness analyses. 
Of note, when estimating single-age or age-group-specific 
VE for PPSV23 based on existing observational studies, it 
should be considered that most observational studies stratify 
age groups according to the age at occurrence of the diseases 
and not according to the age at vaccination.
4.2  Duration of Vaccine Protection and Waning 
Patterns
The absence of robust empirical evidence about the duration 
of vaccine protection led to a great variation of methodologi-
cal approaches to address this uncertainty. The majority of 
the studies shared the concept of composing the duration of 
vaccine protection from a period of stable immunity equal 
to VE at administration, followed by a period of waning pro-
tection. The CAPiTA trial [7] showed no waning of PCV13 
effectiveness over the study period of 4–5 years and most 
of the studies in this review applied 4–5 years of constant 
protection and made assumptions regarding the subsequent 
waning pattern. For PPSV23, a 2- to 5-year period of sta-
ble protection was frequently used. Overall, the majority 
of the studies reflected in the assumptions the implication 
that PCV13 induced a more profound immune response 
than PPSV23 [7] and applied a longer-lasting protection 
of PCV13. A broadly used approach to modeling the wan-
ing pattern was a linear or a step-wise linear decline to 0% 
effectiveness over some period of time, with the annual wan-
ing rates varying across the studies. A more conservative 
approach, which might ease a comparative analysis of the 
vaccines, was to set the same duration of the protection for 
both vaccines, which was done in one study in this review 
[26]. However, the conjugate vaccine is expected to protect 
for longer due to the stronger vaccine-induced response [16].
In addition, upon the comparison of the reported VE val-
ues and constructed waning patterns, we calculated expected 
vaccine protection over time (EVPOT) to facilitate com-
parison of the combination of these constituents of vaccine 
protection between and within the studies. EVPOT was esti-
mated by computing the area under the curve of VE over 
time and represents a measure of years of vaccine protection 
adjusted for the initial VE value, that is, it is composed of 
multiplicative effects of the initial VE and the applied years 
of waning protection. Although EVPOT allows for the com-
parison of modeled vaccine effects between the studies using 
a single value, this approach has certain limitations. Firstly, 
upon combining two constituents of the vaccine effects into 
a single value, the information about the effects and magni-
tude of each of them becomes hidden; therefore, we reported 
both constituents of EVPOT separately for each reviewed 
study. Secondly, when a relatively long waning period is 
applied, EVPOT can lead to a biased representation of the 
vaccine effects, which are actually simulated in the mod-
eling. In particular, the waning patterns with a very long 
tail to the right may result in high EVPOT but substantial 
vaccine benefits resulting from the assumed long protection 
may not actualize in the projection, for instance, due to high 
mortality rates or due to the herd effect of infant vaccina-
tion. To avoid this limitation, we chose a cut-off point of 
20 years since vaccination to calculate EVPOT. An alterna-
tive method of comparison of applied vaccine effects is the 
calculation of the half-time duration; that is, estimation of 
the time since vaccination at which VE is reduced to 50% of 
its initial value [69]. This measure, however, may introduce 
a bias towards the waning patterns that start with a slow 
waning of the initial VE followed by a rapid waning phase 
as compared with waning with constant rates. This, how-
ever, reflects the fact that the present effects have more value 
than the future effects for instance, due to mortality, quality 
of life decreasing with age, discounting of health outcomes 
and costs, and the herd effects. This preference for a slow 
followed by a rapid waning phase may provide a different 
conclusion about the outcomes of the vaccination over time 
as compared with the calculation of the area under the curve; 
that is, a vaccine may have longer half-time duration but a 
lower area under the curve. Furthermore, it does not include 
the impact of the initial VE and the combined effect of initial 
VE and the waning function.
4.3  Indirect Effects of Infant Vaccination
We observed different methodological approaches for pre-
dicting the serotype evolution. The first was to start from 
equilibrium of the childhood PCV-type serotypes in the 
elderly IPD incidence and assume no further herd effects, 
which was done in the Australian studies [8, 9, 30] and 
one Dutch study [25]. This approach is reasonable when 
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the national epidemiological data sufficiently indicates that 
new post-PCV equilibrium has been reached or if there are 
no net indirect changes in the preventable PD incidence. It is 
important to note that Australia implemented a 3 + 0 sched-
ule of the PCV13 program in children that is unique among 
high-income countries. The reported possible consequences 
of the schedule without a booster dose include increased 
PCV13 breakthrough cases and decreased herd effects in 
PCV13-serotype-induced IPD incidence in the older popula-
tion [17]. The unique epidemiological settings of Australia 
make it difficult to transfer the cost-effectiveness projections 
reported in the Australian studies to other countries.
The second method was to increase the herd effect of 
PCV13 serotypes step-wise and assume that the maximum 
reduction of the IPD incidence was reached between years 
5 and 7 of the time horizon [27, 31]. A slight variation of 
this approach was found in two Belgian studies [10, 26], 
which applied an average annual decline of the PCV13-type 
incidence without the successive steady state. Finally, four 
studies predicted forward the distribution of the six addi-
tional serotypes contained in PCV13 (PCV13-minus-PCV7). 
The methodological choice was either to assume that the six 
serotypes followed a similar decline as the PCV7 serotypes 
followed by stabilization [24, 28, 29] or to predict a decline 
in the incidence using a regression equation estimated on 
the data for the previous years and assume stabilization after 
some years [33].
Another important indirect effect of the PCV childhood 
vaccination is the vaccine-induced serotype replacement that 
might counteract the beneficial impact of the herd effect in 
the unvaccinated population. Not all studies that modeled 
the herd effect included the serotype replacement. We found 
five studies [10, 24, 26, 28, 32] that reported the serotype 
replacement. The methodological approaches were either to 
apply an increase in non-vaccine-type PD incidence modeled 
as a fixed proportion of the reduction in the IPD incidence 
due to the herd effect or to project the effects of childhood 
vaccination with PCV7. It is important to note that if the 
pneumococcal vaccine under evaluation contains serotypes 
that are not included in the conjugated vaccine used for the 
childhood vaccination, the replacement effects potentially 
caused by these additional serotypes should be examined 
and incorporated into the model.
Extrapolation of the historical effects caused by PCV7 
vaccination onto the six additional serotypes in PCV13 
should be done with caution as pointed out by Chen et al. 
[8]. This statement was based on the findings that the circu-
lation of the six additional serotypes declined in a shorter 
period than PCV7 serotypes in Australia, which may lead to 
a considerable shift in the steady-state predictions. However, 
post-PCV13-vaccination studies showed the persistence of 
serotype 3 in the population; that is, PCV-13 infant immu-
nization has no or very limited indirect effect on the IPD 
incidence caused by serotype 3 [70]. Recently published 
epidemiological data also indicates that serotype 19A, after 
a substantial decrease due to the herd effect, may stabilize 
at a low level [71, 72]. Therefore, the common approach 
to group the serotypes by vaccine (e.g., PCV7 serotypes, 
PCV13 serotypes, PCV13-minus-PCV7 serotypes) may 
be misleading and can result in poor predictions, underes-
timating the remaining burden of pneumococcal diseases 
caused by PCV13 serotypes. The application of the serotype-
specific epidemiology of invasive and non-invasive PD in 
the model allows a more realistic estimation of the vaccina-
tion effects. Any-serotype and all-cause approaches lead to 
a false presentation of the indirect effects on the selected 
groups of serotypes, particularly PCV13-type (see ESM file 
S1: section 1.2.2), favoring the outcomes of the elderly vac-
cination and improving its cost effectiveness. It is important 
to note that assumptions and input data used to inform a 
decision-analytic model become outdated with time and the 
results of an economic evaluation have to be updated when 
new information regarding country-specific S. pneumoniae 
epidemiology becomes available.
In addition, the studies by Stoecker et al. [28] and Chen 
et al. [9] demonstrated that model type (single cohort vs 
multi-cohort) substantially affected the results when time-
varying serotype epidemiology is to be modeled. The 
authors point out that single-cohort models do not produce 
valid ICERs over a series of years because they do not cap-
ture variation of the serotype distribution, which in turn are 
differently affected by VE. The resulting ICERs over a set of 
calendar years in the papers by Chen et al. [9] and Stoecker 
et al. [28] show substantial variation between the cohorts 
that are vaccinated in different calendar years. Single-cohort 
models provide valid results only when epidemiological 
equilibrium has been reached before the start of the model 
period. Otherwise, when the dynamic indirect effects are 
present, application of a multi-cohort model is required to 
capture the ongoing changes in the PD incidence.
Furthermore, in this review we did not identify dynamic 
transmission models and application of PCV13 VE against 
the bacterial nasopharyngeal carriage. Currently, there is lit-
tle empirical evidence on the protective effects of vaccine-
induced reduction of the bacterial carriage in the elderly. 
Van Deursen et al. [73] reported that PCV13 induced a small 
and short-lived decline in the vaccine-type nasopharyngeal 
carriage in people aged ≥ 65 years. This may lead to addi-
tional herd effects with the elderly vaccination, which can 
be particularly beneficial in the communities with higher 
concentration of the elderly [74].
Overall, these considerations should be seen as relevant 
for the decision-making process and the studies that aim to 
support the decision outcomes should describe their meth-
odological choices and assumptions and provide a transpar-
ent reporting of the disease incidence rates for all relevant 
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serotype groups over the modeling time horizon or until a 
new post-vaccination equilibrium is reached.
4.4  Cost Effectiveness
The current evidence about the cost effectiveness of pneu-
mococcal vaccination of the elderly in the presence of a 
higher valent PCV infant vaccination program is incon-
clusive. Reviewing the studies with a higher relevance and 
validity score, we found predominant evidence that vacci-
nating the elderly with PCV13 is not cost effective when 
an ongoing decline in the incidence of PCV13-type PD is 
modeled either until extinction of PCV13 serotypes or until 
a very low PCV13 PD incidence level is reached. However, 
the current epidemiologic evidence suggest that PCV13 IPD 
incidence initially substantially declines but then persists on 
a moderate level in the presence of PCV13 infant vaccina-
tion [67, 70–72, 75]. In the Australian studies [8, 9, 30], 
similar stabilization of PCV13 serotypes was applied and 
ICERs of PCV13 versus no vaccination were in the range 
of US$50,000–US$100,000/QALY. However, at the time of 
the evaluations, the unique 3 + 0 PCV13 infant vaccination 
schedule was applied. Jayasinghe et al. [17] found fast wan-
ing of PCV13 effectiveness under this schedule, which may 
have resulted in a higher persistent PCV13 PD incidence 
compared with the settings of more commonly used vaccina-
tion schedules (2 + 1 or 3 + 1). Thorrington et al. [32], who 
also modeled the moderate persistent incidence, reported 
ICERs of US$50,000–US$100,000/QALY for PCV13 versus 
no vaccination but the effects of the replacement of PCV10 
with PCV13 in the infant vaccination was based on many 
assumptions. In contrast to Dirmesropian et al. [30], Thor-
rington et al. [32] found that PPSV23 showed better value 
for money than PCV13 in the vaccination of the elderly. A 
key difference between the studies was the application of a 
moderate PPSV23 VE against NBPP in the study by Thor-
rington et al. [32] as compared with the assumption of no 
protective effects by Dirmesropian et al [30].
The findings by Blommaert et al. [26], Thorrington et al. 
[32], and Willem et al. [10] indicate that PPSV23 is likely 
to be a cost-effective vaccination strategy in all reviewed 
epidemiologic scenarios if it is at least moderately effec-
tive against NBPP and the expected duration of protection 
lasts at least 3–4 years. The outcomes of the vaccination 
with PPSV23 were less affected by the indirect effects of 
the childhood vaccination due to the wide serotype cover-
age of the vaccine, but the childhood vaccination still played 
a crucial role for the vaccination benefits. In the absence 
of a protective effect against NBPP, evidence for the cost 
effectiveness of PPSV23 is not conclusive. Childhood vac-
cination with PCV10 makes the elderly vaccination with 
PCV13 more attractive due to the three additional serotypes 
preventable by PCV13.
Currently, there is a lack of studies that model the impor-
tant PCV13 serotypes such as serotype 3 separately from other 
groups of serotypes when evaluating pneumococcal vaccination 
of the elderly in the presence of a PCV13 infant vaccination. 
Besides the accurate presentation of epidemiologic effects, 
there are still issues regarding the effectiveness of both vaccines 
(PCV13 and PPSV23) against serotype 3 [15, 17, 67, 76, 77], 
which may also require the separation of serotype 3 from other 
groups in the presence of PCV10 infant vaccination to inves-
tigate scenarios with the reduced vaccine effectiveness [78].
5  Conclusion
To summarize, in this review we found major differences in 
the methods and assumptions applied in the modeling of VE 
and the indirect effects of the childhood vaccination with the 
higher valent vaccines (PCV10 and PCV13). Results of the 
cost-effectiveness analyses are largely determined by the pre-
dictions of PD incidence and the estimates of pneumococ-
cal VE over time on which they are based. Insight into the 
modeling of these processes can help to rationally interpret 
obtained cost-effectiveness estimates and to understand the 
variation of conclusions among the studies. It is also impor-
tant to take into consideration all dimensions of economic 
evaluation that may drive the ICER estimates; these include 
characteristics of vaccination strategy (age range, dose and 
uptake), vaccine price, cost per PD case, utility estimates, 
modeling time horizon, and discount rates. Taken together, 
country-specific S. pneumoniae epidemiology, vaccination 
strategy, and country-specific economic inputs require the 
development of a decision-analytic model specific for this 
country. Any comparisons between outcomes of models 
from different countries should be made with caution due 
to the large number of parameters that determine the results.
Overall, a major pneumococcal vaccination campaign for 
the elderly is largely resource-consuming and with all the 
other social and public health challenges at hand the oppor-
tunity cost of such a vaccination campaign may be high. For 
this reason, the need for well-designed modeling studies that 
produce representative and non-biased cost-effectiveness 
estimates cannot be overemphasized.
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S1. Methods  
1. Constituents of vaccination effects: a theoretical framework 
In the following, we describe key parameters which are essential for the qualitative assessment and/or 
comparison of effectiveness and cost-effectiveness outcomes of health economic evaluations of adult 
pneumococcal vaccination.             
1.1. Effectiveness against vaccine-type pneumococcal diseases   
1.1.1. Maximal vaccine effectiveness 
We define the maximal vaccine effectiveness (MVE) as the effectiveness at the time of administration (or shortly 
after) before the occurrence of waning immunity. Clinical trials typically report average vaccine effectiveness 
over a defined period of time (study follow-up). Therefore, if the follow-up time of a modeling study is rather 
long and a strong waning rate of effectiveness is assumed, the maximal vaccine effectiveness is typically higher 
than the average effectiveness reported in the clinical study. 
1.1.2. Waning pattern 
The effect of a vaccine is dependent on the maximal vaccine effectiveness and the duration of the protection, i.e., 
a vaccine with a low MVE but a long duration of protection might result in a similar number of prevented cases 
than a vaccine with a high MVE but a short duration of protection. To make these input parameters of the 
different models easily comparable, we calculated two different indices: years of full protection and expected 
vaccine protection over time.  
Years of full protection approach looks at each year after the initial year of immunization and calculates the 
percentage of the remaining vaccine effectiveness compared to the baseline vaccine effectiveness. For example, 
a baseline vaccine effectiveness of 0.80 in the first year and 0.40 in the second year would yield 1.5 years of full 
protection (1 year in 100% of baseline protection (0.80/0.80) and 1 year in 50% baseline protection (0.40/0.80). 
Years of full protection can be seen as a single measure that summarizes the waning of the vaccine protection. 
Expected vaccine protection over time supplements the years of full protection by the duration of the vaccine 
protection. It is calculated as the sum of the vaccine effectiveness over time. From the above example (VE 0.80 
in the first year and 0.40 in the second year) we would calculate 1.2 years as the average duration of protection. 
The average duration of protection corresponds to the area under the curve of vaccine effectiveness over time. 
 
Figure 1: Comparison of the two indices for the measurement of vaccine effectiveness, Years of Full Protection and Expected 




Figure 1 compares the two indices on an example, where the VE is constant at maximum level of 75% over 4 
years after the vaccination and then decreases linearly over 15 years, reaching 0% in 19 years after the 
vaccination. The expected vaccine protection over time would be 8.625 efficacy adjusted protection years while 
we would calculate 11.5 years of full protection. 
For the studies where the waning lasted over 20 years after the period of the stable protection, in the calculation 
of EVPOT we stopped the projection on year 20 after the vaccine reception.     
It has to be noted that these estimators are biased to some extend because the form of the waning function has an 
impact on the results of the disease incidence when it is changing with age and/or time. It also has an impact on 
the economic results when discounting is applied. However, it is still a good metric to compare the assumed 
effects of vaccination including MVE and waning.        
1.1.3. Calculation of age group specific initial vaccine effectiveness based on vaccine-age interaction 
effects: 
To compare the applied effects of vaccination across studies, we reported the initial VE and EVPOT for four age 
groups: 50-64 years old, 65-74 years old, 75-84 years old and 85+ years. For studies which applied vaccine-age 
interaction effects [1–6], age group specific VE estimates were calculated as follows:   
1. Age specific age VE estimates were calculated based on applied vaccine-age interaction effects and 
specific VE/age anchor points (for instance PCV13 VE against VT-IPD of 89.2% in 65 years old and vaccine-
age interaction effect of 7.8% per year of age). 
2. An unweighted average was calculated for each age group based on the age specific vaccine estimates. 
Willem et al. [2] did not provide a VE/age anchor point, so that age specific PCV13 VE estimates could not be 
calculated. Therefore, the reported age independent base VE for IPD and NBPP was used in the comparison of 
vaccine effects. 
For Kuchenbecker et al. [1], age specific VE estimates were calculated based on the linear interpolation 
technique described in the supplements of the paper.  
Kuchenbecker et al. [1] is the only study that applied age specific waning patterns based on linear interpolations 
of VE against IPD since time of vaccination assumed by Smith et al. 2008 [11] for 50, 65 and 80 years old. 
Kuchenbecker et al. describe the interpolation technique in detail in the supplements. However, calculated values 
differ substantially from values reported in the paper. Therefore, we linearly interpolated values reported in the 
paper. Therefore, our calculation of waning patterns (shown in Figure 3 of our paper) and calculated EVPOTs 
may differ from the original values applied by Kuchenbecker et al. [1] 
1.2. Incidence of vaccine-type pneumococcal disease over time 
Observed vaccine-type disease incidence varies across countries and risk groups due to the differences in the 
overall disease incidence and/or serotype distribution. For the application of vaccine-type disease effectiveness, 
estimates of vaccine-type disease incidence are required. While this data usually exist for IPD, there is little 
information on the serotype distribution in non-invasive pneumococcal disease. While there are differences in 
the distribution between IPD and non-invasive pneumococcal diseases, the assumption of comparable serotype 
distribution is likely less biased and more transparent in the absence of data than using overall incidence data and 
estimates of effectiveness against non-invasive pneumococcal disease of any serotype (see arguments in section 
vaccine-type specific effectiveness).               
1.2.1. Indirect herd effect and replacement effects 
The observed magnitude of the vaccine induced indirect herd effects and replacement disease differ across 
countries. The main drivers are the implemented vaccine type for the immunization of infants (PCV7, PCV10 or 
PCV13) and the vaccination uptake. However, the serotype distribution before the implementation of PCV infant 
vaccination may also impact the magnitude of effects  
The time since the implementation of the infant vaccination program is a crucial factor for the performance and 
cost-effectiveness of adult vaccination programs. In order to avoid drawing the wrong conclusions on the mid-
term performance and cost-effectiveness of adult vaccination, a multi-cohort approach is required. 
If the prevention of nasopharyngeal carriage is indeed the cause for the indirect effects on the incidence among 
the adults, the effects on specific serotypes should at least not completely differ between invasive and non-
invasive diseases because the reduced carriage should lead to a decrease in IPD as well as non-IPD cases. 
However, the indirect effects can differ between the serotypes and the distribution of serotypes may differ 
 
 
between IPD and non-IPD. These differences may result in varying effects if these serotypes are combined in 
groups. Van Werkhoven et al. [7] reported that indirect effects of the PCV7 serotypes in IPD and non-invasive 
disease are comparable. In addition, Rodrigo et al. [8] reported a very low proportion/incidence of PCV7 
serotypes after several years of infant vaccination and a decline of the additional PCV13 serotypes in non-IPD 
after introduction of the PCV13 infant vaccination. In contrast, another US study [9] reported a relatively high 
burden of PCV7 serotypes in non-invasive pneumonia ten years after the implementation of PCV7 infant 
vaccination. 
For non-invasive disease, in the absence of data, we consider the extrapolation of the effects in IPD the most 
appropriate method. Using reductions in all-serotype pneumococcal diseases or all-cause non-invasive 
pneumonia incidence as a predictor for effects in vaccine-type non-IPD is not considered as an appropriate 
method.            
1.2.2. Application of effectiveness data against vaccine type pneumococcal disease 
Due to a lack of serotype-specific PD data over time, in particular in non-IPD, effectiveness against PD of any 
serotype is applied in some studies. This serotype non-specific approach is problematic because it is based on the 
effectiveness against vaccine serotypes and a specific serotype distribution which is then fixed over time. If the 
parameter value is directly taken from the clinical trial, it includes the specific serotype distribution in the trial 
population. If the observed serotype distribution in the target population and the effectiveness against vaccine 
serotypes are used to calculate the effectiveness against PD of any serotype, it includes the serotype distribution 
at that specific point in time (for instance pre PCV infant vaccination). The effects of the vaccine are then 
calculated by applying the vaccine effectiveness against any type to changes in the overall PD incidence over 
time. The serotype distribution in the overall PD incidence, however, is changing over time due to the indirect 
effects (herd and replacement) of the childhood vaccination. The reduction of vaccine-type serotypes does not 
only cause a decrease in the overall PD incidence but also the proportion of vaccine-type serotypes in the 
remaining overall serotype epidemiology. This time varying proportion of the vaccine-preventable serotypes in 
the overall serotype distribution is not accounted for in the serotype non-specific approach.            
Therefore, such approach would lead to considerable underestimation of the herd effect i.e. decrease in incidence 
of pneumococcal disease caused by serotypes included into the infant conjugate vaccine. Application of vaccine 
effectiveness against pneumococcal disease of any serotype or all cause disease brings a high risk of bias due to 
the changing serotype distributions (regional as well as temporal). Application of vaccine effectiveness against 
any serotype is therefore not a solution to missing data on serotype distribution which is often the case in non-
invasive pneumococcal disease. Additional source of potential bias in incidence of non-invasive pneumococcal 
disease is usually unknown etiology of pneumonia reported in hospital records. Applying vaccine effectiveness 
for all cause pneumonia fixes the vaccine effectiveness parameter to a specific serotype distribution as well as a 
specific proportion of disease caused by S. pneumonia, which aggravates the underestimation of the herd effect 
on the incidence of vaccine type of non-invasive pneumococcal pneumonia. 




NBP – non-bacteraemic pneumonia 
NBPP – non-bacteraemic pneumococcal pneumonia 
Assumptions: 
 NBP incidence (per 100,000) in 2018: 1% 
 NBPP (attributed to Streptococcus pneumoniae) in 2018: 20% of NBP 
 Proportion of vaccine serotypes in NBPP in 2018:  40% 
 Effectiveness against vaccine-type NBPP:  50% 
 Decline of overall NBP incidence over the following five years due to infant conjugate pneumococcal : 
5% 
 No replacement diseases 
Calculated: 
 Vaccine effectiveness against NBPP: 0.5*0.4=0.2 













100,000 x 0.01 = 
1,000 
S.pn. NBPP: 
1,000 x 0.2 = 200 
PCV13-type NBPP:  
200 x 0.4=80 
assumptions of the example are applied 
to calculate initial incidence  
Prevented cases in 





caused NBP = 
0.5*0.4*0.2=0.04] 
200 x 0.2=40 
[VE against NBPP = 
0.5*0.4=0.2] 
0.5 x 80 = 40 
[VE against vaccine-
type NBPP = 0.5 ] 
applied VE to the initial incidence in 
year 1 of the modelling time horizon 
shows no difference in prevented cases 
justifying the all-cause and all-serotype 
approaches 
During the modelled 5 years the incidence of all-cause NBP decreased by 5% due to the herd effect of childhood conjugate 
vaccination: 50 cases less   
Incidence 2023: 
under the indirect 
effect (per 
100,000) 
1,000 x 0.95 = 950 
observed decline is 
50 cases 
200-50=150 80-50=30 We suggest that observed herd effect 
(reported as percentile decline of all-
cause NBP) can occur only due to the 
serotypes contained in the childhood 
conjugate vaccine and the observed 
decline should be attributed to the 
PCV13 vaccine-type NBPP incidence. 
Here the decline of 50 cases is applied to 
each incidence to show the differences 
in the approaches.  
Prevented cases in 
2023 due to adult 
vaccination 
0.04 x 950 = 38 0.2 x 150 = 30 0.5 x 30 = 15 Adult vaccination outcomes at the end 
of the modelling time horizon. 
 
The example shows that after the application of the herd effect in the model the predictions alter leading to 
underestimation of the herd effects of childhood vaccination in the vaccine-type pneumococcal disease incidence 
and overestimation of the adult vaccination outcomes vaccine effects.  
 
2. Study selection process 
2.1. Search syntax 
The present syntax including the planned limits was used for PubMed: 
(technology assessment, biomedical[MESH] OR “technology assessment” OR “health technology 
assessment” OR HTA OR policy making[MESH] OR 
decision making[MESH] OR costs and cost analysis[MESH] OR “Cost Benefit Analysis” OR “Cost 
Benefit Analyses” OR “Cost Effectiveness Analysis” OR 
“Cost Effectiveness Analyses” OR “Cost Utility Analysis” OR “Cost Utility Analyses” OR “Economic 
Evaluation” OR “Economic Evaluations” OR “cost 
minimization” OR “economic impact” OR “economic models”) AND ("Pneumococcal 
Vaccines"[Mesh] OR pneumococc* AND (vaccin* OR immun*)) 
AND (elder* OR old* OR adult OR geriatric* OR years). 
The publication bibliographies of the retrieved systematic reviews and the articles selected for the full text 
review were manually screened to search for related articles.  
 
 
2.2. Screening of the identified studies 
Two reviewers (MT, SMS) independently performed the screening of the identified titles and abstracts for 
eligibility following the above described inclusion criteria. In case of any disagreement, a third reviewer (AK) 
arbitrated in to reach a consensus. We recorded the reasons for exclusion of ineligible studies. After the 
screening of the abstracts, the same two reviewers performed the full text review of the selected papers to 
confirm that the articles met the inclusion criteria.  
2.2.1. Inclusion criteria 
We included studies with full economic evaluations (cost-effectiveness analyses (CEA), cost-utility analyses 
(CUA), and cost-benefit analyses (CBA)) of adult vaccination programs with PCV13, PPSV23 or a combination 
of both. Eligible studies had to include a target population comprising of adult individuals over 50 years old 
(y.o). We restricted the articles to those that had been published during the period from 2006 to present time. We 
chose 2006 as a start date because it overlapped with the end date of the literature review published by Ogilvie et 
al in 2009 [10] We restricted the search to the papers published in English. All countries were included.    
2.2.2. Exclusion criteria 
We excluded public health-, economic- and budget impact analyses (BIA), systematic reviews, editorials, and 
conference abstracts, studies evaluating pediatric pneumococcal immunization programs and vaccinating adults 
younger than 50 years old; the studies which evaluated vaccination against pneumococcal diseases in 
combination with the vaccination against influenza and the studies which did not explicitly state the type of 
pneumococcal vaccine under evaluation.  
2.2.3. Data extraction 
For each of the selected for the full review studies, we firstly extracted the following data on study 
characteristics: authors, title, DOI/ PMID, year of publication, country, type of economic evaluation, model type, 
modeled population, vaccine for adult vaccination, comparator,  vaccination strategy, vaccination coverage, time 
horizon,  considered morbidities, applied parameters of the vaccine effectiveness, sources of the vaccine 
effectiveness, duration of protection (waning rate),  infant vaccination, inclusion of  the indirect effects of 
childhood vaccination, pneumococcal disease incidence and data sources, perspective, vaccine price and 
reference year, included costs, discount rate, health outcomes, estimated cost-effectiveness ratios, sensitivity 
analysis results, conclusions and funding sources.  
The same two authors analyzed the extracted the data on the vaccine effectiveness against the vaccine-type 
pneumococcal serotypes (maximal vaccine effectiveness and duration of protection) and the development of the 
incidence of vaccine-type pneumococcal diseases over time, which included the disease incidence before the 
implementation of PCV immunization of infants, its indirect herd- and replacement effects. The data on vaccine 
effectiveness and duration of protection were used to calculate years of full protection and average duration of 
protection (see section 1.1.2). These summaries enabled a comparison of applied vaccine protection over time 
between the studies. 
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Vaccine effectiveness (VE) and 
Expected vaccine protection over time (given in efficacy 
adjusted protection years) 
Effects of a pneumococcal paediatric 
vaccination on the incidence in the target 
population, development of incidence over 
time 
Merito et al, 
2007, Lazio,  
Italy(Merito et 
al. 2007) 
 Analysis: CEA of PPSV23 ag. IPD vs no 
vaccination  
Perspective: public health service 
Time horizon: 5 years  
Model type: Markov, single cohort 
Health Outcomes: LYG 
Vaccine price, year: €12.28, 2004 
Discount: Cost: 3%;Outcomes: no 
Conclusion: can be cost-effective, great 
variability of estimates      
≥65 y.o, 
100% 
Source of VE: refers to Shapiro et al.(Shapiro et al. 1991), 
hospital-based case-control study 
Parameter: age-dependent, 65–74y.o: 80%|  
75–84y.o: 67%|> 85y.o: 46% 
Waning: at rate after 3 y. 
Expected vaccine protection over time:  
65–74y.o: 3.8 | 75–84y.o: 3 | > 85y.o: 1.8   
Paediatric vaccination: PCV7 or PCV13 not 
included 
Indirect effects: not included   
Methods: n/a 






zenbaum et al. 
2010) 
Analysis: CEA of PCV13 ag. IPD and nIPD vs 
no vaccination  
Perspective: societal 
Time horizon: 5 years  
Model type: decision tree, single cohort 
Health Outcomes: LYG 
Vaccine price, year: €50, assumption 
Discount: Cost:4%; Outcomes:1.5% 
Conclusion: might be considered cost-effective   
≥65 y. o; 83% - 
high-risk; 65% - 
low-risk 
Source of VE: assumption 
Parameter: 60% ag. IPD and nIPD, range 30-90% 
Waning: 5 y. stable, waning is not stated 
Expected vaccine protection over time:  
 3 y.  
  
Paediatric vaccination: PCV7 
Indirect effects: scenarios:  
no indirect effects; pessimistic – 100% 
increase in non-PCV7 serotype incidence    
Methods: assumptions  
No. VE of PCV13 






Akin et al, 2011, 
Turkey(Akin et 
al. 2011)  
Analysis: CEA of PPSV23 ag. IPD and nIPD vs 
no vaccination  
Perspective: public payer 
Time horizon: 5 years 
Model type: decision tree, single cohort 
Health Outcomes: LYG 
Vaccine price, year: €16,2008 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: cost-saving 
at-risk adults  18-59 
y.o40%; ≥60 y.o, 
60%  
Source of VE: assumption based on several observation 
studies 
Parameter: IPD – 60%, nIPD – 21% 
Waning:10% annual decrease over 5 y. 
Expected vaccine protection over time:  
 IPD-2.5y., nIPD-0.86y 
Paediatric vaccination: PCV7 not included 
Indirect effects: not included 
Methods: n/a 
No. Indirect 
effects are not 
applied 
Neto et al, 2011, 
Brazil(Neto et 
al. 2011) 
Analysis: CEA of PPSV23 ag. IPD and nIPD 
vs no vaccination  
Perspective: social, public healthcare 
Time horizon: 5 years 
Model type: decision tree, single cohort 
Health Outcomes: LYG 
Vaccine price, year: US$15, 2008 
Discount: Cost: 5%; Outcomes: 5% 
Conclusion: clinically and economically 
≥60 y.o, 
60% 
Source of VE: assumption based on several observation 
studies 
Parameter: IPD – 64%, nIPD – 21% 
Waning:10% annual decrease over 5 y. 
Expected vaccine protection over time:  
 IPD-2.62y., nIPD-0.86y 
Paediatric vaccination: PCV10 
Indirect effects: not included 
Methods: n/a 
No. Indirect 




al, 2012, Poland 
(Grzesiowski et 
al. 2012) 
Analysis: CEA of PPSV23 ag. IPD and nIPD 
vs no vaccination Perspective: public health care 
Time horizon: 35 years, lifetime horizon 
Model type: Markov, 10 cohorts 
Health Outcomes: QALY 
Vaccine price, year: not given, 2009 
Discount: Cost: 5%; Outcomes:5% 
Conclusion: cost-effective regardless of risk 
status 
strategies:  
all individuals  ≥65 
years old; high-risk 
individuals ≥65 
years old; coverage 
is not stated 
Source of VE: assumption based on several observation 
studies 
Parameter: IPD – 64%, nIPD – 21% 
Waning: peak at the 1st year, waning to y. 9. Refers to 
Sisk et al(Sisk et al. 2003) and Middleton et al 
(Middleton et al. 2008) 
Expected vaccine protection over time:  
 cannot calculate 
Paediatric vaccination:PCV7 
Indirect effects: not in base case, included in 
SA 
Methods: applied based on epidemiological 
data of USA and Germany 
No. Indirect 
effects are not 
included into base 
case analysis 
Kuhlmann et al, 
2012, 
Germany(Kuhl
mann et al. 
2012)  
Analysis: CEA, CBA of PPSV23, PCV13 ag. 
IPD and nIPD vs no vaccination  
Perspective: Statutory Health Insurance 
Time horizon: 100y 
Model type: cross-sectional steady state Markov  
Health Outcomes: LYG 
Vaccine price, year: PCV13: €71.57, PPSV23: 
€35.89, 
2010 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: PCV13 is cost-effective vs PPSV23 
and no vaccination, dominates both strategies 
PPSV23: 
 ≥60 y.o; all 
patients >5 y.o at 
high risk + booster 
+revaccination at 
50 with PCV13 
PCV13: ≥ 50 y.o 
and the adults at 
risk + booster for 
every patient at risk 
and every second 
without any risk. 
Coverage:  




Source of VE: PCV13: assumption is based on clinical 
data for PCV7 in children, expecting similar levels of 
efficacy against the additional 6 serotypes which are not 
included in PCV7, refer to Black et al (Black et al. 2000). 
PPSV23: Cochrane systematic literature 
review(Moberley et al. 2008) 
Parameter:  
PCV13 ag.IPD: 50-59y.o:59.5%|60-69y.o: 60%|70-
79y.o:67%|80-89y.o:70.2%| >=90y.o:71.6% 
PCV13 ag. CAPin : 26%|CAPout:6% 
PPSV23 ag.IPD: 50-59y.o:58.4%|60-69 y.o:61.9%|70-
79y.o:57.9%|80-89y.o :62.5%|>=90y.o:67% 
Waning: assumed years of full protection and complete 
waning afterwards 
PCV13: 10 y. PCV13: 5y. 
Expected vaccine protection over time:  
 cannot calculate 
Paediatric vaccination: PCV7 
Indirect effects: applied herd effects 
Methods: as a factor for correction of indirect 
(herd) effects based on US data adjusted for 
German serotype coverage. 
No. VE of PCV13 
is not based on 
CAPITA 





Analysis: CEA of PCV13 ag. IPD and nIPD vs 
no vaccination and current practice with 
PPSV23 
Perspective: societal  
Time horizon: lifetime 
Model type: Markov state-transition model 
Health Outcomes: QALY 
Vaccine price, year: PPSV23 $43, PCV13 $128, 
2006 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: PCV13 vaccination was favoured 
compared to PPSV23 
strategies: 
- PCV13 in current 
ACIP* 
recommendations 
- PCV13  at 50y.o + 
PPSV23 65y.o 
- PCV13 at ages 50 
and 65 
- PCV13 at ages 50 
and 65, then 
PPSV23 at age 75. 
Coverage: 60.1% 
age-based;  33.9%  
comorbidity-based  
Source of VE:  estimates of a Delphi expert panel 
Parameter: age, risk dependent 
PCV13 ag IPD: 50y.o: 90%|65y.o:85% 
Immunocompromised (all ages): 50% 
PCV13 ag.nIPD:50y.o: 74%|65y.o:64% 
Immunocompromised (all ages): 35% 
PPSV23: 50y.o: 93%|65y.o:85%|80y.o:67% 
Immunocompromised (all ages): 0% 
Waning: age dependent VE by years since vaccination 
PCV13 - over 15 y., PPSV23 – over 10 y. 
Expected vaccine protection over time (healthy): 
PCV13 ag. IPD: 50y.o: 9.6y.| 65y.o:8.1y  
PCV13 ag. nIPD: 50y.o: 8y.|65y.o:7.3y 
PPSV23 ag. IPD: 50y.o: 8.1y.|65y.o:5.2y.| 80y.o:3.2y. 
Paediatric vaccination: PCV13 
Indirect effects: applied herd immunity 
Methods: extrapolated based on observed age-
related PCV7 effects (except serotypes 1 and 
5). Potential indirect PCV13 effects for NPP 
were modelled using point estimates for 
decreases observed after PCV7 introduction. 
No. VE of PCV13 
is not based on 
CAPITA 
Weycker et al, 
USA, 2012 
(Weycker et al. 
2012) 
Analysis: CEA od PCV13 ag. IPD and nIPD vs 
no vaccination, current vaccination program 
with PPSV23  
Perspective: healthcare 
Time horizon: lifetime 
Model type: microsimulation framework and a 
≥50 y.o 





Source of VE: PCV13 - assumed based on observed 
PCV7 data in children. Refer to Black et al (Black et al. 
2000) 
PPSV23 – Delphi expert panel. Refer to Smith et al, 
2008(Smith et al. 2008) 
Parameter: 
Paediatric vaccination:PCV13 
Indirect effects: applied herd immunity 
Methods: assumption 
No. VE of PCV13 
is not based on 
CAPITA 
Markov type process  
Health Outcomes: disease-related cases, deaths 
Vaccine price, year: PPSV23 $49, PCV13 $108  
2010 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: routine use of PCV13 – in lieu of 
PPSV23 – would result in a greater reduction in 
the overall burden of pneumococcal disease 
recommendations.  
Coverage varies by 
age, risk profile, 
and vaccination 
history 
Varies for low and high risk groups; and for those with 
NBP requiring inpatient and outpatient care. 
Here are the values for low risk group:  
PCV13 ag IPD: 50-64y.o: 90%|65-74y.o:85% 
75-84y.o:80%|>85y.o:73% 
PCV13 ag NBP inpatient: 50-64y.o:25%|65-
74y.o:24%|75-84y.o:23%|>85y.o:22% 
PPSV23 ag. IPD: 50-64y.o: 83%| 65-74y.o:77%|75-
84y.o:68%|>85y.o:57% 
Waning: efficacy by years since vaccination, PCV13 - 
over 15 y., PPSV23 – over 10 y. 
Expected vaccine protection over time:  
PCV13 ag IPD: 50-64y.o: 8.2y.|65-74y.o:6.8y. 
75-84y.o:5.5y.|>85y.o:3.4y. 
PCV13 ag NBP inpatient: 50-64y.o: 2.3y|65-
74y.o:2.3y|75-84y.o:1.8y|>85y.o:1.5y 
Zhao et al, 
2016, Shanghai, 
China (Zhao et 
al. 2016) 
Analysis: CEA of PPSV23 ag IPD vs no 
vaccination 
Perspective: societal 
Time horizon: lifetime 
Model type: static cohort 
Health Outcomes: QALY, LYG 
Vaccine price, year: PPSV23 - $23.2, 2015  
Discount: Cost: 5%; Outcomes:5% 
Conclusion: is cost-effective 
≥60 y.o, 63% Source of VE: systematic review and meta-analysis 
(Kraicer-Melamed et al. 2016; Diao et al. 2016) 
Parameter: PPSV23 ag IPD: 50%, ag nIPD: 0% 
Waning: given as % of initial VE by years since 
vaccination, waning to 0% by year 9; refer to (Jiang et al. 
2012) 
Expected vaccine protection over time:  
 PPSV23 ag IPD: 2.2y 
Paediatric vaccination: no vaccination of 
children according to the current data 
(International Vaccine Access Center) 
Indirect effects: n/a 
Methods: n/a 
No. No childhood 
vaccination 
program 




Analysis: CEA of PCV13, PPSV23, combination 
ag IPD and nIPD vs no vaccination 
Perspective: societal 
Time horizon: lifetime 
Model type: Markov state-transition model 
Health Outcomes: QALY 
Vaccine price, year: : PPSV23 $43, PCV13 
$128, 2006 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: single-dose PCV13 strategies are 
likely to be economically reasonable in older 
adults 
Strategies:  
Cohort 65 y.o -15 
strategies; 
Cohort 75y.o -7 
strategies, include 
different age of 
administration, 
PCV13 and 
PPSV23 alone and 
in combination 
 
Source of VE: Delphi expert panel 
Parameter: age, risk dependent 
PCV13 ag IPD: 65y.o: 85%|75y.o:79% 
Immunocompromised (all ages): 50% 
PCV13 ag nIPD: 65y.o: 64%|75y.o:59% 
Immunocompromised (all ages): 35% 
PPSV23 ag IPD: 65y.o: 80%|80y.o:67% 
Immunocompromised (all ages): 0% 
Waning: age dependent VE by years since start PCV13 - 
over 15 y., PPSV23 – over 7 y. 
Expected vaccine protection over time (healthy): 
PCV13 ag IPD:65-75y.o:9.6y.|>=75y.o:8y 
PCV13 ag nIPD: 65-75y.o:7.3y.|>=75y.o:6y 
PPSV23 ag IPD: 65-80y.o:5.2y.|>=80y.o:3.4y 
Paediatric vaccination: PCV13  
Indirect effects: herd immunity and serotype 
replacement  
Methods: projections of PCV7 effects 
No.VE of PCV13 
is not based on 
CAPITA 
Chen et al, 
2014, USA 
(Chen et al. 
2014) 
Analysis: CEA of PCV13, combination with 
PPSV23 ag IPD and nIPD vs no vaccination 
Perspective: payer 
Time horizon: lifetime 
Model type: static single cohort  
Health Outcomes: QALY 
Vaccine price, year: PCV13 $120.95, PPSV23 
$57.70, administration - $15.00 ,2012 
Discount: Cost: 3%; Outcomes:3% 









Source of VE: estimates by a Delphi expert panel 
Parameter: 
PCV13 ag IPD:  
Healthy: 50y.o:80%|65y.o:72.5% 
Immunocompetent with comorbidities: 
50y.o:67.5%|65y.o:61.2% 
Immunocompromised: 50y.o:53%|65y.o:48% 
PCV13 ag nIPD:  
Healthy: 50y.o:68%|65y.o:60.5% 
Paediatric vaccination: PCV13 
Indirect effects: non in base case, applied in 
SA herd immunity and replacement  
Methods: projections of observed PCV7 
effects, three sets of assumptions 
No. VE of PCV13 
is not based on 
CAPITA; indirect 
effects are applied 
in SA 
Conclusion: additional dose 
of PCV13 at age 65, followed by PPSV23, for 
adults with immunocompromising conditions 
is cost-effective 
Immunocompetent with comorbidities: 
50y.o:56%|65y.o:49.8% 
Immunocompromised: 50y.o:7%|65y.o:6.2% 
PPSV23 ag IPD:  
Healthy: 50y.o:82.7%|65y.o:73.7% 
Immunocompetent with comorbidities: 
50y.o:70.3%|65y.o:62.7% 
Immunocompromised: 50y.o:18%|65y.o:16.1% 
PPSV23 ag nIPD: 
Healthy: 50y.o:49.5%|65y.o:36.5% 
Immunocompetent with comorbidities: 
50y.o:36.5%|65y.o:26.9% 
Immunocompromised: 0% 
Waning: assumed linear waning, PCV13 over 15y., 
PPSV23 over 10y. 
Expected vaccine protection over time:  
 cannot calculate  






Analysis: BIA,CEA of PCV13 ag pneumococcal 
pneumonia (PP) vs no vaccination 
Perspective: National Health Service 
Time horizon: 5 years 
Model type: economic model 
Health Outcomes: disease-related cases 
Vaccine price, year: €42.5, not stated  
Discount: Cost: 3%; Outcomes: none 
Conclusion: both hypothesized immunization 
strategies could produce savings 
2 scenarios 
- high risk people of 
50-79 years old 
- high risk people of 
50-64 years old and 
people ≥65 years 
old 
Coverage: 60% 
Source of VE: previously published studies 
Parameter: PCV13 ag PP: 87.5% 
Waning: not stated. The study does not provide in detail 
information about the input parameters. It may be 
assumed that the VE of PCV13 was applied for 5 years of 
full protection.  
Expected vaccine protection over time:  
 n/a 
Paediatric vaccination: PCV13 
Indirect effects: the authors do not mention 
the paediatric vaccination 
Methods: n/a 
No VE of PCV13 
is not based on 
CAPITA; indirect 





nez and Orozco 
2014) 
Analysis: CEA of PCV13 ag IPD and nIPD vs 
no vaccination and PPSV23. 
Perspective: third party payer 
Time horizon: 5 years 
Model type: Markov microsimulation model 
Health Outcomes: disease-related cases, deaths 
Vaccine price, year: PCV13  U.S.$ 15.84, 
PPSV23 U.S.$6.60, 2013 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: cost-saving strategy  
individuals ≥50 y.o, 
70% 
Source of VE: PCV13 -  adapted from VE of PCV7 for 
children with assumption: similar VE ag. 6 serotypes not 
included in PCV7. Refer to (Black et al. 2000),(Hansen et 
al. 2006) 
PPSV23 - estimates of Delphi expert panel. Refer to 
Smith,2008 (Smith et al. 2008), Shapiro et al(Shapiro et 
al. 1991)  
Parameter: 
PCV13 ag IPD: 50-64y.o:88.9%|65-74y.o:81.5% 
75-79y.o:75.7%|80-99y.o:70.3% 
PCV13 ag CAP-inpatient/CAP-outpatient 
50-64y.o:24.2%; 5.6%|65-74y.o:21.9%/5.1%| 
75-79y.o:20.2%/4.7%|80-99y.o:18.7%/4.3% 
PPSV23 ag IPD: 50-64y.o:79.2%|65-74y.o:61.6% 
75-79y.o:50.4%|80-99y.o:42.1% 
Waning: not explicitly given, assumed rate of decline, for 
PPSV23 refer to (Alonso-Fernández and La Fuente 
2011), for PCV13- decline assumed as 50% of the 
corresponding rate of decline for PPSV23. 
Expected vaccine protection over time:  
 cannot calculate 
Paediatric vaccination: PCV10 
Indirect effects: the authors do not mention 
the paediatric vaccination 
Methods: n/a 
No. VE of PCV13 
is not based on 
CAPITA; indirect 
effects are not 
applied 
Soarez et al, 
2015, Brazil 
(Soarez et al. 
2015) 
Analysis: CEA of universal PPSV23 vaccination 
ag IPD and nIPD vs vaccination of 
institutionalized elderly and elderly with 
underlying  diseases 
Perspective: health system, societal 
Time horizon:10 years  
Model type: Markov, single cohort 
Health Outcomes: life years saved (LYS) 
Vaccine price, year: USD$6.25, not stated 
Discount: Cost: 5%; Outcomes:5% 
Conclusion: universal vaccination with PPSV23 
is very cost-effective 
≥50 y.o, single 
dose, 80% 
Source of VE: ag IPD: a meta-analysis of 18 randomized 
control trials and 7 non randomized studies (Moberley et 
al. 2013);  
ag nIPD: observational studies (Ochoa-Gondar et al. 
2014; Vila-Córcoles et al. 2006) 
Parameter: PPSV23 ag IPD: 68%; ag nIPD: all cause Pn: 
25%;  NBPP: 45% 
Waning: protection ag IPD: 3rd - 5th year: 6.8% 
6th-10th year: 8.5% waning 
Protection ag nIPD: full for 5 years.  
Expected vaccine protection over time:  
ag IPD: 5.8y.; ag nIPD: 1.25y. 
Paediatric vaccination: PCV10 
Indirect effects: not included 
Methods: n/a 
No. Indirect 
effects are not 
applied 
Hoshi et al, 
2015, Japan 
(Hoshi et al. 
2015) 
Analysis: CEA of PPSV23, PCV13 ag IPD and 
nIPD vs current vaccination with PPSV23, no 
vaccination 
Perspective: payers’ 
Time horizon: 15 years 
Model type: Markov 
Health Outcomes: QALY 
Vaccine price, year: PPSV23- US$43, PCV13 - 
US$65, 2014 
Discount: Cost: 3%; Outcomes:3% 
Conclusion: scenarios with different 
levels of share of PCV13 have favourable ICERs 
but were not cost-saving compared to 
current strategy; ≥65 PPSV23 strategy or 




year olds, ≥65 year 




dose. 10 scenarios 
with varying 
PCV13 diffusion 
levels. Coverage for 
all 50.4% 
 
Source of VE: based on 3 sources: 
Smith et al (2012),(Smith et al. 2012) for both vaccines; 
Cochrane literature review(Moberley et al. 2013) for 
PPSV23; CAPITA study for PCV13(Bonten et al. 2015) 
Parameter: 
PCV13 ag IPD: 65-79y.o:75%|≥80y.o:62.8% 
PCV13 ag nIPD: 65-79y.o:45%|≥80y.o:37.7% 
PPSV23 ag IPD:65-79y.o:82%|≥80y.o:68.7% 
PPSV23 ag nIPD:0% 
Waning: PCV13 over 15y., PPSV23 over 7y. VE by 
years since vaccination, age-dependent.  
Expected vaccine protection over time: 
PCV13 ag IPD: 65-79y.o:7.1y|≥80y.o:3.4y 
PCV13 ag nIPD: 65-79y.o:4.9y|≥80y.o:2.1y 
PPSV23 ag IPD: 65-79y.o:5.3y|≥80y.o:3.4y 
Paediatric vaccination: PCV7, PCV13 
Indirect effects: indirect effects not included 
because of "fear of bias" 
Methods: n/a 
No. Indirect 
effects are not 
applied 
 
Abbreviations: ACIP  the Advisory Committee on Immunization Practices; CAP -community-acquired pneumonia; CEA  - cost-effectiveness analysis; LYG - life years gained; n/a – not applicable;  nIPD – non-invasive pneumococcal diseases; PD - pneumococcal disease; Pn - pneumonia; 
SA - sensitivity analyses; STIKO - the German standing committee for vaccination;  VE- vaccine effectiveness; y.- years; y.o - years old  
 
 
* ACIP at the time of the study: vaccinate all persons with PPSV23 at age 65; those who received PPSV23 before age 65 for a comorbid condition are 
recommended to receive another dose at age 65 or later if at least 5 years have passed since the previous dose 
**ACIP,2012 - to include a sequential regimen of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide 
vaccine (PPSV23) for certain high-risk adults with immunocompromising conditions (Chen et al. 2014). 
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S3: Summaries of the main studies used as sources for the vaccine 
effectiveness estimates. 
Pneumococcal conjugate vaccines. 
PCV7 
Black et al. 2000: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate 
vaccine in children. (RCT) [1] 
Population Healthy infants  
Intervention PCV7 vaccinated at 2, 4, 6 and 12 to 15 months 
Comparator meningococcus type C conjugate vaccine 
Outcome Primary: Invasive disease caused by vaccine serotype 
Secondary: Invasive disease regardless of serotype, effectiveness against clinical 
otitis media visits and episodes, impact against frequent and severe otitis media and 
ventilatory tube placement 
Setting 23 medical centers within Northern California 
Kaiser Permanente (NCKP) 
The authors present the results of a double blind, randomized trial in which 37,868 children at 2, 4, 6 
and 12 to 15 months were assigned to the heptavalent pneumococcal or the meningococcus type C 
vaccine. Enrollment was between October 1995 and August 1998. The interim analysis was conducted 
in August 1998 and showed the following results. VE against IPD showed to be 97.4% for per 
protocol fully vaccinated and 93.9% for the intention to treat population. No age-stratification or 
information on waning are given. 
 
PCV13 
Bonten et al. 2015: Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in 
Adults. (RCT) [2] 
Population Adults 65 years of age or older 
Intervention PCV13 (+ influenza vaccine), one shot 
Comparator Placebo (+ influenza vaccine) 
Outcome first episodes of vaccine-type strains of pneumococcal CAP, nonbacteremic and 
noninvasive pneumococcal, CAP, IPD 
Setting 101 temporary community-based sites throughout the Netherlands 
The efficacy of PCV13 was evaluated via a randomized, double-blind, placebo-controlled trial (the 
CAPITA study) involving 84,496 adults 65 years of age or older for the end-points pneumococcal 
community-acquired pneumonia (CAP), nonbacteremic and noninvasive pneumococcal community-
acquired pneumonia (NCAP), and invasive pneumococcal disease (IPD). The mean follow-up time 
was 3.97 years for which the VE showed to be 45.6% against CAP, 45.0% against NCAP and 75.0% 
against IPD for the per protocol analysis and 37.7%, 41.1%% and 75.8% for the intention to treat 
analysis, respectively. The VE was persistent throughout the duration of the trial. 
Frenck et al. 2016: Immunogenicity and safety of a second administration of 13-valent 
pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. 
(Cohort) [3] 
Population Adults 55 to 65 years of age or older 
Intervention Revaccination with PCV13 (+ influenza vaccine) five years after initial vaccination 
Comparator NA 
Outcome Antipneumococcal polysaccharide opsonophagocytic activity (OPA) geo-metric 
mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations 
(GMCs) 
Setting 34 sites in the United States 
This study reports on the waning antibody titers within five years of the vaccination of 50 to 59 year 
old (at first vaccination) and the ability of re-vaccination to boost titers. The study reports no patient 
relevant outcomes besides adverse events. The authors state that “antibody titers were maintained for 
at least 5 years after vaccination”. However, the plots indicate a decline in titers over the five years. 
Patterson et al. 2016: A post hoc assessment of duration of protection in CAPITA (Community 
Acquired Pneumonia immunization Trial in Adults). (RCT) [4] 
Population Adults 65 years of age or older 
Intervention PCV13 (+ influenza vaccine), one shot 
Comparator Placebo (+ influenza vaccine) 
Outcome first episodes of vaccine-type strains of pneumococcal CAP, nonbacteremic and 
noninvasive pneumococcal, CAP, IPD 
Setting 101 temporary community-based sites throughout the Netherlands 
This paper presents a re-analysis of the data presented in Bonten et al. 2015 from the CAPITA trial 
with an emphasis on the duration of protection (i.e., waning). The results show that PCV13 was 
protective over the 5-year duration of the study, with no waning of efficacy observed. VE against 
vaccine-type CAP varies between 42.9% and 50.0%, vaccine-type IPD between 66.7% and 75.0% and 
nonbacteremic/noninvasive-vaccine-type CAP between 36.2% and 48.9% for the first five years after 
vaccination. 
van Werkhoven et al. 2015: The Impact of Age on the Efficacy of 13-valent Pneumococcal 
Conjugate Vaccine in Elderly. (RCT) [5] 
Population Adults 65 years of age or older 
Intervention PCV13 (+ influenza vaccine), one shot 
Comparator Placebo (+ influenza vaccine) 
Outcome first episodes of vaccine-type strains of pneumococcal CAP, nonbacteremic and 
noninvasive pneumococcal, CAP, IPD 
Setting 101 temporary community-based sites throughout the Netherlands 
This paper presents a re-analysis of the data presented in Bonten et al. 2015 from the CAPITA trial 
with an emphasis on the impact of age on VE. Age-dependent VE was estimated via a Cox 
proportional hazard model and the results by age are given as graphical representation including a 95% 
confidence interval based on 2,000 bootstrap samples. 
Pneumococcal polysaccharide vaccines. 
PPSV23 
Andrews et al. 2012: Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine 
against invasive pneumococcal disease in the elderly in England and Wales. (Case control) [6] 
Population Adults 65 years of age or older 
Intervention PPSV23 (and PCV7 vaccination for children) 
Comparator No vaccination 
Outcome IPD 
Setting England and Wales between 1998/99 and 2009/10 
The authors present a combined ecological and case-control study. The ecological study documents 
the changes in overall and serotype specific incidence of IPD in England and Wales between 1998/99 
and 2009/10.  The proportion of cases with specified serotypes increased over time from 36% to 83% 
over the covered period. Stratification by serotype includes the categories “Non23v”, “23v”, “23v-7v” 
and “7v”. Results on PPSV23 effectiveness against IPD are available for the age groups 65-74, 75-84 
and ≥85 years and are given for the time periods <2 years, 2 to <5 years and ≥ 5 years. 
Diao et al. 2016: Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing 
community-acquired pneumonia among immunocompetent adults: A systematic review and 
meta-analysis of randomized trials. (Meta-analysis) [7] 
Population Immunocompetent adults ≥15 years 
Intervention PPSV23 
Comparator Placebo, influenza vaccine or no intervention 
Outcome all-cause pneumonia, pneumococcal pneumonia, all-cause mortality and mortality 
due to pneumonia 
Setting worldwide 
This study presents the results of a systematic review and meta-analysis on RCTs on the effectiveness 
of PPSV23 in immunocompetent adults ≥15 years. 7 randomized trials involving 156,010 participants 
were included in the meta-analysis and found a weak association between PPSV23 vaccination and 
all-cause pneumonia [RR 0.87, 95%CI 0.76–0.98]. The protective effect was stronger for the target 
population, defined as adults ≥65 years and patients at high risk for pneumonia, with [RR 0.72, 95%CI 
0.69–0.94] and against pneumococcal pneumonia [RR 0.54, 95%CI 0.18–1.65]. No results on vaccine-
serotypes, age or time since vaccination (waning) are given. 
Falkenhorst et al. 2017: Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine 
(PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. 
(Meta-Analysis) [8] 
Population Adults 60 years of age or older 
Intervention PPSV23 
Comparator NA 
Outcome IPD, pneumococcal pneumonia 
Setting Industrialized countries 
This publication presents the results of a systematic literature review and a meta-analysis of the VE of 
PPSV23 in the elderly, defined as ≥60 years of age, against pneumococcal pneumonia (PP) and 
invasive pneumococcal disease (IPD). 13 observational studies and four RCTs are included that 
compare PPSV23 with a “no vaccination” strategy or placebo. For IPD pooled results for all-type IPD 
showed a VE of 73% in the clinical trials vs. 58% for cohort studies and 59% for case-control studies. 
Vaccine-type IPD was only reported in two case-control studies (73% VE). For PP pooling resulted in 
a VE of 25% in clinical trials, 53% in one case control study an 37% in one case-case study. The 
results are not available by age or over time. 
Gutierrez Rodriguez et al. 2014: Effectiveness of 23-valent pneumococcal polysaccharide vaccine 
in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. (Cohort) [9] 
Population Adults 60 years of age or older 
Intervention PPSV23 (within and after the fifth year after vaccination) 
Comparator NA 
Outcome IPD 
Setting Region of Madrid, Spain, 2008–2011 
The study analyzes the IPD incidence in the region of Madrid between 2008 and 2011 of persons 60 
years and older and estimates the vaccine effectiveness (VE) via two different approaches, i.e., the 
screening method and the indirect cohort method. Persons were deemed as “vaccinated” if vaccination 
happened at least 15 days before the onset of IPD symptoms, but no upper limit on the period since 
vaccination has been applied. Analysis of VE were stratified by the groups “vaccinated within 5 years” 
and “vaccinated more than 5 years ago”. The unadjusted VE of PPSV23 was estimated to be 40.5% 
[95%CI 28.3%-59.4%] and increased to 72.8% [95%CI 59.1%-81.8%] in the adjusted analysis. The 
unadjusted VE varies by the time since vaccination with 44.5% if persons were vaccinated within the 
previous five years and 32.5% if the vaccine had been administered more than five years. 
Huss et al. 2009: Efficacy of pneumococcal vaccination in adults: a meta-analysis. (Meta-
analysis) [10] 
Population Adults (no age boundary given) 
Intervention PPSV 
Comparator Placebo, other vaccines or no intervention 
Outcome (a) definitive pneumococcal pneumonia, defined as typical clinical or radiologic 
findings and S. pneumoniae isolated from normally sterile body fluid such as blood; 
(b) presumptive pneumococcal pneumonia, defined as typical clinical or radiologic 
findings, and either S. pneumoniae isolated from respiratory tract samples or 
seroconversion against S. pneumoniae; (c) pneumonia from all causes; (d) 
bronchitis from all causes; (e) death from all causes; (f) death from pneumonia; (g) 
death from pneumococcal infection; and (h) bacteremia or invasive pneumococcal 
disease, defined as S. pneumoniae isolated from a usually sterile body fluid such as 
blood 
Setting worldwide 
This meta-analysis includes 22 studies to pool the evidence on the effectiveness of PPSV vaccines, 
with 8 trials reporting findings on the 23 valent vaccine. The authors found the vaccines to be more 
effective on definitive pneumococcal pneumonia (RR0.62, 95%CI 0.05–8.61) than on all-cause 
pneumonia (RR0.73, 95%CI 0.56–0.94). The protective effect on bacteremia was not significant 
(RR0.90, 95%CI 0.46–1.77) which they also found for death from pneumococcal infections (RR0.93, 
95%CI 0.29–3.05). No stratification according to the valency of the vaccine, age group or time since 
vaccination (waning) is provided. 
Kraicer-Melamed et al. 2016: The effectiveness of pneumococcal polysaccharide vaccine 23 
(PPV23) in the general population of 50 years of age and older: A systematic review and meta-
analysis. (Meta-analysis) [11] 




Outcome IPD, pneumococcal pneumonia 
Setting General population (i.e., no nursing home residents) 
 
This paper presents the results of a systematic review and meta-analysis of the PPSV23 VE in persons 
50 years and older against IPD and CAP. 32 studies have finally been included in the analyses with 12 
studies reporting only on IPD and 12 only on CAP. 3 publications were reporting results from trials, 
11 cohort studies, 10 case control studies, 3 ecological studies and 5 studies using data from 
surveillance systems. The pooled VEs were 50% (95%CI 21–69%) for cohort studies and 54% 
(95%CI 32–69%) for case–control studies against IPD, and 4% (95%CI -26% to 26%) for trials, 17% 
(95%CI −26% to 45%) for cohort studies, and 7% (95%CI -10% to 21%) for case–control studies 
against CAP. No further stratification of the results can be found. 
Middleton et al. 2008: Economic Evaluation of Standing Order Programs for Pneumococcal 
Vaccination of Hospitalized Elderly Patients. (Economic Evaluation) [12] 
Population Hospitalized adults 65 years of age or older 
Intervention PPSV23 vaccination according to SOP 
Comparator PPSV23 vaccination without SOP 
Outcome Vaccination rates, cost-effectiveness 
Setting The University of Pittsburgh Medical Center Health System 
This study is a cost-effectiveness analysis using data on VE from another cost-effectiveness study 
(Weaver et al. 2001) that uses data from Shapiro et al. 1991 in the form as reported by another cost-
effectiveness study (Sisk et al. 1997).   
Ochoa-Gondar et al. 2014: Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine 
Against Community-Acquired Pneumonia in the General Population Aged ≥60 Years: 3 Years 
of Follow-up in the CAPAMIS Study. (Cohort) [13] 
Population Adults 60 years of age or older 
Intervention PPSV23 
Comparator NA 
Outcome bacteremic pneumococcal CAP 
nonbacteremic pneumococcal CAP 
all-cause CAP 
Setting General population in Tarragona, Spain 
This paper presents the results of a population-based cohort study including 27,204 persons 60 years 
and older between 2008 and 2011 which evaluates the effectiveness of PPSV23 against pneumococcal 
and all-cause CAP, respectively. Comparing vaccinated with un-vaccinated persons revealed no 
significant protective effect of PPSV against bacteremic pneumococcal CAP, nonbacteremic 
pneumococcal CAP, all-cause CAP or mortality, even when adjusting for available co-variates. Only 
considering persons vaccinated during the study period showed a protective, significant effect of the 
vaccine agains pneumococcal CAP (hazard ratio 0.09). 
Shapiro et al. 1991: The protective efficacy of polyvalent pneumoccal polysaccharide vaccine. 
(Case control) [14] 
Population Adults 60 years of age or older 
Intervention PPSV23 and PPSV14 
Comparator No vaccination 
Outcome S. pneumonia infections as confirmed isolations 
Setting 11 large hospitals in Connecticut, USA 
The authors present the results of a case control study analyzing the effectiveness of the 14-valent and 
the 23-valent vaccine. From 1,054 cases with isolated S. pneumoniae 137 had received a vaccine 
compared to 211 vaccinated persons of 1,054 controls. 191 cases were categorized as immune-
compromised. The VE against vaccine-serotypes, calculated as 1 minus odds ratio of being vaccinated 
divided by 100, was 56% [95%CI 42%-67%]. VE was higher for immune-competent patients with 
61% [95%CI 47%-72%]. Results for immune-competent patients are further stratified by age groups 
(<55, 55-64, 65-74, 75-84, ≥85) and time since vaccination (<3 years, 3-5 years, >5 years). VE 
decreases with age and time since vaccination. 
Smith et al. 2008: Alternative strategies for adult pneumococcal polysaccharide vaccination: A 
cost-effectiveness analysis (Economic evaluation) [15] 
Population Adults 50 years of age or older 
Intervention Different strategies of PPSV23 vaccination 
Comparator No vaccination 
Outcome Cost-effectiveness 
Setting USA 
This study presents the results of a cost-effectiveness analysis on different vaccination strategies using 
PPSV23. The VE is estimated via a Delphi expert panel that used the data of Shapiro et al. 1991 as 
basis for the expert estimates. Values are estimated for healthy persons in three age groups (50 years, 
65 years and 80 years) and for immunocompromised of all ages, each for different time points after 
vaccination (1, 3, 5, 7, 10 and 15 years). 
Smith et al. 2012: Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal 
Conjugate Vaccine Compared with Pneumococcal Polysaccharide Vaccine. (Economic 
evaluation) [16] 
Population Adults 50 years of age or older 
Intervention PCV13 
Comparator PPSV23 
Outcome Pneumococcal disease cases prevented, cost-effectiveness 
Setting USA 
This study presents an update of Smith et al. 2008 which examines the cost-effectiveness of PCV13 
compared to PPSV23. The VE estimates for PPSV23 are taken from this previous study and the 
effectiveness of PCV13 against IPD and NPP is also estimated via a Delphi expert panel. These new 
estimates are given for 50-year old, healthy persons, 65-year old healthy persons and 
immunocompromised persons of all ages. Reduced effectiveness (waning) is given at 1, 3, 5, 10 and 
15 years after vaccination. 
Vila-Corcoles et al. 2006: Protective Effects of the 23-Valent Pneumococcal Polysaccharide 
Vaccine in the Elderly Population: The EVAN-65 Study. (Cohort) [17] 
Population Adults 65 years of age or older 
Intervention PPSV23 
Comparator NA 
Outcome invasive pneumococcal disease, pneumococcal pneumonia, overall pneumonia rate, 
death due to pneumonia 
Setting 8 primary health care centers in Tarragona, Spain, January 2002 through April 2005 
 
This study examined the VE of PPSV23 in community-dwelling persons ≥65 years of age against IPD, 
pneumococcal pneumonia, overall pneumonia and pneumonia-related mortality. The prospective 
cohort study collected data on 11,241 subjects and lasted from January 2002 until April 2005. 4,986 
persons were already vaccinated at the begin of the study of which 4,314 had been vaccinated within 2 
years before the study. 1,449 of the 6,255 unvaccinated persons at the begin were vaccinated during 
the study period. The multi-variable Cox model showed a protective effect of PPSV23 against 
serotype-related IPD of HR 0.61 [95%CI 0.13-2.76], a HR of 0.60 [95%CI 0.22-1.65] against all-type 
IPD, a HR of 0.45 [95%CI 0.15-1.40] against bacteremic pneumococcal pneumonia and a HR of 0.61; 
[95%CI 0.35–1.06] against overall pneumococcal pneumonia. 
Vila-Corcoles et al. 2009: Clinical effectiveness of 23-valent pneumococcal polysaccharide 
vaccine against pneumonia in middle-aged and older adults: A matched case–control study. 
(Case control) [18] 
Population Adults 50 years of age or older 
Intervention PPSV23 
Comparator No vaccination 
Outcome Pneumococcal pneumonia (bacteremic and non-bacteremic), stratified by vaccine- 
and non-vaccine serotypes 
Setting 19 participating PHCCs and Laboratory Departments of 3 reference hospitals in 
Tarragona, Spain, January 2002 to April 2007. 
In this study the VE of PPSV23 is estimated via a matched case control study of 304 cases of 
radiographically confirmed pneumococcal pneumonia above the age of 50 years and 608 matched 
controls taken from January 2002 to April 2007. Study participants are considered vaccinated if they 
received the vaccine at least 14 days before the onset of the disease. No information is given on the 
average duration of vaccine protection. VE is calculated via a conditional logistic regression resulting 
in adjusted odds ratios (OR). Against all pneumococcal pneumonia the VE was 48% [OR: 0.52; 
95%CI 0.37–0.73] and more effective against bacteremic pneumococcal pneumonia with 66% [OR: 
0.34; 95%CI 0.27–0.66]. VE against vaccine-type serotypes was 76% [OR: 0.24; 95%CI 0.09–0.66]. 
PPSV9 
Klugmann et al. 2003: A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with 
and Those without HIV Infection. (RCT) [19] 
Population Infants 
Intervention PPSV9 + Haemophilus influenzae type b conjugate vaccine  
administered at 6, 10, and 14 weeks of age 
Comparator Placebo + Haemophilus influenzae type b conjugate vaccine 
administered at 6, 10, and 14 weeks of age 
Outcome Invasive pneumococcal disease 
Setting Soweto, South Africa 
The efficacy of a PPSV9 vaccine was evaluated on 19,922 children with and without HIV vaccinated 
at 6, 10 and 14 weeks of age in Lesotho, South Africa, and compared to 19,914 controls. It is unclear 
what the distribution of the HIV serostatus of the children is, but results are reported stratified by HIV 
status. In HIV-negative children, the VE against IPD against the serotypes covered by PPSV9 was 
83% [95%CI 39%-97%] with 3 cases in the vaccinated group and 17 in the control group. Efficacy 
against pneumonia is not reported stratified by serotype and is estimated to be 20% [95%CI 2%-35%] 
in HIV-negative children.  
PPSV 
Moberley et al. 2008: Vaccines for preventing pneumococcal infection in adults. (Meta-analysis) 
[20] 
Population Adults ≥16 years 
Intervention PPSV vaccination 
Comparator No vaccination, placebo, control vaccines 




This study presents the results of a Cochrane systematic review and meta-analysis on the VE of PPSV 
vaccines in persons ≥16 years of age. 22 studies are included in the meta-analysis. Unfortunately, the 
studies are not group by valency and the results are pooled of 7 studies using 23-valent vaccine, 1 
study on a 17-valent, 8 studies on a 14-valent, 2 studies on 12-valent, 3 studies on 6-valent, 1 study on 
2-valent and 1 study with an unspecified vaccine. The meta-analysis found a strong VE against IPD of 
74% (95% CI 55% to 86%) [OR 0.26; 95%CI 0.15-0.46], but inconclusive evidence against all cause 
pneumonia with a VE of 29% [OR 0.71; 95%CI 0.52-0.97]. Immunosuppressed persons seem to be 
less protected. No estimates for vaccine-serotypes are reported. No stratification by age or time since 
vaccination is performed. 
Moberley et al. 2013: Vaccines for preventing pneumococcal infection in adults. (Meta-analysis) 
[21] 
Population Adults ≥16 years 
Intervention PPSV vaccination 
Comparator No vaccination, placebo, control vaccines 




This paper is an update on the previously published Cochrane meta-analysis of Moberley et al. 2008. 
The analysis includes three more studies, all of which examine the effectiveness of PPSV23. The 
results against IPD are fairly similar with a VE of 74% [OR 0.26, 95%CI 0.14-0.45] and higher than in 
the previous analysis with 46% [OR 0.54, 95%CI 0.43-0.67] against all-cause pneumonia. 
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S4 Table 1: Base-case incidence rates per 100,000 people and vaccine effectiveness parameters in the studies included into the quality assessment of 







Rates per 100,000 population used in base-case analysis 
 
Source of incidence 
IPD indication non-IPD of pneumococcal origin  























33.0-3581 different age 
groups as for IPD 
NBPP = 40% of NBP; 
No vaccine type division   
IPD incidence is also given for vaccine-related serotype groups. 
Estimated based on findings from the German prospective laboratory-based surveillance [2]. 








































10% of NBP are attributable to  
PCV13 vaccine serotypes 
Incidence of IPD, inpatient- and outpatient CAP is stratified by age- (18-≥84y.o) and risk-
group. Serotype (PCV13 and nonPCV13) distribution of IPD stratified by age-group. IPD: 
Dutch surveillance from nine Dutch sentinel microbiology laboratories[5]. in-CAP: CAP-
START and DHC:  cluster-randomized-cross-over trial in seven Dutch hospitals. out-CAP: 
Julius GP Network - database containing anonymous routine healthcare data from the digital 
patient records of 45 GP practices 
Blommaert 























27.3% of NBP IPD or non-IPD cases per year are calculated using the disease-specific hospitalization rates. 
Incidence for BP and NBPP are calculated based on assumptions which are tested in SA: age-
independent proportion BP and case-fatality are equal for BP and NBP. Source: the Belgian 
government’s hospitalisations database 
R-G-Moro 






















Not given  IPD: [8]; nIPD: a retrospective epidemiological study, Spain[9]; data from the Centers for 
Disease Control and Prevention; No proportion of all cause-NBP cases attributable to vaccine 
























10% NBPP due to PCV13 
serotypes 
 
IPD: Active Bacterial Core Surveillance data of 2013, unpublished data  
in- NBPP:  analysis of data from a private inpatient discharge record database by Simonsen et 
al. (2014) [11] 
out-NBPP: population-based pneumonia surveillance, Nelson et al. (2008)[12] 
van Hoek 

















Vaccine-type incidence of IPD is 
reported for modelled years. 
Vaccine-type incidence of IPD is reported for modelled years. Here are the IPD rates caused by 
PCV13 serotype for 2015/2016y.  
In 2018/2019 a steady-state is assumed 
Source: surveillance data collected by Public Health England: July-June from 2002/03 to 
2013/2014 [13]. 
Dirmesropi





























IPD by PCV13 types:  
0.284, 0.293, 0.299, 0.324 0.330 
nIPD by PCV13: 0.139 of NBP   
IPD by PPSV23 types: 0.678, 
0.597,0.546,0.521, 0.518 for age 
Vaccine-type incidence of IPD is reported for modelled years. Here are the IPD rates caused by 
PCV13 serotype for 2015/2016y.  
In 2018/2019 a steady-state is assumed 
≥85 0 0 18.15 3502 groups Source: surveillance data collected by Public Health England: July-June from 2002/03 to 
2013/2014 [13]. 










IPD NBPP IPD by: 
PPSV23 types: 59.5%; 
PCV13 types: 35.1%; 
PPSV23+PCV13 types: 60.8% 
nIPD by:  
PPSV23 types: 49.8% 
PCV13 types 35.2% 
PPSV23+PCV13 types 53.4%  
Age-specific incidence rates for IPD and NPP are based on data from a national catchment 
area. Risk-group specific incidence rates are calculated based on the assumption that the risk 








































































nIPD: 13.9% of NBP Australian Department of Health and Ageing. National Notifiable Disease 
Surveillance System (NNDSS), Publics datasets 
Thorringto





≥60 IPD due to PPSV23-
PCV13 types in 2015: 
20.63 
IPD due to non-vaccine 
types in 2015: 6.75 
the pre-vaccination steady 
state of IPD 54/100,000 
  Incidence is stratified by age and the probability of IPD and CAP were age-specific and data 
obtained from the Dutch (registry) data. 










































IPD by:  
PPSV23 types - 66% of all IPD 
PCV13 types - 25% of all IPD 
nIPD by:  
PCV13 -25% of non-IPP 
PPSV23 -51% of non-IPP 
hospitalised nIPP:82.7% 
IPD data is from the National Reference Centre (NRC), 2015; all-cause &PP: INTEGO 2013 
R81 codes and pooled estimates from Capelastegui et al (2012)[20] and Holm et al (2007) [21]. 
Kuchenbec






































































PCV13 types - 29.3% 
PPSV23 types - 58.7-74.5% 
nIPD 
PCV13 types - 29.3% 
PPSV23 types – 29.9% of NBP 
Incidence is given for age- and health risk group. Here age groups 18-49y.o and 50-59y.o are 
omitted.  IPD incidence rates are derived based on the data of a publication on IPD in North-
Rhine Westphalia Germany by Reinert et al. (2005)[2]  extrapolating the incidence of the 
overall population; health-risk adjustment is based on van Hoek et al. (2012)[23]. The study 
refers to four sources which are used to derive incidence rates without reporting the methods. 
Abbreviations: all-CAP – all-cause community-acquired pneumococcal pneumonia; BPP - bacteraemic pneumococcal pneumonia; IP – invasive pneumonia; NBBP – non-
bacteraemic pneumococcal pneumonia;  NBP – non-bacteremic pneumonia; NPP - non-bacteremic pneumococcal pneumonia; NVT – non-vaccine type serotypes; PCV13-PCV7 
- serotypes in PCV13, but not in PCV7;PB – pneumococcal bacteraemia, PM – pneumococcal meningitis; PP – Pneumococcal pneumonia; PPSV23-PCV13  - serotypes in 
PPSV23, but not in PCV13;  PS - pneumococcal septicaemia 
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 S5 Results of quality assessment with EVIDEM of the selected studies (n=13) 
 





Results of quality assessment of economic evaluation with EVIDEM (for detail see supplement, S5:EVIDEM) 
Jiang et al, 
2012, 
Germany [1] 
Completeness and consistency: 
The reporting lacks description of the modelling approach to the waning of VE against NBPP and for immunocompromised people. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
Validity and relevance of the study are limited due to application of foreign data (stemming from clinical and cost-effectiveness studies) to inform the model induced by lack of the 
corresponding German data. These include QALY weights, indirect effects, mortality by serotype. Single-cohort model does not provide accurate estimates of incidence when equilibrium is not 
reached. 
Score:1☐ 2☒ 3☐ 4 ☐ 




Completeness and consistency: 
The paper has some gaps about applied age-specific VE and applied resources used per case. 
Score: 1☐ 2☐ 3☐ 4 ☒ 
Relevance and validity: 
The study assumes that herd effects of PCV7 childhood vaccination have reached full presence at the time of the initiation and infant vaccination with PCV10 has no indirect effects of for 
adults. 




Completeness and consistency: 
The paper has some gaps in reporting the exponential waning of VE applied in SA. 
Score: 1☐ 2☐ 3☐ 4 ☒ 
Relevance and validity: 
Chosen population, comparator, perspective, time horizon, discount rates, costs and health outcomes are relevant. Applied epidemiological - and cost data are obtained from the national sources 
The study examines the effects of the uncertainty around the duration of the vaccine protection and indirect effects of the paediatric vaccination as well as around the incidence of non-
bacteremic hospitalized pneumonia on the cost-effectiveness estimates. 
Score:1☐ 2☐ 3☐ 4 ☒ 
Rodriguez 
Gonzalez-
Moro et al, 
2016, Spain 
[4] 
Completeness and consistency: 
Modelling of herd effects and calculation of applied costs are not transparently described. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
The evaluated vaccination strategy is limited to vaccinating individuals with COPD. Applied costs are limited to the direct costs per case of the disease due to the taken perspective. The costs 
are aggregated. The target population is difficult to compare to the population of the studies in which VE data is obtained. The study models a cohort of COPD patients and assumes that the 
patients are immunocompetent. IPD incidence is obtained from a study conducted in England looking at clinical conditions which cause a risk for IPD development. Modelling of the herd 
effects of the paediatric vaccination with PCV13 are not described making it difficult to assess its plausibility. 




Completeness and consistency: 
The paper has minor gaps in reporting the waning rate of VE and estimation of costs per case, namely applied resources used per case. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
IPD is not divided by specific diseases in the cost calculations and reporting the results. The reported costs are aggregated as cost per case for each considered disease making it difficult to 
conclude whether all relevant costs are included. 
Score:1☐ 2☐ 3☒ 4 ☐ 
van Hoek et 
al, 2016, 
England [6] 
Completeness and consistency: 
The reporting can be considered partly transparent. The paper has gaps about the structure of the developed model, applied PPSV23 VE, estimation of costs per case and details of the sensitivity 
analyses. The aggregated costs per case are given. 
Score: 1☐ 2☒ 3☐ 4 ☐ 
Relevance and validity: 
The study does not contain a description of the model design and methods of sensitivity analyses making it hard to evaluate validity and relevance. Epidemiological parameters, costs and 
utilities are based on the national data. The study applies a conservative approach to the duration of the vaccine protection. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Dirmesropian 
et al, 2017, 
Australia [7] 
Completeness and consistency: 
The model is very detailed as many parameters are age-stratified and almost all parameter values are reported. However, some information is not stated (e.g., vaccination rates) or it is 
ambiguous which values are used in the base case (e.g. PCV13 vaccine efficacy). Some information on the resource use is either missing or the costing is simplified. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
Epidemiological- and cost data is obtained from the national sources. The utilities are taken from study conducted in Netherlands. Regarding the event pathway it is not clear how mutually 
exclusive the different health states are, e.g. if a patient that is hospitalized for CAP can also have GP visits and if there is a treatment pathway used for the costing. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Heo et al, 
2017, Korea 
[8] 
Completeness and consistency: 
The study reports all of the main input parameter values in great detail but is less precise on the perspective and the time horizon of the model. Model structure contains “disabled” disease state 
but neither costs and nor QALY losses are given for it. The reference year for the costs is not clearly stated. No figures or sources of background mortality are given. Results are reported not in 
detail. All scenarios are only compared to a “no vaccination” scenario and no ICER is reported comparing the different strategies. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
The validity of the study is difficult to assess due to incompleteness in reporting cost calculations, model structure, discounting and the results. The time horizon is not long enough to capture all 
meaningful differences in costs and outcomes. It is set to 15 years in the base case and no sensitivity analyses are performed. As the age group being vaccinated spans 20 years and vaccine 
efficacy is longer than 15 years, a longer time horizon may lead to different results. The authors only state to conduct the analysis in a “societal context”, which can be interpreted as a societal 
perspective. No guidelines are cited, making it difficult to judge the validity of the perspective in the Korean context. Indirect cost calculations seem to be missing for some disease states or 
manifestations of IPD. Indirect costs seem only to be calculated for the productivity loss of the patient for the length of stay. It is unclear whether forgone productivity loss due to pre-mature 
mortality is included or if the Human Capital or the Friction Cost approach have been used. Discount rate is assumed without reporting a reference and no sensitivity analysis on it is conducted. 
Values in the deterministic sensitivity analysis are considered to be unusual and the corresponding tornado plot looks skewed. Not all critical values are covered in SA. 
Score: 1☐ 2☒ 3☐ 4 ☐ 
Chen et al, 
2018, 
Australia [9] 
Completeness and consistency: 
The study reports most parts of the study in great detail, but this study paper represents an adaption of a previous paper and is used to analyse effects of the age at vaccination on the cost-
effectiveness. The study lacks a graphical representation of the model. Nearly all parameters of the model are given, although the costing for the different health states seems to have a very 
simple treatment pathway. CAP fatality rates are not reported. No sensitivity analyses are conducted which is justified by the focus of the study. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
The study question is not a classical cost-effectiveness analysis, but on the timeliness of PCV13 vaccination, i.e. what the optimal age for the vaccination. The target population, comparator, 
perspective, time horizon, discounting and costs are relevant. QALY losses are taken from a Dutch study and combined with the Australian population norms. 
Score: 1☐ 2☐ 3☒ 4 ☐ 




Completeness and consistency: 
The paper reports the results of an additional analysis conducted with the model from a previously published study[9]. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
The study performs a cost-effectiveness analysis of vaccination of elderly with PCV13, comparing two different scenarios of the future serotype evolution, probably against a “no vaccination” 
scenario. The study design is of the previous study by Chen et al (2018) [9]. The study can be seen as a sensitivity analysis to that study, looking at the impact of the assumptions about the 
serotype evolution after the introduction of a new vaccination on the cost-effectiveness estimate. The question is relevant and the design appropriate to answer this question. 
Score: 1☐ 2☐ 3☐ 4 ☒ 
Thorrington 
et al, 2018, 
Netherlands 
[11] 
Completeness and consistency: 
This study reports some parts of the economic evaluation in great detail, especially parts about incidence and mortality data, costing and QALY parts are rather simplified. The values for those 
cost and QALY parameters are taken from another modelling study. Only indirect costs are considered and split into IPD and CAP. No reference year of the costs is stated. The model is 
described as a static model and no illustration of the model is given. There is no information about the cycle length, but a yearly time step can be assumed. Disease states are not clearly 
identified, although IPD and CAP can be assumed to be the modelled health states. No probabilistic sensitivity analysis is performed. No ranges for the deterministic sensitivity analyses are 
given. Only the different mortality-parameters are age-specific. Sources of population sizes, background mortality/life-expectancy are not clearly stated. 
Score: 1☐ 2☐ 3☒ 4 ☐ 
Relevance and validity: 
The study is relevant, but in many cases, there are unnecessary simplifications in the model, i.e. ignoring age-specific data, no prices-resources framework and arbitrary scenario/sensitivity 
analyses. The population is hardly comparable with the trial population and age-specific results from the trial are not incorporated. The event pathway includes only IPD, CAP and death are 
included in the model without further stratification. IPD mortality is age- and vaccine-type specific from the Dutch surveillance data. CAP mortality is taken from a German source. No age-
specific costs are used. Administration costs are omitted. QALY losses are estimated to be identical for IPD and CAP and another model is referenced as the source. No other information is 
provided about the values of population norms, the duration of the health states or the utility decrements. 
Score: 1☐ 2☐ 3☒ 4 ☐ 




Completeness and consistency: 
Minor limitation is that the ranges for PSA cannot be found for all parameters and values of the distributions for PSA are only reported for the incidence of pneumonia and the case fatality ratio. 
Score: 1☐ 2☐ 3☐ 4 ☒ 
Relevance and validity: 
The study design is relevant. Event pathway includes all relevant disease stages. For meningitis, long-term effects of hearing loss and neurological sequalae are considered and death may occur 
from any state. The events are mutually exclusive. Vaccine failure is considered in the model structure. 
Most of the data stem from the national sources. Sensitivity analyses are conducted on a wide range of parameters. The target population is relevant and represents the intended target group of 
the intervention. But it does not coincide with the study population in CAPITA and with the PPSV23 VE study population by Andrews et al. (2012) [13]. 
Score: 1☐ 2☐ 3☐ 4 ☒ 
Kuchenbecke
r et al, 2018, 
Germany 
[14] 
Completeness and consistency: 
The study adopts an earlier developed US microsimulation framework with Markov-type process by Weycker et al (2012) [15]. The model structure is incomplete reported. The study shows 
inconsistency in the reporting the methods applied to estimation of the waning rate and calculation of the herd effects of PCV7/PCV13. Table 2 shows inconsistency in the reporting of the 
values of VE for PCV13 ag IPD in the low risk group of 65-74 y.o., for year 10 (VE =1%) and for PPSV23 ag IPD for high risk group of 50-59y.o. for year 10 (VE =37%, though initial VE 
=15%). Approach to the waning of protection is inconsistently described: main text reports exponential function, the supplemental material stats a liner interpolation. The costs per unit are not 
reported. The representation of the applied parameters for PSA is not intuitively interpretable. No reference year for the costs is reported. 
Score: 1☐ 2☒ 3☐ 4 ☐ 
Relevance and validity: 
Due to incompleteness in reporting it is difficult to assess plausibility and relevance in the important dimensions of the study. The event pathway applied in the model is not described in detail. 
The study refers to four sources which are used to derive incidence rates without reporting the methods of how the data is adjusted making it difficult to assess the relevance. IPD age trends 
differ from those of NBPP (inpatient and outpatient) incidence showing for people over 60y.o. largest rates in 65-74y.o age group. NBPP (inpatient and outpatient) incidence shows lower rates 
for high health risk groups than for moderate-risk groups for all age groups. The study lacks a description of the methods for calculation of the presented cumulative herd effects from the 
reported predicted serotype-distributions in IPD by that making it difficult to assess relevance of applied herd effects. It is not clear how the applied values of the herd effects for nIPD are 
obtained. Applied PPSV23 VE is based on the estimates by a Delphi expert panel [16]. The authors do not justify applied linear interpolation of VE over age-year increments. Uncertainty of the 
assumption that PCV13 VE is 50% of the values of PPSV23 VE applied in extrapolations to calculate age-specific PCV13 VE values and waning rates is not tested. Reporting of the ranges 
applied in the PSA is not complete and the table is not easy to interpret. 
Score: 1☐ 2☒ 3☐ 4 ☐ 
Abbreviations: CAP – community-acquired pneumococcal pneumonia; CE – cost-effectiveness; CI – confidence interval; ICER – incremental cost-effectiveness ratio; IPD – invasive pneumococcal diseases; LYG – life years gained; NBPP –  non bacteraemic pneumococcal pneumonia; PSA – 






Table S5.2: Full results of assessment of quality of economic evaluations with EVIDEM (n=13).  
An economic evaluation was considered to be relevant and valid when it presented relevancy of the chosen population, comparator, perspective, time horizon, discount rates, 
costs and health outcomes; applied epidemiological – and cost data were obtained from the national sources; sensitivity analyses covered the most critical parameters within a 
valid range; the methods applied in modelling waning of the vaccine protection were clearly described; and the applied indirect effects of the childhood vaccination were based 
on epidemiological data.  
 
 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23) 
Setting: Germany 
Study:  Jiang, Yiling; Gauthier, Aline; Annemans, Lieven; van der Linden, Mark; Nicolas-Spony, 
Laurence; Bresse, Xavier (2012): Cost-effectiveness of vaccinating adults with the 23-valent 
pneumococcal polysaccharide vaccine (PPV23) in Germany. In Expert review of pharmacoeconomics 
& outcomes research 12 (5), pp. 645–660. DOI: 10.1586/erp.12.54. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
This study reports all the dimensions of the economic evaluation. The reporting can be 
considered complete and transparent. The information is consistent across the sections of 
the study.  
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The study defines the target population as German adults (aged 18 years and older) eligible for PPSV23 vaccination and who 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Intervention: vaccination of elderly and at-risk adults in Germany with PPSV23 against IPD and NBPP.  Based on the German 
recommendation at the time of the study it was assumed that only people younger than 60 years at initial vaccination would 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The study includes a population-based Markov model with cycle length of 1 year. The structure is presented by a figure without 
attribution of the cost and transition probabilities between the events. The flow of events is described in the main text. The 
model incorporates possible impact of vaccinating children with PCV7 and PCV13 by including future changes into the 
epidemiology of IPD in adults. Indirect protection of vaccination adults with PPSV23 is not included due lack of evidence.  
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The hypothetical vaccination program is compared with no vaccination. 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
Cost-effectiveness analysis of adult vaccination with PPSV23 compared to no vaccination. Health outcomes are measured in 
quality-adjusted life years (QALYs). The study assumes an arbitrary threshold of €50,000 per QALY gained as the primary 
threshold of cost–effectiveness because “the German health technology assessment authorities do not set a fixed threshold of 
incremental cost–effectiveness ratio (ICER) and the threshold of €50,000/ QALY is commonly used in this context. A 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence: 
IPD and nonbacteremic pneumonia incidence across age groups are presented for 2005 and the sources are described. The IPD 
incidence is given for vaccine-related serotype groups. The methods applied to predict the impact of the childhood vaccination 
on the incidence are described and the applied parameters are provided. The risk parameters (risk of IPD, risk of death, case-
fatality ratios) are given. 
Vaccine effectiveness:  
VE parameter is not age-specific due to the source used to obtain the data.  
Against IPD: 74% for immunocompetent- and 35% for immunocompromised individuals [17] 
Against NBPP: 39% for immunocompetent- and 0% for immunocompromised individuals [18] 
Duration of protection: parameters are given as proportions of remaining VE in percent for each year over 10 years where the 
individuals no longer protected after 8 years from the initial vaccination. References are given however rationale is not 
provided. We calculated years of full protection and average duration of protection with PPSV23 against IPD: 5.3 years of full 
protection and 2.7 years of average duration of protection against IPD for immunocompetent people. It is not clear whether the 
same waning function is applied for the VE against NBPP and for immunocompromised people. Coverage is 3% of eligible 












Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Univariate- and probabilistic sensitivity analyses are conducted for a wide range of parameters. The ranges are reported with the 
respective references.  
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
ICER of PPSV23 vaccination vs no vaccination: €17,065/ QALY gained from the third-party payer’s perspective and 
€25,687/QALY gained from the societal perspective. Resulted discounted and undiscounted costs are reported across 
categories: IPD, vaccine, vaccine administration from two perspectives. The results of SA are reported. Variation of the ICER 
across the parameters varied in the univariate sensitivity analysis is illustrated by a diagram. The ICER was sensitive to the 
vaccine effectiveness against NBPP, waning function and incidence of NBPP.  
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation Is the study question relevant (choice of comparator, This study uses a relevant comparator, outcomes and performs analyses from two 1 ☐ Low relevance/ validity 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
relevant perspectives. The modeled population is a single cohort of eligible for 
vaccination adults which limits the model outcomes. Due to lack of the German data, 
application of the clinical and cost-effectiveness studies to inform the model is valid.  
Where relevant and possible the sources of the German data are included. All relevant 
costs are included. The inclusion of the indirect effects of the infant vaccination is 
limited to the projection of the USA data on the effects of the PCV7 infant vaccination. 
Estimation of incidence of NBPP can be also seen as a limitation. This is based on an 
assumption that the proportion of NBPP in community-acquired pneumonia cases can be 
attributed to NBPP similarly to pneumococcal infection. 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The modeled population consists of “individuals younger than 60 years of age who were at higher risk of developing IPD 
diseases (‘at-risk adults’) and individuals aged 60 years or older (‘the elderly’)”. One cohort of individuals eligible for 
vaccination with PPSV23 is considered. The population is not divided into age group, but additionally split into 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates adult vaccination with PPSV23 against IPD and NBPP with revaccination for people <60 years old. 
Applied coverage rate is based on sales data for PPSV23 due to a lack of publicly available information on the vaccination 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The employed model includes five health states: no pneumococcal disease, nonbacteremic pneumococcal pneumonia (NBPP), 
IPD (including pneumococcal meningitis and bacteremic pneumococcal pneumonia), postmeningitis sequelae (PMS) and death. 
The model include in indirect effects of vaccinating children via incorporation of time-dependent probabilities of developing 
IPD. This was based on US data observed during the 7 years following introduction of the PCV7 vaccine in children, the change 
in the incidence of IPD associated with PCV7 in adults was found to be related to cumulative vaccine uptake in children.  
Rationale for the approach to the indirect effects is provided.  




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The study performs analyses from two perspectives: the third-party payer’s perspective and societal perspective. 
The vaccination costs include vaccine’s unit price and vaccine administration costs. The treatment costs of pneumococcal 
diseases are not further categorized but given for each health state and perspective based on the German data. All costs are 





Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
The baseline QALY weights ae obtained from a US cost–effectiveness study assuming no utility decrement for NBPP. For 





Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Incidence:  
The IPD incidence is estimated based on the German surveillance. Indirect effects are modelled as a function of cumulative 
vaccine coverage rate in children based on the USA data. A cumulative gamma distribution is selected for its goodness of fit. 
“Coverage rates observed in German children were then used in order to estimate the change in IPD incidence from 2005. A 
stable incidence was assumed beyond 2012 due to a lack of longer term data.” 
The case–fatality rate was estimated from a Dutch retrospective surveillance study.  
“It was estimated that approximately 40% of community acquired pneumonia cases were attributable to pneumococcal 
infection, based on the German Competence Network for Community-Acquired Pneumonia study. Case–fatality rates also came 
from the Competence Network for Community- Acquired Pneumonia study. Due to a lack of data, a similar incidence of NBPP 
was assumed across risk groups.” 
Mortality by serotype was estimated based on a Danish nationwide population-based study 
VE against IPD and NBPP differs between the risk groups but not the ages. The data for VE against IPD for immunocompetent 
people is taken from a Cochrane systematic literature review and meta-analysis of ten prospective clinical trials [17]; for at-risk 
immunosuppressed individuals, VE against IPD is obtained from a prospective trial conducted on HIV-infected patients in the 
USA[19]. VE against NBPP is taken from a prospective cohort study conducted between 2002 and 2005 in Spain[18]. It is 
assumed that the vaccine does not protect the immunosuppressed patients against NBPP. Approach to the duration of protection 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
A probabilistic sensitivity analyses (PSA) are performed for the for the following parameters:  
 Risk of developing IPD 
 Incidence of IPD 
 Herd protection effect 
 Serotype replacement effect 
 Incidence of nonbacteremic pneumonia across age groups 
 Case–fatality rates 
 Relative risk of dying from IPD by serotype 
 Vaccine effectiveness against IPD 
 Vaccine effectiveness against NBPP 
 Waning function of vaccine effectiveness 
 Administration of PPV23 vaccine 
 Costs of treatment of IPD and NBPP in- and outpatient 
 Costs of  PMS 
 Cost per day off 
 Discount rate 
 Health related quality of life by age group 
 
The distributions associated with each model parameter are selected based on the German guidelines on economics evaluations 
and the published literature. PSA includes 1000 iterations and the cost–effectiveness acceptability curve is plotted.  
11 Conclusion Are conclusions supported by results? Based on the results the study concludes that that adult PPSV23 vaccination is cost-effective in Germany, due to its broad 
serotype coverage.  
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal conjugate vaccine (PCV13) 
Setting:  Netherlands 
Study:  Mangen, Marie-Josee J.; Rozenbaum, Mark H.; Huijts, Susanne M.; van Werkhoven, Cornelis 
H.; Postma, Douwe F.; Atwood, Mark et al. (2015): Cost-effectiveness of adult pneumococcal 
conjugate vaccination in the Netherlands. In The European respiratory journal 46 (5), pp. 1407–1416. 
DOI: 10.1183/13993003.00325-2015. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
This study reports all the dimensions of the economic evaluation. The reporting can be 
considered complete and transparent. The information is consistent across the sections of 
the study. The paper has some gaps about applied age-specific vaccine efficacy and 
estimation of costs per case, namely applied resources used per case. The aggregated 
costs per case are given.  
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☐ 
4 ☒ Complete and consistent 




Is the target population for this intervention defined? 
The target population is defined as consisting of five age cohorts (18–49, 50–64, 65–74, 75–84 and ⩾85 y.o.) of 2012, 
Netherlands. Three health risk groups for pneumococcal diseases are considered:  low-, medium- and high-risk groups. The 
comorbidities which are attributable to the medium- and high-risk state as well as the proportion of people belonging to these 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Intervention: “vaccination of adults aged 65–74 years with a single dose of PCV13 administered at the start”. 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The study applies a probabilistic Markov-type model with a 1-year cycle length. The structure is illustrated in the supplemental 
material with a schematic representation without attribution of costs and transition probabilities.  
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The vaccination with PCV13 is compared to no vaccination. Rationale is stated.  





Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
Cost-effectiveness analysis of elderly vaccination with PCV13 compared to no vaccination. The outcomes of the analyses are 
estimated incidences of IPD, inpatient CAP, outpatient CAP, deaths, costs, life years and 
QALYs. Cost-effectiveness is estimated as cost per QALY gained and cost per LYG. “In 2012, the Dutch gross domestic 
product (GDP) per CAPITA was €35 300. A strategy is considered highly cost-effective if ICER is <1×GDP per CAPITA and 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence  
In the supplemental material the following model input parameters are provided:  
 Incidence of IPD stratified by age- and risk-group 
 Incidence of inpatient CAP stratified by age- and risk-group 
 Incidence of outpatient CAP stratified by age- and risk-group 
 Serotype (PCV13 and nonPCV13) distribution of IPD stratified by age-group 
Vaccine-related parameters  
The authors base the calculations on the CAPITA trial. The study does not contain explicit numbers for age-specific VE. The 
supplemental material gives a plot where it is shown that the VE would deteriorate and VE would be lower for the higher ages. 
For CAP: the age at which the predicted efficacy equaled the VE from the CAPITA-trial (45.56%) was 76.2 years 
Waning immunity 
The following assumptions are made:  
 stable during the first 5 years following vaccination 
 afterwards: wane annually at a rate of 5% during years 6–10 
 wane 10% annually during years 11–15 
 no efficacy was assumed from year 16 onwards 
We calculated years of full protection and  average duration of protection with PCV13 against IPD: 
Years of full protection (Average duration of protection):  ag IPD:  
12.2y (10.6y for 65y.o, 9.7y for 73 y.o, 8.5 y for 80.y.o)  
Ag non-IPD: 12.2y (7.9 y for 65y.o, 6.1y for 73 y.o, 4.9 y for 80.y.o) 
Coverage: 
 is stratified by age- and risk-group 
 63.9% for low risk groups  
 81.5% for medium- and high risk groups 
Costs  
A full list of included unit cost prices is provided (2012 €) in the supplemental material 
Aggregating categories of  the unit cost prices  are : 
 Direct healthcare costs 
 Direct non-healthcare costs 
 Indirect non-healthcare costs 
The utilization of resources per case is not provided. Applied aggregated costs per case (direct healthcare costs and indirect non-
healthcare costs) are given for IPD, inpatient- and outpatient CAP for the “survivor” and “fatal” outcomes. The values are 
stratified by age- and risk-group and expressed in 2012 euros. 












Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
The following SA are reported:  
 Univariate sensitivity analyses: each parameter is varied separately by 25% (increasing/decreasing) 
 Multiway sensitivity analyses 
 An additional scenario to test the impact of herd protection on ICER: “by decreasing the proportion of PCV13 
serotypes for IPD and CAP with 0% (base-case) up to 90%, with herd effects remaining stable from year 1 
onwards.” 
The ranges of the parameters are reported with the made assumptions.  
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
The results are reported for the baseline analyses and sensitivity analyses. ICERs for the evaluated vaccination strategies are 
graphically represented. The incidence over the modeled time horizon for IPD, inpatient CAP and outpatient CAP as well as 
aggregated direct- and indirect healthcare costs, vaccination costs and net societal costs are reported in the supplemental 
material. The results of SA are presented in the table in the supplement and as a tornado diagram in the main text.  
Base case ICER: €8650 per QALY (95% CI 5750–17 100) gained; €7650 per LYG (95% CI 5300–12450). 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
This study evaluates adult vaccination with PCV13 against IPD, inpatient CAP and 
outpatient CAP.  Chosen population, comparator, perspective, time horizon, discount 
rates, costs and health outcomes are relevant. The analysis is performed from a societal 
perspective. Variable vaccination strategies are compared with no vaccination scenario. 
A model of Markov type was developed with states reflecting the considered diseases. 
Vaccine efficacy was obtained from CAPITA trial. Epidemiological - and cost data 
applied in the study were obtained from national sources. It was assumed that there were 
no indirect effects of PCV10 childhood vaccination based on epidemiological data. The 
effects of PCV7 childhood vaccination were stated to be reflected in the applied 
incidence data.  However, it is not really clear from the source that IPD does not decline 
or reached plateau: none of the serotypes shows signs stopped declining or are plateauing 
as depicted in Figure 2 of Knol et al[21].   
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The study considers an adult population. The division of the population into age cohorts and risk groups is based on the Dutch 
data. Demographics: national statistics of 2012. Division in the risk groups is based on “the prevalence of clinical risk factors 
from electronic medical records in a large network of general practitioners (GPs) in the Netherlands”. Three health risk groups 
for pneumococcal diseases are considered:  low-, medium- and high-risk groups. The prevalence of the listed clinical risk 
factors is described in the supplemental material and the estimation is based on the defined risk-groups for influenza vaccination 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates adult pneumococcal vaccination against IPD, inpatient – and outpatient CAP. 12 evaluated vaccination 
strategies vary in the age range of eligibility and the group of pneumococcal disease risk: Base-case (65-74-all),  65-74-low, 65-
74-medium, 65-74-high, 65-74-at risk, 65plus-at risk, 65plus-all, 50plus-at risk, 50plus-all, 18plus-at risk,50plus-all &18-49-at 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The following events are included into the structure: IPD, CAP inpatient, CAP outpatient, death. These disease states are 
modeled for each health risk, where the subjects can transit to the state of higher risk than the current state. Transition to the 
disease states are influenced by vaccination effects and herd protection stemming from the childhood vaccination with PCV10. 
4 Comparator Does the choice of comparators reflect current practice? 
The vaccination with PCV13 is compared to no vaccination. Current practice states that there is no other universal adult 
pneumococcal vaccination. Vaccine coverage is assumed based on the data from the “Dutch influenza vaccination coverage 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The analysis is performed from a societal perspective and the healthcare payer perspective is evaluated in SA. The direct 
healthcare costs contain all relevant costs. “Costs were estimated by multiplying resources used, as extracted from different 
studies with their corresponding unit cost prices”.  Although, the study reports a broad list of prices per unit of healthcare 
services and diagnostics, it does not provide the disease specific resource utilization.  
“Direct healthcare and non-healthcare costs were considered to start at symptom onset or first contact with the healthcare 
system up to a maximum 28 days or until recovery for outpatient CAP, and up to 1 month post-discharge for IPD and inpatient 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
Utility estimates in the Dutch general population are reported.  




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
The age- and risk-group specific incidence and case fatality rates of IPD are estimated from the national surveillance data of 
2014. Methods are not described.  
Vaccination coverage rates are obtained from the Dutch National Influenza Prevention Program 
Incidence, stratified by age- and risk-groups: 
 IPD incidence and serotype distribution of IPD are derived  from the Dutch surveillance data (“June 1,2012 to May 31, 
2014”)  
 Inpatient CAP incidence is obtained from radiography-confirmed CAP admissions in a “cluster-randomized-cross- over 
trial in seven Dutch hospitals (CAP-START trial, from February 2011 to January 2014)”, “with adjustment for coverage 
(i.e. proportion of International Classification of Diseases, 9th revision codes 480–486 in the CAP-START hospitals 
compared to the total Dutch population, using Dutch hospital data)”.   
 Case-fatality rates of inpatient CAP are obtained from the CAPITA and CAP-START trials. 
 Incidence of outpatient CAP is obtained from a “database containing anonymous routine healthcare data from the digital 
patient records of 45 GP practices (160 GPs, full time and part time) in Utrecht and its vicinity (Julius GP Network)”. 
“Incidence rates were multiplied by 0.57 to adjust for the proportion not confirmed using radiography”.  
Indirect effects of PCV10 childhood vaccination:  
The study assumes that there are no net indirect effects of infant PCV10 vaccination for adults. The effects of its precursor 
 
 
PCV7 are reflected in the applied incidence data and “herd effects were assumed to be fully present at the time of initiation of 
PCV13 vaccination”. These assumptions are made based on a published study which provides serotype-specific incidences 
based on sentinel surveillance data, however,  it is not really clear from the source that IPD incidence does not decline or has 
reached a plateau.      
Vaccine-related parameters  
The study applied the vaccine efficacy data from the CAPITA trial. Age-specific VE is illustrated in a plot. It does not allow 
assessing the applied age effects of VE. Duration of PCV13-protection is applied based on assumptions. 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
The uncertainty of the following parameters are tested in multiway SA: case-fatality rates, vaccine effectivity, waning 
immunity, changes in vaccination coverage, discount rates, general utilities, perspective and vaccination costs.  
 
11 Conclusion Are conclusions supported by results? 
Based on the defined cost-effectiveness threshold, all strategies of PCV13 (except PCV13 vaccination of only low-risk patients 
aged 65–74 years) are considered highly cost-effective in the Netherlands. 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention: Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting:  Belgium 
Study:  Blommaert, Adriaan; Bilcke, Joke; Willem, Lander; Verhaegen, Jan; Goossens, Herman; 
Beutels, Philippe (2016): The cost-effectiveness of pneumococcal vaccination in healthy adults over 
50: An exploration of influential factors for Belgium. In Vaccine 34 (18), pp. 2106–2112. DOI: 
10.1016/j.vaccine.2016.03.003. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
This study reports all the dimensions of the economic evaluation. The reporting can be 
considered complete and transparent. The information is consistent across the sections of 
the study. The paper has some gaps about the exponential waning of the vaccine 
effectiveness applied in SA. Applied indirect effects are described with provision of the 
respective parameters. 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☐ 
4 ☒ Complete and consistent 
See dimensions below 




Is the target population for this intervention defined? 
The modeled population is age-stratified (by single year of age between 50 and 90) and consists of multiple cohorts of general 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Intervention: adult pneumococcal conjugate vaccination against IPD and non-IPD. The study evaluates the following 
vaccination strategies: 
 vaccination with PCV13  
 vaccination with PPSV23 
 addition of PCV13 vaccination to PPSV23  





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The developed model is age-structured, static and multi-cohort. The model tracks for the cohorts the costs and effects of the 
vaccination. The description and the structure of the model as a scheme are given in the supplement. The transition parameters 
are assigned and described.  
IPD include bacteremic hospitalised pneumonia, septicaemia and meningitis 
Non-IPD include outpatient pneumonia and non-bacteremic hospitalised pneumonia 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The study uses the following comparators:  
 vaccinations with PCV13 and PPSV23 are compared to no vaccination 
 addition of PCV13 vaccination to PPSV23 is compared to vaccination with PPSV23 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
This study conducts a cost-effectiveness analysis of adult vaccination against IPD and non-IPD. Three options are compared: 
vaccination with only PPSV23, vaccination only with PCV13 and addition of PCV13 to the vaccination with PPSV23. The 
health outcomes are expressed in quality-adjusted life years. The conclusion about the cost-effectiveness is made based on cost 
/QALY gained threshold of 35,000 Euro. The study also investigates effects of vaccine prices, indirect effects of pediatric 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence:  
The age- and cohort-specific proportion of people under the risk of development IPD and non-IPD i.e. not vaccine protected, is 
calculated using the following parameters: vaccination coverage, vaccine effectiveness, age dependent and serotype group-
specific initial (prior vaccination) incidence and the serotype specific incidence factor that reflects the incidence changes due to 
the pediatric vaccination with PCV13 (as a cohort- and serotype group-specific ratio of observed- to the initial incidence). 
The numbers of IPD or non-IPD cases per year are calculated using the disease-specific hospitalization rates which are provided 
with the respective references. Due to limitations of the Belgian data, the incidence for bacteremic pneumonia (BP) and non-
bacteremic pneumonia (NBP) are calculated based on assumptions which are tested in SA: age-independent proportion BP and 
case-fatality are equal for BP and NBP.  
Case-fatality rates are given for each disease. 
Probabilities of complications after meningitis (bilateral hearing loss and neurological sequelae) are given with the references.  
Serotypes are divided into four groups: (PPSV23-PCV13)-type, (PCV13-PPSV23)-type, “both” (in both vaccines), non-
vaccine-type 
Indirect effects:  
Indirect impact of the pediatric vaccinations with PCV7 and PCV13 on the incidence among adults consists of herd immunity 
and replacement effects. These are incorporated into computation of the proportion of vaccine unprotected people who may 
develop IPD or non-IPD. The factor is serotype-group specific and incorporated based on assumptions which are described in 
the main text and obtained from the data from England and Wales. 
Vaccine-related parameters 
Vaccine efficacies are assumed to be age independent 
PCV13 against IPD: 
75% 




PPSV23 against IPD: 
55% 




Waning rate:  
Made assumptions are the same for both considered vaccines:  
5 years of full protection than instant drop to zero.  
Waning varies in SA: (i) constant protection over time period between 4 and 15 years, and (ii) 5 years of full protection 
followed by an exponential decay (half-life varies between 0-10 years). 
Health outcomes: 
Average QALY loss decrement: disease- and age-group-stratified.  
Costs: 
 Vaccine administration cost per dose is given.  
 Hospitalization costs: age- and IPD-stratified.  
 Non-age specific medical cost for outpatient pneumonia  








Is the discount rate reported? Discount rate is reported:  




Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Sensitivity analyses are performed for vaccination with PCV13 or PPSV23 versus no vaccination and for vaccination with 
PCV13 and PPV23 versus the vaccination with PPSV23 alone. SA are performed to test the duration of VE, the indirect effects 
of the pediatric vaccination and  “the proportion of outpatient pneumonia cases caused by pneumococcus and of non-bacteremic 
hospitalized pneumonia”. 
The ranges are reported.  
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
The results are reported for the baseline analyses and sensitivity analyses. The results include “incremental effects, direct 
medical costs, vaccination costs, quality-adjusted life-years and incremental cost-effectiveness ratios vs no vaccination” for  
vaccination of different age groups (50-64,64-75,75+y.o.) under the assumptions of equal uptake (75%) and duration of 
effectiveness for PPSV23 and PCV13 (5 years). 
Reported ICER:  
PCV13 vs no vaccination ( EUR/QALY, discounted)  
“presented as median (mean)” of 1000 simulations 
PPSV23 vs no vaccination ( EUR/QALY, discounted) 
“presented as median (mean)” of 1000 simulations 
50-64y.o. 64-74y.o. 75+ y.o. 50-64y.o. 64-74y.o. 75+ y.o. 
232,352 (218,774) 106,399 (99,620) 72,556 (67,507) 130,051 (128,859) 67,791 (67,182) 50,263 (49,760) 
  
 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
This study evaluates scenarios of the introduction of PCV13 for the adult vaccination 
against invasive and non-invasive pneumococcal diseases. The study uses the relevant 
comparators providing the analyses in comparison with the current vaccination practice 
and no vaccination. The age structure of the modeled population complies with the 
targeted population for the intervention, however, the population is not risk-stratified. 
The vaccine effectiveness for PCV13 is obtained from the data of the CAPITA trial.  
Epidemiological - and cost data applied in the study are obtained from the national 
sources.  The applied perspective, time horizon, discount rates, costs and health 
outcomes are relevant. The study applies possible herd effects of the pediatric 
vaccination with PCV13 based on the projections of the effects of the PCV7 vaccination 
observed in children. The replacement effects are applied based on assumptions. The 
study examines the effects of the uncertainty around the duration of the vaccine 
protection and indirect effects of the pediatric vaccination as well as around the incidence 
of non-bacteremic hospitalized pneumonia on the cost-effectiveness estimates.   
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☐ 
4 ☒ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates adult pneumococcal vaccination against IPD and non-IPD. The evaluated vaccination strategies vary in the 





Does the model reflect a realistic event pathway 
according to current knowledge? 
Each modeled age and cohort is followed from the vaccination point to the “death of the last survivor.” 
The model includes calculation of the age- and cohort-specific proportion of the population at risk of development IPD or non-
IPD. This is governed the vaccination coverage, vaccine effectiveness and the incidence. Vaccine effectiveness and incidence 
are stratified by the four serotype groups.  For the population at risk the model includes the following events: development of 
IPD (bacteremic hospitalised pneumonia, septicaemia and meningitis) or non-IPD, and disease-related death (governed by the 
case-fatality rates). In the case of meningitis the model includes development of disability: hearing problems or neurological 
sequelae. 
The model simulates costs and effects of pneumococcal vaccination programs.  
The model is static and does not include the transmission process.  
4 Comparator Does the choice of comparators reflect current practice? 
The analysis is performed in comparison to no vaccination and the vaccination with one dose of PPSV23 (the current 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The perspective is of health care payer. Cost data are obtained from a survey of the Belgian population (published in 2006). The 
reported costs are categorized into hospitalization costs, which aggregated various costs categories (listed in the supplement), 
and medical cost for the patients with outpatient pneumonia.   




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
The incremental QALY losses due to IPD and non-IPD are age specific. Average QALY loss decrements are obtained from a 
published study by Melegaro et al[22]. These are multiplied “by the ratio of the average age specific health related quality of 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Incidence:  
Serotype coverage is obtained from “the Belgian pneumococcal reference centre for the period 2012-2014”. 
Assuming same serotype distribution for both IPD and non-IPD cases. 
Initial incidence at the start of the vaccination program is obtained from the National reference centre. 
The herd immunity effects are incorporated into the model by a projection of the effects of the PCV7 vaccination observed 
among children (“2–4 year olds over the period 2003–2008”) in Belgium. The herd effects are modelled as an annual decline of 
24% in circulating PCV13-type serotypes (”varied from 0 over 12% to 24%”). 
Serotype replacement effects are modeled as “compensation of this PCV13 incidence reduction” due to herd effects. The 
following values are applied: 0%, 50% and 100% replacement. 
Case-fatality rates, all-cause death rate, life expectancy and disease-specific hospitalization rates are obtained from the national 
data sources.  
Vaccine effectiveness:  
The VE effectiveness parameter for PCV13 is obtained from the CAPITA trial.  




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 




Is the recommended discount rate applied? 
The applied discount rates are in accordance with the Belgian guidelines for economic evaluations and budget impact analyses:  
 Life-years and QALYs: an annual rate of 1.5% 






Do sensitivity analyses cover the most critical 
parameters within a valid range? 
In the sensitivity analyses for PCV13 or PPSV23 versus no vaccination the uncertainty of the following parameters is tested:   
 duration of vaccine efficacy  
 reduction in PCV13-type serotype  incidence 
The duration of the VE is varied in two scenarios of waning:  
 no waning over the assumed period of vaccine protection which is also varied between 4 and 15 years 
 exponential waning: “assumed 5 years of no waning (period of complete vaccine protection) followed by an 
exponential decay with its half-life varied between 0 and 10 years” 
Impact of herd effects is varied as 0%, 12% and 24% reduction in PCV13-type incidence.  
Replacement effects variation is 0%,50%,100%.  
A particular focus is placed on influence of the vaccine duration of the maximum vaccine price so that the vaccination is cost-
effective vs no vaccination at the threshold of 35,000 Euro/QALY.  
In the sensitivity analysis for adding PCV13 to PPSV23 versus PPV23 alone the uncertainty of “the proportion of outpatient 
pneumonia cases caused by pneumococcus and of non-bacteremic hospitalized pneumonia” is tested. 
Other input parameters are given with confidence intervals or a distribution applied in the simulations. Ranges are plausible.  
11 Conclusion Are conclusions supported by results? 
Based on the results the study concludes that the adult vaccination with PCV13 is unlikely to be cost-effective in Belgium. 
Vaccinations with PPSV23 dominate vaccinations with PCV13 or addition of PCV13 to PPSV23 comparing to no vaccination. 
The authors point out that the difference in the cost-effectiveness between vaccinations with PCV13 and PPSV23 is caused by 
the large vaccine price difference.   
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting:  Spain 
Study:  Rodriguez Gonzalez-Moro, Jose Miguel; Menendez, Rosario; Campins, Magda; Lwoff, 
Nadia; Oyaguez, Itziar; Echave, Maria et al. (2016): Cost Effectiveness of the 13-Valent 
Pneumococcal Conjugated Vaccination Program in Chronic Obstructive Pulmonary Disease Patients 
Aged 50+ Years in Spain 
https://www.sciencedirect.com/science/article/pii/S0264410X16002814?via%3Dihubate Vaccination 
Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. In Clinical 
drug investigation 36 (1), pp. 41–53. DOI: 10.1007/s40261-015-0345-z. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
This study reports all the dimensions of the economic evaluation. The reporting can be 
considered partly complete and transparent. The paper has gaps in reporting the rationale 
for the applied methods to incorporate herd effects and applied categories of the 
healthcare costs. 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 
discussion)? 
See dimensions below 




Is the target population for this intervention defined? 





Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
Model is of the Markov type. The states are named. The structure of the model is illustrated in a figure without assigning 
respective costs and transition states. Coverage is 59.5 % (both vaccinations) of COPD patients ≥ 50 years old. 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
Comparator is vaccination with a single dose of PPSV23 at model entry.  
5 Perspective Are the perspective of analysis and its rationale stated? 
The analysis is performed from the perspective of the Spanish National Healthcare System. The rationale for the selection is not 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence:  
Herd protection from the pediatric vaccination is reported. The rationale for applied effects is not given. Age group specific 
incidence rates are provided for IPD, inpatient NBP and outpatient NBP. The sources are stated.  Age group-specific mortality 
rates are given for general population, IPD, and inpatient IPD. The sources are stated.  
Vaccination related parameters:  
Vaccine effectiveness parameter is age-specific and sated as:  
PCV13 against 
IPD: 
50-64y.o.:  82.0%  
65-74y.o.:  76.8%  
75-84y.o.:: 72.2%  
>85y.o.:  67.6%  
PCV13 against  
inpatient NBP: 
50-64y.o.: 9.5%  
65-74y.o.: 8.9%  
75-84y.o.: 8.4%  
>85y.o.:  7.9% 
 
PCV13 against  
outpatient NBP: 
50-64y.o.: 9.5%  
65-74y.o.: 8.9%  







75-84y.o.: 67.8%  
>85y.o.:  59.4% 








Sources are given. 
Waning rate:  
Vaccine efficacy by years since vaccination is given for all age groups and vaccines for the years: 1-5, 6-10,11-15, >15.  
We calculated years of full protection and  average duration of protection with PPSV23 against IPD: 
Years of full protection (Average duration of protection in years): 
PCV13 against IPD: 
50-64y.o.: 9.7 (8.0) 
65-74y.o.:8.6  (6.6) 
75-84y.o.:7.1  (5.1) 
>85y.o.:4.7     (3.2) 
PCV13 against NBP: 
50-64y.o.: 9.7 (0.9) 
65-74y.o.:8.6  (0.8) 
75-84y.o.:7.1  (0.6) 
>85y.o.:4.7     (0.4) 
PPSV23 against IPD: 
50-64y.o.: 5.1 (4.9) 
65-74y.o.:3.2  (3.6) 
75-84y.o.:7.1  (2.6)  
>85y.o.:4.7     (1.7) 
Healthcare costs 
Attributed costs and the used sources are described. The study gives unit cost per vaccine and aggregated management disease 
cost per case of IPD, inpatient NBP and outpatient NBP. 
Utilities:  








Is the discount rate reported? 
The discount rate is reported. In the base case the applied discount rate is 3% for both costs and QALY. In SA: undiscounted 




Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
A probabilistic sensitivity analysis and a one-way deterministic sensitivity analysis are performed. Rationale for the distribution 
and its parameterization is not provided.  
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
The resulted ICERs, total costs, QALYs and LYG are listed per age group. Overall, ICER is €1,245 per additional LYG and 
€1,844 per QALY gained compared to vaccination with PPSV23.  
The results of SA are also given in a tornado diagram. 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
This study provides a cost-effectiveness analysis of vaccinating adults with COPD aged 
≥50 years.  The model structure, assumptions about the time horizon, discount rates and 
vaccine waning rates are considered reasonable.  The analysis is performed from the 
perspective of the National Healthcare System and the considered costs are limited to the 
direct costs per case of the disease. The evaluated vaccination strategy is limited to 
vaccinating individuals with COPD. This vaccination strategy is compared with the 
current vaccination program with PPSV23 which is recommended for 
immunocompromised patients and those with chronic diseases. The study models a 
cohort of COPD patients and assumes that the patients are immunocompetent.  PCV13 
VE is obtained from CAPITA trial. IPD incidence is obtained from a study conducted in 
1 ☐ Low relevance/ validity 
2 ☒ 
3 ☐ 
4 ☐ High relevance/validity 
England.  Modelling of the herd effects of the pediatric vaccination with PCV13 are not 
described making it difficult to assess its plausibility. The sensitivity analyses are 
performed for the critical parameters.  




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The study models an age-stratified cohort of patients ≥50 years old with COPD. No other comorbidities are stated.   
Age groups are 50–64, 65–74, 75–84, and ≥85 years. The population size is based on the statistics from the Spanish National 
Statistical Institute. The number of COPD patients is obtained from a Spanish published study which considers prevalence of 
COPD in Spain. The PCV13 vaccine efficacy is obtained from the CAPITA trial. The population of the trial does not include 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates vaccinating adult COPD patients with a single dose of PCV13 against IPD and all- cause NBP. The 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The model is of Markov structure and includes the following states: alive without IPD or all-cause NBP; alive with IPD; alive 
with all-cause inpatient NBP; alive with all-cause outpatient NBP; and death. It is assumed that the modeled individuals enter 
the model in the non-PD state and without being previously vaccinated and receive a single dose of the respective vaccine at the 
model entry.   
4 Comparator Does the choice of comparators reflect current practice? 
The comparator is the current vaccination with a single dose of PPSV23. The study does not compare both vaccinations with no 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The study assumes a third-party payer perspective. The costs contain only direct healthcare costs. The data for aggregated 
disease management costs is obtained from published studies considering Spain. All costs are given in euros and adjusted to 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
Due to lack of the Spanish data, the stated health-state utilities for the COPD general population are obtained from published 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Age-specific incidence:  
Herd protection from the pediatric vaccination is given in percentages. Age stratified percentages represent maximum reduction 
in disease due to PCV13 vaccination. In the modeled year 5 and the following years of the time horizon the herd effects are 
assumed to achieve this maximum. The values of the maximum reduction in IPD due to herd effects are obtained from the 
Spanish National Health Survey 2011/2012.  Those for NBP are obtained from published studies. The rationale is not given. 
The methods are not stated. There is not enough data to assess the used approach for modelling of herd effects.  
Age group specific IPD incidence and case-fatality rates are obtained from a published study looking at clinical conditions 
 
causing risk of IPD development conducted in England[23]. The incidence of inpatient NBP is obtained from a Spanish 
database of hospitalizations in 2012. The incidence of outpatient NBP is estimated as a percentage of total all-cause NBP (58.5 
%). The estimate is based on a retrospective epidemiological study conducted Badalona (Barcelona, Spain). It is not stated 
whether the incidence rates are obtained for COPD patients or for a general population. The methods are not described. All-
cause mortality rates for COPD population are obtained from the Spanish National Statistical Institute.  
The inpatient NBP-related mortality is obtained from a published Spanish study looking at the patients with pneumonia and 
chronic obstructive pulmonary disease.  
Vaccine Efficacy:  
The study assumes that the COPD patients are “at risk but immunocompetent individuals”. The parameters for the age-specific 
PCV13 vaccine efficacy against IPD and all-cause NBP are obtained from the CAPITA trial.  
The parameters for the age-specific PPSV23 vaccine efficacy against IPD is obtained froth the study by Andrews t al[13]. The 
VE of PPSV23 is assumed to be zero. Age-specific waning rates are applied as VE for the years after the initial vaccination 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
In the probabilistic SA the uncertainty of the following parameters is tested: age-specific incidence rates and case-fatality rates 
for IPD (Beta distributions), inpatient- and outpatient NBP; costs per disease case (Log-normal distributions); indirect effects, 
utilities and disease-related disutility (uniform distributions for these parameters). The parameters of the respective distributions 
are provided without a description or a rational making plausibility difficult to assess. In the one-way deterministic SA the 
following parameters are varied:  time horizon, discount rate, revaccination at 5 years for 56.4 % with current vaccination 
policy, vaccination coverage, waning effect, utility values, vaccine effectiveness, disease incidences, mortality and the reduction 
of the vaccine price for both PPV23 and PCV13. The results of SA indicate that the indirect effects are improperly modeled. 
11 Conclusion Are conclusions supported by results? 
Conclusion: Based on the threshold of 30,000 Euro/QALY (“accepted Spanish cost-effectiveness threshold”) the PCV13 
vaccination of COPD patients aged ≥50 years is considered to be cost-effective. The results show a lower ICER (vs. the current 
vaccination with PPSV23) than the considered threshold.  
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease: Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting: USA 
Study:  Stoecker, Charles; Kim, Lindsay; Gierke, Ryan; Pilishvili, Tamara (2016): Incremental Cost-
Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in 
the United States. In Journal of general internal medicine 31 (8), pp. 901–908. DOI: 10.1007/s11606-
016-3651-0. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
This study reports all the dimensions of the economic evaluation. The reporting can be 
considered complete and transparent. The information is consistent across the sections of 
the study. The paper has minor gaps about the waning rate of age-specific vaccine 
efficacy and estimation of costs per case, namely applied resources used per case. The 
aggregated costs per case are given. Methods for applying indirect effects are described 
with provision of the respective parameters and data 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The modeled population is reported. It consists of immunocompetent adults in three cohorts:  50-year-olds, 60-year-olds, 65-
year-olds. The sizes of the initial cohorts are given. From these immunocompromised individuals are subtracted. The rational is 
given. The final size of the population is not stated. The immunocompetent population is risk-stratified: healthy and high-risk. 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Intervention: vaccinating adult population with PCV13 against IPD and non-bacteremic pneumococcal pneumonia.  
The following strategies are evaluated:  
 addition of PCV13 to existing PPSV23 recommendation at ages 50, 60, or 65 years 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The study applies a probabilistic model with Monte Carlo simulations. The model structure is illustrated in a figure with 
assigned arms and schedules.  
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The vaccination strategies are compared to the current vaccination practice: “a dose of PPSV23 at diagnosis of high-risk 
condition for ages 50–64, followed by a dose of PPSV23 at age 65 (or 5 years later)”.  




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
This is a cost-effectiveness analysis of adult vaccination with PCV13 compared to current vaccination practice. The outcomes 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence: 
The serotypes are classified as PCV13-type, PPSV23-type, (PPSV23-PCV13)-type and nonvaccine serotypes.  
The following parameters are provided with the respective sources:  
 The IPD incidence rates by the serotype group across the age groups and risk groups.  
 The inpatient and outpatient NBP incidence rates across the age- and risk groups.  
 Proportion of the NBP due to the PCV13 serotypes  
 The case-fatality rates for IPD and NBP 
All-cause mortality is not provided.  
The methods of inclusion indirect effects of pediatric vaccination with PCV13 are described and the parameters are stated.   
Vaccine-related parameters 




50-64y.o.: 75% ≥65y.o.:75% 
 
PCV13 against  
NBP: 












Waning immunity:  
The following assumptions are made for PCV13: 
 “no declines in effectiveness between the ages of 50 and 65”.  
 after age 65 the waning rate of 10% every 5 years 
The following assumptions are made for PPSV23: 
 Linear waning by 5 years increment: 1-5 years after the initial vaccination down to 50%, 6-10 down to 30% and 11-
15 down to 0% of initial effectiveness.   
The slopes are not given.  
Due to lack of data we could not calculate years of full protection and  average duration of protection 
Coverage rates:  
Coverage rates are given for age- and health risk group:  
 over age 65 - 59.9 % 
high-risk 50–64-year-olds - 20 % 
Costs 
Age- and risk group stratified aggregated costs are given per case of IPD, inpatient NBP and outpatient NBP.  
Vaccine price is stated and  is a government contract vaccine 
Health outcomes:  













Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
The following SAs are reported: 
 multivariate SA, ranges are given  
 one-way sensitivity analyses 
 a scenario with more rapid waning of PCV13  
 a scenario with PPSV23 effectiveness against NBP is 45% (analogously to PCV13)   
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
The results are reported for all evaluates strategies in the baseline analyses and sensitivity analyses. 
The resulted costs consist of total, medical and vaccine costs. 
In the base case the ICERs (95% CI) are:  
 addition of PCV13 to existing PPSV23 recommendation at age 50 years: 333,200 (159,370, 431,171) $/QALY 
 addition of PCV13 to existing PPSV23 recommendation at age 60 years: 238,227 (131,641, 355,424) $/QALY 
 addition of PCV13 to existing PPSV23 recommendation at age 65 years: 62,065 (26,951, 147,828) $/QALY 
 replacement PPSV23 at age 65 with PCV13 at age 65: 46,396 (cost-saving, 509,987) $/QALY 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
This study uses a relevant population, comparator, time horizon, outcomes and 
perspective. The population is divided into three age cohorts and consists of the healthy 
individuals. The comparator is the current recommendation. The vaccine effectiveness 
estimates are obtained from the relevant sources: CAPITA trial for PCV13 and 
systematic literature reviews for PPSV23. The study includes serotype division and gives 
respective incidence rates. The rates are based on the national data. The indirect effects 
of the pediatric vaccination with PCV13 are incorporated as changes in the serotype 
specific incidence based on the national surveillance data. The study includes not age-
stratified disease-specific QALY decrements.  
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The sizes of the modelled three age-cohorts are defined by the United States population of 2013. 
The immunocompromised individuals are excluded from the analysis due to “this group was recommended to receive PCV13 in 
2012 and the cost effectiveness of that recommendation has already been evaluated in previous work”. The modelled population 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates pneumococcal vaccination against IPD, inpatient – and outpatient NBP for adult immunocompetent 
population. Evaluated vaccination strategies vary in the age range of eligibility, the group of pneumococcal disease risk and the 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The developed model computes disease cases and deaths due to invasive pneumococcal disease (IPD) and nonbacteremic 
pneumococcal pneumonia (NBP). The model tracks the assigned costs.  
The following events are included into the structure: vaccination schedule and vaccination status, IPD, NBP (inpatient- and 
outpatient visit), death from pneumococcal diseases.  
4 Comparator Does the choice of comparators reflect current practice? 
Different vaccination strategies are compared to the vaccination of the current recommendation: “a dose of PPSV23 at diagnosis 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The analysis is performed from a societal perspective. There is no variation in the perspective in SA. The reported costs are 
aggregated as cost per case for each considered disease making it difficult to conclude whether all relevant costs are included.  
The cost data are obtained from the national sources: “paid health insurance claims from the Truven Health Analytics 
MarketScan database 2010”.  Vaccine costs are based on published government contract vaccine prices of 2013 ($85.189). All 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
The applied QALY decrements for inpatient- and outpatient NBP are obtained from a published cost-effectiveness analysis 
conducted for England and Wales [22]. The QALY decrement for IPD is estimated based on the data from the US Centers for 
Disease Control and Prevention’s Active Bacterial Core Surveillance for 2013. The study also investigates a scenario with 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
The IPD incidence and case-fatality rates stratified by the serotype-groups, age-cohorts and health risk groups are obtained the 
Centers for Disease Control and Prevention’s Active Bacterial Core surveillance in 2013.The incidence rates and case-fatality 
for inpatient- and outpatient NBP stratified by age-cohorts and health risk groups are obtained from previously published 
studies conducted for the US. These rates are modified to account for the indirect effects of the pediatric vaccination with 
PCV13. The changes in the rates are given for the years between 2003 and 2009 across the serotypes groups (“PCV7 types”, 
“PPSV23 types not in PCV7”, “Types in neither PCV7 nor PPSV23”) and are based on data of the Active Bacterial Core 
Surveillance for 2013. The vaccine effectiveness estimates for PCV13 are obtained from the CAPITA trial. The vaccine 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
The uncertainty of the following parameters are tested in the multivariate SA:  
 costs (as the 5th and 95th percentiles for a log-normal distribution) 
 QALY (a uniform distribution between the high and low QALY scenario) 
 IPD incidence rate  
 Inpatient NBP rate  
 Case-fatality rates for NBP  
 Percentage of NBP due to PCV13 types  
 Effectiveness parameters for both vaccines   
 Vaccine coverage  
 




 PCV13 with much more rapid waning: “no waning for 5 years followed by waning to zero over 15 years” 
 vaccine prices (2 scenarios)  
 PPSV23 effectiveness of 45 % against vaccine-serotype NBP 
Additionally: increased herd protection.  
11 Conclusion Are conclusions supported by results? 
The conclusion of this study is that the addition of one dose of PCV13 to the vaccination with PPSV23 and replacement of 
PPSV23 with PCV13 are cost-effective strategies. Herd effects of the pediatric vaccination strongly influence the cost-
effectiveness estimate of PCV13.  
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting:  England 
Study:  van Hoek, Albert Jan; Miller, Elizabeth (2016): Cost-Effectiveness of Vaccinating 
Immunocompetent /=65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England. 
In PloS one 11 (2), e0149540. DOI: 10.1371/journal.pone.0149540. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
This study reports all the dimensions of the economic evaluation to some extent. The 
reporting can be considered partly transparent. The information is consistent across the 
sections of the study. The paper has gaps about the structure of the developed model, 
applied PPSV23 VE, estimation of costs per case and details of the sensitivity analyses. 
The aggregated costs per case are given. Methods for applying indirect effects are 
described with provision of the respective incidence rates.  
1 ☐ Many gaps/ inconsistent 
2 ☒ 
3 ☐ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 





Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Intervention: adding PCV13 to the current PPVS23 vaccination practice of individuals aged 65 years and over.   
Two strategies are considered: 
 add PCV13 for immunocompetent population 
 add PCV13 for people in clinical risk-groups 
Vaccine coverage is 69%. 
The cost-effectiveness is evaluated using a threshold of £20,000 as is recommended in by the National Institute for Health and 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The model is a static cohort cost-effectiveness model. Model start is the autumn of 2016. The model computes future incidence, 
costs and health outcomes across age groups.  
The model structure is not reported.  
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The analyses are performed in comparison with vaccination with a dose of PPSV23 of individuals aged 65 years and over.   




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
The study reports a cost-effectiveness analysis of adding PCV13 to the current pneumococcal vaccination practice. The cost-






Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence:  
IPD and CAP incidences for vaccine types (“PCV7 and PCV13 minus 7”) are reported with the sources.  
The approach to calculation of the incidence for the non-risk population is reported.  
Observed and projected incidence is reported. 
The projections of the indirect effects of the pediatric vaccination with PCV7 and PCV13 are described.  
Vaccine-related parameters:  
Vaccine effectiveness and duration of the protection for the PCV13 against IPD and CAP are reported.  
 VE PCV13 against IPD: 75% 
 VE PCV13 against CAP: 45.6% 
The following waning rate for PCV13 is reported: 
 against IPD: constant for 9 years, 43% for year 10-14, 9% for year 15-19, 5% for 20+.  
 against CAP: constant for 9 years, 26% for year 10-14, 5% for year 15-19, 3% for 20+. 
We calculated years of full protection and average duration of protection with PCV13 against IPD and CAP: 
 12.53 years of full protection against IPD and 12.46 against CAP 
 average duration of protection is 9.4 years against IPD and 5.7 against CAP. 
Although the study compares an addition of PCV13 to the current vaccination with PPSV23, PPSV23 VE is not reported. 
Costs: the study reports costs of hospitalization due to IPD (age-dependent range) and CAP and vaccination costs.    












Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Sensitivity analyses are briefly described.  
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
The results are reported for the base-line and sensitivity analyses. The results of the economic evaluation include estimated 
cases, deaths, total costs, QALYs lost and ICERs. 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
The resulted cost-effectiveness ratio is £257,771/QALY gained 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
This study evaluates elderly vaccination with both PCV13 and PPSV23 against IPD and 
CAP. It uses a relevant population, comparator, costs and outcomes and performs 
analyses from the relevant perspective.  The modeled population is a single cohort. The 
study does not contain a description of the model design and methods of sensitivity 
analyses making it hard to evaluate validity and relevance. The study includes the herd 
effects of the pediatric vaccination with PCV13 projecting the effects of PCV7 on the 
IPD incidence among adults based epidemiological data from the country. The study 
applied relevant vaccine effectiveness for PCV13 and a conservative approach to the 
duration of the vaccine protection.   
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The studied population is a cohort of immunocompetent people 65 years old and older. The co-morbidities include diabetes, 
asthma, splenectomy or heart, liver or lung disease. The modelled population is intended to resemble the targeted population of 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study considers addition of PCV13 to the current vaccination strategy using PPSV23, so that both vaccines are used for the 
vaccination. Other scenarios such as replacement of PPSV23 with PCV13 are not considered. The program under evaluation 
includes additional GP visit for administration of PPSV23 which is included in the cost calculation.  




Does the model reflect a realistic event pathway 
according to current knowledge? 
The study does not provide a description of the model structure making it difficult evaluate the modeled event pathway. 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The perspective is a health care payer’s in accordance with the “Guide to the methods of technology appraisal” by NICE[25]. A 
personal social services perspective is not considered. The relevant aggregated hospitalization costs for IPD and CAP are 
obtained from a previously published economic analysis of vaccinating risk groups with PCV13 in England [26]. The vaccine 
price is given by the British National Formulary. 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
The selected health outcomes, QALY, are in accordance with the requirements of NICE. The values for QALY loss are 
obtained from a previously published cost-effectiveness study for England[26].  





Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
IPD incidence by the vaccine-type is obtained from “the serotype-specific surveillance data collated by Public Health England” 
(July to June, 2002/03 -2013/2014). CAP incidence by the vaccine-type is obtained from a longitudinal survey conducted in 
“two large teaching hospitals in Nottingham (UK)”. The values for case-fatality rates, life expectancy and costs are obtained 
from national sources. Herd effects of the pediatric vaccination with PCV13 are applied as a projection of PCV7 effects based 
on the assumptions that circulation of PCV7 serotypes reached a post-vaccination steady state in IPD (made based on 
epidemiological data) and that the CAP incidence experience the same trends as IPD. Vaccine effectiveness for PCV13 is 
obtained from the CAPITA trial. 
The duration of protection is applied based on recommendation from Pfizer stated in its report: “ Cost-effectiveness analysis of 
adult vaccination with the 13-valent Pneumococcal Conjugate Vaccine in the United Kingdom, unpublished report provided to 
the authors by Pfizer” 
Vaccine effectiveness for PPSV23 is not stated. 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
The effects of the following parameters are tested in the sensitivity analyses:  
 Double hospital costs  
 0.05 QALY loss both IPD CAP  
 15%/ 5% CFR IPD/CAP  
 30%/ 15% CFR IPD/CAP  
 Variation of age at vaccination 70, 75, 80  
 No waning  
 No back ground QALY loss  
 Extra long life expectancy  
 Double the CAP incidence 
 Long term equilibrium (2018)  
 Incidence 55%, to reflect no risk 
 
Additionally relation between the cost-effectiveness ratio and vaccine is evaluated in the sensitivity analysis to determine the 
vaccine price “at which the vaccine becomes cost-effective using a threshold of £20,000 as is recommended in the UK”.  
11 Conclusion Are conclusions supported by results? 
The study concludes that usage of both PCV13 and PPSV23 for vaccinating the immunocompetent elderly can be efficacious 
but is unlikely to be cost-effective with given threshold of £20,000. The optimal age of vaccination is suggested 75 years “due 
to the waning protection and the increase in incidence with age”. The study points out that the effects of the pediatric 
vaccination with PCV13 on the incidence among the elderly make the elderly vaccination with PCV13 not cost-effective. 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal conjugate vaccine (PCV13) 
Setting: Australia 
Study:  Dirmesropian, S.; Wood, J. G.; MacIntyre, C. R.; Beutels, P.; McIntyre, P.; Menzies, R. et al. 
(2017): Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older 
Australians. In Vaccine 35 (34), pp. 4307–4314. DOI: 10.1016/j.vaccine.2017.06.085. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
The model is very detailed as many parameters are age-stratified and almost all 
parameter values are reported. However, some information is not stated (e.g., vaccination 
rates) or it is ambiguous which values are used in the base case (e.g. PCV13 vaccine 
efficacy). All estimates are based on data or published literature and the information is 
consistent across the different parts of the paper. Some information on the resource use is 
missing or the costing is simplified. 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The modeled population is defined as a single-cohort of the general population, stratified by age groups 65-69, 70-74, 75-79, 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
The intervention is the vaccination of 65-year-old persons with PCV13 or PPSV23 at the start of the model. Other ages of the 
vaccination start are explored in the model. Vaccination for PPSV23 uptake is: 
65-67 years: 33.4% ; 68-69 years: 44.5% ; 70-74 years: 55.2% ; 75-79 years: 67.6% ; 80-84 years: 62.9% 
≥85 years: 61.9% 
Additionally, the administration of PPSV23 5 years after PCV13 is explored. 
The uptake for PCV13 is not stated in the methods section, but the results section indicates, that a 60% vaccine uptake is 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The study applies a single cohort Markov model with a cycle length of one year, following 65 year old persons up until the age 
of 100. No illustration of the model layout is shown. The health states/disease categories are hospitalizations and death due to 
IPD as well as GP consultations, hospitalizations and deaths from non-invasive CAP. A detailed outline of the related 
calculations is given in the appendix. IPD cases are further stratified into meningitis, bacteremia and (invasive) pneumonia. It is 
unclear if the states are mutually exclusive, e.g. if a patient may be hospitalized after a GP visit. Probabilities are given for GP 
consultations, hospitalizations, deaths and IPD manifestations. Detailed, age-stratified data on costs is given in the appendix. 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
PCV13 is compared to the current practice of PPSV23 vaccination, assuming the same uptake for both strategies. In the base 
case both strategies are applied to 65-year-old persons and compared against each other and against a “no vaccination” scenario. 
5 Perspective Are the perspective of analysis and its rationale stated? 
The analysis is conducted from a healthcare system perspective. No recommendation for the perspective is cited. No other 
perspective is explored in the sensitivity analyses. 
6 Type of Is the type of analysis stated? Is the rationale for Cost-effectiveness analysis of PCV13 vaccination for the elderly (65 years) compared to the current PPSV23 strategy. The main 
analysis outcomes selection (effectiveness measure or utilities) 
stated? 
outcome of the study is incremental costs per QALY gained (ICER). The outcomes of the analyses are total costs stratified into 
program costs and healthcare costs and QALYs. Avoided hospitalizations and deaths are reported for IPD and CAP and 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Age-specific (65-69, 70-74, 75-79, 80-84, ≥85) input parameters are given on the number GP visits for CAP, the respective 
probabilities of hospitalizations and death for meningitis, bacteremia, pneumonia and CAP. Also, the age-specific proportion of 
CAP due to pneumococci and the respective proportions of IPD due to PCV13 and PPSV23 are given. Sources are given for all 
these parameters. Following national data, the incidence rates of the vaccine-preventable serotypes is assumed to be stable. 
Vaccination related parameters: 
Efficacy: 
PCV13  
IPD: 89.2% for 65-year-old. Adapted from Van Werkhoven et al. Fitted logistic regression for age-specific values, but only 
examples are given (89.2% for 65 years, 77.1% at age 75). All values are given as a plot of the logistic curve. 
CAP: 60.4% for 65-year old. Same as for IPD with example values being 60.4% at 65 years and 35.5% at 75 years. 
PPSV23 
IPD: Fitted logistic regression resulting in age-specific VE of 0.58/(1+2.2898^age-85.5). Data used for fitting is 
58% for 65-74-year old, 56% for 75-84-year old and 48% for ≥85-year old, calculated from the 12% VE for this age group in 
Andrews et al. and the 58% and 56% of the previous age groups. 
CAP: none 
Waning:  
Vaccine efficacy for PCV13 was assumed to stay constant for the first 5 years following the CAPITA study, followed by a 
linear decline to zero for the next 5 years. For PPSV23 a 2-year period of constant efficacy was assumed followed by a 3-year 
linear decline. 
Years in full protection: 
PCV13:   IPD 7.50, CAP 7.50 
PPSV23: IPD 3.73, CAP n.a. 
Vaccination costs were A$65 for PCV13 and A$35 for PPSV23 with A$10 for administration costs for both vaccinations. Costs 
for a GP visit are priced at A$114 and detailed hospitalization costs are given in the appendix. Sources and calculations are also 
given in the appendix. 
QALY loss was 0.0709 for IPD and CAP inpatients and 0.0045 for CAP outpatient patients. Another model is cited for the 












Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Sensitivity analyses include univariate, multivariate (scenario) and probabilistic analyses. Results from the latter are reported as 
CEACs. A complete list of the parameters varied in the SA are given in the appendix along with the parameter distributions 
used for the probabilistic analysis. SA for different sources of input parameters are explored. 
The most influential parameters are 
 Proportion of CAP due to PCV13 serotypes 
 PCV13 vaccine price 
 Duration of protection 
 VE for the vaccine-type pneumococcal CAP 
 Proportion of CAP due to S. pneumoniae 
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
Disaggregated results are reported for the cost components as program costs and healthcare costs as well as for total QALYs 
lost. Further information is given about the avoided hospitalizations, deaths and GP consultations. ICER vs no vaccination: 
PCV13 =  A$ 88,000/QALY and PCV13+PPSV23  A$ 297,200/QALY 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The research question is relevant as this seems to be the first study to examine the cost-
effectiveness of PCV13 compared to PPSV23 in Australia. It is not stated if disease 
states are mutually exclusive and if there is a treatment pathway used for the costing. 
Indirect effects through childhood immunization are not incorporated and the model only 
uses a single cohort. 
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The study considers five age groups of a single cohort without consideration of risk groups or risk factors. The demographic 
distribution follows data from the national statistical office (Australian Bureau of Statistics) between 2014 and 2016. The age of 
the studied population is comparable to the study population of CAPITA by age and it does correspond to the population mainly 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study compares the current vaccination scheme with PPSV23 in 65-year old persons with a PCV13 vaccination strategy for 
the same age. Additionally, different ages of the vaccination are explored. The study evaluates the effectiveness of the different 
strategies against IPD-related mortality and hospitalizations as well as CAP-related mortality, hospitalizations and GP visits. 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The following events are included in the model: IPD and CAP hospitalization, IPD and CAP death, CAP GP visit. All IPD 
events are further stratified into meningitis, bacteremia and pneumonia. It is not clear how mutually exclusive the different 
health states are, e.g. if a patient that is hospitalized for CAP can also have GP visits.  
Transition to the disease state is influenced/prohibited for vaccinated persons under consideration of vaccine effectiveness. 
4 Comparator Does the choice of comparators reflect current practice? 
The authors state that PCV13 has already been recommended for older adults. It seems that no previous study has been 
conducted to evaluate the cost-effectiveness of this decision to replace PPSV23 by PCV13 in older adults.  
5 Perspective Is the perspective chosen valid? Are all relevant costs The analysis is conducted from the healthcare payer perspective and no other perspective is evaluated in the sensitivity analyses. 
and costs considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
Direct health care costs consist of inpatient costs, GP visits and vaccine and administration costs. All cost data are based on 
published data and are listed in the appendix. The costs are aggregated per health state making it hard to assess the details of the 
price-resources framework, e.g. we did not find the number of GP visits associated with the different health states. All costs are 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
National, age-specific population norms are used to calculate the QALY losses. Utility weights for IPD and CAP hospitalization 
and for a CAP-related GP consultation are taken from the literature, i.e., a previously published model from a different country 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Incidence, by age group: 
IPD hospitalization incidence is derived from Australian data collected by the National Notifiable Disease Surveillance System 
(NNDSS) 
CAP hospitalization incidence is taken from the National Hospital Morbidity Database (NHMD), all-cause CAP was used to 
extract data from this database, the proportion of S. pneumoniae-related CAP is taken from Charles et al. (2008) 
IPD mortality is also based on NNDSS data. 
CAP mortality has been taken from the study by Kothe et al. (2008)[27] 
CAP GP consultations were taken from a previous, Australian model (Newall et al. 2011). 
Indirect effects through herd immunity induced by the childhood vaccination are incorporated in the model. 
Age-specific vaccine efficacy of PCV13 is taken from the CAPITA study [28]. PPSV23 age-specific, vaccine efficacy is taken 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 
The time horizon is 35 years to follow all persons initially vaccinated at the age of 65 to be followed until their death of the age 




Is the recommended discount rate applied? 
The discount rate for costs and outcomes is 5% annually, but no guideline for the discount rate is cited. However, the discount 




Do sensitivity analyses cover the most critical 
parameters within a valid range? 
Six different scenarios are explored in the sensitivity analyses as described in the appendix. The following are reported to be 
most influential: 
 Proportion of CAP due to PCV13 serotypes 
 PCV13 vaccine price 
 Duration of protection 
 VE for the vaccine-type pneumococcal CAP 
 Proportion of CAP due to S. pneumoniae 
One additional analysis was performed on the vaccine price of PCV13. 
Distributions for the parameters are given in the appendix. 
11 Conclusion Are conclusions supported by results? 
The results indicate that both PCV13 and PPSV23 are not cost-effective compared to a no-vaccination strategy ( A$ 




practice of PPSV23 (A$35,300/QALY). 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting:  Korea 
Study:  Heo, Jung Yeon; Seo, Yu Bin; Choi, Won Suk; Lee, Jacob; Noh, Ji Yun; Jeong, Hye Won et 
al. (2017): Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. In PloS 
one 12 (5), e0177342. DOI: 10.1371/journal.pone.0177342. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
The study reports all of the main input parameter values in great detail but is less precise 
on the perspective and the time horizon of the model. Results are not presented in great 
detail. 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The target population is the general population above 65 years. The model population is stratified into the age groups 19-49, 50-
64, 65-74 and ≥75 years. There is a further stratification into low, moderate and high-risk groups taken from a previous study.  
High risk: (1) splenic dysfunction including post-splenectomy status, (2) hematologic malignancy such as multiple myeloma, 
leukemia, or lymphoma, (3) a condition affecting the bone marrow or lymphatic system, such as chemotherapy with alkylating 
drugs or antimetabolites, or radiation within the previous three months, (4) solid organ or stem cell transplantation, (5) chronic 
renal disease such as nephrotic syndrome or chronic renal failure, (6) HIV infection, (7) high-dose corticosteroid use (≥ 20 
mg/day of prednisone or an equivalent) lasting two or more weeks, or (8) treatment with a recombinant human 
immunomodulator. 
Moderate risk: (1) diabetes mellitus, (2) chronic liver disease, (3) chronic pulmonary disease, such as asthma or chronic 
obstructive lung disease, or (4) chronic cardiovascular disease, such as heart failure, cardiomyopathy, or other chronic 
conditions affecting cardiac function.  




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
The model evaluates the effectiveness of a PCV13 and/or PPSV23 vaccination scheme for persons ≥65 years compared to the 
current practice of PPSV23 alone. It is unclear whether the vaccine administration happens at the model start, but it is stated that 
the age group 65-74 is vaccinated in the base case. 
Vaccine uptake: Vaccine uptake for persons 65 years and older is assumed to be either 60% or 80% assuming the same 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The study applies a Markov model which is illustrated in figure 1. It is unclear whether it is a multi-cohort model, but as no 
information is given about the re-entering of new cohorts, it may thus be assumed to be a single-cohort model. Patients from 
each risk group can develop IPD or NPP, each leading to disability or death. Costs and PROs as measured by QALY loss are 
attributed to the health states IPD and NPP. No costs and QALY losses are given for the “Disabled” disease state. Transition 
probabilities are given as independent proportions and incidence rates. 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The current status quo – PPSV23 only – in adults 65 years and older is compared to PCV13 alone and PCV13 and PPSV23 
combined for the same age group. This is also tested for vaccination of the age group 50-64 years. The rationale is the necessity 
to update the national immunization program. 
5 Perspective Are the perspective of analysis and its rationale stated? 
The perspective is not directly described. However, the authors state that cost-effectiveness is assessed in a “societal context” 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
The analysis estimates the cost-effectiveness of a vaccination with PCV13 and/or PPSV23 in the elderly (65 to 74 years) 
compared to the current strategy of PPSV23 alone in the same age group. Results are mainly given as ICERs (Costs per 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence:  
The age-specific incidence rates for IPD and NPP are taken from a previous study examining data between 2011 and 2014. Risk 
ratios from a national database for CAP are used to adjust for risk group specific incidence rates. IPD age and risk group 
specific fatality rates are taken from a national, multi-center study and NPP fatality rate have been taken from the same study as 
the incidence rates. Sources are given for all parameters. The case-fatality rate is modified ex-post through expert opinions 
elicited via a Delphi panel.  
Vaccination related parameters: 
Efficacy: 
PCV13  
IPD: 79.4% (< 65 years), 75.0% (65-74 years), 62.8% (≥75 years) 
CAP: 52.0 (< 65 years), 45.0% (65-74 years), 37.7% (≥75 years) 
PPSV23 
IPD: 95.3% (< 65 years), 82.0% (65-74 years), 68.7% (≥75 years)  
CAP: none 
Vaccine efficacy is modified ex-post through expert opinions elicited via a Delphi panel, i.e. PPSV23 VE against IPD was 
lowered by 20% and to 20% for moderate and high-risk patients, respectively, and 15% and 22% lower for PCV13. For NPP 
PCV13 VE is 20% and 35% lowered for moderate and high-risk patients. 
Waning:  
Estimates on waning are taken from Smith et al. 2012 [29]. For PCV13 VE is still 39.7/29.1/0 percent against IPD and 
25.9/17.5/0 for the age groups <65/65-74/≥75 years after 15 years. 
Years in full protection: 
PCV13: IPD 9.83/9.65/4.23 years in the <65/65-74/≥75 years age groups CAP 9.78/9.66/4.22 years 
PPSV23: IPD 6.68/5.10/3.84 years CAP: none 
Vaccination costs are $50.31 for PCV13 and $14.13 for PPSV23 with $15 for administration costs for both vaccinations. Direct 
medical costs are age- and risk group specific, based on a previous study and varied between $5,404 and 8,609 for IPD and 
$1,055 and $2,986 for NPP. Sources are given. 
QALY loss is calculated using the age- and risk-group stratified length of stay and the Korean population norms.  The utility-




Is the time horizon reported? 
The time horizon is 15 years, but it is stated that costs and outcomes if survivors of this time frame are considered using their 
further life-expectancy. It can therefore be assumed that the time horizon is life-long. No sensitivity analysis was performed on 




Is the discount rate reported? 
Costs and benefits are discounted at 5% per annum as recommended by national guidelines. No sensitivity analysis is conducted 




Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Deterministic sensitivity analysis is performed by setting parameters values to 25% for the lower bound and 125% for the upper 
bound. Additionally, PPSV23 efficacy against NPP is varied between 20% and 50% in the sensitivity analysis (0% in the base 
case). Results are presented for: 
Vaccine Effectiveness: PCV13 NPP &IPD, PPSV23 IPD 
Disease incidence: NPP & IPD 
Costs: Medical costs NPP & IPD, Vaccine price PCV13 & PPSV23, Other direct costs NPP & IPD, Productivity loss NPP & 
IPD 
Mortality: NPP & IPD case fatality, general mortality 
Utility: Population norms, NPP & IPD utility values 
Probabilistic sensitivity analysis was performed with 1,000 draws from triangular distributions. 
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
Costs and QALYs are reported disaggregated, but not further stratification of results is provided. Results are reported for the 
base case and the sensitivity analyses. PCV13 alone compared to the current strategy of PPSV23 alone showed an ICER of 
$797/QALY for 60% vaccination rate and $701/QALY for 80% vaccination rate. This strategy is also cost-effective for each of 
the risk and age groups. 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The graphical representation of the model is somewhat ambiguous and the range for 
parameter values in the deterministic sensitivity analysis are very unusual. Indirect cost 
calculations seem to be missing for some disease states or manifestations of IPD. 
1 ☐ Low relevance/ validity 
2 ☒ 
3 ☐ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
The target population is relevant. The model population consists of persons of 65 years and older and is stratified by age and 
different risk groups. It is comparable to the study population of VE regarding the age of the study population. Age group 
distribution has been taken from national statistics and distribution across risk groups has been taken from a national study. The 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates single-dose PCV13 vaccination and sequential PCV13/PPSV23 vaccination compared to a single-dose 
PPSV23 vaccination against NPP and IPD. No further stratification is made into outpatient and inpatient CAP or IPD. The 
vaccination strategies are only evaluated for the age group of 65 to 74 years of age.Coverage rates are based on observed 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The graphical representation of the model lists the health states “NPP”, “IPD”, “disabled” and “death” and it does not 
differentiate between inpatient and outpatient treatment. It is unclear, what constitutes the health state “disabled”, i.e. no list of 
sequelae is given, no costs or QALY losses are given for this health state. After suffering IPD or NPP, patients may return to 
their “healthy” state or progress to “disabled” or “death”. Transition to these states is influenced by vaccination coverage, 
vaccine effectiveness and the age- and risk-group. Indirect effects from childhood vaccination are also incorporated, assuming a 
similar decrease of the PCV13 serotypes as being observed after the introduction of PCV7. 
4 Comparator Does the choice of comparators reflect current practice? 
The PCV13 vaccination as a single dose or a combination with PPSV23 is compared to the current practice of PPSV23 alone 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The authors only state to conduct the analysis in a “societal context”, which can be interpreted as a societal perspective. No 
guidelines are cited, making it difficult to judge the validity of the perspective in the Korean context.  
Costs for IPD and NPP are listed in an aggregated form and they are taken from a previous national study on direct health care 
costs. Indirect cost seems only to be calculated for the productivity loss of the patient for the length of stay. It is unclear whether 
forgone productivity loss due to pre-mature mortality is included or if the Human Capital or the Friction Cost approach have 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
QALYs are given as the only and primary outcome measure. Utility estimates are based on national population norms and are 
multiplied with the utility weights from the study of Smith et al. QALY loss is only calculated for IPD and NPD. No utility 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Serotype distribution is taken from national surveillance data. Age-specific incidence rates for IPD and NPP are based on data 
from a national catchment area. Risk-group specific incidence rates are calculated based on the assumption that the risk ratio of 
CAP versus the general population is transferable to IPD and NPP.  
Case fatality rates for IPD are age- and risk group specific and taken from a national multi-center study. NPP case fatality rates 
are based on a multi-center catchment area study. Inconsistent values have been resolved via Delphi panel. No figures or 
sources of background mortality are given. 
Indirect effects are calculated from the observed effects after the introduction of PCV7. The trajectory of an American study by 
Moore et al. (2015) [30] are applied to the national data. Based on the Delphi panel, indirect effects on NPP are assumed to be 
50% of the IPD effects. Using non-serotype specific data is not a valid method and biases the analysis towards PCV13. 
Methods for the extrapolation of Moore data are not described. 




PPSV23 VE is age-adjusted according to Smith et al. 2012 [29]. 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 
The time horizon is set to 15 years in the base case and no sensitivity analyses are performed on the time horizon. As the age 









Do sensitivity analyses cover the most critical 
parameters within a valid range? 
The values in the deterministic sensitivity analysis are set to 25% and 125% of the base case value. Vaccine effectiveness, costs 
and QALYs are varied in the analyses, but time horizon or discount rate are not explored. The ranges are set to rather unusual 
values and the corresponding tornado plot looks skewed. 
11 Conclusion Are conclusions supported by results? 
Based on the results the study concludes that PCV13 alone or in combination with PPSV23 is more cost-effective than PPSV23 
alone. All scenarios are only compared to a “no vaccination” scenario and no ICER is reported comparing the different 
strategies. 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention: Pneumococcal conjugate vaccine (PCV13) 
Setting: Australia 
Study:  Chen, C.; Wood, J. G.; Beutels, P.; Menzies, R.; MacIntyre, C. R.; Dirmesropian, S. et al. 
(2018): The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of 
pneumococcal conjugate vaccine in Australia. In Vaccine 36 (10), pp. 1265–1271. DOI: 
10.1016/j.vaccine.2018.01.052. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
The study reports most parts of the study in great detail, but the paper represents an 
adaption of a previous paper and is used to analyze the effect of the age at vaccination on 
the cost-effectiveness.  
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 
 Dimension Question Comment 
1 Target Is the target population for this intervention defined? The model considers a multi-cohort population representative for the general population between 65 and 100 years with an one-
population year age stratification. Persons above 100 years are aggregated into one age group. There is no consideration of risk groups or 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
The study aims to compare a no vaccination scenario with the current uptake pattern of PCV13 vs. a scenario where vaccination 
takes place exactly at the age of recommendation for all eligible persons, respectively. 
Vaccine uptake: 
The vaccine uptake from the status quo is presented in a graphical form for every year of age with a peak of 66 of roughly 7% 
and an exponential decay over the following years of age. Average age is 70.5 years with 54.9% of persons being vaccinated 
over the age of 70 years. In the alternative scenario 54.9% were vaccinated at the age of 65. The study also explored the optimal 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The model has been adapted from a previously published CEA analysis. There is no graphical representation of the model. The 
cycle length is one year. The model attributes costs and QALYs to the events “inpatient IPD” stratified into meningitis and non-
meningitis IPD, “outpatient CAP”, “inpatient CAP”.  
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The current vaccination strategy is compared with a hypothetical uptake of the vaccine “at once” at the recommended age. The 
rationale for the analysis is given, as recommendations for the age of vaccination should consider that not every eligible person 
is vaccinated exactly at that age. 
5 Perspective Are the perspective of analysis and its rationale stated? 
The evaluation is conducted from a health care payer perspective as recommended by the national guidelines. No sensitivity 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
The cost-effectiveness of “no vaccination” vs. the recommended vaccination age or the observed vaccination age is calculated 
as costs per QALY (ICER). Other outcomes include the number of GP visits as well as the number of deaths (prevented) and 
the number of hospitalizations due to meningitis, bacteremia, IPD pneumonia and CAP, respectively. The administered doses, 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence:  
IPD incidence and fatality rates are stratified by 5-year age groups, CAP incidence, fatality and hospitalization rates are not 
stated to be age-specific. It was assumed that vaccine-type incidence of CAP was equal to IPD incidence. 
IPD incidence is also inflated to a “no vaccination” scenario which unfortunately not described in the appendix. Indirect effects 
of PPSV23 are not included as there is no evidence supporting this assumption, but indirect effects for PCV13 childhood 
vaccination are considered. 
Vaccination related parameters: 
Efficacy: 
PCV13  
IPD:  Maximum(1 – 0.118 x 1.078^(age-65),0) CAP:  Maximum(1 – 0.396 x 1.050^(age-65),0) 
PPSV23 
IPD: 0.58 (50-74 yoa), 0.56 (75-84 yoa), 0 (>85 <yoa) CAP: none 
Waning:  
PCV13 It is assumed that waning sets in after 5 years and that the efficacy thereafter declines linearly to zero over the next 6 
years 
PPSV23  It is assumed that waning sets in after 2 years and that the efficacy thereafter declines linearly to zero over the next 3 
years 
Years in full protection: 
PCV13 IPD 7.50 years CAP 7.50 years 
Vaccination costs were $AUD 65, costs for a GP visit were $AUD 126. Hospitalization costs are based on a previous study. 
QALY loss was 0.0709 for IPD and CAP inpatients and 0.0045 for CAP outpatient patients. Another model is cited for the 




Is the time horizon reported? 
It can be assumed that the time horizon of the model is 10 years, which marks the end of the program. The sentence “with each 
cohort being followed until vaccine-induced immunity has fully waned and the full consequences of any death included” also 
allows to interpretation for a life-long time horizon. 








Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
No sensitivity analyses are conducted. The justification is that authors did not want to focus on uncertainty. 
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
Results are reported for prevented deaths, program costs and health care savings as well as QALYs and cost-effectiveness. The 
cost-effectiveness estimate is $AUD83,538/QALY for the recommended age of vaccination and $AUD65,269/QALY for the 
observed uptake approach, each compared against no vaccination. 
The ideal age for the recommended scenario is 75 years and 72 years in the observed scenario. 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The study question is not a classical cost-effectiveness analysis, but on the timeliness of 
PCV13 vaccination, i.e. what the optimal age for the vaccination. Nearly all parameters 
of the model are given, although the costing for the different health states seems to have 
a very simple treatment pathway. No sensitivity analyses have been conducted which is 
justified by the focus of the study. 
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The study considers a population above 65 years and has a one-year age stratification. The stratification and the demographic 
process follow the numbers from the national bureau of statistics. 
IPD incidence is calculated for 5-year age bands from data of the National Notifiable Diseases Surveillance System. 






Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates adult pneumococcal vaccination against IPD, inpatient and outpatient CAP. The primary aim of the study 
compares an “all at once” vaccination strategy at the recommended age vs. the current vaccination accumulating over the years. 
The latter strategy uses real world data from a  New South Wales (NSW) survey. The secondary aim of the study examines the 




Does the model reflect a realistic event pathway 
according to current knowledge? 
IPD (as meningitis and bacteremia, respectively), inpatient and outpatient CAP are modelled. All probabilities are taken from 
national data or sources. 
4 Comparator Does the choice of comparators reflect current practice? 
The comparator is the actual current practice, i.e. vaccine uptake for PCV13 for persons over 65 years builds up cumulative, 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The perspective of the healthcare payer is recommended by national guidelines. No other perspective is taken in the sensitivity 
analyses. The costing is described in the appendix and it seems that all relevant aspects have been considered (vaccine costs, 
administration costs, inpatient costs for IPD and CAP and outpatient costs for CAP). However, no treatment pathway is 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
QALYs are given as the primary outcome measure. QALY losses have been taken from a Dutch study and have been combined 
with Australian population norms. QALY loss is differentiated between IPD inpatient, CAP inpatient and CAP outpatient. No 
information is given on the duration and the utilities used to arrive at the QALY values. Decrements for deaths are also included 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
IPD incidence, serotype distribution and case fatality is calculated from national registry data and all sources and calculation 
procedures are described in the appendix. 
CAP prevalence is based on the assumption that pneumococcal diseases cause 13.9% of all CAPs and that the proportion of 
CAP attributable to the PCV13 serotypes was the same as for IPD. CAP fatality rates are not reported. 
Indirect effects for childhood vaccination are incorporated. The appendix states that due to the stabilized incidence of the 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 
The duration of the vaccination program in the model is 10 years and the model states that all consequences have been included 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
No sensitivity analyses have been conducted. 
11 Conclusion Are conclusions supported by results? 
Based on the results the authors conclude that the timeliness of vaccination plays an important role and should be considered for 
vaccination recommendations.  
 
 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease:  Invasive and non-invasive pneumococcal diseases 
Intervention: Pneumococcal conjugate vaccine (PCV13) 
Setting: Australia 
Study:  Chen, C.; Beutels, P.; Newall, A. T. (2018): Evolution over time in the cost-effectiveness of 
pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant 
vaccination. In Vaccine 36 (16), pp. 2057–2060. DOI: 10.1016/j.vaccine.2018.03.006. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
The paper reports the results of an additional analysis conducted with the model from a 
previously published study.  
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The target population are persons 65 years and older, which are modelled as a multi-cohort Markov model. The model 
population represents the general population of that age group. The population is stratified into single years of age. No further 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
The model aims to investigate the influence of serotype evolution on cost-effectiveness estimates for PCV13 in the elderly. 
Therefore, there is no clear intervention. 
The two scenarios include one (base case) scenario “[…] of no future serotype changes, only exploring how the past variation in 
serotypes would have impacted on cost-effectiveness” and one where “[…] 6 additional types in PCV13 were assumed to 
continue to decline from 2016 in the same way that PCV7 types declined […]”. While the alternative scenario is relatively 
clear, it is not clearly stated how the base case scenario is modelled. Also, the results suggest, that both strategies have been 
compared to a “no vaccination” scenario.  
Vaccine uptake: 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The model has been adapted from a previous study and no model diagram is given. The cycle length is one year. Cost 
attributions to health states are not stated but referenced to the original model (in this source, costs are attributed to IPD, 
inpatient and outpatient CAP).  
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
YES. The comparator is described as a scenario where the 6 additional serotypes of PCV13 (vs. PCV7) continue to decline in 
the same way that PCV7 declined after the introduction of the PCV7 vaccination. The rationale is to explore the uncertainty of 
the future serotype evolution. 
5 Perspective Are the perspective of analysis and its rationale stated? 
The analysis is conducted from a healthcare system perspective as recommended by national guidelines. No other perspective is 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
The study performs a cost-effectiveness analysis of an PCV13 vaccination of the elderly, comparing two different scenarios of 
the future serotype evolution, probably against a “no vaccination” scenario. The cost-effectiveness (Costs per QALY) of the 
scenario assuming no change in adult serotypes is lower, than in the scenario with serotype changes. No other outcome 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 




Is the time horizon reported? 
The paper states that the vaccination program is evaluated between the hypothetical start in 2012 and the end in 2021, but it is 
unclear over which period costs and outcomes are documented. This is also somewhat unclear in the first publication of the 




Is the discount rate reported? 
Costs and outcomes are discounted at 5% as recommended by national guidelines. No sensitivity analysis has been performed 




Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
No sensitivity analyses are conducted and no rationale is given for their omission. 
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
Disaggregated results are reported for program costs, healthcare cost savings, incremental (total) costs, QALY gains and the 
ICER (Costs/QALY). The ICER for the base case scenario (2016 serotypes) is $AU 71,000 and for the modelled serotype 
evolution $AUD 171,000. Program costs are identical with $AU 5,690,000 and healthcare savings are $AU 1,164,000 for the 
base case and $AU 521,000 in the alternative scenario. 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The study can be seen as a sensitivity analysis to a previously published model, looking 
at the impact of the assumptions about the serotype evolution after the introduction of a 
new vaccination on the cost-effectiveness estimate. The question is relevant and the 
design appropriate to answer this question. 
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☐ 
4 ☒ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The study considers the population of persons 65 years and older. The model uses data from the national statistical office as 
stated in the cited, predecessor model. The age stratification is in one year bands. 
From the previous model:   
IPD incidence is calculated for 5-year age bands from data of the National Notifiable Diseases Surveillance System. 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study aims at the comparison of different assumptions about the serotype evolution after the introduction of a vaccination. 
It evaluates the impact of a possible decline of the six additional serotypes covered by PCV13 vs. PCV7 to decline in the same 
way the serotypes of PCV7 have declined after PCV7 introduction on cost-effectiveness compared to the current “stable” 
incidence scenario. IPD and inpatient and outpatient CAP are included in the analysis. Uptake data is implemented age-specific 




Does the model reflect a realistic event pathway 
according to current knowledge? 
IPD, inpatient and outpatient CAP as well as death are included in the model. The probabilities for these events are modelled 
independently via the incidence rates of the respective events. Most details are outlined in the appendix of the original model. 
4 Comparator Does the choice of comparators reflect current practice? 
The base case reflects the current status quo. The comparator explores an equally valid assumption about the serotype evolution. 
In both scenarios PPSV23 childhood vaccination is incorporated via an indirect effect. No indirect effect of the adult PCV13 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The perspective of the healthcare payer is recommended by national guidelines. No other perspective is taken in the sensitivity 
analyses. The costing is described in the appendix of the original model and it seems that all relevant aspects have been 
considered (vaccine costs, administration costs, inpatient costs for IPD and CAP and outpatient costs for CAP). Inpatient costs 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
QALYs are given as the primary outcome measure. QALY losses are taken from a Dutch study and have been combined with 
Australian population norms.  
QALY loss is differentiated between IPD inpatient, CAP inpatient and CAP outpatient. No information is given on the duration 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
IPD incidence, serotype distribution and case fatality are calculated from national registry data. 
CAP prevalence is based on the assumption of pneumococcal diseases causing 13.9% of all CAPs and that the proportion of 
CAP attributable to the PCV13 serotypes was the same as for IPD. CAP fatality rates are not reported. 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 
The time horizon of the model is 10 years and the model states that all consequences are included in the results. A 5-year 
duration has been explored in a sensitivity analysis. 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
No sensitivity analyses are conducted, besides a five-year time period for the vaccination program. 
11 Conclusion Are conclusions supported by results? 
Based on the results the authors conclude that the assumptions on the herd protection from infant PCV13 programs is “critical 
when assessing the cost-effectiveness of adult PCV13 vaccination in Australia”. 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease: Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting: Netherlands 
Study:  Thorrington, Dominic; van Rossum, Leo; Knol, Mirjam; Melker, Hester de; Rümke, Hans; 
Hak, Eelko; van Hoek, Albert Jan (2018): Impact and cost-effectiveness of different vaccination 
strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. In PloS 
one 13 (2), e0192640. DOI: 10.1371/journal.pone.0192640. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
This study reports some parts of the economic evaluation in great detail, especially parts 
about incidence and mortality data, but has a very simple costing and QALY part. Only 
indirect costs are considered and split into IPD and CAP. The values for those cost and 
QALY parameters are taken from another modeling study. The study does not take the 
full possibility of age-stratified effects into account. Indirect effects are taken into 
account and an alternative scenario for childhood vaccination is analyzed. 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☒ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The model population is stratified into age groups “60-64”, “65-69”, “70-74”, “75-79”, “80 plus” and size of the age groups are 
given that suggest, that the study aims at the general population. 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Several alternative strategies to the current scheme (no vaccination for elderly) to vaccination of elderly at age 60/65/70 with 
PCV13 and/or PPSV23 with and without re-vaccination. Additionally, switching infant vaccination from PCV10 to PCV13 was 
explored. 
Vaccine uptake: 
50% uptake for elderly was assumed as well as 100% uptake for children for all vaccinations, respectively. 
Administration of the vaccines was modelled at the model start and scenario analyses have been carried out for different age 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The model is described as a static model and no illustration of the model is given. There is no information about the cycle 
length, also a yearly time step can be assumed. Disease states are not clearly identified, although IPD and CAP can be assumed 
to be the modelled health states. Costs and utilities are attributed to these two disease states. 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The intervention strategies are compared to the current vaccination scheme for elderly, which is no vaccination, and under the 
consideration of childhood/infant vaccination with PCV10. The rationale for the comparator is stated. 
5 Perspective Are the perspective of analysis and its rationale stated? 
The analysis is performed from the perspective of a health care provider following national guidelines. No other perspectives 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
The analysis is conducted as a cost-effectiveness analysis giving incremental costs per incremental QALY. Prevented cases and 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
Incidence:  
Incidence estimates are based on Dutch national surveillance data from 2004 to 2015, for the different serotypes of the vaccines. 
Serotype prevalence is projected using six assumptions: 
1. IPD incidence of PCV7 types remains stable 
2. IPD incidence of (PCV10-PCV7) serotypes will decline for 5 more years and then drops to 0.8/100,000 
3. IPD incidence of (PCV13-PCV10) serotypes remains stable for current childhood vaccination. It will decline for the 
scenario of PCV13 infant vaccination. 
4. IPD incidence of (PPSV23-PCV13) serotypes will continue to increase (serotype replacement) 
5. IPD incidence of non-PPSV23 serotypes will continue to increase (serotype replacement) 
6. Overall IPD incidence will increase (by estimated linear trend of PPSV23 and non PPSV23 serotypes) to the pre-
PCV level of 2005/06 of 54/100,000 among 60plus year old. 
Vaccination related parameters: 
Efficacy: 
PCV13  
IPD: 75% Non-IPP: 38% (no age-stratification) 
PPSV23  
IPD: 64% Non-IPP: 19.6% (no age-stratification) 
Waning:  
Linear reduction in waning is assumed for PCV13 and PPSV23 for IPD and CAP. PCV13 reduced to 0% VE after 15 years for 
both IPD and CAP, respectively. PPSV23 reduces to 0% after 6 years. Concrete values are given in Figure 1. 
Years in full protection: 
PCV13 provides 10.0 years in full protection for IPD and 10.03 years for CAP. 
PPSV23 provides 3.5 years in full protection for IPD and 3.55 years for CAP. 
Costs: 
Costs are €14,584 for IPD and €7,872 for CAP. No further stratification is provided. 
Utilities: 
QALY loss is 0.0709 for IPD and CAP, respectively.  
8 Time Is the time horizon reported? The time horizon is 10 years in the base case. 5, 15 and 50 years and an “unlimited” (life-long) scenario are explored in the 








Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Deterministic, univariate sensitivity analyses have been performed on: 
 assumptions on vaccine effectiveness, 
 age at vaccination 
 mortality assumptions 
 cost assumptions 
 adding administration costs 
 QALY assumptions 
 discounting  
 time horizon 
 the level of herd protection generated by the infant programme 
No probabilistic sensitivity analysis is performed. No ranges for the deterministic sensitivity analyses are given. 
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
Results are reported for Cases, Cases Prevented, Deaths, Deaths Prevented, QALYs, QALYs gained and Cost Savings. Cost-
effectiveness estimates are given for different ages at vaccination and time horizons. The most cost-effective strategy is a single 
vaccination of PPSV23 at the age of 70 years with an ICER of €6,201/QALY. 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The study is relevant, but in many cases, there are unnecessary simplifications in the 
model, i.e. ignoring age specific data, no prices-resources framework and arbitrary 
scenario/sensitivity analyses. 
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☒ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
The study does explicitly state that it models the general population, although this can be assumed. The model is stratified by 
age, but vaccine efficacy, costs and utilities are not age-specific. Only the different mortality-parameters are age-specific. 
Sources of population sizes, background mortality/life-expectancy are also not clearly stated. 
The population does not match the trial population and age-specific results from the trial are not incorporated. 
2 Intervention Are assumptions/design regarding interventions (dose The study evaluates different strategies of vaccination of the elderly against IPD and CAP without further stratification. The 
and setting and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
authors state that the adult vaccine uptake (50%) to be based on the corresponding value for influenza without sources and 
assume 100% vaccination uptake for pneumococcal infant vaccine although the cited source says 93.6%. Different ages for 




Does the model reflect a realistic event pathway 
according to current knowledge? 
Only IPD, CAP and death are included in the model without further stratification. IPD mortality is age- and vaccine-type 
specific from the Dutch surveillance data. CAP mortality is taken from a German source. The probability of the three health 
states is influenced by direct effects from the elderly vaccination and indirect effects from infant vaccination. 
4 Comparator Does the choice of comparators reflect current practice? 





Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The analyses are performed from a health care provider’s perspective and no other perspective is explored in the sensitivity 
analyses. The authors state, that a societal perspective is usually applied in the Netherlands, but do not give reasons, why they 
did not consider this perspective. No guidelines are mentioned in this context. 
The cost components are taken from another Dutch study (Mangen et al.[2]), but no detail is given in this study which cost 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
QALY losses are estimated to be identical for IPD and CAP (0.0709) and another model has been referenced as the source. No 
other information is provided about the values of population norms, the duration of the health states or the utility decrements. It 





Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Incidence is stratified by age and the probability of IPD and CAP were age-specific and data obtained from the Dutch (registry) 
data. Age-stratified IPD mortality is based on the Dutch surveillance data and CAP mortality from a German study. Background 
mortality is taken from a survival curve (without reporting the source).  
Indirect effects were modelled on 6 different assumptions listed in (7) in the first part. Not all assumptions are backed by data or 
literature. 
The study applied PCV13 vaccine efficacy from the CAPITA study, without using age-specific effectiveness. PPSV23 
effectiveness is taken from a meta-analysis by Falkenhorst et al. (2017)[32] and waning from Andrews et al. (2012)[13]. 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 
The time horizon is 10 years, but extensive sensitivity analyses have been conducted on different time frames to capture all 
relevant effects. 




Do sensitivity analyses cover the most critical 
parameters within a valid range? 
Sensitivity analyses are performed for vaccine effectiveness, age at vaccination, mortality assumptions, cost assumptions, 
adding administration costs, QALY assumptions, discounting, time horizon and the level of herd protection generated by the 
infant programme. The ranges of the different analyses are described in table 6 in the results section, but it is questionable, if it 
is plausible to explore “no mortality” scenarios. There are no other sources or rationales for the ranges applied in the sensitivity 




11 Conclusion Are conclusions supported by results? 
The study concludes a PPSV23 single dose vaccination of elderly between 60 and 70 to be the most cost-effective strategy. All 
ICERs lie beneath a threshold of €50,000/QALY and most strategies are beneath €20,000/QALY 
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease: Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting: Belgium 
Study:  Willem, Lander; Blommaert, Adriaan; Hanquet, Germaine; Thiry, Nancy; Bilcke, Joke; 
Theeten, Heidi et al. (2018): Economic evaluation of pneumococcal vaccines for adults aged over 50 
years in Belgium. In Human vaccines & immunotherapeutics, pp. 1–12. DOI: 
10.1080/21645515.2018.1428507. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
The study analyses the cost effectiveness of several vaccination strategies involving 
PCV13 and PPSV23 compared to the current state, PPSV23 alone. The study uses a 
multi-cohort Markov model for persons above 50 years incorporating indirect effects 
from childhood vaccination. PCV13 effectiveness is based on CAPITA-data and waning 
is assumed to start after 5 years with a logistic reduction to 50% after 10 years. PPSV23 
effectiveness is based on Andrews et al. 2012. 
1 ☐ Many gaps/ inconsistent 
2 ☐ 
3 ☐ 
4 ☒ Complete and consistent 




Is the target population for this intervention defined? 
General population in Belgium above 50 years stratified into the age groups “50 to 64 years”, “65 to 74 years”, “75 to 84 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Table 1 lists the current treatment regime (PPSV23) in 2015 and the vaccine uptake for different scenarios. This includes: 
PPSV23 and/or PCV13 vaccination with and without re-vaccination, respectively. However, there is no clearly stated 
list/enumeration of the different scenarios.  
Vaccine uptake: 
Current situation: 0.79% (50-65y) 2.46% (65-74y) 3.01% (75-84y) 2.48% (85-105y) 
Intervention scenario: 25% (50-65y) 50% (65-74y) 60% (75-84y) 40% (85-105y) 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The model type is a multi-cohort static model. Figure 3 contains the model diagram. It is not entirely clear how to categorize the 
model, but it can be assumed that it is a markov model of cycle length of one year. Input parameters are found in Appendix E. 
The disease states are IPD cases, further stratified by pneumonia, meningitis and other IPD with meningitis cases possibly 
showing hearing loss or neurological sequelae. Non-invasive pneumococcal pneumonia is also considered and stratified by 
inpatient and outpatient treatment. Death is an additional health state. Costs and utilities are given per disease state. 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
Comparator is the current (2015) vaccination schedule for adults in Belgium, which consists of PPSV23 vaccination in elderly 
with low vaccination coverage. 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
The study is conducted as a cost-effectiveness study using QALYs as the main outcome, but a range of other outcome 
parameters are evaluated as well (Key outputs include: averted hospitalized invasive pneumococcal pneumonia, meningitis, 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
There is a 35-page long appendix, which lists all the parameters used in the model from page 23 to page 31 and giving their 
sources.  
Incidence:  
Incidence is based on data from the National Reference Centre (NRC), 2015, INTEGO 2013 R81 and pooled estimates from 
Capelastegui et al and Holm et al. 
Vaccination related parameters: 
Efficacy: 
PCV13  
IPD: 50-84 years: 75.5% [47-90%]; ≥85 years: 0% 
Non-IPP: 50-84 years: 41.1% [12.7-62%]; ≥85 years: 0% 
PPSV23  
IPD: 50-84 years: 56% [40-68%]; ≥ 85 years: 0% 
Non-IPP: 50-84 years: 30.8% [31-52%]; ≥85 years: 0% 
Waning:  
PCV13: a logistic waning function with parameter k = 0.75 and mid-point of 10 years. 
PPSV23: an exponential waning function with mid-point of 1.5 years.  
Years in full protection: 
PCV13: 9.54 years (IPD & non-IPP) 
PPSV23: 2.29 (IPD & non-IPP) 
Serotype Coverage: 
PCV13 25% (IPD & non-IPP) 
PPSV23 66% (IPD), 51% (non-IPP) 
 
A full list of included unit cost prices is provided  
Aggregating categories of the unit cost prices are the health states. 
Costs are not divided into resource use and prices. 
The sources are given  




Is the time horizon reported? 
The model used a life-long time-horizon and costs and outcomes have been calculated until the last intervention cohort had 








Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Sensitivity analyses are reported in appendix C (page 11 to 21 in the supplement) and include deterministic, uni- and 
multivariate as well as scenario and probabilistic sensitivity analyses. Univariate sensitivity analysis is performed on: 
 Higher PPV23 protection against non-IPP 
 Five years of PCV13 protection followed by no protection 
 Minimum/Maximum  duration of PCV13 protection 
 Age-independent PCV13 efficacy in all ages between 50-84 year old 
 Two years of complete PPV23 protection followed by no protection 
 Five years of PPV23 protection without waning 
 Five years of both PCV13 and PPV23 protection without waning 
 Minimum/Maximum serotype shift 
 Quick/Slow serotype relapse 
 Higher hospitalized pneumococcal pneumonia incidence 
 Higher percentage of pneumococcal pneumonia in outpatient CAP 
 PCV13/PPSV23 price reduction 
 Higher PPV23 vaccine efficacy 
Multivariate SA consists of combinations of the above, while the results of the PSA are presented as CEAFs. 
Ranges for PSA cannot be found for all parameters and values of the distributions for PSA are only reported for the incidence of 
pneumonia and the case fatality ratio. 
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
Appendix B (pages 5 to 10) lists comprehensive tables on the different components (costs and effectiveness). 
Mean ICER of €201,172/QALY for PCV13 compared to the current situation (low PPSV23 in adults). 
Cost categories are Total Medical Costs (discounted/undiscounted), Total Vaccination Costs, QALY (discounted/undiscounted), 
ICER 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The model has a relevant study question and considers all relevant health states. If 
parameter values are taken from other countries, they are usually neighboring countries. 
Sensitivity analyses are conducted on a wide range of parameters, but not all ranges have 
been reported.  
1 ☐ Low relevance/ validity 
2 ☐ 
3 ☐ 
4 ☒ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
The target population (general population, 50 years+; age groups “50 to 64 years”, “65 to 74 years”, “75 to 84 years”,”≥85 
years”) is relevant and represents the intended target group of the intervention. But it does not coincide with the study 
population in CAPITA nor with the PPSV23 effectiveness study population of Andrews et al. (2012).  
Demographics are based on national data from Eurostat. 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates adult pneumococcal vaccination against inpatient IPD, (IP pneumonia, Meningitis, Other IPD) – and CAP 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The following health events are included: (I) IPD in the form of IP pneumonia Meningitis, other IPD and (II) non-IPP stratified 
by inpatient and outpatient care. For meningitis, long-term effects of hearing loss and neurological sequalae are considered and 
death may occur from any state. The events are mutually exclusive. Vaccine failure is considered in the model structure. 
4 Comparator Does the choice of comparators reflect current practice? 





Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The perspective is the perspective of the health care payer and is demanded by national guidelines. The direct health care costs 
are given as per-event-total costs and no prices-resources framework is used. The costing of the events is not comprehensively 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
QALYs are used as the primary outcome. Utilities are taken from a French study and decrements have been subtracted from the 
age-specific population norm. QALY losses are calculated for hospitalizations, non-hospitalized pneumonia and long-term 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
unit costs)? Are assumptions valid? 
Incidence data and serotype distribution are taken from the Belgian National Reference Center and serotype distribution was 
adopted from Germany. A Danish study (Benfield et al.) are used to calculate the distribution of non-IPP serotypes. Pneumonia 
incidence is estimated from data of a primary care network (INTEGO) and complications and mortality from hospital data. All-
cause mortality is based on national statistics. Indirect effects are based on SPIDNET data, a pooled analysis from 10 European 
countries (Hanquet et al. 2016). 
The study applied age un-specific vaccine effectiveness from the CAPITA study for PCV13 and Andrews et al. for PPSV23. It 
explores age-stratification in the sensitivity analyses. However, it is not described how the hazard ratio of 1.058 per year of age 
for the vaccine efficacy has been derived, which has been applied to the effectiveness of PPSV23 in a scenario analysis. 





Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 











Do sensitivity analyses cover the most critical 
parameters within a valid range? 
Given ranges seem plausible, but ranges are not given for all parameters. 
11 Conclusion Are conclusions supported by results? 
The results are mainly reported in the context of cost-effectiveness acceptability frontiers. The conclusion is in line with the 
results, stating that for a WTP of €50,000 per additional QALY the current strategy of PPSV23 is cost-effective.  
EVIDEM instrument – Assessment of quality of economic evaluations (adapted) 
Disease: Invasive and non-invasive pneumococcal diseases 
Intervention:  Pneumococcal polysaccharide vaccine (PPSV23); 
Pneumococcal conjugate vaccine (PCV13) 
Setting: Germany 
Study:   Kuchenbecker, Ulrike; Chase, Daniela; Reichert, Anika; Schiffner-Rohe, Julia; Atwood, 
Mark (2018): Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for 
adults in Germany. In PloS one 13 (5), e0197905. DOI: 10.1371/journal.pone.0197905. 
Completeness and consistency of reporting economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Are all the dimensions of the economic evaluation 
reported? Is the reporting complete and transparent? 
Are estimates used in analysis in agreement with 
clinical literature/data? Are estimates used consistent 
with sources? Is information consistent across sections 
of study report/publication (abstract, methods, results, 
discussion)? 
See dimensions below 
The study analyses the cost-effectiveness of several vaccination strategies involving 
PCV13 and PPSV23 compared to the current state from the payer’ and societal 
perspectives. It adopts an earlier developed US microsimulation framework with 
Markov-type process by Weycker et al (2012). All dimensions but discounting are 
reported. The VE data for PCV13 comes from the CAPITA study and VE for PPSV23 is 
based on the previous estimates by an expert panel. The study shows inconsistency in the 
reporting the methods applied to estimation of the waning rate and calculation of herd 
effects. The representation of the applied parameters for PSA is not intuitively 
interpretable.  The results are reported in detail.  
1 ☐ Many gaps/ inconsistent 
2 ☒ 
3 ☐ 
4 ☐ Complete and consistent 




Is the target population for this intervention defined? 
The target population is defined as the German population aged ≥ 18 years. The population is stratified by health risk (high, 
moderate, low) and single age increment. The definition of the risk groups is given. The percentages assigned to each risk group 
are given for the age groups: 18-59 y.o, 60-64y.o, 65-74y.o, 75-99 y.o. 
 Low-risk: “immunocompetent patients without any chronic medical conditions”; 
 Moderate-risk: “immunocompetent patients with at least one chronic medical condition”; 
 High-risk: “immunocompromised/immunosuppressed patients, with or without chronic medical conditions 




Are intervention & setting described (dose, duration, 
mode of delivery, hospital specialist, etc)? 
Intervention: 7 vaccination scenarios vs current practice. 
The vaccination scenarios are defined for the risk groups and age groups: 18-59 y.o., 60-65y.o., 66-99y.o. 
The study defines sequential vaccination as a strategy with initial vaccination with PCV13, followed by PPSV23 after 6-12 
months and revaccination every 6 years afterwards. 
3 hypothetical scenarios include:  
 sequential vaccination for all but low-risk 18-59y.o. people 
 60-65y.o., 66-99y.o. in low-risk group with PPSV23 (current policy) and people at high- and middle risk groups 
with the sequential strategy 
 18-59y.o. in middle risk, and 60-99y.o. in low- and moderate risk groups are vaccinated with PCV13 and all rage 
groups in high risk group are vaccinated with the  sequential strategy 
Other 4 scenarios are evaluated in SA  
Vaccination rate fall all strategies is 31.4% which is observed for the current policy. Revaccination rate is assumed to be 100% 





Is the model described (model diagram/figure 
preferred), with details of the event pathway & 
attribution of costs to each node/part/arm/option/branch 
of the model? 
The model is briefly described. A descriptive figure is given in the main text. The model type is described as a static incidence 
model with a microsimulation framework with Markov-type process which was adopted from an US study by Weycker et al 
(2012)[15]. The cycle length is 1 year. The outcomes are produced for each modeled individual. The modeled events include 
diseases (IPD: bacteremia and meningitis; nIPD: non-bacterial pneumonia in-and outpatient) and death. The costs depend on the 
disease. The study performs 1,000 simulations in each scenario. 
4 Comparator 
Are comparators described? Is the rationale for 
comparator selection stated? 
The analysis is performed in comparison with the current policy. 
The current policy is vaccination with PPSV23 of all elderly (≥60) and adults ≥16 with at least one chronic disease not 
associated with immune suppression and a sequential vaccination (PCV13 initial, followed with PPSV23) for adults at high 
risk. 




Is the type of analysis stated? Is the rationale for 
outcomes selection (effectiveness measure or utilities) 
stated? 
Cost-effectiveness analysis of alternative scenarios of pneumococcal vaccination with PCV13 and/or PPSV23 compared to the 
current practice.  
The outcomes of the analyses are: number of cases prevented, LYG, QALY, costs. 





Are all the parameters used in the model (effectiveness 
data, adverse-event data, resource use, unit costs, health 
states, utilities) and their sources reported? Are the 
methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation 
adjustments, calculation of transition probabilities, 
expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
The parameters are listed in the main text and the supplemental material.  
Incidence:  
The applied incidence rates are reported with the respective sources. The rates are age- and risk group stratified. The rates are 
given for all modelled diseases: meningitis and bacteremia (IPD) and inpatient- and outpatient non-bacteremic pneumonia 
(nIPD).  
Inclusion of the herd effects of the paediatric vaccination with PCV13 is described. The maximum reduction in % due to herd 
effects is calculated based on prediction of serotype distribution in IPD performed using unpublished serotype-specific IPD data 
from the National Reference Laboratory (NRZ) on Streptococcal Diseases. The observed effects are extrapolated over the next 
5 years based on predicted serotype distribution in IPD. The prediction of the serotype distribution is performed using a model 
showing the best fit to the data observed over 5 years (2010/11-2015/16). The study does not report the method used to obtain 
cumulative herd effects by year of modelling from the predicted serotype distribution. Table S2 shows the applied values, which 
illustrate a significant jump from 0% to approx. 80% in the modelled year 2. This trend is not discussed in the paper. Cited 
bibliography in the respective supplemental tables is not reported.  
Case-fatality- and general mortality rates are reported with the cited references.  
Vaccination related parameters: 
Efficacy: 
PCV13: The values for the VE parameters are obtained from the CAPITA study. Serotype coverage PCV13 against IPD is 
assumed to be 29.3%. PCV13 VE against IPD for immunocompromised is taken as 78% of VE for people of the low and 
moderate risk. PCV13 VE against nIPD for immunocompromised is taken as 65% of VE for people of the low and moderate 
risk.      
PPSV23: The values for the VE against IPD parameters are obtained from Smith et al. (2008) [16]for immunocompetent and 
Shapiro et al. (1991)[33] for (immunocompromised) individuals. PPSV23 VE against nIPD is assumed to be 0%.  
The approach is described in the supplement. 





18-49y.o. 50-59 y.o. 60-64 y.o. 65-74 y.o. 75-99 y.o. 
low/mod high low/mod high low/mod high low/mod high low/mod high 
ag IPD 85% 66% 82% 64% 80% 62% 77% 60% 70% 55% 
ag nIPD 4% 3% 4% 3% 4% 3% 4% 3% 4% 2% 
PPSV23 
ag IPD 
93% 21% 88% 15% 83% 8% 76% 2% 64% 0% 
Waning: VE rates are for years since vaccination. VE of both vaccines wanes over 15 years. VE of PPSV23 is assumed to wane 
starting with the 1st year, PCV13 is assumed to show stable protection over the first 5 years. 
The waning rates are estimated based on published literature.  
Methods for the estimation of the waning of PPSV23 VE for the immunocompromised people are no reported.  
The approach is inconsistently described:  
 the main text reports estimation of an exponential function, whereas in the supplement it is stated that the rates are 
obtained using a linear interpolation based on the values obtained from Smith et al (2008)  
 Table 2 represents VE rates aggregated by age- and health risk groups. The table shows the vaccine effectiveness 
over time, although in in text it is stated that “the values represent percentage of decline in corresponding year from 
prior period”. 
The rate of PCV13 waning is 50% of the rate of PPSV23 waning but is applied first after the initial 5year period of constant 
protection.  
We calculated years of full protection and  average duration of protection with PCv13 ag IPD and nIPD, PPSV23 ag IPD:  
To note, these calculations were based on the values of VE given in Table 2 of the main text. Table 2 shows inconsistency in the 
reporting of the values of VE for PCV13 ag IPD in the low risk group of 65-74 y.o., for year 10 (VE =1%) and for PPSV23 ag 
IPD for high risk group of 50-59y.o. for year 10 (VE =37%, though initial VE =15%) 
VE 
PCV13: 
18-49y.o. 50-59 y.o. 60-64 y.o. 65-74 y.o. 75-99 y.o. 
low/mod high low/mod high low/mod high low/mod high low/mod high 
ag IPD 12.7y 9.9y 12.2y 9.5y 11.3y 8.8y 8.3y 8y 8.3y 6.5y 
ag nIPD 0.6y 0.45y 0.6y 0.45y 0.6y 0.45y 0.55y 0.35y 0.4y 0.25y 
PPSV23 
ag IPD 
10.2y 2.8y 11.1y 3.8y 11.7y 1.35y 11.7y 0.29y 10.1y 0y 
 
Costs and Health outcomes: 
The applied costs are reported per case for each modeled disease and age-group. Medical costs include hospitalization- and 
outpatient costs. Non-medical costs comprise of work-loss days and costs due to productivity loss. The sources are stated.  




Is the time horizon reported? The time horizon is reported and is modeled as until death or 100 years of age. 





Are sensitivity analyses reported? Are rationales for 
selection of parameters and ranges used in sensitivity 
analyses reported? 
Sensitivity analyses are described in the main text and include univariate- and probabilistic SA. The parameters with the taken 
distributions are stated in the supplemental material.  
Univariate sensitivity analysis is performed on: 
 assumption of PCV13 constant protection over 5 years  
 PPSV23 effectiveness against all-cause NBP of 64%  
 revaccination rate of 50% in 2 vaccination scenarios 
Parameters for PSA are reported for incidence, effectiveness of PCV13 and PPSV23, mortality and medical costs. 
The PSA is shortly described only in the main text. The study reports the applied distributions. The table with the PSA 
parameters is not described and methods for application of the stated parameters are not reported making it difficult to assess 
completeness and consistency of the information. The sources are numbered but not reported in the respective supplemental 
material making it unclear what bibliography is cited.   
11 Results 
Are disaggregated results reported (cost & effectiveness 
per component, direct and indirect costs, total costs and 
effectiveness, incremental costs and effectiveness, and 
incremental cost-effectiveness ratios)? 
The results of base case scenarios are reported. For resulted ICERs the study presents a scatterplot. The reported costs are 
divided into medical-, non-medical and vaccination cost. The major outcomes are given also per patient for each evaluated 
scenario. The results are reported also for all adults, adults <60 years old and ≥60 years old.  
The ICER per LYG ranged from €3,662 to €23,061 (payer) and €3,258 to €29,617 (societal). All scenarios but one are 
considered to be cost-effective. 
Relevance and validity of economic evaluation 
Type of evidence Question Rationale Score 
Economic evaluation 
Is the study question relevant (choice of comparator, 
time horizon, patient population, outcome, 
perspective)?  
Is the design appropriate? (how close to real disease 
progression, costs included, strength of assumptions, 
sensitivity analyses, quality of sources (clinical, costs, 
epidemiology, utilities)? 
See dimensions below 
The study applies relevant comparator, time horizon, perspective, targeted population, 
outcomes and costs. Due to incompleteness in reporting it is difficult to assess 
plausibility and relevance in the important dimensions of the study. The event pathway 
applied in the model is not described in detail.  The study refers to four sources which are 
used to derive incidence rates without reporting the methods of how the data is adjusted 
making it difficult to assess the relevance. The study lacks description of methods for 
calculation of cumulative herd effects from the reported predicted serotype-distributions 
in IPD by that making it difficult to assess relevance of applied herd effects. It is not 
clear how the applied values of the herd effects for nIPD are obtained. Applied PPSV23 
VE is based on the estimates by a Delphi expert panel. Report on applied discounting is 
missing. Reporting of the ranges applied in the PSA is not complete and the table is not 
easy to interpret. Uncertainty of the assumption that PCV13 VE is 50% of the values of 
PPSV23 VE applied in extrapolations to calculate age-specific PCV13 VE values and 
waning rates is not tested.       
 
1 ☐ Low relevance/ validity 
2 ☒ 
3 ☐ 
4 ☐ High relevance/validity 




Is the target population relevant (age, gender, disease 
stage, co-morbidities, etc…)? Is it comparable to the 
The modeled population is a hypothetical cohort of German adult population aged 18 years and older stratified by health risk 
groups and one-year age increments. The modeled population is relevant for the evaluated intervention but does not correspond 
trial/study population in which efficacy/effectiveness 
data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
to the population of the CAPITA trial (≥65y.o) based on which PCV13 VE parameters are derived.  
Population size estimates are obtained from official data of the Federal Health Monitoring of 2012. The division of the 
population on the risk groups is based on the data from published observational studies conducted in Germany and on the 




Are assumptions/design regarding interventions (dose 
and duration, mode of delivery) & setting 
(hospital/community, country, etc) valid with respect to 
the indication/proposed coverage & clinical context? 
The study evaluates adult pneumococcal additional vaccination strategies against inpatient IPD (meningitis and bacteremia) and 




Does the model reflect a realistic event pathway 
according to current knowledge? 
The developed model includes following events: model entry, vaccination, disease in form of IPD and nIPD, death. 
For meningitis, long-term effects of hearing loss and neurological sequalae are not considered. The model is not described in 
detail making it difficult to assess the event pathway.  
4 Comparator Does the choice of comparators reflect current practice? 
The different scenarios are compared to the current PPSV23 vaccination for elderly issued by the German standing committee 
for vaccination (STIKO). 
The current recommendation comprises of “PPSV23 for all elderly (≥60) and all patients ≥16 with at least one chronic disease 
not associated with immune suppression. For all other patients at risk (high-risk representing 
(congenital or acquired) immunocompromised/immunosuppressed patients, with or without chronic medical conditions), 
sequential immunization with PCV13 first is recommended, followed by PPSV23. Repeated vaccination with PPSV23 is 
recommended for patients in all risk groups. Elderly are recommended revaccination every 6 years with PPSV23 following 




Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits 
& procedures, hospitalization, long-term care, lab 
tests)? Are assumptions for cost selection valid? 
The taken perspectives are of the health care payer and societal as suggested by the “German Recommendations on Health 
Economic Evaluation: Third and Updated Version of the Hanover Consensus”[20].  
The direct health care costs are divided into hospitalization and outpatient costs given per case and stratified by the age-group. 
The costs are derived from national tariff manuals. Inpatient costs are estimated using DRG specific calculations using data 
from the Institute for the Hospital Remuneration System (InEK) (reference of 2013).  Outpatient costs comprise of physician 
costs (per case) and medication costs. The costs per unit are not reported. Calculation of vaccination costs are made using 
pharmacy retail price of a package size of ten for PCV13 (62.93 €/dose) and PPSV23 (28.32 €/dose) (of 2018). 
For the societal perspective, the indirect costs are derived based on number of sick-leave days (of 2012) and the value of a 
single sick-leave day (of 2014). 




Are the selected outcomes measures (efficacy, safety 
and patient reported outcomes [PRO]) relevant? Are the 
primary efficacy/effectiveness measures used, and 
major side effects included? Are instruments to estimate 
PRO valid? Are assumptions for outcomes selection 
valid? 
QALYs and LYG are used as the primary outcomes. Utilities for the general German population are given by age- and risk-
group and obtained from a German study which examines and compares cross-section surveys. Disutilities originate from 
published cost-effectiveness studies of pneumococcal vaccination in England and Wales and USA. Reduction utilities due to 
disease is given as one value for IPD and  another value for all-cause NBP, the parameter  is not age-group or risk-group 




Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, 
Incidence.  
IPD incidence rates are derived based on the data of a publication on IPD in North-Rhine Westphalia Germany by Reinert et al. 
(2005)[34]  extrapolating the incidence of the overall population; health-risk adjustment is based on van Hoek et al. (2012)[23]. 
unit costs)? Are assumptions valid? The study refers to four sources which are used to derive incidence rates without reporting the methods of how the data is 
adjusted making it difficult to assess the relevance.  
Indirect effects of the pediatric vaccination with PCV13 are included into the study. The herd effects are major effects 
considered in the study. The methods are not thoroughly described, a rationale is not provided. For the IPD incidence the study 
reports cumulative herd effects expressed in % for each modelled age-group for the first 5 years assuming 100% of the herd 
effects reached in the 5th year and keeping absolute maximum herd effects constant for the modeled time horizon. The reported 
rates show that the cumulative herd effects reach over 80% by year 2 in all age groups but 75-99y.o. These percentages are 
derived from projections of serotype distributions in IPD. Regarding these projections, although the non-liner model applied to 
project the serotype distribution and it results are reported, the methods of how the reductions in the IPD incidence are derived 
from these results are not reported. Given the ways the information is reported it is difficult to assess its validity. The herd 
effects for NBP are obtained from published study by Pletz et al (2016) [35]. 
Vaccine Effectiveness.      
The values for the PPSV23 VE for the individuals of the low- and moderate risk are obtained from the estimates by Delphi 
expert panel reported by Smith et al. (2008) [16]. Smith et al. (2008) report estimated PPSV23 VE values for healthy 
individuals by age group 50-64y.o., 65-79y.o., 80y.o. The study applies a linear interpolation to estimate the VE values for age-
year increment anchoring the VE values given by Smith et al. (2008) to age 50, 65 and 80 years: 93%, 80% and 67%. The 
waning rates estimates are taken from the same source by Smith et al (2008) and are linearly interpolated by age increment and 
modeled year. For the immunocompromised people of age 18-68 y.o. the study obtains the estimate (21%) reported in a 
controlled study by Shapiro et al (1991) who also state that the resulted estimate is not statistically significant. For 51-68 year 
olds the VE estimate is extrapolated by interpolating between the two data points: 21% for 50y.o. and 0% for 69y.o. For the 
immunocompromised people of age ≥69 y.o the VE is assumed to be 0%. Methods for the estimation of the waning of PPSV23 
VE for the immunocompromised people are no reported.  
The values for the PCV13 VE against IPD and nIPD are estimated based on the reported VE estimates in the CAPITA study. 
Based on the average age of 73y. of the participants in the trial, the resulted VE of 75% against IPD and 45 against nIPD are 
assigned to persons aged 73y. The VE values for younger and older age are obtained using extrapolation by age-year increment. 
The extrapolation is performed using the age-specific differences of PPSV23 VE resulted from the interpolation and applying 
50% of these differences for PCV13. PCV13 protection against IPD is assumed to be constant for 5 years and then to wane with 
the rate of 50% of the corresponding PPSV23 waning rates by year increment (setting the year 5 as the first year when the 




Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the 
intervention and comparator? Are assumptions used 
valid? 








Do sensitivity analyses cover the most critical 
parameters within a valid range? 
Given ranges applied in the univariate SA seem plausible. Not comprehensive reporting of PSA parameters and absence of the 
bibliography make it difficult to assess plausibility of the applied ranges.  
11 Conclusion Are conclusions supported by results? The conclusion is in line with the results that most of the evaluated strategies are cost-effective. 
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S6. Conversion of ICER, costs and utilities extracted from the evaluated studies 
 
S6 Table 1: Reported and converted ICER estimates for the studies selected for quality assessment of economic evaluation 
(n=13). 
* If the reference year was not reported, it was assumed that the reference year was two years before publication as this 
was the most common time period between reference year and publication year in the other studies. 
Scenario results in publication  
(Country/Publication year/reference year*) 
ICER per Model value in 2017 $US 
Jiang et al, 2012 (Germany/2010/Euro)      
basecase payer QALY 17,065  $      24,559  
basecase societal QALY 25,687  $      36,967  
Mangen et al, 2015 (The Netherlands/2012/Euro)      
Basecase QALY 8,650  $      12,003  
95% CI lower QALY 5,750  $        7,979  
95% CI upper QALY 17,100  $      23,729  
basecase LYG 7,650  $      10,616  
95% CI lower LYG 5,300  $        7,355  
95% CI upper LYG 12,450  $      17,277  
Blommaert et al, 2016 (Belgium/2014/Euro)      
PCV13 vs. No; 50-64 yoa QALY 218,774  $   287,917  
PCV13 vs. No; 65-74 yoa QALY 99,620  $   131,104  
PCV13 vs. No; ≥75 yoa QALY 67,507  $      88,842  
PPSV23 vs. No; 50-64 yoa QALY 128,859  $   169,584  
PPSV23 vs. No; 65-74 yoa QALY 67,182  $      88,415  
PPSV23 vs. No; ≥75 yoa QALY 49,760  $      65,486  
Gonzalez-Moro et al, 2016 (Spain/2015/Euro)      
basecase PCV13 vs current with PPSV23 QALY 1,844  $        2,992  
50–64 years, PCV13 vs current with PPSV23 QALY 9,800  $      15,901  
65–74 years, PCV13 vs current with PPSV23 QALY 3,475  $        5,638  
basecase,PCV13 vs current with PPSV23 LYG 1,245  $        2,020  
Stoecker et al, 2016 (USA/2013/US-$)      
add PCV13 at 50 yoa; basecase QALY 333,200  $   365,482  
add PCV13 at 50 yoa; 95% CI lower QALY 159,370  $   174,810  
add PCV13 at 50 yoa; 95% CI upper QALY 431,171  $   472,944  
add PCV13 at 60 yoa; basecase QALY 238,227  $   261,307  
add PCV13 at 60 yoa; 95% CI lower QALY 131,641  $   144,395  
add PCV13 at 60 yoa; 95% CI upper QALY 355,424  $   389,859  
add PCV13 at 65 yoa; basecase QALY 62,065  $      68,078  
add PCV13 at 65 yoa; 95% CI lower QALY 26,951  $      29,562  
add PCV13 at 65 yoa; 95% CI upper QALY 147,828  $   162,150  
replace PPSV23 at 65 yoa; basecase QALY 46,396  $      50,891  
van Hoek et al, 2016 (England/2014/GBP)      
Basecase QALY 257,771  $   375,622  
Dirmesropian et al, 2017 (Australia/2016/AUS-$)      
PCV13 vs. No; basecase QALY 88,000  $      62,417  
PPSV23 vs. No; basecase QALY 297,200  $   210,800  
PCV13 vs PPSV23  QALY 35,300  $      25,038  
Heo et al, 2017 (Korea/NA/US-$)      
60% coverage >65y.o. with PCV13; basecase vs Current QALY 797  $        1,099  
80% coverage; >65y.o. with PCV13; basecase vs Current QALY 701  $           967  
60% coverage >65y.o. with PPSV23;  vs No QALY 25,786  $      35,565  
80% coverage >65y.o. with PPSV23;  vs No QALY 17,354  $      23,936  
60% coverage >65y.o. with PCV13;  vs No QALY 4,529  $        6,247  
80% coverage >65y.o. with PCV13;  vs No QALY 5,045  $        6,958  
Sequential PCV13-PPSV23, 60% vs Curr QALY 1,228  $        1,694  
Sequential PCV13-PPSV23, 80% vs Curr QALY 10,645  $      14,682  
Chen et al, 2018 (Australia/2016/AUS-$)      
recommended age; basecase vs No QALY 83,538  $      59,252  
observed age; basecase vs No QALY 65,269  $      46,294  
Chen et al, 2018 (Australia/2016/AUS-$)      
basecase  QALY 71,000  $      50,359  
serotype evolution QALY 171,000  $   121,288  
Thorrington et al, 2018 (The Netherlands/NA/Euro)      
basecase QALY 6,201  $        7,925  
Willem et al, 2018 (Belgium/2015/Euro) 
 
     
PCV13 in 50-64 y.o. vs current PPSV23 low uptake QALY 201,172  $   260,611  
PPSV23  in 50-64 y.o. vs current PPSV23 low uptake QALY 82,814  $   107,282  
PCV13+PPSV23  in 50-64 y.o. vs current PPSV23 low uptake QALY 168,879  $   218,776  
PCV13 in 65-74y.o. vs current PPSV23 low uptake QALY 171,344  $   221,970  
PPSV23  in 65-74y.o. vs current PPSV23 low uptake QALY 57,212  $      74,116  
PCV13+PPSV23 in 65-74 y.o. vs current PPSV23 low uptake QALY 132,590  $   171,765  
PCV13 in 75-84y.o. vs current PPSV23 low uptake QALY 338,159  $   438,072  
PPSV23  in 75-84y.o. vs current PPSV23 low uptake QALY 52,147  $      67,554  
PCV13+PPSV23 in 75-84 y.o. vs current PPSV23 low uptake QALY 155,395  $   201,308  
Kuchenbecker et al, 2018 (Germany/NA/Euro)      
LR and MR initial vaccination with PCV13, high risk , sequential,  payer LYG 3,662  $        4,794  
LR and MR initial vaccination with PCV13, high risk , sequential,  payer QALY 5,828  $        7,630  
LR and MR initial vaccination with PCV13, high risk , sequential, societal LYG 3,258  $        4,265  
LR and MR initial vaccination with PCV13, high risk , sequential, societal QALY 5,186  $        6,789  
Sequential for all risk groups PCV13+PPSV23, payer LYG 8,964   
Sequential for all risk groups PCV13+PPSV23, payer QALY 14,881  $      19,482  
Sequential for all risk groups PCV13+PPSV23,  societal LYG 8,447  $      11,059  
Sequential for all risk groups PCV13+PPSV23,  societal QALY 14,023  $      18,358  
LR according to STIKO, sequential only for MR and HR , payer LYG 7,013  $        9,181  
LR according to STIKO, sequential only for MR and HR , payer QALY 11,584  $      15,165  
LR according to STIKO, sequential only for MR and HR , societal LYG 6,459  $        8,456  










S6 Table 2: Reported and converted cost estimates (n=13) 
Cost component in publication  
(Country/Publication Year/Reference Year/Model currency) 
Perspective Model value in 2017 US-$ 
Jiang et al. 2012 (Germany/2010/Euro)    
PPSV23 vaccine TTP 30,25 € $44,94 
Adminstration TTP 6,95 € $10,33 
Meningitis TTP 11.664,00 € $17.329,46 
Invasive pneumonia TTP 8.075,00 € $11.997,20 
NBPP inpatient TTP 5.762,00 € $8.560,73 
NBPP outpatient TTP 78,00 € $115,89 
Meningitis Sequelae Hearing Loss (per year) TTP 1.552,00 € $2.305,84 
Meningitis Sequelae Neurological (per year) TTP 862,00 € $1.280,69 
PPSV23 vaccine societal 38,25 € $56,83 
Adminstration societal 13,95 € $20,73 
Meningitis societal 11.671,00 € $17.339,86 
Invasive pneumonia societal 8.082,00 € $12.007,60 
NBPP inpatient societal 5.769,00 € $8.571,13 
NBPP outpatient societal 85,00 € $126,29 
Meningitis Sequelae Hearing Loss societal 1.559,00 € $2.316,24 
Meningitis Sequelae Neurological societal 869,00 € $1.291,09 
Productivity loss IPD societal 1.612,80 € $2.396,17 
Productivity loss NBPP societal 1.612,80 € $2.396,17 
Productivity loss PMS societal 35.064,00 € $52.095,34 
Mangen et al, 2015 (The Netherlands/2012/Euro)    
Vaccine costs societal 79,19 € $107,84 
DHC IPD societal Age-, risk-group and outcome dependent 
DHC inpatient CAP societal Age-, risk-group and outcome dependent 
DHC outpatient CAP societal 78,25 € $106,56 
DNHC IPD fatal case societal 11,90 € $16,20 
DNHC IPD survivor societal 27,70 € $37,72 
DNHC inpatient CAP fatal case societal 11,90 € $16,20 
DNHC inpatient CAP survivor societal 27,70 € $37,72 
DNHC outpatient CAP societal 20,26 € $27,59 
INHC IPD societal Age-, risk-group and outcome dependent 
INHC inpatient CAP societal Age-, risk-group and outcome dependent 
INHC outpatient CAP societal 453,01 € $616,88 
Blommaert et al, 2016 (Belgium/2014/Euro)    
Vaccine price PCV13 TTP 74,55 € $99,85 
Vaccine price PPSV23 TTP 28,46 € $38,12 
Vaccine administration TTP 23,32 € $31,23 
Cost of hearing aids (every 7 years) TTP 1.000,00 € $1.339,40 
Cost of long-term sequelae TTP 35.000,00 € $46.878,97 
DHC outpatient pneumonia TTP 1.032,00 € $1.382,26 
DHC inpatient pneumonia (50 yoa) TTP 9.118,00 € $12.212,64 
DHC inpatient meningitis (50 yoa) TTP 9.415,00 € $12.610,44 
DHC inpatient septicemia (50 yoa) TTP 7.365,00 € $9.864,67 
DHC inpatient pneumonia (65 yoa) TTP 11.476,00 € $15.370,94 
DHC inpatient meningitis (65 yoa) TTP 9.925,00 € $13.293,54 
DHC inpatient septicemia (65 yoa) TTP 10.961,00 € $14.681,15 
DHC inpatient pneumonia (75 yoa) TTP 12.096,00 € $16.201,37 
DHC inpatient meningitis (75 yoa) TTP 10.254,00 € $13.734,20 
DHC inpatient septicemia (75 yoa) TTP 12.673,00 € $16.974,21 
DHC inpatient pneumonia (90 yoa) TTP 14.267,00 € $19.109,21 
DHC inpatient meningitis (90 yoa) TTP 10.909,00 € $14.611,51 
DHC inpatient septicemia (90 yoa) TTP 14.940,00 € $20.010,62 
Stoecker et al, 2016 (USA/2013/US-$)    
Vaccine societal $85,19 $97,15 
Vaccine administration societal $40,00 $45,61 
DHC IPD 50-64 healthy societal $40.161,00 $45.797,47 
DHC IPD 50-64 high risk societal $40.161,00 $45.797,47 
DHC IPD >65 healthy societal $27.097,00 $30.899,98 
DHC IPD >65 high risk societal $27.097,00 $30.899,98 
DHC inpatient NBP 50-64 healthy societal $34.948,00 $39.852,84 
DHC inpatient NBP 50-64 high risk societal $34.948,00 $39.852,84 
DHC inpatient NBP >65 healthy societal $23.296,00 $26.565,52 
DHC inpatient NBP >65 high risk societal $23.296,00 $26.565,52 
DHC outpatient NBP 50-64 healthy societal $127,00 $144,82 
DHC outpatient NBP 50-64 high risk societal $127,00 $144,82 
DHC outpatient NBP >65 healthy societal $254,00 $289,65 
DHC outpatient NBP >65 high risk societal $254,00 $289,65 
van Hoek et al, 2016 (England/2014/GBP)    
Vaccine TTP £49,10 $72,56 
Vaccine administration TTP £7,51 $11,10 
Hospitalization IPD (65 yoa) TTP £4.865,00 $7.189,48 
Hospitalization IPD (100 yoa) TTP £4.780,00 $7.063,87 
Hospitalization CAP TTP £715,00 $1.056,62 
Dirmesropian et al, 2017 (Australia/2016/AUS-$)    
Vaccine costs PPSV23 TTP $35,00 $25,22 
Vaccine costs PCV13 TTP $65,00 $46,83 
Vaccine administration TTP $10,00 $7,20 
DHC outpatient CAP TTP $114,00 $82,13 
Meningitis hospitalisation (≥65) TTP $35.499,00 $25.575,64 
Bacteraemia (all non-meningitis ) hospitalisation (65-69) TTP $18.610,00 $13.407,78 
Bacteraemia (all non-meningitis ) hospitalisation (70-74) TTP $18.695,00 $13.469,01 
Bacteraemia (all non-meningitis ) hospitalisation (75-79) TTP $16.803,00 $12.105,90 
Bacteraemia (all non-meningitis ) hospitalisation (80-84) TTP $18.023,00 $12.984,87 
Bacteraemia (all non-meningitis ) hospitalisation (≥85) TTP $15.036,00 $10.832,85 
Non-invasive CAP hospitalisation (65-69) TTP $8.140,00 $5.864,55 
Non-invasive CAP hospitalisation (70-74) TTP $8.316,00 $5.991,35 
Non-invasive CAP hospitalisation (75-79) TTP $8.387,00 $6.042,50 
Non-invasive CAP hospitalisation (80-84) TTP $8.429,00 $6.072,76 
Non-invasive CAP hospitalisation (≥85) TTP $8.340,00 $6.008,64 
Chen et al. 2018a & 2018b (Australia/2016/AUS-$)    
Vaccination cost PCV13 TTP $65,00 $46,83 
Vaccine administration TTP $10,00 $7,20 
DHC outpatient CAP TTP $126,00 $90,78 
DHC inpatient Meningitis (50-64 yoa) TTP $31.178,00 $22.462,53 
DHC inpatient Meningitis (>= 65 yoa) TTP $37.848,00 $27.268,00 
DHC inpatient Non-Meningitis IPD (50-64 yoa) TTP $29.609,00 $21.332,12 
DHC inpatient Non-Meningitis IPD (65-69 yoa) TTP $19.650,00 $14.157,05 
DHC inpatient Non-Meningitis IPD (70-74 yoa) TTP $19.740,00 $14.221,90 
DHC inpatient Non-Meningitis IPD (75-79 yoa) TTP $17.743,00 $12.783,14 
DHC inpatient Non-Meningitis IPD (80-84 yoa) TTP $19.031,00 $13.711,09 
DHC inpatient Non-Meningitis IPD (≥85 yoa) TTP $15.877,00 $11.438,76 
DHC inpatient CAP (50-64 yoa) TTP $7.899,00 $5.690,92 
DHC inpatient CAP (65-69 yoa) TTP $8.595,00 $6.192,36 
DHC inpatient CAP (70-74 yoa) TTP $8.781,00 $6.326,37 
DHC inpatient CAP (75-79 yoa) TTP $8.856,00 $6.380,40 
DHC inpatient CAP (80-84 yoa) TTP $8.900,00 $6.412,10 
DHC inpatient CAP (≥85 yoa) TTP $8.806,00 $6.344,38 
Thorrington et al, 2018 (The Netherlands/NA/Euro)    
Vaccine cost PCV13 TTP 72,67 € $95,12 
Vaccine cost PPSV23 TTP 21,20 € $27,75 
Vaccine cost PCV10 TTP 60,56 € $79,27 
DHC IPD TTP 14.584,00 € $19.089,08 
DHC CAP TTP 7.872,00 € $10.303,71 
Willem et al. 2018 (Belgium/2015/Euro)    
Vaccine costs PPSV23 TTP 28,46 € $37,15 
Vaccine costs PCV13 TTP 74,55 € $97,31 
Vaccine administration TTP 11,70 € $15,27 
DHC inpatient Meningitis 50-64 yoa TTP 7.686,00 € $10.032,95 
DHC inpatient Meningitis 65-74 yoa TTP 8.900,00 € $11.617,65 
DHC inpatient Meningitis 75-84 yoa TTP 9.103,00 € $11.882,63 
DHC inpatient Meningitis ≥85 yoa TTP 6.973,00 € $9.102,23 
DHC inpatient Septicemia 50-64 yoa TTP 8.114,00 € $10.591,64 
DHC inpatient Septicemia 65-74 yoa TTP 6.317,00 € $8.245,92 
DHC inpatient Septicemia 75-84 yoa TTP 5.003,00 € $6.530,68 
DHC inpatient Septicemia ≥85 yoa TTP 3.137,00 € $4.094,89 
DHC inpatient Pneumonia 50-64 yoa TTP 5.669,00 € $7.400,05 
DHC inpatient Pneumonia 65-74 yoa TTP 5.909,00 € $7.713,33 
DHC inpatient Pneumonia 75-84 yoa TTP 1.679,00 € $2.191,69 
DHC inpatient Pneumonia ≥85 yoa TTP 3.466,00 € $4.524,36 
DHC outpatient pneumonia TTP 80,90 € $105,60 
hearing loss 1st year TTP 11.619,00 € $15.166,90 
hearing loss following years TTP 1.498,00 € $1.955,42 
























S6 Table 3: Reported utilities (n=13) 
 
Study Parameter Value  
Jiang et al. 2012 IPD utility 0.2 
IPD duration 0.09315068 
IPD QALY loss 0.01863014 
NBPP utility 0 
NBPP duration NA 
NBPP QALY loss 0 
PMS Hearing Loss utility 0.8 
PMS neurological utility 0.6 
Mangen et al. 2015 QALY loss IPD 0.0709 
QALY loss inpatient CAP 0.0709 
QALY loss outpatient CAP 0.0045 
Blommaert et al. 2016 QALY loss inpatient pneumonia 0.006 
QALY loss outpatient pneumonia 0.004 
QALY loss Meningitis 0.46 
QALY loss Septicemia 0.0079 
Stoecker et al. 2016 QALY loss inpatient NBP 0.006 
QALY loss outpatient NBP 0.004 
QALY loss IPD 0.009 
van Hoek and Miller 2016 QALY loss IPD (65 yoa) 0.14 
QALY loss IPD (100 yoa) 0.01 
QALY loss CAP 0.006 
Dirmesropian et al. 2017 IPD (acute phase) hospitalisation 0.0709 
Non-invasive CAP (acute phase) 0.0709 
General practitioner visit 0.0045 
Chen et al. 2018a & 
2018b 
QALY loss IPD inpatient 0.0709 
QALY loss CAP inpatient 0.0709 
QALY loss CAP outpatient 0.0045 
Thorrington et al. 2018 QALY loss IPD 0.0709 
QALY loss CAP 0.0709 
Willem et al. 2018 QALY loss IPD <65 yoa 0.0491 
QALY loss non-IPP <65 yoa 0.0203 
QALY loss IPD ≥65 yoa 0.0679 
QALY loss non-IPP ≥65 yoa 0.1741 
QALY loss outpatient pneumonia 0.0118 
Utility weight hearing loss 0.635 
Utility weight neurological 0.319 
 
